ާ∛ᘒ೙ᓮቇ⻠ᐳި
㧔1㧕⸃೬ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽㧘⡺⌒⥃ᐥ⸃೬ቇ⊛⎇ⓥߣ㧘㛽ߣࠞ࡞ࠪ࠙ࡓઍ⻢ེቭߩታ㛎ᒻᘒቇ⊛⎇ⓥࠍࡔࠗࡦߣߒ
ߡ㧘એਅߩ⎇ⓥࠍዷ㐿ߒߚ‫ޕ‬1㧕ࡅ࠻ⴊ▤♽࡮╭♽࡮ᧃ᪳␹⚻♽ߩ⡺⌒⸃೬ቇ⊛⸃ᨆ㧦⸃೬ታ⠌ㆮ૕ࠍ↪޿㧘ⴊ▤♽࡮╭♽࡮ᧃ᪳␹⚻♽ߩᄌ⇣಴⃻ࡄ࠲࡯ࡦߩ࠺࡯࠲⸃ᨆࠍⴕߞߚ‫ޕ‬
2㧕⡺⌒⥃ᐥ⸃೬ቇߩᢎ⢒ࠪࠬ࠹ࡓ߅ࠃ߮ᢎ᧚ߩ㐿⊒㧦කቇㇱቇ↢ߦኻߔࠆലᨐ⊛ߥ⸃೬ቇᢎ⢒㧔⥃ᐥ਄․ߦᔅⷐߣߐࠇࠆ⸃೬ቇ㧕ࠍⴕ߁ߚ߼ߩᣇᴺ߅ࠃ߮ᢎ᧚ߩᮨ⚝࡮㐿⊒ࠍⴕߞߚ‫ޕ‬ᐔᚑ 18 ᐕᐲ߅ࠃ߮ 19ᐕᐲߩጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔ᢎ⢒㧕ߦណᛯߐࠇ㧘ቇ↢߇┙૕⊛ߦℂ⸃ߔࠆߩ߇࿎㔍ߢ޽ࠆㇱ૏ߩᮨဳ૞⵾㧘⡺⌒⸃೬ታ⠌ߩᚻ㗅╬ࠍ⸃⺑ߔࠆࡆ࠺ࠝߩ૞⵾ࠍⴕߞߚ‫ޕ‬
3㧕⠧ᐕᕈ㛽☻㝃∝ࡕ࠺࡞ࡑ࠙ࠬ㧔SAMP6㧕ࠍ↪޿ߚ㧘ṽᣇ⮎߇㛽ߩᓸ⚦᭴ㅧߦ෸߷ߔᓇ㗀ߩᒻᘒቇ⊛⎇ⓥ‫ޕ‬4㧕ࡅ࠻ᄢ⣽㛽㗪ㇱߩᒻᘒቇ⊛⸃ᨆ‫ޕ‬
5㧕ࡅ࠻↪ኻᶏ✎㛽ߩᒻᘒቇ⊛⸃ᨆ‫ޕ‬
2㧚ฬ★
ಎᢎ᝼㧦 ᣧᎹᄢテ
⻠Ꮷ㧦
᧲ ⪇ጪ

Daisuke Hayakawa
Kagaku Azuma

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᣧᎹᄢテ㧚᫪ጊᘮሶ㧘Ⴎፒ ⛽✬㧚ੱ૕ߩߒߊߺ߇ࠃߊࠊ߆ࠆ㧍Q&A㧔PART㧞‫ޟ‬ౝಽᴲ࡮╭࡮㛽࡮ᗵེⷡ࡮↢ᱺེ࡮ߘߩઁߩ Q&A㧕㧦ࡊ࠴࠽࡯ࠬ ╙ 16 Ꮞ㧘᧲੩㧦ᾖᨋ␠㧧2007 ᐕ㧦30㧙41㧚
2㧕 ᣧᎹᄢテ㧚ᓟ⮮⧷ม㧘ᧁ᧛৻㓶㧘ዊ⷏⌀ੱ✬㧚᭴ㅧߣᯏ⢻㧦ᓴⅣེ♽ ࠦࠕ࡮ࠞ࡝ࠠࡘ࡜ࡓ࠹ࠠࠬ࠻㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦20㧙32㧘36㧙37㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 Ꮉዥ வ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘ᤊ ඳᤘ. 3 ᰴరㅧᓇ CT↹௝ߦ߅ߌࠆᐔ㕙ಽഀࠍ↪޿ߚᔃ⤳᭴ㅧߩ⹺⼂ߣ⢖ⴊ▤ಽ㘃߳ߩᔕ↪㧘ାቇᛛႎ 2006 ᐕ㧧MI2005-135㧦
109㧙112㧚
2㧕 ዊፉᘕᐔ㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘㒸 ⪇ጪ㧘ᮮጊ㦖ੑ㇢㧘ᤊ ඳᤘ. ੱ૕ߩ⸃೬ቇ⊛᭴ㅧ⹺⼂ߩߚ߼ߩ૕ᐙㇱ X ✢ CT ↹௝ߦ߅ߌࠆ㛽ᩰ᭴ㅧߩ⥄േ⸃ᨆ㧘ାቇᛛႎ 2006 ᐕ㧧MI2006-77㧦43㧙48㧚
3㧕 ᳯ᧛ᱜ৻㧘ᅏ᧛ᐕᒾ㧘㒸 ⪇ጪ㧚࠾ࡎࡦࠩ࡞⥠੃㗡ߩ⚿ว❱⧌ߩⷰኤ㧘ᒻᘒ࡮ᯏ⢻ 2007 ᐕ㧧5 Ꮞ㧦69㧙
73㧚
4㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X
✢ CT ௝ߦ߅ߌࠆᬁ૕㑆ߩ㛽ኒᐲ୯ߩ⋧㑐ᕈߩ⎇ⓥ㧘㔚ሶᖱႎㅢାቇળᛛⴚ⎇ⓥႎ๔ 2007 ᐕ㧧107 Ꮞ㧦
53㧙57㧚
5㧕 ␹⼱⋥Ꮧ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚૕ᐙㇱ X ✢CT ↹௝ߦ߅ߌࠆ㛽ᩰߩ૏⟎ᖱႎࠍ↪޿ߚ஥⣻╭ߣᄢ⣶╭ߩ⥄േ⹺⼂㧘㔚ሶᖱႎㅢାቇળᛛⴚ⎇ⓥႎ๔
2007 ᐕ㧧107 Ꮞ㧦23㧙27㧚
6㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘ᤊ ඳᤘ㧚X ✢ CT ௝ߦ߅ߌࠆ⣄ᬁᬁ૕ㇱߩ㛽ኒᐲߩ⺞ᩏ㧘ක↪↢૕Ꮏቇ 2007 ᐕ㧧45 Ꮞ㧦256㧙266㧚
7㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ௝ߦ߅ߌࠆੱ૕ߩᬁ૕ᶏ✎㛽ߩ㛽ኒᐲߩਇဋ⾰ᕈߦ㑐ߔࠆ⎇ⓥ㧘ାቇᛛႎ 2008 ᐕ㧧MI2007-143㧦435㧙438㧚
8㧕 ᳯ᧛ᱜ৻㧘ᅏ᧛ᐕᒾ㧘㒸 ⪇ጪ㧚࠲࠿ࠠ߅ࠃ߮ࡂࠢࡆࠪࡦ⥠੃㗡ߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ㧘ᒻᘒ࡮ᯏ⢻ 2008 ᐕ㧧6 Ꮞ㧦75㧙81㧚㧙㧙

9㧕 ੑች໪ᓆ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝ߦ߅ߌࠆ⢷ㇳਅญߩ⥄േ᛽಴ߣᮮ㓒⤑ߩ⥄േផቯ߳ߩᔕ↪㧘ାቇᛛႎ 2008 ᐕ㧧MI2007-85㧦107㧙110㧚
10㧕 㖧 ᣿ᣩ㧘ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚૕ᐙㇱ㨄✢ CT ↹௝ߦ߅ߌࠆ⸃೬ቇ⊛૏⟎ᖱႎߦၮߠߊਅ⢇㛽ߩ⥄േ⹺⼂㧘ାቇᛛႎ 2008 ᐕ㧧MI2008-14㧦
75㧙80㧚
11㧕 ␹⼱⋥Ꮧ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚૕ᐙㇱ X ✢CT ↹௝ߦ߅ߌࠆᮮ㓒⤑ߩ૏⟎ᖱႎࠍ↪޿ߚᄢ⣶╭⥄േ⹺⼂ᴺߩᡷ⦟㧘ାቇᛛႎ 2008 ᐕ㧧MI2008-13㧦
71㧙74㧚
12㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ௝ߦ߅ߌࠆ᳇▤࡮᳇▤ᡰߩᒻ⁁ᖱႎߩ⸘᷹㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2008 ᐕ㧧25 Ꮞ㧦18㧙21㧚
13㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝߆ࠄߩᬁ૕ᶏ✎㛽ㇱߦ߅ߌࠆ㛽ኒᐲߩಽᏓߩ⸃ᨆ㧘ାቇᛛႎ 2008 ᐕ㧧MI2008-26㧦35㧙40㧚
14㧕 ๟ ะᩕ㧘Song Wang㧘Pahal Dalal㧘Mike McLaughlin㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚3 ᰴరߩ㕙࿑ᒻߩ૏⟎วࠊߖߦࠃࠆᮮ㓒⤑ߩᒻ⁁ࡕ࠺࡞ߩ᭴▽㧘ାቇᛛႎ 2008 ᐕ㧧
MI2008-34㧦73㧙78㧚
15㧕 ᳯ᧛ᱜ৻㧘ᅏ᧛ᐕᒾ㧘㒸 ⪇ጪ㧚ࠬ࠭ࡔߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ㧘ᒻᘒ࡮ᯏ⢻ 2008 ᐕ㧧7 Ꮞ㧦7㧙12㧚
16㧕 ᳯ᧛ᱜ৻㧘ᅏ᧛ᐕᒾ㧘㒸 ⪇ጪ㧚ࠝࠝ࠲ࠞߩ⥠੃㗡ߣߘߩ⚿ว❱⧌ߩ⿛ᩏဳ㔚ሶ㗼ᓸ㏜ߦࠃࠆⷰኤ㧘⸃೬
⹹ 2008 ᐕ㧧83 Ꮞ㧦77㧙80㧚
17㧕 ␹⼱⋥Ꮧ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚㛽ᩰߣ㛽ᩰ╭ߩ⸃೬ቇ⊛૏⟎㑐ଥߦၮߠߊ૕ᐙㇱ X ✢ CT ↹௝߆ࠄߩ㛽ᩰ╭ߩ⥄േ᛽಴㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹
2008 ᐕ㧧J91-D㧦1918㧙1922㧚
18㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝߆ࠄߩੱ૕ߩᬁ૕ᶏ✎㛽ㇱߦ߅ߌࠆૐ㛽ኒᐲ㗔ၞߩಽᏓߦ㑐ߔࠆ⎇ⓥ㧘↢૕කᎿቇ 2008 ᐕ㧧46 Ꮞ㧦451
㧙457㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Chen H, Shoumura S, Emura S. Bilateral thoracic ducts with coexistent persistent left superior vena
cava. Clin Anat. 2006;19:350-353.
2㧕 Chen H, Emura S, Shoumura S. Ultrastructure of the water-clear cell in the parathyroid gland of
SAMP6 mice. Tissue Cell. 2006;38:187-192.
3㧕 Taguchi H, Chen H, Yano R, Shoumura S. Comparative effects of milk and soymilk on bone loss inadult ovariectomized osteoporosis rat. Okajimas Folia Anat Jpn. 2006;83:53-59.
4㧕 Chen H, Yao XF, Emura S, Shoumura S. Morphological changes of skeletal muscle, tendon andperiosteum in the senescence-accelerated mouse (SAMP6): a murine model for senile osteoporosis.
Tissue Cell. 2006;38:325-335.
5㧕 Yao XF, Chen H, Ohtake N, Shoumura S. The morphological alterations in the growth plate cartilageof ovariectomized mice. Medical Mol. Morphol. 2006;39:193-197.
6㧕 Emura S, Okumura T, Chen H, Shoumura S. Morphology of the lingual papillae in the raccoon dog andfox. Okajimas Folia Anat. Jpn. 2006;83:73-76.
7㧕 Yao XF, Chen H, Emura S, Otake N, Shoumura S. Effects of hPTH (1-34) and Gosga-jinki-gan on thetrabecular bone microarchitecture in ovariectomized rat tibia. Okajimas Folia Anat. Jpn. 2007;83:
107-114.
8㧕 Otake N, Chen H, Yao XF, Shoumura S. Morphologic study of the lateral and medial collateral
Ligaments of the human knee. Okajimas Folia Anat Jpn. 2007;83:115-122.
9㧕 Abe C, Tanaka K, Awazu C, Chen H, Morita H. Plastic alteration of vestibulo-cardiovascular reflex
induced by 2 weeks of 3-G load in conscious rats. Exp Brain Res. 2007;181:639-646.
10㧕 Zhou X, Ninomiya H, Hara T, Fujita H, Yokoyama R, Chen H, Kiryu T, Hoshi H. Automated estimationof the upper surface of the diaphragm in 3-D CT images. IEEE Transactions on Biomedical
Engineering. 2008;55:351-353.
11㧕 Chen H, Okumura T, Emura S, Shoumura S. Scanning electron microscopic study of the human
auditory ossicles. Ann Anat. 2008;190:53-58.
12㧕 Chen H, Shoumura S, Emura S, Bunai Y. Regional variations of vertebral trabecular bone
microstructure with age and gender. Osteoporos Int. 2008;19:1473-1483.
13㧕 Chen H, Zhou X, Washimi Y, Shoumura S. Three-dimensional microstructure of the bone in a hamster
model of senile osteoporosis. Bone. 2008;43:494-500.
14㧕 Emura S, Okumura T, Chen H. Scanning electron microscopic study of the tongue in the peregrine
falcon and common kestrel. Okajimas Folia Anat Jpn. 2008;85:11-15.
15㧕 Emura S, Okumura T, Chen H. Morphology of the lingual papillae and their connective tissue cores in
the cape hyrax. Okajimas Folia Anat Jpn. 2008;85:29-34.
16㧕 Zhou X, Han M, Hara T, Fujita H, Sugisaki K, Chen H, Lee G, Yokoyama R,Kanematsu M, Hoshi H.
Automated segmentation of mammary gland regions in non-contrast X-ray CT images. Comput Med
Imaging Graph. 2008;32:699-709.

㧙㧙

IF 0.702
IF 1.132

IF 1.132

IF 2.302
IF 0.672
IF 3.718
IF 3.829

IF 0.909

17㧕 Aoki H, Hara A, Motohashi T, Chen H, Kunisada T. Iris as a recipient tissue for pigment cells:organized in vivo differentiation of melanocytes and pigmented epithelium derived from embryonicstem cells in vitro. Dev Dyn. 2008;237:2394-2404.
IF 3.16918㧕 Emura S, Chen H. Scanning electron microscopic study of the Tongue in the Owl (Strix uralensis).
Anat Histol Embryol. 2008;37:475-478.
IF 0.593

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᣧᎹᄢテ㧧ᐔᚑ 18 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌(ᢎ⢒)㧦ੱ૕᭴ㅧࠦ࡯ࠬ(ࡑࠢࡠ✬)(ࡆ࠺ࠝߩ૞⵾╬)㧧ᐔᚑ 18 ᐕᐲ㧧430 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦ᣧᎹᄢテ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌(ᢎ⢒)㧦ੱ૕᭴ㅧࠦ࡯ࠬ(ࡑࠢࡠ✬)(ࡆ࠺ࠝߩ૞⵾╬)㧧ᐔᚑ 19 ᐕᐲ㧧355 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᧲ ⪇ጪ㧦
1㧕 ᣣᧄ⥃ᐥಽሶᒻᘒቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ㗼ᓸ㏜ቇળ㑐⷏ᡰㇱᐙ੐(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᧲ ⪇ጪ㧦
1㧕 Convention of the pharmaceutical society of Korea (2008.10, Soul,‫ޟ‬Herbal medicines in theprevention and treatment of osteoporosis.‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᐢᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘㒸 ⪇ጪ㧘ᤊ ඳᤘ㧦㔚ሶᖱႎㅢାቇળᐔᚑ 19 ᐕᐲቇⴚᅑബ⾨(ᐔᚑ 20 ᐕᐲ)9㧚␠ળᵴേ᧲ ⪇ጪ㧦
1㧕 ጘ㒂⋵ಎ⋴⼔Ꮷ⹜㛎ᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
ߥߒ
11㧚ႎ㆏
1㧕 ⏷㊁ᣣ಴ᄦ㧘ᱜ᧛㕒ሶ㧘᧲ ⪇ጪ㧦ࠕࡑ࠼ࠦࡠߦ⟤⡼ലᨐ ࡑ࠙ࠬታ㛎ߢ⏕⹺㧦Ფᣣᣂ⡞(2006 ᐕ
10 ᦬ 19 ᣣ)
2㧕 ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ᧲⪇ጪ⻠Ꮷࠄߩ⎇ⓥࠣ࡞࡯ࡊ㧦࡙࡝⑼ߩࠕࡑ࠼ࠦࡠߦ⟤ኈലᨐࡑ࠙㧙㧙ࠬታ㛎ߢ⏕⹺㧦ᣣᧄㄘᬺᣂ⡞(2007 ᐕ 9 ᦬ 21 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔቇౝᄖߦ߅ߌࠆ▤ℂ࡮ㆇ༡╬ߦ㑐ߔࠆᬺോߦߣࠄࠇࠆᤨ㑆߇Ⴧടߒߚਛߢ㧘ᢎ⢒ߩᲧ㊀߇ᭂ߼ߡᄢ߈
޿ಽ㊁ߢ޽ࠆ‫ޕ‬ᐔᚑ 19 ᐕᐲࠃࠅᢎຬߪ 2 ฬߣߥࠅ㧘ᄢቇ㒮↢߅ࠃ߮⎇ⓥ↢ߣ޿ߞߚ⎇ⓥࠬ࠲࠶ࡈ߽ᣂߚ
ߦㄫ߃ߡ޿ߥ޿‫ߥ߁ࠃߩߎޕ‬෩ߒ޿⃻⁁ߩਛ㧘ᬺ❣ߩਇ⿷ߪุ߼ߥ޿‫ޕ‬ᢎ⢒ߦゲ⿷ࠍ߅޿ߚ⎇ⓥߦ㧘৻ጀߩദജ߇ᔅⷐߣᕁࠊࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᷓೞߥࡑࡦࡄࡢ࡯ਇ⿷ࠍᛴ߃ߡ޿ࠆ߇㧘᳿ቯ⊛ߥ⸃᳿╷ߪߥ޿‫ߚ߹ޕ‬㧘⡺⌒⸃೬ቇ⊛⎇ⓥߪ㧘ᄙߊߩᤨ㑆ߣഭജࠍⷐߔࠆഀߦ㧘ᓧࠄࠇࠆ⚿ᨐ߇ዋߥߊ㧘ᚑᨐ߇⋡┙ߚߥ޿‫ోޕ‬࿖⊛࡮ో਎⇇⊛ߦ㧘⡺⌒⸃೬ቇࠍኾ㐷ߣߔࠆ⸃೬ቇ⠪ߪᷫዋߩ৻ㅜࠍㄡࠅ㧘ߘߩሽ⛯߇ෂ߱߹ࠇߡ޿ࠆ‫ߒ߆ߒޕ‬㧘⥃ᐥකߩߺߥࠄߕ
ࠦࡔ࠺ࠖࠞ࡞㗔ၞߩක≮ᓥ੐⠪ߦߣߞߡߘߩᔅⷐᕈ࡮㊀ⷐᕈߪ⸒߁߹ߢ߽ߥ޿‫⊛ੱߚߒ߁ߎޕ‬ਇ⿷ߣ⃻ታߩ࠾࡯࠭ߣߩਵ㔌߇ᦨᄢߩ໧㗴ߢ޽ࠆߣ⠨߃ࠆ߇㧘ౕ૕⊛ߥ⸃᳿╷ߪ⷗಴ߐࠇߥ޿‫ޕ‬⥃ᐥ⸃೬ቇᢎ⢒߅ࠃ߮ߘߩ⎇ⓥߦ㑐ߒ㧘ᐔᚑ 19 ᐕᐲߦ⊒⿷ߒߚ‫ޟ‬කቇᢎ⢒࡙࠾࠶࠻㧔⸃೬♽㧕‫ߩޠ‬ᵴേߪᧂߛᧄᩰ⊛ߥ゠㆏ߦਸ਼ߞߡ޿ߥ޿߇㧘ᓢ‫ߩߘߦޘ‬ᵴേࠍᵴᕈൻߒߡ޿ߊḰ஻ࠍㅴ߼ߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ⡺⌒⸃೬ቇ߅ࠃ߮⥃ᐥ⸃೬ቇߩᢎ⢒࡮⎇ⓥߦ៤ࠊࠆ⸃೬ቇ⠪߇⪺ߒߊᷫዋߒߡ޿ࠆᤓ੹㧘ߎࠇࠄߩ㗔ၞߦ⥝๧ࠍᜬߟੱ᧚ࠍᄙߊ⏕଻ߒ㧘⢒ᚑߔࠆߎߣ߇ᕆോߢ޽ࠆ‫ઁޕ‬ᄢቇߩ⸃೬ቇಽ㊁╬޽ࠆ޿ߪࠦࡔ࠺
ࠖࠞ࡞♽ኾ㐷ቇᩞ╬ߣߩኒធߥㅪ៤ߦࠃࠆ౒ห⎇ⓥ߽ᔅⷐߣᕁࠊࠇࠆ‫ߚ߹ޕ‬㧘ቇౝߦ߅޿ߡ‫⥃ޡ‬ᐥ⸃೬ቇ⎇ⓥળ‫ߜ┙ࠍߩ߽ߥ߁ࠃߩޢ‬਄ߍࠆߥߤߒߡ㧘⥃ᐥ♽ಽ㊁ߣߩㅪ៤ࠍ৻ጀኒߦߒ㧘౒ห⎇ⓥࠍㅴ߼ߡ޿ߊน⢻ᕈࠍតࠅߚ޿‫ߪߦࠄߐޕ‬㧘ᮨဳ߿ࠦࡦࡇࡘ࡯࠲ࠣ࡜ࡈࠖ࠶ࠢࠬ㧘ฦ⒳↹௝⸃೬ቇ⊛ᚻᴺࠍ㚟૶ߒ㧘ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ᧚ࠍ߽฽߼ߚ✚วකቇ⊛ߥ⥃ᐥ⸃೬ቇᢎ⢒ߩࠪࠬ࠹ࡓࠍ㐿⊒࡮ታ〣ߒߚ޿‫ޕ‬㧙㧙㧔2㧕ಽሶ∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᒰᢎቶߢߪ㧘ࡅ࠻ Aurora ㆮવሶߩ 3 ⒳ࠍ਎⇇ߦవ㚟ߌߡࠢࡠ࡯࠾ࡦࠣߒ㧘ߘߩ⚦⢩↢‛ቇ⊛ߥᯏ⢻ࠍ᣿ࠄ߆ߦߒࠃ߁ߣ⎇ⓥࠍㅴ߼ߡ᧪ߚ‫ޕ‬Aurora A ߪਛᔃ૕ߦዪ࿷ߒߡߘߩᚑᾫ߿ಽ㔌ߦ㑐ਈߒߡ⚦⢩ಽⵚߩዉ౉ࠍଦㅴߒߡ⚜㍝૕ᒻᚑߦᭂ߼ߡ㊀ⷐߥᓎഀࠍᨐߚߔ‫ޕ‬Aurora B ߪᨴ⦡૕ߩ࠮ࡦ࠻ࡠࡔࠕߦዪ࿷ߒ
ߡ⚦⢩ಽⵚೋᦼߩ੐⽎ߣߒߡߩࡅࠬ࠻ࡦ H3 ߩ࡝ࡦ㉄ൻ߿ᨴ⦡૕ߩಝ❗ߦ㑐ࠊࠅ㧘ಽⵚᓟᦼએ㒠ߪ෼❗ベߩᒻᚑ߿⚜㍝૕ߩ⣕㊀วߦ㊀ⷐߥᓎഀࠍᨐߚߔ‫ޕ‬Aurora C ߪ㧘ၮᧄ⊛ߦ Aurora B ߣห᭽ߩᓎഀࠍᨐߚߔ‫ޕ‬⒳‫⚦ࠎ߇ߩޘ‬⢩߿߇ࠎ⚵❱ߢ Aurora ࠠ࠽࡯࠯ࡈࠔࡒ࡝࡯࠲ࡦࡄࠢ⾰߇㜞⊒⃻ߒߡ޿ࠆߎߣ߽⍮ࠄࠇ㧘
ή⒎ᐨߥ⚦⢩Ⴧᱺ߳ߣ❬߇ࠆߣ⠨߃ࠄࠇߡ޿ࠆ‫ޕ‬ᚒ‫ ߪޘ‬Aurora A ߿ Aurora B ߩࡊࡠࡕ࡯࠲࡯㗔ၞࠍࠢࡠ࡯࠾ࡦࠣߒ㧘ߘߩ⊒⃻⺞▵ߦ㑐ࠊࠆ࠲ࡦࡄࠢ⾰ᕈォ౮࿃ሶߢ޽ࠆ Ets ࡈࠔࡒ࡝࡯㧘․ߦ㛽⡺⣲ߦ㑐ਈߔࠆ EWS-Fli1 ߦࠃࠆォ౮⺞▵ࠍ⸃ᨆߒߚ‫ޕ‬RNA ᐓᷤߦࠃࠆㆮવሶࡁ࠶ࠢ࠳࠙ࡦߩᚻᴺߪ㧘࠲ࡦࡄࠢ⾰ߩᯏ⢻ࠍ⸃ᨆߔࠆ਄ߢᭂ߼ߡ᦭↪ߥᚻᲑߢ޽ࠆ‫ޕ‬ਛᔃ૕ࠠ࠽࡯࠯ Aurora A ߩ siRNA ߦࠃࠆࡁ࠶ࠢ࠳࠙ࡦߦࠃࠅ⚦⢩ᱫ㧔apoptosis㧕߇߽ߚࠄߐࠇ
ࠆ߇㧘ઁߩਛᔃ૕࠲ࡦࡄࠢ⾰ߣߩ࠳ࡉ࡞ࡁ࠶ࠢ࠳࠙ࡦ߿߇ࠎᛥ೙ㆮવሶ p53 ߣߩ㑐ㅪߦߟ޿ߡ⸃ᨆߒߡ
޿ࠆ‫ޕ‬⋴⼔ቇ⑼࡮ᱞ⮮ศᓼᢎ᝼ߪ㧘ᚒ‫ߣޘ‬หߓߊਛᔃ૕ߦ⥝๧ࠍ߽ߞߡ߅ࠄࠇ㧘౒ห⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬ᱞ⮮ᢎ᝼ߪ㧘ਛᔃ૕ߩਛߢ߽ਛᔃዊ૕ߦዪ࿷ߒߡ coiled-coil ߿ leucine zipper ᭴ㅧࠍ߽ߟᣂⷙࡅ࠻ CLERC ㆮવሶࠍࠢࡠ࡯࠾ࡦࠣߒߚ‫ߩߘޕ‬ㆮવሶዉ౉ߦࠃࠆㆊ೾⊒⃻߿㧘siRNA ዉ౉ߦࠃࠆࡁ࠶ࠢ࠳࠙ࡦ߇⚦⢩ಽⵚߩ⇣Ᏹࠍ߽ߚࠄߔߎߣࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬⚦⢩ౝߩㆬᛯ⊛ߥ࠲ࡦࡄࠢ⾰ಽ⸃ߦ࡙ࡆࠠ࠴ࡦ-ࡊࡠ࠹ࠕ࠰࡯ࡓ♽߇㊀ⷐߥᓎഀࠍᨐߚߒߡ޿ࠆ‫ޕ‬ᒰᢎ
ቶߢߪ N ᧃિ㐳ဳ࡙ࡆࠠ࠴ࡦઃട㉂⚛㧔ubiquitin-conjugating enzyme, E2㧕ߩ UBE2E2 ߿ UBE2E3ߩㆮવሶࠍࠢࡠ࡯࠾ࡦࠣߒ㧘ߘߩ⚦⢩↢‛ቇ⊛ߥᯏ⢻ࠍ᣿ࠄ߆ߦߒࠃ߁ߣ⎇ⓥࠍㅴ߼ߡ᧪ߚ‫ޕ‬㉂Უ
two-hybrid system ࠍ↪޿ߡ UBE2E2 ߩ⚿วࡄ࡯࠻࠽࡯ߣߒߡ࡙ࡆࠠ࠴ࡦ࡝ࠟ࡯࠯ (ubiquitin ligase,E3) ߩ RNF8 ࠍࠢࡠ࡯࠾ࡦࠣߒߡߘߩᯏ⢻ࠍ⸃ᨆߒࠃ߁ߣߒߡ޿ࠆ‫ޕ‬2007 ᐕᧃߦ 4 ߟߩࠣ࡞࡯ࡊ߆ࠄ
RNF8 ߇㧘᡼኿✢ߦࠃࠆ DNA2 ᧄ㎮ಾᢿߦ㓙ߒߡࡅࠬ࠻ࡦ H2A ߿ H2AX ࠍ࡙ࡆࠠ࠴ࡦൻߒߡ㧘៊்ㇱ૏ߦୃᓳ࠲ࡦࡄࠢ⾰ࠍ㓸߼ࠆߚ߼ߦ㊀ⷐߥᓎഀࠍᨐߚߒߡ޿ࠆߎߣ߇ႎ๔ߐࠇߚ‫⚡ޕ‬ᄖ✢߿ฦ⒳⮎೷ߥߤߦࠃࠆ DNA ்ኂߦ߅ߌࠆ RNF8 ߩᓎഀ߿㧘ߘߩਅᵹߩࠪࠣ࠽࡞♽ߦߟ޿ߡ⸃ᨆߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ഥᢎ㧦
ഥᢎ㧦

ጟ㊁ᐘ㓶
ᧁ᧛ᱜᔒ
ศጟ ቁ

Yukio Okano
Masashi Kimura
Takashi Yoshioka

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ਛፉ ⨃㧘ጟ㊁ᐘ㓶㧚৻ἑ⊕Ꮲ㧘㋈ᧁብᴦ✬⪺㧚࿑⺑ ಽሶ∛ᘒቇ㧙Τಽሶ∛ᘒቇၮ␆⍮⼂ ⚦⢩ౝࠪࠣ࠽࡞વ㆐㧙 ╙ 4 㧘᧲੩㧦ਛᄖකቇ␠㧧2008 ᐕ㧦46㧙49㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Kuwata H, Yoshioka T, Muto Y, Kuwata K, Okano Y. Structural and functional characterization of
NP25, a single CH domain protein. Acta Schol Med Univ Gifu. 2006;54:1-7.
2㧕 Plans V, Scheper J, Soler M, Loukili N, Okano Y, Thomson TM. The RING finger protein RNF8
recruitsUBC13 for Lysine 63-based self polyubiquitylation. J Cell Biochem. 2006;97:572-582.
IF 3.381

㧙㧙3㧕 Kimura M, Okano Y. Human Misato regulates mitochondrial distribution and morphology. Exp Cell
Res. 2007;313:1393-1404.
4㧕 Yoshimura K, Muto Y, Shimizu M, Matsushima-Nishiwaki R, Okuno M, Takano Y, Tsurumi H, Kojima
S, Okano Y, Moriwaki H. Phosphorylated retinoid X receptor D loses its heterodimeric activity withretinoic acid receptor E. Cancer Sci. 2007;98:1868-1874.
5㧕 Banno Y, Nemoto S, Murakami M, Kimura M, Ueno Y, Ohguchi K, Hara A, Okano Y, Kitade Y,
Onozuka M, Murata T, Nozawa Y. Depolarization㧙induced differentiation of PC12 cells is mediatedby phospholipase D2 through the transcription factor CREB pathway. J Neurochem.
2008;104:1372-1386.
6㧕 Muto Y, Yoshioka T, Kimura M, Matsunami M, Saya H, Okano Y. An evolutionarily conserved
leucine-rich repeat protein CLERC is a centrosomal protein required for spindle pole integrity. Cell
Cycle. 2008;7:2738-2748.
7㧕 Wakahara K, Ohno T, Kimura M, Masuda T, Nozawa S, Dohjima T, Yamamoto T, Nagano A, Kawai G,
Matsuhashi A, Saitoh M, Takigami I, Okano Y, Shimizu K. EWS-Fli1 up-regulates expression of theaurora a and aurora B kinases. Mol Cancer Res. 2008;6:1937-1945.

IF 3.695

IF 3.165

IF 4.451

IF 3.314

IF 4.3174㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ጟ㊁ᐘ㓶㧘⎇ⓥಽᜂ⠪㧦ᱞ⮮ศᓼ㧘ศጟ ቁ㧧ᢥㇱ⑼ቇ⋭ൻቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦࡟࠴ࡁࠗ࠼ X ฃኈ૕ߣ RING ࠲ࡦࡄࠢ⾰ߩ⋧੕૞↪ߣߘߩ࡙ࡆࠠ࠴ࡦൻ࡮ォ౮߳ߩലᨐ㧧ᐔᚑ 16㧙17 ᐕᐲ㧧3,700 ජ౞(1,900㧦1,800 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦᫪⣁ਭ㓉㧘⎇ⓥಽᜂ⠪㧦ጟ㊁ᐘ㓶㧘↰ਛථੑ㧘ዊ᎑⡡৻㧘⷏ญୃᐔ㧘ᷡ᳓㓷ੳ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦ᩭౝฃኈ૕Ⱞ⊕ࠍᮡ⊛ߣߒߚ⢄≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧
ᐔᚑ 17㧙21 ᐕᐲ㧧82,300 ජ౞(16,300㧦16,300㧦16,300㧦16,300㧦17,100 ජ౞)
3㧕⎇ⓥઍ⴫⠪㧦ᧁ᧛ᱜᔒ㧘⎇ⓥಽᜂ⠪㧦ጟ㊁ᐘ㓶㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦ࠝ࡯ࡠ࡜ࠠ࠽࡯࠯ߩ⚦⢩ಽⵚߦ߅ߌࠆ⊒߇ࠎߩ㑐ㅪߩ⸃ᨆ㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ

3㧕౒ห⎇ⓥߥߒ

5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ጟ㊁ ᐘ㓶㧦
1㧕 ᣣᧄ↢ൻቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᐔᚑ 19 ᐕᐲᣣᧄ↢ൻቇળਛㇱᡰㇱ࡮ᡰㇱ㐳(ᐔᚑ 19 ᐕ 9 ᦬㨪20 ᐕ 8 ᦬)
2㧕ቇળ㐿௅
ጟ㊁ᐘ㓶㧦
1㧕 ╙ 72 ࿁ᣣᧄ↢ൻቇળਛㇱᡰㇱ଀ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ࠪࡦࡐࠫ࠙ࡓ‫⚦ޟ‬⢩๟ᦼ೙ᓮߩᦨ೨✢‫ޠ‬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳
ጟ㊁ᐘ㓶㧦
1㧕 ╙ 72 ࿁ᣣᧄ↢ൻቇળਛㇱᡰㇱ଀ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫⚦ޟ‬⢩๟ᦼ೙ᓮߩᦨ೨✢‫ޠ‬ᐳ㐳)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
ߥߒ

㧙㧙

9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 ጟ㊁ᐘ㓶㧘ᱞ⮮ศᓼ㧘ศጟቁ㧦࡟࠴ࡁࠗ࠼ X ฃኈ૕ߣ RING ࠲ࡦࡄࠢ⾰ߩ⋧੕૞↪ߣߘߩ࡙ࡆࠠ࠴
ࡦൻ࡮ォ౮߳ߩലᨐ㧦ᐔᚑ 16 ᐕᐲ㧙17 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2) ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙53(2006 ᐕ 4 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᐔᚑ 20 ᐕ 5 ᦬ߦጘ㒂ߢᣣᧄ↢ൻቇળਛㇱᡰㇱ଀ળ࡮ࠪࡦࡐࠫ࠙ࡓࠍ㐿௅ߢ߈ߚߩߪ㧘⚦⢩๟ᦼ೙ᓮߩ
㗔ၞߢߩ⪺᣿ߥࠪࡦࡐࠫࠬ࠻ߦߏ⻠Ṷ޿ߚߛߌߚߎߣߦട߃ߡ㧘ᢎቶຬ৻ห෸߮ቇౝߦ⇐߹ࠄߕቇᄖߩ
㑐ଥฦ૏ߦ߽ߏදജ޿ߚߛ޿ߚ⾦‛ߣᗵ⻢ߒߡ޿ࠆ‫ޕ‬ᚻ૞ࠅߩዊߐߥቇળߣ޿߁ශ⽎ߢߪ޽ߞߚ߇㧘ጘ㒂ߢߩ㐿௅ߦ᜔߽ࠊࠄߕቇౝᄖ߆ࠄߩදജߦࠃࠅ 50 㗴ࠍ⿧߃ࠆ৻⥸Ṷ㗴߇㓸߹ࠅ㧘ෳട⠪ߦߪᭉߒࠎߢ
޿ߚߛߌߚߎߣߣ⏕ାߒߡ޿ࠆ‫ޕ‬ᢎቶຬ৻ห߇ജࠍวࠊߖߡ⎇ⓥߩផㅴ߿ᢎቶߩ⊒ዷߦദ߼ࠆߎߣߩ㊀ⷐᕈࠍታᗵߢ߈ߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⾗㊄㕙෸߮ੱ⊛⾗Ḯ㕙ߢ⧰ᚢߒߡ޿ࠆ߇㧘ᄢቇ㒮↢ߩ₪ᓧߥߤࠍ⋡ᜰߒߡቇㇱቇ↢ߣߩធ⸅ߩᯏળࠍ
Ⴧ߿ߔദജ߇ᔅⷐߢ޽ࠆ‫ޕ‬ၮ␆࡮␠ળකቇ♽ᢎቶ߳㈩ዻߐࠇࠆೋᦼ૕㛎ታ⠌Τߩᦼ㑆߇ 2008 ᐕᐲ߆ࠄ 6ㅳ㑆ߦჇ߃ࠆߎߣ߿㧘MD. PhD.ࠦ࡯ࠬߩ⹜ߺ߇ᆎ߹ࠈ߁ߣߒߡ߅ࠅ㧘ၮ␆♽ᢎຬ߇ቇ↢₪ᓧߦߐࠄߦദ
ജߔࠆᔅⷐ߇޽ࠆ‫ޕ‬੹ᓟߩዷᦸ
Aurora ߪ⚦⢩๟ᦼߩ೙ᓮߦ㊀ⷐߥࠠ࠽࡯࠯ߢ޽ࠅ㧘ߘߩ⎇ⓥߪ⪺ߒ޿⊒ዷࠍ␜ߒߡ޿ࠆ‫ࡦ࠴ࠠࡆ࡙ޕ‬-ࡊࡠ࠹ࠕ࠰࡯ࡓ♽ߪ㧘⚦⢩๟ᦼߩ೙ᓮߩߺߥࠄߕ⒳‫ߦ⽎⃻‛↢ߩޘ‬㑐ㅪߒߡ޿ࠆ‫ޕ‬RNF8 ߪ DNA ୃᓳ
ߦ㊀ⷐߥ࠲ࡦࡄࠢ⾰ߢ޽ࠆߎߣ߽᣿ࠄ߆ߣߥߞߚ‫⎇ޕ‬ⓥ࠹࡯ࡑߣߒߡߪ⚦⢩Ⴧᱺ߿߇ࠎߩࠠ࡯ࡢ࡯࠼ߦ
❬߇ࠆ⎇ⓥಽ㊁ߢ޽ࠆ‫ޕ‬୘‫ࠆߡ߽߇࡯ࡃࡦࡔߩޘ‬ജࠍචಽߦ⊒ើߒߡ㧘ߘࠇߙࠇߩ⎇ⓥࠍ௖߆ߕߟߢ߽
ㅴ߼ࠆ࿾㆏ߥദജࠍ㊀ߨߡⴕ߈ߚ޿‫ޕ‬㧙㧙㧔3㧕㜞ᐲవㅴᄖ⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
౰േ⣂ࡃࠗࡄࠬⴚߦ߅ߌࠆࠣ࡜ࡈ࠻ㆬᛯߪ㊀ⷐߥ⺖㗴ߢ޽ࠅ㧘㐳ᦼ੍ᓟࠍ᳿ቯߔࠆ‫ޕ‬ౝ⢷േ⣂ߪᣢߦ㐳ᦼ㐿ሽ߇⦟ᅢߢ޽ࠆߎߣ߇⸽᣿ߐࠇߡ޿ࠆ߇㧘ߘߩ૶↪ߦߪᢙߩ೙㒢㧘ᐕ㦂ߦࠃࠆ೙㒢߇޽ࠆ‫৻ޕ‬ᣇ㕒⣂ࠣ࡜ࡈ࠻ߩ㐳ᦼ㐿ሽ₸ߪਇ⦟ߢ޽ࠆ߇㧘ᧂߛߦ᦭↪ߥࠣ࡜ࡈ࠻ߢ޽ࠆ‫ߩߘޕ‬㕒⣂ࠣ࡜ࡈ࠻ߩ㐳ᦼ㐿ሽߩᡷༀߩߚ߼ߦ㧘ౝ⊹Ⴧᱺ㧘ਛ⤑Ⴧᱺࠍᛥ೙ߢ߈ࠇ߫↹ᦼ⊛ߥ⎇ⓥߦߥࠆ‫ޕ‬ᢎቶߢߪേ‛ࡃࠗࡄࠬࡕ࠺࡞ࠍ૞
⵾ߒ㧘᛫≸೷㧘᛫↢‛⾰ߩᛩਈ߇㧘ౝ⤑Ⴧᱺࠍᛥ೙ߔࠆߎߣࠍ⸽᣿ߒߚ‫੹ޕ‬ᓟ⥃ᐥᔕ↪߳ߩ⊒ዷࠍ࿑ࠆ‫ޕ‬߹ߚ౰േ⣂޽ࠆ޿ߪਅ⢇േ⣂ߦ߅ߌࠆⴊ▤ᣂ↢ක≮ߪ੹ᓟ߽㊀ⷐߥ࠹࡯ࡑߢ޽ࠆ‫ޕ‬ᢎቶߢߪᄢ✂ߩ VEGFߦ⌕⋡ߒ㧘ᔃ╭᪪Ⴇࡕ࠺࡞ࠍ૞⵾ߒ㧘G-CSF ోりᛩਈߣᄢ✂࡜࠶ࡇࡦࠣߦࠃࠆⴊ▤ᣂ↢ߩ⋧ਸ਼ലᨐࠍ⸽
᣿ߒߚ‫ޕ‬
ᶖൻེᄖ⑼ߢߪ㧘㓚ኂ⢄ߩᴦ≮߿ⴚᓟ⢄ౣ↢ߦ㑐ߔࠆ⎇ⓥࠍਛᔃߦㅴ߼ߡ޿ࠆ‫ޕ‬㓚ኂ⢄ߩᴦ≮ߪ㧘NASH⢄⎬ᄌߦኻߒ h-HGF ࠍㆮવሶዉ౉ߔࠆߎߣߦࠃࠅ⢄✢⛽ൻߩᛥ೙߇น⢻ߢ޽ࠆߎߣࠍ⏕⹺ߒߚ‫ⴚޕ‬ᓟ⢄ౣ↢ߦ㑐ߔࠆ⎇ⓥߪ㧘⢄⒖ᬀᤨߩ⢄㕒⣂ౣᑪਇ⦟ߢ໧㗴ߣߥࠆ߁ߞⴊߦࠃࠆ⢄ౣ↢ਇ⦟ㇱಽࠍ G-CSF ߢᡷༀߢ߈ࠆߎߣࠍ␜ߒߚ‫ߚ߹ޕ‬㧘ᄢ㊂⢄ಾ㒰೨ߦⴕ߁㐷⣂ႧᩖⴚࠍੑᲑ㓏ߦಽߌߡⴕ߁ߎߣߦࠃࠅ㧘ࠃࠅᄢ߈ߥ⢄ౣ↢߇ᓧࠄࠇࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫⃻ޕ‬࿷ NFǲB 㒖ኂ೷ߦࠃࠆ NASH ⢄ߩ⯯ⴊ⠴ኈ⢻ᡷༀ㧘
LPS ᗵ૞ߦࠃࠆⴚᓟ⢄ਇో੍㒐㧘ᄢᑪਛḡߦࠃࠆᄢ㊂⢄ಾ㒰ᓟ⢄ౣ↢ᡷༀ㧘PGI2 ߦࠃࠆ㐽Ⴇᕈᄢ⣺Ἳߩᴦ≮㧘᛫⩶ࡍࡊ࠴࠼ߦࠃࠆ૕ౝੱᎿ‛ᗵᨴߩᴦ≮ࠍ⎇ⓥਛߢ޽ࠆ‫ޕ‬⢖⪲ಾ㒰ᓟߩ⢖േ⣂ⴊ▤ᐥᷫዋߦࠃࠆฝᔃ⽶⩄ߪߒ߫ߒ߫ㆣㆄߔࠆว૬∝ߢ޽ࠆ‫ޕ‬േ‛ߢߩ⢖⪲ಾ㒰ࡕ࠺࡞ࠍ૞⵾ߒ㧘G-CSF ࠍ↪޿ߚ⢖ಾ㒰ᓟߩ⢖ౣ↢ଦㅴലᨐࠍᬌ⸛ߒߚ⚿ᨐ㧘ฝᔃਇนߩシᷫ㧘ฝቶᔃ╭㊀㊂Ⴧടߩᛥ೙߇ߢ߈㧘⢖േ⣂ᣂ↢ߩ⸽᣿߇ߢ߈ߚ‫੹ޕ‬ᓟ߽Ⴧടߔࠆ COPD ว૬⢖ಾ㒰ߥߤߦኻߒߡߩ
ᴦ≮ᚢ⇛਄㧘㊀ⷐߥ⎇ⓥߢ޽ࠅ㧘੹ᓟߪ⢖⢩ᣂ↢ߦ㑐ߒߡ߽⎇ⓥࠍ⛯ߌࠆ‫ޕ‬એ਄㧘⥃ᐥ਄ߩ⺖㗴ߦኻߒߡၮ␆ታ㛎ࠍⴕ޿ߟߟ㧘ᔃ⤳ⴊ▤ᄖ⑼㧘๭ๆེᄖ⑼㧘ᶖൻེᄖ⑼ߩ㗔ၞߢ⥃ᐥᔕ↪ࠍ⋡ᜰߒߚ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
┻᧛ඳᢥ
ᢎ᝼(૬છ)㧦 ጊ↰ථ਽
ጤ↰ ዏ
⻠Ꮷ㧦
ፉⴼൎ਽
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦 ⊕ᯅᐘᵗ⥃ᐥ⻠Ꮷ㧦 ศ↰⋥ఝ⥃ᐥ⻠Ꮷ㧦 ᳓㊁ศ㓷⥃ᐥ⻠Ꮷ㧦 㑸㊁⠨ผ
⍹↰ᚑฮᵗ
කຬ㧦
ᧁ᧛⌀᮸
කຬ㧦
᧻෹዁⚐
කຬ㧦
ฬ⍮ ␽
කຬ㧦
ട⮮༑ᒾ
කຬ㧦

Hirofumi Takemura
Takuya Yamada
Hisashi Iwata
Katsuya Shimabukuro
Koyo Shirahashi
Naomasa Yoshida
Yoshimasa Mizuno
Takafumi Sekino
Narihiro Ishida
Masaki Kimura
Masasumi Matsutomo
Syo Nachi
Yoshihiko Katou

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ೨ේᱜ᣿㧘ဈ↰㓉ㅧ㧘ፉᧄశ⤿㧘㜞ේༀᴦ㧘┻᧛ඳᢥ㧚⁜ዊᑯベߦኻߔࠆᄢേ⣂ᑯ⟎឵ⴚ੍̆ቯ⸛⺰̆㧦⢷ㇱᄖ⑼ߦ߅޿ߡ૗߇ᮡḰⴚᑼߣߥࠅ߁ࠆ߆㧦ᣣᧄ⢷ㇱᄖ⑼ቇળතᓟᢎ⢒ᆔຬળ✬㧚᧲੩㧦․ቯ㕖༡೑ᴺ
ੱᣣᧄ⢷ㇱᄖ⑼ቇળ㧧2007 ᐕ㧦52㧙70㧚
2㧕 ┻᧛ඳᢥ㧚ᄖ⑼∔ᖚࠍ⷗ㅏߔߥ㧍ߎࠎߥᖚ⠪ߤ߁ߔࠆ㧫́⢷߇∩޿㧍́㧦ች࿾⦟᮸✬㓸ਥᐙ㧘㇭ ⟵᣿㧘਄↰⵨৻㧚᦯ㇱ㓉৻✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦14㧙20㧚
3㧕 ┻᧛ඳᢥ㧚౰ⴊⴕౣᑪⴚ́ⴚ೨࡮ⴚਛ࡮ⴚᓟ▤ℂ́㧦㦖㊁ൎᒾ㧘㊀᧻ ብ㧘᐀ౝ᥍ᦶ㧘྾ᵤ⦟ᐔ㧚቟⮮⑲㓶✬㧚ᔃ⤳ⴊ▤ᄖ⑼࠹ࠠࠬ࠻㧘᧲੩㧦ਛᄖකቇ␠㧧2007 ᐕ㧦236㧙242㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ጤ↰ ዏ㧘┻᧛ඳᢥ㧚⢖≸́ⴚ೨⸻ᢿߦ߅ߌࠆ FDG-PET ߩ᦭↪ᕈ́㧘⥃ᐥ㔀⹹‫ޟ‬ᄖ⑼‫ޠ‬2006 ᐕ㧧68 Ꮞ㧦㧙㧙661㧙666㧚
2㧕 ጤ↰ ዏ㧘⊕ᯅᐘᵗ㧘᧻ᧄ⌀੺㧘᧻੗㓷ผ㧘┻᧛ඳᢥ㧚ᄖ⑼ߩᏱ⼂࡮㕖Ᏹ⼂́ੱߦߪ⡞ߌߥ޿⚛ᧉߥ⇼໧
42́㐿⢷ᚻⴚߪᓟ஥ᣇಾ㐿߇ᮡḰ߆㧘⥃ᐥᄖ⑼ 2007 ᐕ㧧62 Ꮞ㧦822㧙823㧚
3㧕 ᾢ↰ᕺ੺㧘ศ↰㓉ᶈ㧘⼾↰ᴰ㧘ዊୖ⌀ᴦ㧘ጊ↰ථ਽㧘᧛਄໪㓶㧘⑔↰లብ㧚࿾ᣇߦ߅ߌࠆᢇᕆක≮૕೙ߩ⃻⁁ߣ໧㗴ὐ ੹㧘૗߇ᔅⷐᕆോߢ޽ࠆ߆㧘߳߈࿾࡮㔌ፉᢇᕆක≮⎇ⓥળ⹹ 2008 ᐕ㧧9 Ꮞ㧦75㧙78㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ችේ೑ⴕ㧘㘵↰ㄖ⟤㧘᳓⼱ᙗᆭ㧘቟᧛ᐙᄩ㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚3 ᐲߩ㐿⣻ᚻⴚߦࠃࠅᢇ๮ߒߚ഍∝ဳࠕࡔ࡯ࡃᕈᄢ⣺Ἳߩ 1 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦122㧙126㧚
2㧕 ችේ೑ⴕ㧘㘵↰ㄖ⟤㧘᳓⼱ᙗᆭ㧘቟᧛ᐙᄩ㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚⿥㖸ᵄౝⷞ㏜ਅๆᒁ⚦⢩⸻߇᦭ലߢ޽
ߞߚ㕖ᯏ⢻ᕈ⤟ፉ⚦⢩⣲ߩ 1 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦429㧙433㧚
3㧕 ችේ೑ⴕ㧘㘵↰ㄖ⟤㧘ᓟ⮮ోብ㧘᳓⼱ᙗᆭ㧘቟᧛ᐙᄩ㧘᫜ᯅବ੺㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚㥘ᓘࡋ࡞࠾ࠕ߇
㑐ਈߒߚߣ⠨߃ࠄࠇࠆ㊎㊄ߦࠃࠆ࿁⣺⓫ሹߩ 1 ଀㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26 Ꮞ㧦455㧙458㧚
4㧕 ᧻የ ᶈ㧘ጊ↰ථ਽㧘㑸㊁⠨ผ㧘ศ↰⋥ఝ㧘ᧁጊ ⨃㧘ጤ↰ ዏ㧘⊕ᯅᐘᵗ㧘┻᧛ඳᢥ㧚Hand-assisted
laparoscopic surgery(HALS)ਅߦ⣛⤳៰಴ⴚࠍⴕߞߚ⣛Ἳ∝ᕈன⣲≌ߩ 1 ଀㧘ᣣᧄౝⷞ㏜ᄖ⑼ቇળ㔀⹹
2006 ᐕ㧧11 Ꮞ㧦185㧙189㧚
5㧕 ጤਅᜏม㧘቟↰৻ᦶ㧘ਛ੗ ታ㧘ᄢፉ㕏ᐢ㧘⊕ᧁ ੫㧘᫪⣁ਭ㓉㧘᧻የ ᶈ㧘㑸㊁⠨ผ㧘ጊ↰ථ਽㧘ᑝἑༀା㧚ਥ⤟▤⁜⓰ࠍ߈ߚߒߚ⤟ౝಽᴲ⣲≌ߩ 1 ଀㧘⢄⢙⤟ᴦ≮⎇ⓥળ⹹ 2006 ᐕ㧧4 Ꮞ㧦63㧙68㧚
6㧕 ᧁ᧛⌀᮸㧘ጊ↰ථ਽㧘㑸㊁⺈ผ㇢㧘ᧁጊ ⨃㧘ฬ⍮ ␽㧘㑸㊁⠨ผ㧘㒋ᧄ⎇৻㧘┻᧛ඳᢥ㧚ⴚᓟ 4 ᐕ㑆ήౣ⊒↢ሽਛߢ޽ࠆ⍹Ἧൻ⢗≸ߩ 1 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦841㧙844㧚
7㧕 ችේ೑ⴕ㧘ᧁጊ ⨃㧘᧻የ ᶈ㧘㑸㊁⠨ผ㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚ǩ-fetoprotein ↥↢⚿⣺≸ߩ 1 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦149㧙153㧚
8㧕 ᧁ᧛⌀᮸㧘ጊ↰ථ਽㧘ᧁጊ ⨃㧘㑸㊁⠨ผ㧘᧻የ ᶈ㧘┻᧛ඳᢥ㧚⤟ౝ೽⣛ߦว૬ߒߚ㘃਄⊹⣲ߩ 2 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦196㧙200㧚
9㧕 ጊ↰ථ਽㧘㑸㊁⠨ผ㧘᧻የ ᶈ㧘੗ේ 㗉㧘ᧁ᧛⌀᮸㧘ᧁጊ ⨃㧘┻᧛ඳᢥ㧚ೋ࿁ᚻⴚᄢ㊂಴ⴊᓟ㧘ੑᦼ⊛ߦಾ㒰ߒߚ㛽⋚⊒↢ Solitary fibrous tumor ߩ 1 ଀㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26 Ꮞ㧦889
㧙892㧚
10㧕 㑸㊁⠨ผ㧘ጊ↰ථ਽㧘ศ↰⋥ఝ㧘ችේ೑ⴕ㧘ᧁጊ ⨃㧘┻᧛ඳᢥ㧚ᕆᕈ㛽㜑න⃿ᕈ⊕ⴊ∛ᴦ≮ਛߦ⊒↢ߒߚ⢄⤥≌ߦኻߒ㧘⣻⣧㏜ਅ⤥≌㐿⓹ⴚࠍᣉⴕߒߚ 1 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦975㧙978㧚11㧕 ᧁ᧛⌀᮸㧘ጊ↰ථ਽㧘ᧁጊ ⨃㧘㑸㊁⠨ผ㧘┻᧛ඳᢥ㧚ERCP ᓟ⤟Ἳߩᓟߦ⢄Ꮐ⪲ಾ㒰ⴚࠍᣉⴕߒⴚᓟ⤟⤥≌ࠍ⊒↢ߒߚ⢄ౝ⢙▤≸ߩ 1 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦979-982㧚
12㧕 ᣧᎹ㤗ℂሶ㧘᧛ἑ૫ઍሶ㧘ጊ↰ථ਽㧘ጤ↰ ዏ㧘┻᧛ඳᢥ㧚ዊఽ NST ߦ߅ߌࠆᩕ㙃჻ߩᓎഀ́ᩕ㙃㓚ኂᖚఽߦኻߔࠆ๟ⴚᦼᩕ㙃▤ℂ́㧘ዊఽᄖ⑼ 2007 ᐕ㧧39 Ꮞ㧦823㧙827㧚
13㧕 ፉⴼൎ਽㧘ችౝᔘ㓷㧘⑔ᧄⴕ⤿㧘ೋ㖸ବ᮸㧘᧛਄ᩕม㧘⍹↰ᚑฮᵗ㧘⌀㍿⑲᣿㧘┻᧛ඳᢥ㧚ㅧᓇ CT ࠍ↪
޿ߚ஥೽ⴊⴕ〝⊒㆐ߩ⹏ଔ́㐽Ⴇᕈേ⣂⎬ൻ∝(ASO)ߦႮ㉄ࠨ࡞ࡐࠣ࡟࡜࡯࠻ࠍ૶↪ߒߚ∝଀ߢߩᬌ⸛́㧘
Angiology Frontier 2007 ᐕ㧧6 Ꮞ㧦66㧙69㧚
14㧕 ችౝᔘ㓷㧘ፉⴼൎ਽㧘੹ᴰ᧻ਭ㧘⑔ᧄⴕ⤿㧘┻᧛ඳᢥ㧚౰⁁േ⣂ࡃࠗࡄࠬⴚߦ߅ߌࠆㄭ૏஥ㆤᢿ⹜㛎ߦࠃࠆⴚਛࠣ࡜ࡈ࠻⹏ଔ㧘ᣣᧄ౰∔ᖚቇળ㔀⹹ 2007 ᐕ㧧13 Ꮞ㧦195㧙200㧚
15㧕 ᧻ᧄ⌀੺㧘ጤ↰ ዏ㧘⊕ᯅᐘᵗ㧘ᑝἑༀା㧘᳓㊁ศ㓷㧘᧻੗㓷ผ㧘┻᧛ඳᢥ㧚FDG-PET ߢ⇣ߥࠆᚲ⷗ࠍ
␜ߒߚ⢖⎬ൻᕈⴊ▤⣲ߩ 2 ଀㧘ᣣᧄ๭ๆེᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧21 Ꮞ㧦86㧙91㧚
16㧕 ችౝᔘ㓷㧘ፉⴼൎ਽㧘᧛਄ᩕม㧘⑔ᧄⴕ⤿㧘⍹↰ᚑฮᵗ㧘ೋ㖸ବ᮸㧘⌀㍿⑲᣿㧘┻᧛ඳᢥ㧚ቢోᚱቶࡉࡠ
࠶ࠢ㧘ᔃਇోࠍᄾᯏߦ⸻ᢿߐࠇߚᚑੱᄢേ⣂❗⓰∝ߩ 1 ᚻⴚ଀㧘ᣣᧄᔃ⤳ⴊ▤ᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧37
Ꮞ㧦247㧙251㧚
17㧕 ᧛਄ᩕม㧘ፉⴼൎ਽㧘ችౝᔘ㓷㧘┻᧛ඳᢥ㧘᧻ᯅᑧᄈ㧘⼾↰ ᴰ㧘⊕੗㇌ඳ㧘࿯੗ᥓ┨㧘ዊୖ⌀ᴦ㧚ᄖ்ᕈ⢷ㇱᄢേ⣂៊் 9 ଀ߩᬌ⸛㧘ᣣᧄᄖ்ቇળ㔀⹹ 2008 ᐕ㧧22 Ꮞ㧦322㧙325㧚
18㧕 ᧛਄ᩕม㧘ട⮮ਭ᥏㧘┻᧛ඳᢥ㧘ፉⴼൎ਽㧘ችౝᔘ㓷㧘Ṛ⼱ඳᔒ㧘᧻ᯅᑧᄈ㧘⼾↰ ᴰ㧘ዊୖ⌀ᴦ㧚චಽߥೋᦼᴦ≮ߩᓧࠄࠇߥ߆ߞߚ㊰⊛ᔃ៊்ߩ 4 ᢇ๮଀㧘ᣣᧄᄖ்ቇળ㔀⹹ 2008 ᐕ㧧22 Ꮞ㧦326㧙329㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Iwata H, Itokazu M, Shirahashi K, Matsumoto S, Mizuta K, Takemura H. Sterilization using
antibiotic-impregnated porous hydroxyapatite block for osteomyelitis of rib and sternum : A casereport. J Jpn Coll Surg. 2007;32:150-152.
2㧕 Shimabukuro K, Miyauchi T, Takemura H. Rupture of left common iliac artery aneurysm. J Vasc Surg.
2007;45:1083.
IF 3.311
3㧕 Takemura H, Fukumoto Y, Miyauchi T, Shimabukuro K, Imaizumi M, Ishida N. Easy technique formounting the heartstring system into the sheath. Asian Cardiovasc Thorac Ann. 2007;15:444-445.
4㧕 Iwata H, Kiryu T, Shirahashi K, Matsumoto S, Matsui M, Takemura H. Right lower lobectomy afterright upper lobectomy for multiple metastases in lung cancer of the right lower lobe: benefit of middle
lobe preservation. J Thorac Cardiovasc Surg. 2007;134:1078-1080.
IF 3.560
5㧕 Yoshida N, Iwata H, Yamada T , Sekino T, Matsuo H, Shirahashi K, Miyahara T, Kiyama S, Takemura㧙㧙

H. Improvement of the survival rate after rat massive hepatectomy due to the reduction of apoptosis
by caspase inhibitor. J Gastroenterol Hepatol. 2007;22:2015-2021.
6㧕 Mizuno Y, Iwata H, Matsumoto S, Shirahashi K, Maui T, Takemura H. Three pulmonary resections formetastatic lung cancer from hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2007;14:582585.
7㧕 Marui T, Iwata H, Shirahashi K, Matsumoto S, Mizuno Y, Matsui M, Takemura H. Histologic damageof lung allografts according to magnitude of acute rejection in the re-isotransplant model. J Heart
Lung Transplant. 2008;27:642-648.
8㧕 Kato H, Kanematsu M, Kiryu T, Iwata H, Shirahashi K, Matsumoto S, Hirose Y, Matsutomo H,
Sasaoka I. Nonfunctional mediastinal parathyroid cyst: imaging finding in two cases. Clin Imaging.
2008;32:310-313.
9㧕 Kiyama S, Yamada T, Iwata H, Sekino T, Matsuo H, Yoshida N, Miyahara T, Matsuno Y, Kimura M,
Matsumoto K, Nakamura T, Takemura H. Reduction of fibrosis in a rat model of non-alcoholicsteatohepatitis cirrhosis by human HGF gene transfection using electroporation. J Gastroenterol
Hepatol. 2008;23:471-476.

IF 1.785

IF 1.182

IF 2.830

IF 1.7854㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ථ਽㧘⎇ⓥಽᜂ⠪㧦㑸㊁⠨ผ㧘᧻የ ᶈ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ࠗࡦࡇ࡯࠳ࡦࠬ CT ࠍ↪޿ߚ࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵ᬌ಴ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 15㧙18 ᐕᐲ㧧3,800
ජ౞(2,900㧦200㧦300㧦400 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ጤ↰ ዏ㧘⎇ⓥಽᜂ⠪㧦┻᧛ඳᢥ㧘⊕ᯅᐘᵗ㧘᧻ᧄ⌀੺㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦࠼࠽࡯⢖߳ߩ⥄Ꮖ㛽㜑⚦⢩≹วߦࠃࠆ⢖ౣ↢ߦ㑐ߔࠆታ㛎⊛ᬌ⸛㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,600
ජ౞(3,100㧦500 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦⊕ᯅᐘᵗ㧘⎇ⓥಽᜂ⠪㧦┻᧛ඳᢥ㧘ጤ↰ ዏ㧘᧻ᧄ⌀੺㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦
COPD ߦኻߔࠆ intrathoracic balloon pumping ߩ㐿⊒㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,300 ජ౞(2,300㧦1,000ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦੹ᴰ᧻ਭ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࡏ࠷࡝࠿ࠬ࠻ࠠࠪࡦߦࠃࠆേ⣂ࠣ࡜ࡈ࠻ᡨ
❗੍㒐ߣ᜛ᒛലᨐߦ㑐ߔࠆታ㛎⊛ᬌ⸛㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,500 ජ౞(2,900㧦600 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦ችౝᔘ㓷㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦౰േ⣂ࡃࠗࡄࠬᚻⴚߦ߅ߌࠆᔃ╭⺃㔚․ᕈ
ߦࠃࠆㆡᱜࡃࠗࡄࠬᚻⴚߩ᳿ቯߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,300 ජ౞(3,200㧦100 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦┻᧛ඳᢥ㧘⎇ⓥಽᜂ⠪㧦ፉⴼൎ਽㧘ችౝᔘ㓷㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦⮎೷ᓢ᡼ࠥ࡞ࠪ࡯࠻ࠍ↪޿ߚࠕ࠼࡝ࠕࡑࠗࠪࡦߦࠃࠆⴊ▤่วㇱᣂ↢ౝ⤑⢈ෘᛥ೙ߩᬌ⸛㧧ᐔᚑ 20㧙21 ᐕᐲ㧧3,400 ජ౞(3,000㧦400 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ථ਽㧘⎇ⓥಽᜂ⠪㧦ጤ↰ ዏ㧘㑸㊁⠨ผ㧘ᧁ᧛⌀᮸㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ⴚ೨ൻቇ≮ᴺᓟ⢽⢌ᕈ⢄Ἳߦኻߔࠆ᛫ࡅ࠻ TNF ࡕࡁࠢࡠ࠽࡯࡞᛫૕≮ᴺߩ㐿⊒㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,800 ජ౞(3,400㧦300㧦100 ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦᧻ᧄ⌀੺㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦⢖ಾ㒰ⴚ೨ߩᏱ࿶ૐ㉄⚛࠻࡟࡯࠾ࡦࠣߩ᦭
↪ᕈߩᬌ⸽㧧ᐔᚑ 20㧙21 ᐕᐲ㧧3,400 ජ౞(2,900㧦500 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦⍹↰ᚑฮᵗ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ᘟᕈ⯯ⴊᕈᔃ∔ᖚߦ߅ߌࠆౣ↢ක≮ࠍ૬ᣉߒߚᄖ⑼⊛ⴊⴕౣᑪⴚߩታ㛎⊛ᬌ⸛㧧ᐔᚑ 20㧙21 ᐕᐲ㧧3,300 ජ౞(2,500㧦800 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ┻᧛ඳᢥ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒㨪CMC ⸅ⷡ࠮ࡦࠨߣߘߩᔕ↪㨪㧧ᐔᚑ
16㧙20 ᐕᐲ㧧(6,937㧦6,937㧦2,531㧦4,273㧦3,786 ජ౞(৻⥸▤ℂ⾌㒰ߊ))㧦⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅
2㧕 ┻᧛ඳᢥ㧘ጊ↰ථ਽㧘㑸㊁⠨ผ㧘᧻የ ᶈ㧦ࠛ࡞ࡊ࡜࠶࠻ᵈ኿↪ 100mg ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 17㧙
18 ᐕᐲ㧧150,150 ౞㧦ᩣᑼળ␠ࡗࠢ࡞࠻ᧄ␠
3㧕 ┻᧛ඳᢥ㧘੹ᴰ᧻ਭ㧦ࠞ࡯ࡍࡦ࠲࡯ࠛ࠼ࡢ࡯࠭‐ᔃߩ߁⤑↢૕ᑯ ⁜ዊࠢ࡝࠾ࠞ࡞ࠬ࠲࠺ࠖ㧧ᐔᚑ17㧙18 ᐕᐲ㧧163,800 ౞㧦ࠛ࠼ࡢ࡯࠭࡜ࠗࡈࠨࠗࠛࡦࠬᩣᑼળ␠
4㧕 ┻᧛ඳᢥ㧘੹ᴰ᧻ਭ㧦ࠪ࡝ࠦࡦࠦ࡯࠻ੱᎿ⢖ߩ⥃ᐥലᨐߣ⠴ਭᕈ(૶↪ᚑ❣⺞ᩏ)㧧ᐔᚑ 17㧙18 ᐕᐲ㧧
300,300 ౞㧦ᴰᎿක⑼Ꮏᬺᩣᑼળ␠
5㧕 ┻᧛ඳᢥ㧘ፉⴼൎ਽㧦ᮨဳੱᎿ⢖ࡂࠗ࡜ࠗ࠻ 7000 ߩ․ቯ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧675,675
౞㧦ᩣᑼળ␠࠻࡜ࠗ࠹࠶ࠢ
6㧕 ጊ↰ථ਽㧦ࠕࡃࠬ࠴ࡦὐṢ㕒ᵈ↪ 100mg/4mL, ห 400mg/16mL ․ቯ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙20㧙㧙ᐕᐲ㧧225,225 ౞㧦ਛᄖ⵾⮎ᩣᑼળ␠7㧕 ጊ↰ථ਽㧘㑸㊁⠨ผ㧘ศ↰⋥ఝ㧘ᧁ᧛⌀᮸㧘᧖ᧄ℉຦㧦࠯ࡠ࡯࠳®㍤ 300 ․ቯ૶↪ᚑ❣⺞ᩏ‫ޟ‬DukesC⚿⣺≸ߦ߅ߌࠆⴚᓟ⵬ഥൻቇ≮ᴺ‫ޠ‬㧧ᐔᚑ 20㧙21 ᐕᐲ㧧225,225 ౞㧦ਛᄖ⵾⮎ᩣᑼળ␠8㧕 ጊ↰ථ਽㧘ጤ↰ ዏ㧘ፉⴼൎ਽㧘(ઁ 8 ฬ)㧦₂ⴊࡌ࠾ࡠࡦ-I ૶↪ᚑ❣⺞ᩏ(ૐ෶ߪήࠟࡦࡑࠣࡠࡉ࡝
ࡦⴊ∝㧘㊀∝ᗵᨴ∝ߦ߅ߌࠆ᛫↢‛⾰ߣߩ૬↪㧘․⊒ᕈⴊዊ᧼ᷫዋᕈ⚡᢬∛㧘Ꮉፒ∛ߩᕆᕈᦼ)㧧ᐔᚑ 20㧙22 ᐕᐲ㧧300,300 ౞㧦Ꮲੱࡈࠔ࡯ࡑᩣᑼળ␠
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ┻᧛ඳᢥ㧦
1㧕 ᣣᧄᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄⴊ▤ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ౰േ⣂ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ↲⁁⣼ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄᔃ⤳ⴊ▤ᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 2 ᦬㨪⃻࿷)
6㧕 ᣣᧄ⢷ㇱᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)7㧕 ᣣᧄ౰∔ᖚቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 12 ᦬㨪⃻࿷)8㧕 ᣣᧄᓴⅣེቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)9㧕 ᣣᧄᓴⅣེቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)10㧕 㑐⷏⢷ㇱᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)11㧕 ᧲ᶏᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)12㧕 ᣣᧄ Off-pump CABG ⎇ⓥળᐙ੐(㨪⃻࿷)13㧕 ᣣᧄᄖ⑼ቇળጘ㒂⋵ක≮቟ో▤ℂ⽿છ⠪(ᐔᚑ 19 ᐕ 2 ᦬㨪⃻࿷)
14㧕 ᣣᧄᄖ⑼ቇળਛㇱ࿾඙࿾ၞ቟ో▤ℂㆇ༡ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 2 ᦬㨪⃻࿷)ጊ↰ථ਽㧦
1㧕 ᣣᧄᄖ⑼ቇળઍ⼏ຬ(ᐔᚑ 18 ᐕ 2 ᦬㨪ᐔᚑ 20 ᐕ 2 ᦬)
2㧕 ᣣᧄ⢄⢙⤟ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⢗≸ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᧲ᶏᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)ጤ↰ ዏ㧦
1㧕 ᣣᧄ⢷ㇱᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)2㧕 㑐⷏⢷ㇱᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)
3㧕 ᧲ᶏᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⤳ེ⒖ᬀࡀ࠶࠻ࡢ࡯ࠢਛᣣᧄᡰㇱㆇ༡ᆔຬ(㨪⃻࿷)ፉⴼൎ਽㧦1㧕 ᣣᧄⴊ▤ᄖ⑼ቇળ᧲ᶏ࡮ർ㒽࿾ᣇળ਎⹤ੱ(ᐔᚑ 20 ᐕ 3 ᦬㨪⃻࿷)2㧕ቇળ㐿௅┻᧛ඳᢥ㧦
1㧕 ╙ 85 ࿁᧲ᶏᔃ⤳ᄖ⑼ᙣ⹤ળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ߥߒ㧙㧙

7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳┻᧛ඳᢥ㧦
1㧕 52nd Annual Conference IACTS(2006.02, Bangalore, ᜗ᓙ⻠Ṷ‫ޟ‬Total arch replacement utilizing
home-made branched graft for the cerebral aiming for no cerebral circulatory arrest‫ޠ‬Ṷ⠪)
2㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ᗲ⍮㧘․೎࠮࠶࡚ࠪࡦ‫ޟ‬CABG&Mild
MR ߩ Strategy‫ޠ‬ᐳ㐳)
3㧕 ᐔᚑ 18 ᐕᤐቄጘ㒂ᄖ⑼ᙣ⹤ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᒻᚑᄖ⑼ߩ⃻⁁ߦߟ޿ߡ‫ޠ‬ᐳ㐳)
4㧕 ᣣක↢ᶦᢎ⢒දജ⻠ᐳ ࠮ࡒ࠽࡯⣖࡮ᔃⴊ▤∔ᖚ⻠ᐳ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪ
ࡦ‫ޟ‬౰േ⣂∔ᖚᴦ≮ߩࡐࠗࡦ࠻㨪∝଀ࠍਛᔃߦ㨪 3㧚⁜ᔃ∝ߣ CABG‫ޠ‬Ṷ⠪)
5㧕 ╙ 206 ࿁ጘ㒂ᄖ⑼㓸⺣ળጘ㒂⋵කᏧળᄖ⑼කㇱળ․೎⻠Ṷળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄖ⑼ቇߩߎࠇ߆ࠄ‫ޠ‬มળ)6㧕 The 14th Annual Meeting of the Asian Society for Cardiovascular Surgery(ᐔᚑ 18 ᐕ 6 ᦬㧘ᄢ㒋㧘ࡈࠜ࡯࡜ࡓ‫ޟ‬CABG 9‫ޠ‬ᐳ㐳)7㧕 ╙ 10 ࿁ጘ㒂ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘‫ޟ‬ᔃ⤳ᄖ⑼ߦ߅ߌࠆࡠࡏ࠶࠻ᚻⴚߩ⃻ᴫߣ዁᧪‫ޠ‬Ṷ⠪)8㧕 ╙ 85 ࿁᧲ᶏᔃ⤳ᄖ⑼ᙣ⹤ળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⿥ޟ‬ૐଚⷅᔃ⤳ᚻⴚ‫ޠ‬ᐳ㐳)
9㧕 CCT2006 Surgical(ᐔᚑ 18 ᐕ 9 ᦬㧘␹ᚭ㧘࠺ࠖ࠽࡯ࠞࡦࡈࠔ࡟ࡦࠬ‫ޟ‬ᔃ⤳ⴊ▤ᄖ⑼㗔ၞߢૐଚⷅߪ
ߤߎ߹ߢน⢻߆㧫 ࠣ࡜ࡈ࠻ណข‫ޠ‬Ṷ⠪)10㧕 ╙ 4 ࿁የᒛ↢ᵴ⠌ᘠ∛⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᗲ⍮㧘․೎⻠Ṷ‫ޟ‬ᔃ⤳ᄖ⑼ߩ⃻⁁ߣᧂ᧪‫ޠ‬Ṷ⠪)11㧕 ╙ 31 ࿁ CNP ⎇ⓥળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ᗲ⍮㧘ᢎ⢒⻠Ṷ‫ޟ‬ᩕ㙃▤ℂߦᔅⷐߥᔃ⤳ⴊ▤ᄖ⑼ߩ⍮⼂‫ޠ‬Ṷ⠪)12㧕 2 ᄖ࡮ᧄᎽߩળ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᔃ⤳ᚻⴚߩૐଚⷅൻࠍ⋡ᜰߒߡ‫ޠ‬Ṷ⠪)
13㧕 ╙ 35 ࿁ᣣᧄⴊ▤ᄖ⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ฬฎደ㧘ળ㐳ⷐᦸṶ㗴‫⿥ޟ‬㜞㦂⠪(80 ᱦએ਄)ߩᄢേ
⣂≜ߦኻߔࠆᴦ≮ᣇ㊎ߣⴚᓟߩ QOL‫ޠ‬ᐳ㐳)
14㧕 ╙ 4 ࿁⢷ㇱᄖ⑼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄢേ⣂ၮㇱ⟎឵ⴚߩ Up to Date‫ޠ‬ᐳ㐳)15㧕 Fighting Vascular Events in Gifu 2007(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫∛ޟ‬ᘒ߆ࠄߺߚ㐽Ⴇᕈേ⣂⎬ൻ∝ߩᴦ≮㧙ᦨᣂߩࠟࠗ࠼࡜ࠗࡦ TASKΤࠍ߰߹߃ߡ㧙‫ޠ‬ᐳ㐳)16㧕 ╙ 32 ࿁ᣣᧄᄖ⑼♽ㅪวቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫ޟ‬ᒰ⑼ߦ߅ߌ
ࠆ maze ᚻⴚ∝଀ߩᬌ⸛‫ޠ‬Ṷ⠪)17㧕 ╙ 114 ࿁ᣣᧄᓴⅣེቇળർ㒽࿾ᣇળ(ᐔᚑ 19 ᐕ 7 ᦬㧘㊄ᴛ㧘ᢎ⢒⻠Ṷ‫ޟ‬ጘ㒂ߦ߅ߌࠆᔃ⤳ᄖ⑼ߩ⃻⁁ߣ⹜ߺ㧙OPCAB, ௯ᚱᑯᒻᚑ, ᑿㇱ⟎឵㧙‫ޠ‬Ṷ⠪)18㧕 ╙ 2 ࿁ GIFU Surgical Metabolic Club(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄖ⑼ⴚᓟߩᩕ㙃▤ℂ‫ޠ‬มળ)19㧕 ╙ 12 ࿁ᣣᧄ౰േ⣂ᄖ⑼ቇળቇⴚᄢળ(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘ࠗࡦ࠲࡯࠽࡚ࠪ࠽࡞ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬DES
ᤨઍߩℂᗐߩⴚᑼߣߪ㧫‫ޠ‬Ṷ⠪)20㧕 ᐔᚑ 19 ᐕᐲጘ㒂⋵කᏧળഭἴᜰቯකㇱળᤐቄ✚ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘⻠Ṷ‫ޟ‬ᄬᢌߦቇ߱‫ޠ‬ᐳ㐳)21㧕 ╙ 209 ࿁ጘ㒂ᄖ⑼㓸⺣ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬਄ㇱᶖൻེ≸ᴦ≮ߩᦨ೨✢‫ޠ‬มળ)22㧕 ╙ 21 ࿁ᣣᧄ౰∔ᖚቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 12 ᦬㧘੩ㇺ㧘ᄖ⑼ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ‫ޟ‬CABG ߦ߅ߌ
ࠆ⑳ߩᎿᄦ㧙㐿⢷ེ㧘ౝⷞ㏜ RA ណข㧘ฝ㐿⢷࿁ㆱߣ IABP ૶↪ߦࠃࠆ OPCAB ₸ߩჇട㧙‫ޠ‬Ṷ⠪)23㧕 ╙ 22 ࿁ᔃ⤳ⴊ▤ᄖ⑼࠙ࠖࡦ࠲࡯࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 1 ᦬㧘⑔ፉ㧘ࡆ࠺ࠝࡈࠜ࡯࡜ࡓ‫ޟ‬౰േ⣂ࡃࠗࡄࠬⴚߦ߅ߌࠆ㧘ߎ߹ߏ߹ߣߒߚᎿᄦ‫ޠ‬Ṷ⠪)24㧕 ╙ 19 ࿁ਅํකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㜞㦂ൻ␠ળߦ߅ߌࠆᔃ⤳ⴊ▤ᄖ⑼ߩᓎഀ‫ޠ‬Ṷ⠪)25㧕 ╙ 13 ࿁ጘ㒂⢷ㇱ∔ᖚᴦ≮⎇ⓥળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬EGFR-TKI ᴦ≮ߩᦨㆡൻࠍ⋡ᜰߒߡ‫ޠ‬ᐳ㐳)26㧕 Veritas Cor Cirurugie 㨪࠺ࠖࡌ࡯࠻ࠠࡖ࡜ࡃࡦ in Nagoya㨪(ᐔᚑ 20 ᐕ 4 ᦬㧘ฬฎደ㧘࠮࠶࡚ࠪࡦ‫ⴊ⯯ޟ‬ᕈ MR ߦኻߔࠆᔃᜉേਅᑯベᒻᚑⴚ‫ޠ‬Ṷ⠪)27㧕 ╙ 36 ࿁ᣣᧄⴊ▤ᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘᧲੩㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬๟ⴚᦼ▤ℂߦ߅ߌࠆᣂߚߥᔃ╭଻⼔ᚢ⇛㨪⍴ᤨ㑆૞↪ဳǪㆤᢿ⮎ߩ૶޿ᣇߪ࡮࡮࡮㧫‫ޠ‬ᐳ㐳)28㧕 ᧲ᶏਇᢛ⣂ᄖ⑼⻠Ṷળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬ᔃᚱ⚦േᄖ⑼ᴦ≮́MAZE ᚻⴚේὐߩౣ⏕⹺ߣ Device ᚻⴚ‫ޟޠ‬Surgical Management of Atrial Fibrillatiońᄖ⑼⊛ᔃᚱ⚦േߩᴦ≮‫ޠ‬ᐳ㐳)29㧕 ╙ 49 ࿁⑔੗ᓴⅣེหᅢળቇⴚ⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘⑔੗㧘․೎⻠Ṷ‫੹ޟ‬ᣣߩ౰േ⣂ࡃࠗࡄࠬⴚ́

㧙㧙ࠣ࡜ࡈ࠻ㆬᛯ߆ࠄࡠࡏ࠶࠻߹ߢ́‫ޠ‬Ṷ⠪)30㧕 ╙ 51 ࿁㑐⷏⢷ㇱᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ንጊ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬㐿ᔃⴚᓟߩਇᢛ⣂(ᔃᚱ⚦േ)ߦኻߔࠆᴦ≮ᚢ⇛-⎬⤑ᄖ㤗㈮ߣǪㆤᢿ⮎ߩ૶↪́‫ޠ‬ᐳ㐳)31㧕 ╙ 210 ࿁ጘ㒂ᄖ⑼㓸⺣ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬਄ㇱᶖൻ▤ᖡᕈ∔ᖚߦኻߔࠆౝⷞ㏜ਅ
ᚻⴚߩᦨ೨✢‫ޠ‬มળ)32㧕 ╙ 75 ࿁ጘ㒂ᓴⅣེ∔ᖚ⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᔃᚱ⚦േߩᄖ⑼ᴦ≮‫ޠ‬ᐳ㐳)33㧕 ╙ 10 ࿁ᣣᧄ OFF-PUMP CABG ⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘ࠬࡍࠪࡖ࡞ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Techniquein CABG-Indication of OPCAB-‫ޠ‬Ṷ⠪)34㧕 ╙ 61 ࿁ᣣᧄ⢷ㇱᄖ⑼ቇળቯᦼቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘⑔ጟ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬Transit time
ultrasound flow meter ߣ Doppler ᴺߦࠃࠆࠣ࡜ࡈ࠻⹏ଔ‫ޠ‬Ṷ⠪)35㧕 ╙ 6 ࿁ർ㒽ᓴⅣ㓚ኂ⎇ⓥળ(ᐔᚑ 20 ᐕ 11 ᦬㧘㊄ᴛ㧘․೎⻠Ṷ‫ޟ‬ᄢⴊ▤᛹ᶖⴊ▤ᓴⅣਇోߦኻߔࠆᄖ
⑼ᴦ≮‫ޠ‬Ṷ⠪)36㧕 ╙ 211 ࿁ጘ㒂ᄖ⑼㓸⺣ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⋥ޟ‬⣺≸ߦኻߔࠆ⣻⣧㏜ਅᚻⴚߩㅴᱠ‫ޠ‬มળ)37㧕 ATCVS stage5(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘‫ޟ‬Wet lab workshop in CABG, arrhythmia & valve‫ޠ‬Task
Force)
38㧕 ISMICS2008 Winter Workshop(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬What is the optimal CABG
in DES era-Bliateral internal thoracic ateries and endoscopically-harvested radial artery as the
optimal graft selection for CABǴ‫ޠ‬Ṷ⠪)39㧕 ISMICS2008 Winter Workshop(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘Invited Lecture‫ޟ‬The analysis of 125 casesof robotic heart surgery‫ޠ‬ᐳ㐳)40㧕 ISMICS2008 Winter Workshop(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘Morning Seminar ᐳ㐳)41㧕 ╙ 7 ࿁ᔃ⤳ⴊ▤ᄖ⑼ᚻⴚᚻᛛ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ࠗ࡜ࠝ࠺ࡆ࡞ࡖ࠴࡯ࠔࡧޟ‬ࡉ㧦௯Ᏺᑯᚻⴚ́‫ࠆߔ߁ߤࠄߥߚߥ޽ޟ‬㧫‫ޠ‬‫ޠ‬ᐳ㐳)
42㧕 ╙ 9 ࿁⸘᷹⥄േ೙ᓮቇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጘ㒂㧘ၮ⺞⻠Ṷ‫ޟ‬ጘ㒂࡮ᄢ၂࿾඙ࡠࡏ࠹ࠖ࠶ࠢవ┵ක≮ࠢ࡜ࠬ࠲࡯ߦ߅ߌࠆ⎇ⓥ᭎ⷐ‫ޠ‬Ṷ⠪)ጊ↰ථ਽㧦
1㧕 ╙ 106 ࿁ᣣᧄᄖ⑼ቇળ(ᐔᚑ 18 ᐕ 3 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬౰േ⣂ࡃࠗࡄࠬⴚ࡮≸ಾ㒰 1 ᦼ⊛ᚻⴚߩᚑ❣ߣⴚਛ࿁෼ⴊ૶↪ߩᤚ㕖ߦߟ޿ߡ‫ޠ‬Ṷ⠪)
2㧕 International College of Surgeons 17th Joint Congress of Asia & Pacific Federations & 53rd
Annual Congress of the Japan Section(ᐔᚑ 19 ᐕ 6 ᦬㧘੩ㇺ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Our strategy for thepatients of both coronary artery disease and malignant neoplasm, and the feasibility of
intraoperative autotransfusion.‫ޠ‬Ṷ⠪)
3㧕 ╙ 44 ࿁ᣣᧄ⣻ㇱᢇᕆකቇળ✚ળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ᮮᵿ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫ޟ‬⣻ㇱᄢേ⣂≜⎕ⵚߦኻߔࠆ࠴࡯ࡓක≮ᚢ⇛́․ߦ⣺▤⯯ⴊუᱫߦߟ޿ߡ́‫ޠ‬Ṷ⠪)
4㧕 ╙ 108 ࿁ᣣᧄᄖ⑼ቇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘㐳ፒ㧘ࠨ࡯ࠫࠞ࡞ࡈࠜ࡯࡜ࡓ‫ޟ‬⢗(ㆮવሶ⸻ᢿ)‫ޠ‬ᐳ㐳)
5㧕 ᶖൻེ≸ൻቇ≮ᴺࠪࡦࡐࠫ࠙ࡓ́࠴࡯ࡓක≮́(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ᄖ᧪ൻቇ≮ᴺߩታ㓙́੩ㇺᄢቇߢߩขࠅ⚵ߺ́‫ޠ‬ᐳ㐳)
6㧕 ╙ 35 ࿁ CNP ⎇ⓥળ‫⥃ޟ‬ᐥᩕ㙃ᛛ⢻ࠬࠠ࡞ࠕ࠶ࡊ࠮ࡒ࠽࡯‫(ޠ‬ᣣᧄ⥃ᐥᩕ㙃≮ᴺ⎇ⓥળ)(ᐔᚑ 20 ᐕ
12 ᦬㧘ᗲ⍮㧘⻠Ṷ‫ޟ‬ᩕ㙃▤ℂߦᔅⷐߥᶖൻེᄖ⑼ߩ⍮⼂‫ޠ‬Ṷ⠪)ጤ↰ ዏ㧦
1㧕 ╙ 50 ࿁㑐⷏⢷ㇱᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᄢ㒋㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ‫ޟ‬High vision వ┵エᕈ㏜ࠍ↪޿ߚ᜛ᄢ⢷⣼៰㒰ⴚ‫ޠ‬Ṷ⠪)2㧕 7 ᦬ጘ㒂ᄖ⑼ᙣ⺣ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ૐଚⷅࠍ⋡ᜰߒߚ๭ๆེᄖ⑼ᚻⴚ‫ޠ‬Ṷ⠪)
3㧕 ╙ 6 ࿁ጘ㒂⋵⑌ᾍផㅴ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘Lecture‫ⴚޟ‬೨ᓟߦ߅ߌࠆ⑌ᾍߩ⁁ᴫߦߟ޿ߡ‫ޠ‬Ṷ⠪)4㧕 6th Technical Seminar for Thoracic Surgery(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘⻠⟵‫ޟ‬ᒰ⑼ߢᣉⴕߒߡ޿ࠆ⢷⣧㏜ᚻⴚߦ߅޿ߡᵈᗧߒߡ޿ࠆߎߣ ․ߦࠬ࠹࡯ࡊ࡜࡯ߩ૶↪ᤨߦ߅޿ߡ‫ޠ‬Ṷ⠪)5㧕 The 19th International Conference of Society for Medcal Innovation and Technology(ᐔᚑ 19 ᐕ 11᦬㧘ችၔ㧘TUBERO/SMIT Joint Symposium‫ޟ‬Thoracoscopic thymectomy using high vision flexible
thoraco-videoscope‫ޠ‬Ṷ⠪)㧙㧙6㧕 ╙ 33 ࿁ CNP ⎇ⓥળ‫⥃ޟ‬ᐥᩕ㙃ᛛ⢻ࠬࠠ࡞ࠕ࠶ࡊ࠮ࡒ࠽࡯‫(ޠ‬ᣣᧄ⥃ᐥᩕ㙃≮ᴺ⎇ⓥળ)(ᐔᚑ 19 ᐕ
12 ᦬㧘ᗲ⍮㧘⻠Ṷ‫ޟ‬ᩕ㙃▤ℂߦᔅⷐߥ⢷ㇱᄖ⑼⍮⼂‫ޠ‬Ṷ⠪)7㧕 ╙ 51 ࿁㑐⷏⢷ㇱᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ንጊ㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ‫ޟ‬᳇▤ᡰᢿ┵≪ߦኻߔࠆᶖൻེᄖ⑼ߣߩᒝ⺞ᚻⴚ‫ޠ‬Ṷ⠪)8㧕 ╙ 51 ࿁㑐⷏⢷ㇱᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ንጊ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬⢷⣧㏜ਅ⢖⪲ಾ㒰ⴚߩⴊ
▤ಣℂߩᎿᄦ́High vision ᜛ᄢⷞ㊁ߢߩ⚵❱೸㔌ߣ stapler ᠲ૞́‫ޠ‬Ṷ⠪)9㧕 ╙ 16 ࿁๭ๆེᄖ⑼⢷⣧㏜࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 7 ᦬㧘㕒ጟ㧘⻠Ṷ‫ޟ‬ᒰ⑼ߢᣉⴕߒߡ޿ࠆ⢷⣧㏜ਅ⢖⪲ಾ㒰ⴚߢᵈᗧߒߡ޿ࠆߎߣ ․ߦࠬ࠹࡯ࡊ࡜࡯૶↪ᤨߦ߅޿ߡ‫ޠ‬Ṷ⠪)10㧕 Professional Education Seminar Σ‫ޟ‬VATS-Lobectomy‫(ޠ‬ᐔᚑ 20 ᐕ 9 ᦬㧘⑔ፉ㧘⻠Ṷ‫ޟ‬⢷⣧㏜ਅ
⢖⪲ಾ㒰ߦ߅ߌࠆ቟ోߥࠬ࠹࡯ࡊ࡜࡯ᠲ૞‫ޠ‬Ṷ⠪)11㧕 ╙ 17 ࿁๭ๆེᄖ⑼⢷⣧㏜࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 10 ᦬㧘⑔ፉ㧘⻠Ṷ‫ޟ‬⢷⣧㏜ਅ⢖⪲ಾ㒰ⴚࠍ቟ోߦⴕ
߁਄ߢᵈᗧߒߡ޿ࠆߎߣ‫ޠ‬Ṷ⠪)12㧕 ጘ㒂⢖߇ࠎᏒ᳃࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⢖≸㨪ᖚ⠪ߐࠎߦ߿ߐߒ޿ᚻⴚࠍ⋡ᜰߒߡ㨪‫ޠ‬Ṷ⠪)
13㧕 ISMICS2008 Winter Workshop(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Safe stapler procedure forthe pulmonary artery and vein in video-assisted thoracoscopic lobectomy‫ޠ‬Ṷ⠪)
14㧕 ISMICS2008 Winter Workshop(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘ࠗࡉ࠾ࡦࠣ࠮ࡒ࠽࡯
‫ޟ‬Hybid VATS lobectomy& Segmentectomy by the close vision through high vision flexible thoracoscope‫ޠ‬Ṷ⠪)
㑸㊁⠨ผ㧦
1㧕 ╙ 109 ࿁ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ଀ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᣧᦼᄢ⣺≸ߦኻ
ߔࠆౝⷞ㏜⊛ಾ㒰ⴚᓟߩㅊടᄖ⑼ᴦ≮́⣻⣧㏜ਅᚻⴚࠍਛᔃߦ́‫ޠ‬Ṷ⠪)ችౝᔘ㓷㧦
1㧕 Fighting Vascular Events in Gifu 2007(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ਅ⢇㐽Ⴇᕈേ⣂⎬ൻ∝ߦኻߔ
ࠆᒰ⑼ߦ߅ߌࠆᄖ⑼⊛ᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)
2㧕 ╙ 74 ࿁ጘ㒂ᓴⅣེ∔ᖚ⎇ⓥળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬౰േ⣂ࡃࠗࡄࠬⴚߦ߅ߌࠆⴊᵹ㊂߅ࠃ߮ⴊᵹㅦᐲߦࠃࠆⴚਛࠣ࡜ࡈ࠻⹏ଔ‫ޠ‬Ṷ⠪)⊕ᯅᐘᵗ㧦
1㧕 ISMICS2008 Winter Workshop( ᐔ ᚑ 20 ᐕ 11 ᦬ 㧘 ᴒ ✽ 㧘 ࠪ ࡦ ࡐ ࠫ ࠙ ࡓ ‫ ޟ‬Identification ofintersegmental plane with physiological function of oxygen absorption in the lung segmental
resection‫ޠ‬Ṷ⠪)
᧖ᧄ℉຦㧦
1㧕 ጘ㒂ᄢᑪਛḡࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬ᄢᑪਛḡߦࠃࠆ⢄ౣ↢ଦㅴലᨐߩᬌ⸛‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ┻᧛ඳᢥ㧦
1㧕 ጘ㒂⋵කᏧળഭἴᜰቯකㇱળ㘈໧(㨪⃻࿷)2㧕 ጘ㒂⋵り૕㓚ኂ⠪⋧⺣ᚲᦝ↢ක≮್ᢿක(㨪⃻࿷)3㧕 ጘ㒂⋵කᏧળᄖ⑼කㇱળㇱળ㐳(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)4㧕 ጘ㒂⋵␠ળ⑔␩ክ⼏ળᆔຬ(ᐔᚑ 18 ᐕ 11 ᦬㨪⃻࿷)5㧕 ጘ㒂Ꮢ␠ળ⑔␩ክ⼏ળᆔຬ(ᐔᚑ 18 ᐕ 11 ᦬㨪⃻࿷)
6㧕 ⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ ጘ㒂࡮ᄢ၂࿾ၞߦ߅ߌࠆ⍮⊛ࠢ࡜ࠬ࠲࡯ᧄㇱ⎇ⓥ⛔᜝(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ጊ↰ථ਽㧘㑸㊁⠨ผ㧘᧻የ ᶈ㧦ࠗࡦࡇ࡯࠳ࡦࠬ CT ࠍ↪޿ߚ࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵ᬌ಴ᴺߩ⏕┙ߦ㧙㧙㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 15 ᐕᐲ㧙18 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥᚑᨐႎ๔ᦠ(2007 ᐕ 3 ᦬)
2㧕 ጤ↰ ዏ㧘┻᧛ඳᢥ㧘⊕ᯅᐘᵗ㧘᧻ᧄ⌀੺㧦࠼࠽࡯⢖߳ߩ⥄Ꮖ㛽㜑⚦⢩≹วߦࠃࠆ⢖ౣ↢ߦ㑐ߔࠆታ㛎⊛ᬌ⸛㧦ᐔᚑ 18 ᐕᐲ㧙19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥᚑᨐႎ๔ᦠ(2008 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 ┻᧛ඳᢥ㧦‫⚕ޟ‬਄⸻ኤቶ‫ޠ‬᣿ߌᣇߩߎ߻ࠄ㄰ࠅ⮎ߢ߽ᡷༀߖߕ ਅ⢇ߩ⣲ࠇߥߤ࠴ࠚ࠶ࠢࠍ㧦ਛᣣᣂ
⡞(2006 ᐕ 8 ᦬ 25 ᣣ)
2㧕 ጊ↰ථ਽㧦‫ޟ‬ᄢ⣺≸ൻቇ≮ᴺߩ⃻⁁ߣ੹ᓟ‫́ޠ‬ጘ㒂࿾඙ߦ߅ߌࠆᄢ⣺≸ൻቇ≮ᴺߩ᥉෸ߣቯ⌕́㧦
MEDICAMENT NEWS(2007 ᐕ 9 ᦬ 15 ᣣ)
3㧕 ጊ↰ථ਽㧦࿾ၞක≮කቇ࠮ࡦ࠲࡯ ᄖ⑼ᢇᕆ♽ಽ㊁ ᢎ᝼ዞછ᜿ᜦ㧦ጘ㒂⋵∛㒮ᤨႎ╙ 45 ภ(2008ᐕ 3 ᦬ 31 ᣣ)
4㧕 ጊ↰ථ਽㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬⢄⤳߇ࠎᚻⴚ㧘ౣ↢ࠍ⠨ᘦ㧦ጘ㒂ᣂ⡞(2008 ᐕ 7 ᦬ 22 ᣣ)
5㧕 ┻᧛ඳᢥ㧦ᔃᜉߦวࠊߖౝⷞ㏜ㅪേ ᔃ⤳ᱛ߼ߕ቟ోߦᚻⴚ ᣧᄢ࡮ጘ㒂ᄢᡰេࡠࡏ㐿⊒ ᖚ⠪ߩ்ญዊߐߊ㧦ᣣᧄ⚻ᷣᣂ⡞(2008 ᐕ 8 ᦬ 4 ᣣ)
6㧕 ┻᧛ඳᢥ㧦ᔃ⤳ࡃࠗࡄࠬᚻⴚ࡮⢝ఽᴦ≮㨯㨯㨯ක≮ࡠࡏታ↪ൻ߳⌕‫ ޘ‬ክᩏ૕೙ߥߤ࿖߽ᡰេ㧦ᣣ⚻↥ᬺᣂ⡞(2008 ᐕ 8 ᦬ 19 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᄙߊߩᄢቇ㒮↢߇౉ቇߒߡ㧘⎇ⓥ㕙ߢᄢ߈ߥᚑᨐ߇޽ߞߚ‫ޕ‬േ⣂ࡃࠗࡄࠬߦ߅ߌࠆ㕒⣂ࠣ࡜ࡈ࠻ߩౝ
⤑ᛥ೙㧘⢄ᄢ㊂ಾ㒰ᓟߩࠕࡐ࠻࡯ࠪࠬᛥ೙ߦࠃࠆ⢄ౣ↢ଦㅴߣ↢ሽ₸ߩᡷༀ㧘NASH ࡕ࠺࡞ߦ߅ߌࠆ
HGF ߦࠃࠆ⢄✢⛽ൻᛥ೙㧘⢖⒖ᬀߦ߅ߌࠆᕆᕈᦼ఺∉ᛥ೙ߦࠃࠆ㆙㓒ᦼ఺∉ᛥ೙߳ߩലᨐ╬ߩቇ૏⺰ᢥ߇ቢᚑߒߚ‫ⴊߞ߁ߚ߹ޕ‬⢄ಾ㒰ᓟߩ⢄ౣ↢㧘⢖ಾ㒰ᓟߩ⢖ౣ↢ߩ⎇ⓥ߽߹ߣ߹ߞߚ‫⎇ߩࠄࠇߘޕ‬ⓥࠍᡰ߃ࠆᄖㇱ⾗㊄₪ᓧ߽೨ᦼߦᲧߒჇടߒߚ‫ߩࠄࠇߎޕ‬ᚑᨐߪ࿖ౝᄖߩቇળߢ⊒⴫ߐࠇ㧘⹏ଔߐࠇߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ၮ␆⎇ⓥࠍㅴ߼ࠆߦߪ㧘ᄢቇ㒮↢ߩ⏕଻߇㊀ⷐߢ޽ࠆ߇㧘ᣂ⎇ୃක೙ᐲ߇㐿ᆎߒߡ߆ࠄߩᄢቇ㒮౉ቇ߇ᷫዋߒߡ޿ࠆߩߪุ߼ߥ޿‫␠ޕ‬ળੱᄢቇ㒮೙ᐲࠍᵴ↪ߒߥ߇ࠄ㧘ੱຬߩ⏕଻ߦദ߼ࠆ‫⎇ޕ‬ⓥຬ⵬ഥຬߩੱઙ⾌╬ߩ໧㗴߇޽ࠅ㧘⎇ⓥ᧚ᢱࠍᄖᵈߦ࿁ߐߑࠆࠍᓧߕ㧘⎇ⓥ⾌ߩ⤘ᄢൻ߽⺖㗴ߢ޽ࠆ‫ޕ‬ቇౝߩੱ᧚౒ห೑↪߽ᬌ⸛ߒߡ޿߆ߥߌࠇ߫ߥࠄߥ޿‫ޕ‬੹ᓟߩዷᦸേ‛ታ㛎ᣉ⸳ߪలታߒߡ߅ࠅ㧘⎇ⓥߩ߿ࠅ߿ߔ޿ⅣႺߪᢛߞߡ޿ࠆ‫੹ޕ‬ᓟ߽ᔃ⤳ⴊ▤㧘ᶖൻེ㧘๭ๆེߔߴߡߩ⤳ེߩౣ↢ක≮ࠍਥゲߦ⎇ⓥࠍⴕ߁‫ޕ‬translational research ߦゲࠍ߅޿ߡ⥃ᐥᔕ↪߳ߩ㆏ࠍᮨ⚝ߔࠆ‫ޕ‬㧙㧙㧔4㧕ᢛᒻᄖ⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
1㧕エ㛽ࡊࡠ࠹ࠝࠣ࡝ࠞࡦઍ⻢ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩᓎഀߣ⸃᣿
ࡅ࠻ߩエ㛽⚦⢩ߦ߅޿ߡ㧘ࠞ࡞ࡄࠗࡦߦࠃߞߡಾᢿߐࠇߚࡊࡠ࠹ࠝࠣ࡝ࠞࡦಽ⸃↥‛ߩሽ࿷ࠍ⸽᣿ߒ㧘ࠞ࡞ࡄࠗࡦ߇ࡊࡠ࠹ࠝࠣ࡝ࠞࡦઍ⻢ߦ߅޿ߡ㊀ⷐߥᓎഀࠍߪߚߒߡ޿ࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬
2㧕࡝࠙ࡑ࠴Ṗ⤑⚦⢩ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩᓎഀߩ⸃᣿
siRNA ࠍ↪޿ߡࠞ࡞ࡄࠗࡦߩ⊒⃻ࠍᛥ೙ߔࠆߎߣߦࠃࠅ㧘࡝࠙ࡑ࠴Ṗ⤑⚦⢩ߩჇᱺ߅ࠃ߮Ṗ⤑Ἳ߇ᛥ೙ߢ߈ࠆߎߣࠍ⸽᣿ߒߚ‫ޕ‬
3㧕࡙࡯ࠗࡦࠣ⡺⣲ㆮવሶ߇ࠝ࡯ࡠ࡜ࠠ࠽࡯࠯ߩォ౮ߦߪߚߔᓎഀߩ⸃᣿
࡙࡯ࠗࡦࠣ⡺⣲ߦ․⇣⊛ߦ⊒⃻ߔࠆⲢวㆮવሶ EWS/Fli1 ߇㧘⚦⢩᦭♻ಽⵚᦼ⺞▵ࠠ࠽࡯࠯ߢ޽ࠆࠝ
࡯ࡠ࡜ࠠ࠽࡯࠯ߩࡊࡠࡕ࡯࠲࡯ߦ⋥ធ⚿วߒ㧘ߘߩォ౮ࠍଦㅴߔࠆߎߣ߇㧘࡙࡯ࠗࡦࠣ⡺⣲ߩ⊒↢ߦᷓߊ㑐ਈߒߡ޿ࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬
4㧕EWS/Fli1 ߩ⚦⢩ౝࠪࠣ࠽࡞વ㆐࿃ሶࠍ੺ߒߚࠕࡐ࠻࡯ࠪࠬߩ⸃ᨆ
EWS/Fli1 ߇ฦ⒳⚦⢩Ⴧᱺࠪࠣ࠽࡞વ㆐࿃ሶߩ⊒⃻ࠍ⺞▵ߒߡ޿ࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫ࠇߘߦࠄߐޕ‬ࠄߩ࿃ሶࠍᛥ೙ߔࠆߎߣߦࠃࠅ㧘ࠕࡐ࠻࡯ࠪࠬࠍ⺃ዉߒᓧࠆߎߣࠍ⸽᣿ߒߚ‫ޕ‬
5㧕࡙࡯ࠗࡦࠣ⡺⣲ߩಽሶᮡ⊛ᴦ≮ߩ⎇ⓥ࡙࡯ࠗࡦࠣ⡺⣲ㆮવሶ EWS/Fli1㧘⚦⢩Ⴧᱺࠪࠣ࠽࡞વ㆐࿃ሶ㧘ⴊ▤ౝ⊹Ⴧᱺ࿃ሶ㧔VEGF㧕㧘ࠝ࡯ࡠ࡜ࠠ࠽࡯࠯╬ࠍᮡ⊛ߣߒ㧘ߘࠇࠄߦኻߔࠆ siRNA ߿ฦ⒳㒖ኂ೷ࠍ↪޿ߡ㧘዁᧪ߩಽሶᮡ⊛ᴦ≮ࠍ⋡ᜰߒߚ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ޕ‬
6㧕㛽エㇱ⣲≌ߦ߅ߌࠆㆮવሶ⸃ᨆ
Ṗ⤑⡺⣲߿᣿⚦⢩⡺⣲ߦ․⇣⊛ߦ⊒⃻ߔࠆㆮવሶߩᯏ⢻ࠍ㧘․ߦォ౮⺞▵ߩⷰὐ߆ࠄ⸃ᨆߒߡ޿ࠆ‫ޕ‬߹ߚㆮવሶᡷᄌࡑ࠙ࠬߩ᮸┙ࠍ⹜ߺߡ޿ࠆ‫ޕ‬7㧕ᱤ㜑⚦⢩ࠍ↪޿ߚன㑐▵ᴦ≮ߩ⎇ⓥᱤ㜑⚦⢩ࠍன㑐▵ㇱ૏ߦ⒖ᬀߔࠆߎߣߦࠃࠅ㧘ᴦ≹ߩଦㅴࠍ࿑ࠆ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ޕ‬8㧕⣄㜑៊்ߩᴦ≮ߦ㑐ߔࠆ⎇ⓥ⣄㜑៊்ߩࡕ࠺࡞࡜࠶࠻ߦ߅޿ߡࡇࡠࡠࠠࡁ࡝ࡦࠠࡁࡦ㧔PQQ㧕߇៊்ㇱߩ iNOS ߩ⊒⃻ࠍᛥ೙ߒ㧘ᯏ⢻࿁ᓳߦ᦭ലߢ޽ࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬
9㧕ࠦࡦ࠼ࡠࠗ࠴ࡦ⎫㉄ߩ㛽ᩰᒻᚑ㑐ਈߦ㑐ߔࠆ⎇ⓥࠦࡦ࠼ࡠࠗ࠴ࡦ⎫㉄วᚑ㉂⚛ߩᯏ⢻⸃ᨆ‫㉄⎫ࡦ࠴ࠗࡠ࠼ࡦࠦޕ‬วᚑ㉂⚛ㆮવሶᡷᄌࡑ࠙ࠬࠍ↪޿ߚࠦࡦ࠼ࡠࠗ࠴ࡦ⎫㉄ߩ㛽ᩰᒻᚑ߳ߩ㑐ਈߩ⸃᣿‫ޕ‬10㧕 ᬁ㑆᧼⚵❱ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩዪ࿷ߩᬌ⸽
࠙ࠪ෸߮ࡅ࠻ߩᬁ㑆᧼⚵❱ߦ߅޿ߡ㧘ࠞ࡞ࡄࠗࡦߩዪ࿷ߩᬌ⸽ࠍⴕߞߚ‫ޕ‬ᬁ㑆᧼ᄌᕈߣࠞ࡞ࡄࠗࡦߩ
⊒⃻߇㑐ㅪߒߡ޿ࠆߎߣ߇᣿ࠄ߆ߣߥߞߚ‫ޕ‬11㧕 ᬁ㑆᧼⚦⢩ᄖၮ⾰ઍ⻢ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩᓎഀߣ⸃᣿
࠙ࠪ෸߮ࡅ࠻ߩᬁ㑆᧼⚦⢩ࠍ↪޿㧘Ἳ∝࡮ᬁ㑆᧼ᄌᕈߣ޿߁ዪ㕙ߦ߅޿ߡࠞ࡞ࡄࠗࡦ߇ᬁ㑆᧼ၮ⾰ಽ⸃ߦ޿߆ߦ㑐ਈߔࠆ߆ߦߟ޿ߡ⎇ⓥࠍߔߔ߼ߡ޿ࠆ‫ޕ‬12㧕 ࡅ࠻⣶ᬁ⩄㊀⽶⩄ߦ߅ߌࠆᬁ㑆᧼࡮ᬁ㑆㑐▵ߩᒻᘒᄌൻߦ㑐ߔࠆ⎇ⓥ
ࡅ࠻⣶ᬁߩ┙૏⩄㊀⁁ᘒࠍࠪࡒࡘ࡟࡯࠻ߔࠆⵝ⟎ࠍ૶↪ߒ㧘CT ᠟ᓇߦࠃߞߡᓧࠄࠇߚ⣶ᬁ↹௝ࠍ 3ᰴర⸃ᨆߒ㧘ᬁ㑆᧼࡮ᬁ㑆㑐▵ߩ 3 ᰴర⊛ᒻᘒᄌൻࠍ⸃ᨆߒߡ޿ࠆ‫ޕ‬
13㧕 ⣶ᬁⵝౕߩ૕ᐙ૏⟎ⷡ㧘ࠬࡐ࡯࠷ࡄࡈࠜ࡯ࡑࡦࠬߦਈ߃ࠆᓇ㗀ߩᬌ⸛⣶ᬁⵝౕ߇߽ߟ૕ᐙ૏⟎ⷡะ਄ലᨐ߇ࠬࡐ࡯࠷ࡄࡈࠜ࡯ࡑࡦࠬ㧔ࠧ࡞ࡈ㧘࠙ࠜ࡯ࠠࡦࠣ╬㧕ߦ޿߆ߥࠆᓇ㗀ࠍਈ߃ࠆ߆ࠍ 3 ᰴరേ૞⸃ᨆߦߡᬌ⸽ߒߡ޿ࠆ‫ޕ‬
14㧕 ⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜߩ 3 ᰴర⸃ᨆ⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆࡉ࡯ࡔ࡜ࡦဳࠬࡍ࡯ࠨ࡯ࠍ↪޿ߚᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜ߇ᬁ㑆᧼ⷺ㧘ᬁ㑆㑐▵ᒻᘒߦਈ߃ࠆലᨐࠍ 3 ᰴర↹௝⸃ᨆߦࠃࠅᬌ⸽ߒߡ޿ࠆ‫ޕ‬
15㧕 ࡅ࠻㗪ᬁߩዮᦛિዷേᘒߦ߅ߌࠆ⎬⤑▤࡮㗪ㇱ⣄㜑ߩ 3 ᰴర⊛േᘒ⸃ᨆ⣄㜑ㅧᓇᬌᩏᓟߩࡈࠔࡦ࡚ࠢࠪ࠽࡞ CT ࠍ↪޿㧘ࡅ࠻㗪ᬁߩዮᦛિዷേᘒߦ߅ߌࠆ⎬⤑▤࡮㗪ㇱ⣄㜑
ߩ 3 ᰴర⊛േᘒ⸃ᨆࠍฦ⒳∛ᘒߣߩ㑐ㅪߦߡᬌ⸽ߒߡ޿ࠆ‫ޕ‬
16㧕 ⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜߩ 3 ᰴర⸃ᨆ⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆࡉ࡯ࡔ࡜ࡦဳࠬࡍ࡯ࠨ࡯ࠍ↪޿ߚᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜ߇ᬁ㑆᧼ⷺ㧘ᬁ㑆㑐▵ᒻᘒߦਈ߃ࠆലᨐࠍ 3 ᰴర↹௝⸃ᨆߦࠃࠅᬌ⸽ߒߡ޿ࠆ‫ޕ‬17㧕 㗪ᬁ㒰࿶ᚻⴚ㧔೨ᣇ㒰࿶㧘ᓟᣇ㒰࿶㧕߇⎬⤑▤࡮㗪ㇱ⣄㜑ߦਈ߃ࠆᒻᘒᄌൻߩᬌ⸛

㧙㧙㗪ᬁ೨ᣇ㒰࿶ⴚ㧘㗖ᬁᓟᣇ㒰࿶ⴚߩ 2 ⴚᑼ߇⎬⤑▤࡮㗪ㇱ⣄㜑ߦਈ߃ࠆᒻᘒᄌൻߩ⋧㆑ߦߟ޿ߡ
ultrasonography ࠍ↪޿ߡ㧘⥃ᐥᚑ❣ߣ㑐ㅪߐߖߡᬌ⸛ߒߡ޿ࠆ‫ޕ‬18㧕 MRI ߣ⣄㜑ㅧᓇᓟ CT ߩ⎬⤑▤࡮⣄㜑࡮㚍የ␹⚻ᒻᘒ⹏ଔߩ⋧㆑ߦ㑐ߔࠆ⎇ⓥ⣄ᬁ⣄㜑∔ᖚߦኻߔࠆ↹௝⸻ᢿߦ߅ߌࠆ 2 ߟߩઍ⴫⊛ᚻᴺߢ޽ࠆ MRI ߣ⣄㜑ㅧᓇᓟ CT ߦߟ޿ߡ㧘⎬⤑▤࡮⣄㜑࡮㚍የ␹⚻ᒻᘒ⹏ଔߩ⾰⊛࡮㊂⊛⋧㆑ࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬
19㧕 ࡅ࠻⣄㜑ᶧߦ߅ߌࠆㆶరဳ࡮㉄ൻဳࠕ࡞ࡉࡒࡦߩേᘒߩ⎇ⓥ
ࡅ࠻⣖⣄㜑ᶧߦ߅ߌࠆㆶరဳ࡮㉄ൻဳࠕ࡞ࡉࡒࡦߩሽ࿷Ყ₸ߦߟ޿ߡ㧘ᐕ㦂㧘∔ᖚ╬ߩ࿃ሶࠍ฽߼ߡ
ᬌ⸽ࠍⴕߞߡ޿ࠆ‫ޕ‬2㧚ฬ★
ᢎ᝼㧦ᢎ᝼(૬છ)㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

ᷡ᳓సᤨ
⷏ᧄ ⵨
ᄢ㊁⾆ᢅ
⚦ᳯ⧷ᄦ
ᄢ㊁⟵ᐘ
દ⮮⧐Პ
㕍ᧁ㓉᣿
ᄢፉᐽม
↰ਛஜ৻㇢
᫪ ᢕᐘ
ᷡ᳓ቁᔒ
ኹᨋિᄦ
ጊญ⦟ᄢ
┻ౝஜᄥ㇢
ጊጯብᳯ

Katsuji Shimizu
Yutaka Nishimoto
Takatoshi Ohno
Hideo Hosoe
Yoshiyuki Ohno
Yoshiki Itoh
Takaaki Aoki
Koji Oshima
Kenichiro Tanaka
Nobuyuki Mori
Takashi Shimizu
Nobuo Terabayashi
Yoshihiro Yamaguchi
Kentaro Takeuchi
Hiroe Yamagishi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⚦ᳯ⧷ᄦ㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮㧦ᷡ᳓సᤨ✬㧚ߎࠇߛߌߪ⍮ߞߡ߅߈ߚ޿ ⿷⣶ߩ∩ߺߩ⥄Ꮖ▤ℂ㧘ᄢ㒋㧦ක⮎ࠫࡖ㧙࠽࡞㧧2006 ᐕ㧦22㧙37㧚
2㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚⣄ᩇ஥ᒗ∝㧦⩵࿾⤿৻ࠄ✬㧚ᢛᒻᄖ⑼ኾ㐷කࠍ߼ߑߔߚ߼ߩ ⚻㛎ߔߴ߈ᄖ்࡮∔ᖚ 97㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦127㧙133㧚
3㧕 ⚦ᳯ⧷ᄦ㧚⣶ᬁߩ࿕ቯⴚ(PLF‫ޔ‬PLIF)㧦቞ደ⑲❥ࠄ✬㧚ᢛᒻᄖ⑼⸻≮ታ〣ࠟࠗ࠼㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦
225㧙226㧚
4㧕 ᨋ ౖ㓶㧚㕍ᧁ㓉᣿⋙ୃ㧚ᯏ⢻⸃೬ቇ⊛⸅⸻ᛛⴚ ਄ਅ⢇㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2006 ᐕ㧚
5㧕 ⷏ᧄ ⵨㧘ᄢ㊁⾆ᢅ㧚2 ┨‫ޟ‬㛽⣲≌ฦ⺰‫ ޠ‬㘃㛽㛽⣲ 㛽⧘⚦⢩⣲㧦ศᎹ⑲᮸✬㧚ᦨᣂᢛᒻᄖ⑼ቇ૕♽╙ 20Ꮞ‫ޟ‬㛽࡮エㇱ⣲≌߅ࠃ߮㑐ㅪ∔ᖚ‫ޠ‬㧘᧲੩㧦ਛጊᦠᐫ㧧2007 ᐕ㧦201㧙205㧚
6㧕 ⷏ᧄ ⵨㧘ᄢ㊁⾆ᢅ㧚2 ┨‫ޟ‬㛽⣲≌ฦ⺰‫ ޠ‬㕖㛽ൻᕈ✢⛽⣲(✢⛽ᕈ㛽⊹⾰ᰳ៊)㧦ศᎹ⑲᮸✬㧚ᦨᣂᢛᒻᄖ⑼ቇ૕♽╙ 20 Ꮞ‫ޟ‬㛽࡮エㇱ⣲≌߅ࠃ߮㑐ㅪ∔ᖚ‫ޠ‬㧘᧲੩㧦ਛጊᦠᐫ㧧2007 ᐕ㧦233㧙236㧚
7㧕 ⚦ᳯ⧷ᄦ㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮㧦ᷡ᳓సᤨ✬㧚ࡐࠤ࠶࠻  ߎࠇߛߌߪ⍮ߞߡ߅߈ߚ޿ ⿷⣶ߩ∩ߺߩ⥄Ꮖ▤ℂ㧘ᄢ㒋㧦ක⮎ࠫࡖ㧙࠽࡞㧧2007 ᐕ㧦38㧙66㧚
8㧕 ⚦ᳯ⧷ᄦ㧚⢷ᬁᄖ் ਄૏⢷ᬁ೨ᣇ⋥㆐ᚻⴚ㧦㚍႐ਭᢅ✬㧚0S NOW INSTRUCTION No.4, ᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2007 ᐕ㧦103㧙106㧚
9㧕 ᷡ᳓సᤨ㧚⣶ᬁᄌᕈߔߴࠅ∝㧙⑳ߩࠗࡦࡈࠜ㧙ࡓ࠼ࠦࡦ࠮ࡦ࠻㧦࠻࡜ࡉ࡞ߦߥࠄߥ޿ᢛᒻᄖ⑼ࠗࡦࡈࠜ㧙ࡓ࠼ࠦࡦ࠮ࡦ࠻㧘᧲੩㧦㊄ේ಴ 㧧2007 ᐕ㧦212㧙213㧚
10㧕 ਛ᧛ᱜ↢㧘ᷡ᳓సᤨ㧚⣶ㇱ⣄ᬁ⣄ᩇ▤⁜⓰∝㧙⸻ᢿߣᴦ≮㧙㧦⠧ᐕකቇ update2007㧙08㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2007 ᐕ㧦14㧙24㧚
11㧕 ⚦ᳯ⧷ᄦ㧚ォ⒖ᕈ⣄ᬁ⣲≌㧦ᷡ᳓సᤨ✬㧚⣶∩ ⍮ࠆ⸻ࠆᴦߔ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦105
㧙115㧚
12㧕 㕍ᧁ㓉᣿㧚⣶∩ߩㆇേ≮ᴺ㧦ᷡ᳓సᤨ✬㧚⣶∩ ⍮ࠆ⸻ࠆᴦߔ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦130
㧙155㧚
⪺ᦠ㧔᰷ᢥ㧕
1㧕 Shimizu K, Miyamoto K. Inflammatory Diseases of the Spine: Juvenile Rheumatoid Arthritis. In:
Surgery of the Pediatric Spine. New York: Thieme;2007:375-380.
✚⺑㧔๺ᢥ㧕
1㧕 ᷡ᳓సᤨ㧚․㓸 ᚻߩ∩ߺߩ⸻ᢿߣᴦ≮ ᐨ㧘∩ߺߣ⥃ᐥ 2006 ᐕ㧧6 Ꮞ㧦1㧚㧙㧙

2㧕 ㊄᫪ᐽᄦ㧘ᷡ᳓సᤨ㧚⣶∩ ᕆᕈ⣶∩ߣᘟᕈ⣶∩㧘⥃ᐥߣ⎇ⓥ 2006 ᐕ㧧83 Ꮞ㧦12㧙15㧚
3㧕 ᷡ᳓సᤨ㧚ࠪࡦࡐࠫ࠙ࡓ ⣶ㇱ⣄ᩇ▤⁜⓰∝㧙ᦨㄭߩㅴᱠ㧙 ✜⸒㧘⥃ᐥᢛᒻᄖ⑼ 2006 ᐕ㧧41 Ꮞ㧦852㧚
4㧕 ᷡ᳓సᤨ㧚ᣣᧄ⣄ᬁ⣄㜑∛ቇળߣർ☨⣄ᬁ㑐ㅪቇળߣߩ੤ᵹ 㧙Spine Across the Sea ႎ๔㧙㧘⣄ᬁ⣄㜑ࠫࡖ࡯࠽࡞ 2006 ᐕ㧧19 Ꮞ㧦1174㧙1175㧚
5㧕 ᷡ᳓సᤨ㧚ጘ㒂⟤Ớ⥄ォゞ↢ᵴ㧘ᢛᒻᄖ⑼ 2006 ᐕ㧧57 Ꮞ㧦1798㧚
6㧕 ᷡ᳓సᤨ㧚৻⥸ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⣶∩ߩ⸻ᢿᴦ≮㧘ጘ㒂ᏒකᏧળߛࠃࠅ 2007 ᐕ㧧39 Ꮞ㧦25㧙27㧚
7㧕 ⑔↰┨ੑ㧘ᷡ᳓సᤨ㧚⣄ᬁ㛽㜑Ἳߩ⸻ᢿߣᴦ≮㧘㛽࡮㑐▵࡮㕤Ꮺ 2007 ᐕ㧧20 Ꮞ㧦455㧙461㧚
8㧕 ᷡ᳓సᤨ㧚⣄ᬁౝⷞ㏜ਅᚻⴚ‫ޠ‬㧙ၮᧄᚻᛛ߆ࠄᛛⴚ⹺ቯ߹ߢ㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦1656㧚
9㧕 ᷡ᳓సᤨ㧚⣶ߩ∩ߺ(⣶ㇱ⣄ᩇ▤⁜⓰∝)ࠍ㒐ߋ㧘ࠢ࠶ࠢ㧒࡜ࠗࡈ 2007 ᐕ㧧433 Ꮞ㧦8㧙9㧚
10㧕 ㉿⷗๺ᒾ㧘⍹ฬ↰ᵗ৻㧘ᦸ᦬৻↵㧘દ⮮⧐Პ㧘Ꮉ਄♿᣿㧚ICD ᡷቯߣᢛᒻᄖ⑼ක≮㧘⥃ᐥᢛᒻᄖ⑼ 2008ᐕ㧧43 Ꮞ㧦581㧙589㧚
11㧕 ೨ේ⑲੫㧘ᷡ᳓సᤨ㧚ࠞ࡞ࡄࠗࡦߣᄌᕈᕈ㑐▵∝㧘೎ౠᢛᒻᄖ⑼‫ޛ‬ᄌᕈᕈ㑐▵∝㧙ᦨㄭߩ⍮⼂‫ ޜ‬2008 ᐕ㧧
53 Ꮞ㧦38㧙41㧚
12㧕 ᧻ᧄ቞㓶㧘ජ⪲৻⵨㧘ᚭጊ⧐ᤘ㧘┻ਅసᔒ㧘ᤊ࿾੝ㇺม㧘ਛ᧛⠹ਃ㧘᦭᳓ ᷕ㧘⮮ᨋବ੺㧘ᐔᨋ ⨃㧘ᐔ㊁ ᔀ㧘ጤፒᐙቄ㧘㊄ጟᕡᴦ㧘Ꮉญༀᴦ㧘੗ዥᐘᚑ㧘೨↰ ᑪ㧘᧻ጊᐘᒄ㧘ਃ਄㕏ᄦ㧘᧛਄⧷᮸㧘᳗ፉ⧷᮸㧘᳗↰⷗↢㧘ਛේㅴਯ੺㧘㊁ේ ⵨㧘ጟ ผᦶ㧘㒋ᧄ᩵ㅧ㧘₎ᯅᐽ㓶㧘╣↢ ⼾㧘ᷡ᳓సᤨ㧘↰ญᢅᒾ㧘㜞ᯅ ⺈㧘↰ਛ㕏ਭ㧘⼱ ବ৻㧘ᓼᯅᵏ᣿㧘ౝ↰⎇ㅧ㧘ጊᧄ⻞๋㧘ጊፒᱜᔒ㧘ᮮጊ ᔀ㧘ศ↰ቬੱ㧘⷏⣁␭ม㧚⢷ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆᚻⴚᚑ❣ߦᓇ㗀ࠍਈ߃ࠆ࿃ሶߩᬌ⸛㧙ઁᣉ⸳ᓟࠈะ߈⎇ⓥ㧙 ⹹਄ࠪࡦࡐࠫ࠙ࡓ ⢷ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߩᴦ≮㧙ᦨㄭߩㅴᱠ㧘⥃ᐥᢛᒻᄖ⑼ 2008 ᐕ㧧43 Ꮞ㧦531㧙538㧚
13㧕 ᷡ᳓సᤨ㧚㗖ᬁ∝㧘OPLL ߩᚻⴚᴦ≮㧘᧲ᶏ࡮ਛㇱធ㛽ቇળ⹹ 2008 ᐕ㧧89 ภ㧦19㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧚㗖ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆᣂߒ޿ゲᬁㇱᓟᣇ㒰࿶ᴺ㧘⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛ 2006 ᐕ㧧8 Ꮞ㧦79㧙82㧚
2㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘ዊේ᣿㧚⣶ᬁᄌᕈߔߴࠅ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ(cantilever㧙TLIF)ߩ⚻㛎㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧49 Ꮞ㧦31㧙32㧚
3㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⷏ᧄඳᢥ㧚㛽☻㝃∝ᕈ㛽᛬ߦኻߔࠆ⣄ᬁ⍴❗ⴚߩⴚᓟ⚻ㆊ㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧49 Ꮞ㧦967㧙968㧚
4㧕 ⚦ᳯ⧷ᄦ㧚․㓸㧦Ყセߢಽ߆ࠆ⣶ᬁ 2 ᄢ∔ᖚ㧙⣶ㇱ⣄ᩇ▤⁜⓰∝ߣ⣶ᬁᬁ㑆᧼ࡋ࡞࠾ࠕ ᚻⴚ≮ᴺ㧙㧘ᢛᒻᄖ⑼⋴⼔ 2006 ᐕ㧧11 Ꮞ㧦24㧙26㧚
5㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⷏ᧄඳᢥ㧚㗖ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆⴚᑼㆬᛯ㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળ㔀⹹ 2006 ᐕ㧧17 Ꮞ㧦525㧚
6㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘ችᧄ ᢘ㧘ዊේ ᣿㧚⣶ᬁᄌᕈߔߴࠅ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ(cantilever㧙TLIF)㧙PLIF ߣߩᲧセ㧙㧘ᣣᧄᢛᒻᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧80 Ꮞ㧦S285㧚
7㧕 ↰ਛ㗔㧘ᄢ㊁⾆ᢅ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘ᑝἑༀା㧘᧻᳗⎇๋㧚ᧃ▵㛽㛽⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2006 ᐕ㧧18 Ꮞ㧦43㧙44㧚
8㧕 ㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘᧖ጊ⺈৻㧘⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚਄૏⣶ᬁᬁ㑆᧼ࡋ࡞࠾ࠕᓟᣇ៰಴ⴚᓟߦ೨ᣇ࿕ቯ
ࠍⷐߒߚ 1 ଀㧘᧲ᶏ⣄ᬁᄖ⑼ 2006 ᐕ㧧20 Ꮞ㧦5㧙9㧚
9㧕 ㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘᧖ጊ⺈৻㧘⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚⣶ᬁᄌᕈ஥ᒗߦ೨ᣇ࿕ቯࠍⴕߞߚ 2 ∝଀㧘᧲ᶏ⣄
ᬁᄖ⑼ 2006 ᐕ㧧20 Ꮞ㧦102㧙108㧚
10㧕 ᷡ᳓సᤨ㧘⚦ᳯ⧷ᄦ㧘᧖ጊ⺈৻㧘⧯ᨋ ⧷㧘㊁‫⻀᧛ޘ‬㚅㧚Informed Consent ߩታ㓙㧘ᣣᧄᢛᒻᄖ⑼ቇળ
㔀⹹ 2006 ᐕ㧧80 Ꮞ㧦33㧙34㧚
11㧕 Ⴧ↰೰ብ㧘ᷡ᳓సᤨ㧚ᗵᨴᕈ⣄ᬁἻߦኻߔࠆ⣄ᬁࠗࡦࠬ࠷࡞ࡔࡦ࠹㧙࡚ࠪࡦᚻⴚ㧘Orthopaedics 2006ᐕ㧧19 Ꮞ㧦25㧙32㧚
12㧕 ㊁Ỉ ⡡㧘ᷡ᳓సᤨ㧚ࠬࡐ㧙࠷ㆬᚻߦ߅ߌࠆ⣶ᬁಽ㔌∝ߦኻߔࠆᚻⴚ≮ᴺ㧙segmental wire fixation ᴺ㧙㧘
Orthopaedics 2006 ᐕ㧧19 Ꮞ㧦15㧙21㧚
13㧕 ફ⷗৻ᚑ㧘ᷡ᳓సᤨ㧚ᄌᒻᕈ㑐▵∝エ㛽ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩ⊒⃻㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19
Ꮞ㧦81㧙84㧚
14㧕 ᧻ᧄ ๺㧘દ⮮⧐Პ㧘♻ᢙਁᱜ㧘ᱞౝ┨ੑ㧘ᷡ᳓సᤨ㧚㒸ᣥᕈ೸㔌㛽 ߦࠃࠅ↢ߓߚ⤒⬄㛽੝⣕⥓ߩ 1 ଀㧘ᢛᒻᄖ⑼ 2006 ᐕ㧧57 Ꮞ㧦1623㧙1625㧚
15㧕 ᧻ᧄ ๺㧘દ⮮⧐Პ㧘⑔↰ 㓷㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧚Smith㧙Petersen ㅴ౉ᴺ߇᦭↪ߢ޽ߞߚੱᎿ⢆㑐▵ౣ⟎឵ⴚߩ 2 ଀㧘Hip Joint ೎೚ 2006 ᐕ㧧32 Ꮞ㧦411㧙414㧚
16㧕 Ἇ਄દ❱㧘᧻ᧄ ๺㧚ᄢ⣽㛽ォሶㇱ㛽᛬ߦኻߔࠆ PFNA(proximal femoral nail antirotation)ߩ૶↪⚻㛎㧘
Hip Joint ೎೚ 2006 ᐕ㧧32 Ꮞ㧦234㧙236㧚
17㧕 㕍ᧁ㓉᣿㧘ኹፉብ᣿㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧘ਤ⠀᡽⟤㧘ዊ㊁Ⴆኪ㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ᖚ⠪ߩ⚻ญ PGE1 ⺃ዉ૕⵾೷ᛩਈߦ߅ߌࠆ࠻࡟࠶࠼ࡒ࡞⹏ଔ㧘ᣂ⮎ߣ⥃ᐥ 2006 ᐕ㧧55 Ꮞ㧦74㧙76㧚
18㧕 ᄢ㊁⟵ᐘ㧘ᐔᎹ᣿ᒄ㧘ᷡ᳓సᤨ㧚ᚻ㑐▵⚿ᩭߩᚻⴚᴦ≮ߩ⚻㛎㧘ᣣᧄ㛽࡮㑐▵ᗵᨴ∝ቇળ㔀⹹ 2006 ᐕ㧧
20 Ꮞ㧦29㧙31㧚
19㧕 ᄢ㊁⟵ᐘ㧘ᐔᎹ᣿ᒄ㧘ᷡ᳓సᤨ㧚ᧃ▵㛽߇㔺಴ߒߚᜰውㇱ⊹⤏ᰳ៊ߦኻߔࠆㆆ㔌⊹ᑯ⒖ᬀߩ⚻㛎㧘ᣣᧄᚻ
ߩᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧23 Ꮞ㧦209㧙212㧚㧙㧙

20㧕 ᄢፉᐽม㧘ਃቛᥓ㧘ᷡ᳓సᤨ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧚㛽ේ⊒ⴊ▤⡺⣲ߩ৻೬ᬌ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ
⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦463㧙464㧚
21㧕 ⑔↰┨ੑ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘ᷡ᳓సᤨ㧚⿷⢛ߦ⊒↢ߒߚ⍹Ἧൻࠍ઻ߞߚᏂᄢߥⴊ▤ᐔṖ╭⣲ߩ৻଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦515㧙516㧚
22㧕 ᳗㊁ᤘੳ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘ጊ↰৻ᚑ㧘ᷡ᳓సᤨ㧚㛽ᄖᕈ㛽⡺⣲ߩ 1 ೬ᬌ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ
⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦525㧙526㧚
23㧕 ᄢ㊁⾆ᢅ㧘ᄢፉᐽม㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧚ੱᎿ㛽ࠍ↪޿ߚ⦟ᕈ㛽⣲≌ߩⴚᓟᚑ❣㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂ
ᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦627㧙628㧚
24㧕 ᮮ↰ᴦ㧘ᄢ㊁⾆ᢅ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘ᑝἑༀା㧘᧻᳗⎇๋㧚ᄢ⣽エㇱ⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2007 ᐕ㧧19 Ꮞ㧦1㧙2㧚
25㧕 ᄢፉᐽม㧘ᢧ⮮ḩ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘㜞⷗⑲৻㇢㧘᧻᳗⎇๋㧘ᑝἑༀା㧚ᏀᲚㇱ⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2007 ᐕ㧧19 Ꮞ㧦37㧙38㧚
26㧕 Ꮉ㦮᥍ਭ㧘ᩕᨑ⵨ᢥ㧘ጤ᧛⌀੐㧘◉ፒ᣽ੱ㧘ᧁ᧛ብ᮸㧘⷏ᧄ⵨㧘દ⮮⡡㧚ࡃ㧙࠴ࡖ࡞࡝ࠕ࡝࠹ࠖࠍᔕ↪ߒߚᚻᜰ࡝ࡂࡆ࡝࠹㧙࡚ࠪࡦᡰេࠪࠬ࠹ࡓߩ⎇ⓥ㧘VR කቇ 2007 ᐕ㧧5 Ꮞ㧦32㧙39㧚
27㧕 ᄢ㊁⟵ᐘ㧘ᐔᎹ᣿ᒄ㧘ᷡ᳓సᤨ㧚ᛥ೙Ꮺߦࠃࠅ⊒↢ߒߚᚻߦ㒢ዪߒߚ㒖ⴊᕈ᜔❗ߩ 1 ଀㧘ਛㇱᣣᧄᢛᒻᄖ
⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦861㧙862㧚
28㧕 ᫪⟵ᒄ㧘ᄢ㊁⟵ᐘ㧘㕍ᧁ㓉᣿㧚ᚻᜰિ╭⣷⒖ⴕⴚᓟߦ߅ߌࠆᣧᦼㆇേ≮ᴺߩ⚻㛎㧘ጘ㒂૞ᬺ≮ᴺ 2007 ᐕ㧧
10 Ꮞ㧦36㧙37㧚
29㧕 ౝደ⚐㧘ᄢ㊁⟵ᐘ㧘㕍ᧁ㓉᣿㧚ᚻ㑐▵ቢోಾᢿౣធ⌕ᓟߩ 1 ∝଀㧘ጘ㒂૞ᬺ≮ᴺ 2007 ᐕ㧧10 Ꮞ㧦38㧙
39㧚
30㧕 દ⮮⧐Პ߶߆㧚THA 㜞૏⣕⥓⢆ ⣕⥓ᕈ⢆㑐▵∝ߦኻߔࠆォሶਅ⍴❗㛽ಾࠅ૬↪ੱᎿ⢆㑐▵⟎឵ⴚߩ⍴ᦼᚑ❣㧘ᣣᧄੱᎿ㑐▵ቇળ⹹ 2007 ᐕ㧧37 Ꮞ㧦90㧙91㧚
31㧕 ㋈ᧁᓀ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚㜞㦂⠪(75 ᱦએ਄)ߦ߅ߌࠆੱᎿ⢆㑐▵ౣ⟎឵ⴚߩᚑ❣㧘ᣣᧄੱᎿ㑐▵ቇળ⹹ 2007 ᐕ㧧37 Ꮞ㧦370㧙371㧚
32㧕 ᫪ᢕᐘ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚RA ⤒ߦኻߔࠆੱᎿ㑐▵⟎឵ⴚ 㑐▵࡝࠙ࡑ࠴ᖚ⠪ߦ߅ߌࠆ࠮ࡔࡦ࠻
࡟ࠬੱᎿ⤒㑐▵ో⟎឵ⴚߩਛᦼᚑ❣㧘ᣣᧄੱᎿ㑐▵ቇળ⹹ 2007 ᐕ㧧37 Ꮞ㧦60㧙61㧚
33㧕 㥱⮮ḩ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚㜞㦂⠪ߩੱᎿ⢆㑐▵⟎឵ⴚ 75 ᱦએ਄ߩ㜞㦂⠪ߦ߅ߌࠆ࠮ࡔࡦ࠻࡟ࠬ
THA ߩⴚᓟᚑ❣㧘ᣣᧄੱᎿ㑐▵ቇળ⹹ 2007 ᐕ㧧37 Ꮞ㧦34㧙35㧚
34㧕 ♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚㑐▵࡝࠙ࡑ࠴ᴦ≮⮎࠲ࠢࡠ࡝ࡓࠬߩലᨐߣ SF㧙8(Short Form㧙8)ࠍ↪޿ߚ QOL
⹏ଔ㧘ᣣᧄ࡝࠙ࡑ࠴࡮㑐▵ᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧26 Ꮞ㧦403㧙411㧚
35㧕 ᫪ᢕᐘ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚ᄢ⣽㛽㗰਄㛽᛬ࠍ઻ߞߚ RA ⤒ߦኻߒߡ৻ᦼ⊛ੱᎿ⤒㑐▵ో⟎឵ⴚࠍᣉⴕߒߚ 1 ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦1083㧙1084㧚
36㧕 ↰ਛ⮍㧘દ⮮⧐Პ߶߆㧚㜞㦂⠪ߩ㛽⋚࡮ኡ㛽⥓㛽᛬ߩᴦ≮⚻㛎㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007
ᐕ㧧50 Ꮞ㧦1051㧙1052㧚
37㧕 ༑ਭ↢ஜᄥ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚⣊㛽㜞ේ㒱ᴚ㛽᛬ߦኻߔࠆࡂࠗ࠼ࡠࠠࠪࠕࡄ࠲ࠗ࠻ࡉࡠ࠶ࠢࠍ↪
޿ߚᴦ≮ᴺ㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦873㧙874㧚
38㧕 ㋈ᧁᓀ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚㛽⋚ᓟ௑ࠍ઻߁ᖚ⠪ߦኻߔࠆੱᎿ⢆㑐▵ౣ⟎឵ⴚߩᬌ⸛㧘ਛㇱᣣᧄᢛ
ᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦685㧙686㧚
39㧕 ዊᎹኡᕶ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚ஜᐽᚑੱߦ⊒∝ߒߚේ⊒ᕈൻ⤥ᕈ⢆㑐▵Ἳߩ 2 ଀㧘ਛㇱᣣᧄᢛᒻᄖ
⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦749㧙750㧚
40㧕 ጊ↰৻ᚑ㧘દ⮮⧐Პ߶߆㧚⥓⬄ࠦࡦࡐ㧙ࡀࡦ࠻ߩਛᔃᕈ⣕⥓ߦኻߒᓟ⣻⤑ㅴ౉ᴺߢᄖ⣺㛽േ⣂ࠍ⏕଻ߒߚߩߜߦ৻ᦼ⊛ߦౣ⟎឵ⴚࠍⴕߞߚ 1 ଀㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦674㧙676㧚
41㧕 ᧛ἑༀᓆ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚ᧃ┵⢈ᄢ∝ߦ⊒∝ߒߚᕆㅦ⎕უဳ⢆㑐▵∝ߦኻߔࠆ THA ᣉⴕ∝଀㧘࿖┙ᄢቇᴺੱ࡝ࡂࡆ࡝࠹㧙࡚ࠪࡦ ࠦ࡮ࡔ࠺ࠖࠞ࡞ቇⴚᄢળ⹹ 2007 ᐕ㧧28 Ꮞ㧦38㧙41㧚
42㧕 ᧻ᧄ๺㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚ㅘᨆᖚ⠪ߦኻߔࠆੱᎿ⢆㑐▵ᚻⴚߩ๟ⴚᦼว૬∝㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧
58 Ꮞ㧦511㧙515㧚
43㧕 ♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚ᄢ⣽㛽⣕⥓㛽᛬ߦ Austin㧙Moore ੱᎿ㛽㗡⟎឵ⴚࠍᣉⴕߒⴚᓟ 31 ᐕ⚻ㆊߒߚ
1 ଀㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦273㧙276㧚
44㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘ጤ੗ᥓ቞↵㧚⣶ᬁᄌᕈ஥ᒗ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦353㧙354㧚
45㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㗖ㇱ⣄㜑∝ᚻⴚߩว૬∝㧙೨ᣇᴺ㧘
ᓟᣇᴺߩᲧセ㧙㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦579㧙580㧚
46㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㛽☻㝃∝ᕈᬁ૕㛽᛬ߦኻߔࠆࡀࠬࡊ
ࡠࡦࠤ㧙ࡉ࡞ࠍ૶↪ߒߚ⣄ᬁ⍴❗ⴚ㧘ᣣᧄ⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹㧙࡚ࠪࡦቇળ⹹ 2007 ᐕ㧧6 Ꮞ㧦25㧙
28㧚
47㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘ጤ੗ᥓ቞↵㧘⑔↰┨ੑ㧚⣶ᬁᄌᕈ஥ᒗ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯ㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળ㔀⹹ 2007 ᐕ㧧18 Ꮞ㧦223㧚
48㧕 㕍ᧁ㓉᣿㧘ᷰㄝ๺ሶ㧘ਤ⠀᡽⟤㧘⮮↰㓷ᢥ㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧘ዊ㊁Ⴆኪ㧚functionalMRI ߇᦭↪ߢ޽ߞߚᘟᕈᦼ⣖᪪Ⴇ 㤗∽ߩ 1 ∝଀㧘Journal of Clinical Rehabilitation 2007 ᐕ㧧16 Ꮞ㧦558㧙561㧚
49㧕 ዊᎹኡᕶ㧘㜞ᴛ⌀㧘⷏ᧄඳᢥ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ㧚ஜᐽᚑੱߦ⊒∝ߒߚේ⊒ᕈൻ⤥ᕈ⢆㑐▵Ἳߩ 2 ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦749㧙750㧚
50㧕 ዊᎹኡᕶ㧘⍹ਣᄢ࿾㧘ጊ↰৻ᚑ㧘ᷡ᳓ቁᔒ㧚ਇ቟ቯᄖ஥ඨ᦬᧼ߦኻߒ㏜ⷞਅ thermal shrinkage ࠍᣉⴕߒߚ 1 ଀㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦1357㧙1359㧚

㧙㧙51㧕 ዊᎹኡᕶ㧘ᷡ᳓ቁᔒ㧘ዊጊ༑਽㧘⿒ᳰᢕ㧘ၳ⵨ᒾ㧚㜞㦂⠪㗪ㇱ(ォሶㇱ)㛽᛬ᓟߩ╭⪜❗࡮⒖േ⢻ജ࡮㛽᛬ဳ࡮ⴚᑼߩ⋧㑐㑐ଥߦߟ޿ߡߩᬌ⸛㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦47㧙48㧚
52㧕 ⍹ਣᄢ࿾㧘ᄢ㊁⾆ᢅ㧘ዊᎹኡᕶ㧘⷏ᧄ⵨㧘ᷡ᳓సᤨ㧚ᓟ㗖ㇱߦ⊒↢ߒߚ infantile fibromatosis ߩ৻଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦90㧙91㧚
53㧕 ᧻ᧄ ๺㧘♻ᢙਁᱜ㧘દ⮮⧐Პ㧘⑔↰ 㓷㧘Ꮉ੗ ⽕㧘ᷡ᳓సᤨ㧚ㅘᨆᖚ⠪ߦኻߔࠆੱᎿ⢆㑐▵ᚻⴚߩ๟ⴚᦼว૬∝㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦511㧙515㧚
54㧕 ↰ਛ 㗔㧘૒⮮ᱜᄦ㧘┻᧛ᱜ↵㧘྾ᚭ㓉ၮ㧘ᢧ⮮㇌᣿㧘ᷡ᳓ సᤨ㧘ᷡፉ ḩ㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆ↢‛ቇ⊛⵾೷ᴦ≮ߣ࠻࡝ࡊ࠻ࡈࠔࡦઍ⻢ߦߟ޿ߡ㧘ਛㇱ࡝࠙ࡑ࠴(J Chubu Rhuum Assoc) 2007 ᐕ㧧38 Ꮞ㧦
12㧙13㧚
55㧕 ਭፉᵏੳ㧘⍹੗శ৻㧘ᷡ᳓సᤨ㧘૒‫ᤩᧁޘ‬㧘ጊᧄᙗม㧘ᱞౝ┨ੑ㧘ᣣᲧ㊁శ↵㧘ᬢ ਛੳ㧘ᷡ᳓ᢅੱ㧘ᄢᯅീ㧘⥓੗ᱜ᣿㧘⪉↰ ⼾㧘੹੗⑲ᴦ㧘Ᏹ↰᣽ᒄ㧘㋈ᧁ⹷㧘ᐔ᧻ື㧘⋉↰๺᣿㧘የਅ૫ผ㧘⑔↰㓷㧘਄᧛ୃ৻㧘ᷰㄝᢙੱ㧘᫪ஜᄥ㇢㧘⠀႐ℂᒾ㧘⷏ၳᒄ⸥㧚ේ⊒ᕈ㛽☻㝃∝ߦኻߔࠆ࡝࠮࠼ࡠࡀ㧙࠻ߣࡆ࠲ࡒࡦ K2
ߩ૬↪ലᨐߦ㑐ߔࠆᄙᣉ⸳౒ห⎇ⓥ㧙1 ᐕ⚻ㆊ∝଀ߩਛ㑆⸃ᨆ㧙㧘Osteoporosis Japan 2007 ᐕ㧧15 Ꮞ㧚
56㧕 ᳗㊁ᤘੳ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚ᕆᕈ㛽㜑ᕈ⊕ⴊ∛ൻቇ≮ᴺਛߦ⊒∝ߒߚ⣄ᬁ㛽㜑
Ἳߩ 1 ଀㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦1699㧙1702㧚
57㧕 㕍ᧁ㓉᣿㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ߦ߅ߌࠆࠛ࡞ࠞ࠻࠾ࡦߩ SF8 ⹏ଔ㧘ᣂ⮎ߣ⥃ᐥ 2008 ᐕ㧧57 Ꮞ㧦65㧙70㧚
58㧕 ਛ᧛ᱜ↢㧘ᷡ᳓సᤨ㧚⣶ਅ⢇∩ࠍ઻߁㛽☻㝃∝∝଀ߦኻߔࠆᣣᧄ⺆
Roland㧙 Morris Disability
Questionnaire ࠍ↪޿ߚ QOL ⹏ଔ㧙ࠛ࡞ࠞ࠻࠾ࡦ⵾೷ᛩਈਅߢߩ−∩ߦ㑐ㅪߔࠆ QOL ᡷༀߦߟ޿ߡߩᬌ
⸛㧙㧘Osteoporosis Japan 2008 ᐕ㧧16 Ꮞ㧦207㧙215㧚
59㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚⣶ਅ⢇∩࡮ߒ߮ࠇߦኻߔࠆᚻⴚԜ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ(TLIF)㧘MB Orthop
2008 ᐕ㧧21 Ꮞ㧦63㧙68㧚
60㧕 ⚦ᳯ⧷ᄦ㧚࿖㓙ቇળශ⽎⸥ ╙ 4 ࿁਎⇇⣄ᬁቇળ(World Spine Φ)ߦෳടߒߡ㧘⥃ᐥᢛᒻᄖ⑼ 2008 ᐕ㧧
43 Ꮞ㧦152㧙153㧚
61㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘ችᧄᢘ㧘↰ਛஜ৻㇢㧘ጤ੗ᥓ቞↵㧘⑔↰┨ੑ㧚㛽☻㝃∝ᕈᬁ૕࿶ẩߦኻߔࠆᬁᑿࠍ
ߣࠄ߃ࠆ⣄ᬁ⍴❗ⴚ㧙ⴚᓟ㛽᛬ߣᓟᒗ㧙㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹹ 2008 ᐕ㧧51 Ꮞ㧦643㧙644㧚
62㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㗖ᬁ੝ో៰೨ᣇ࿕ቯⴚᓟߩ⣦㛽ቯ⌕ߣౝ࿕ቯ᧚ᢱߩᄌൻ㧙X ✢⹏ଔ㧙㧘⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛ ࡌࠬ࠻ࡍ࡯ࡄ࡯⾨ 2008 ᐕ㧧10 Ꮞ㧦117㧙119㧚
63㧕 ᄢፉᐽม㧘⑔↰┨ੑ㧘ᷡ᳓సᤨ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘᧻᳗⎇๋㧘ᑝἑༀା㧚㗖ㇱ⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2008 ᐕ㧧20 Ꮞ㧦15㧙16㧚
64㧕 ᷡ᳓ቁᔒ㧘ᄢ㊁⾆ᢅ㧘ᄢፉᐽม㧘ᄢ㊁⟵ᐘ㧘ਅᎹ㇌ᵏ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘◉ፒ᣽ੱ㧘ᵻ㊁ᄹ⟤㧘᧻᳗⎇๋㧘ᑝἑༀା㧚ฝ⢀エㇱ⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2008 ᐕ㧧20 Ꮞ㧦27㧙28㧚
65㧕 ᄢ㊁⾆ᢅ㧘ᄢፉᐽม㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧚㘃㛽㛽⣲ߦኻߔࠆ CT ࠟࠗ࠼ਅ࡜ࠫࠝᵄ὾ἳⴚߦࠃࠆૐଚⷅᚻ
ⴚߩ⚻㛎㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦913㧙914㧚
66㧕 ᄢ㊁⾆ᢅ㧚╙ 6 ࿁ᣣ☨ട᰷ᢛᒻᄖ⑼ၮ␆ቇળวหળ⼏ቇળ࡟ࡐ㧙࠻㧘Arthritis 2008 2008 ᐕ㧧9 Ꮞ㧦50
㧙51㧚67㧕 ⍹ਣᄢ࿾㧘ᄢ㊁⾆ᢅ㧘ዊᎹኡᕶ㧘⷏ᧄ⵨㧘ᷡ᳓సᤨ㧚ᓟ㗖ㇱߦ⊒↢ߒߚ infantile fibromatosis ߩ৻଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦93㧙94㧚
68㧕 ᄢ㊁⾆ᢅ㧘ᄢፉᐽม㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧚㘃㛽㛽⣲ߦኻߔࠆ CT ࠟࠗ࠼ਅ࡜ࠫࠝᵄ὾ἳⴚߦࠃࠆૐଚⷅᚻ
ⴚߩ⚻㛎㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦913㧙914㧚
69㧕 ⷏ᧄ ⵨㧘᧻↰ᅢ⟤㧘ᧄ㑆ජ⛗⟤㧘ጊ⾐ኡ㧘ᷰㄝ㇚㓶㧚┹ᛛࠬࡐ㧙࠷ߦ߅ߌࠆ⋴⼔Ꮷߩᓎഀ㧙࿖૕ㆬᚻߥߤ
ߦኻߔࠆࠕࡦࠤ㧙࠻⺞ᩏߦࠃࠆᬌ⸛㧙㧘ጘ㒂ᄢቇකቇㇱ♿ⷐ 2008 ᐕ㧧55 Ꮞ㧦1㧙16㧚
70㧕 ᴡ᧛⌀๋㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚㑐▵࡝࠙ࡑ࠴೨⿷ㇱᄌᒻߦኻߔࠆ╙ 2㧙5 ⿾ MTP 㑐▵᷷ሽᢛᓳⴚߩ
⍴ᦼᚑ❣㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦545㧙546㧚
71㧕 ᷡ᳓ቁᔒ㧘♻ᢙਁᱜ㧘દ⮮⧐Პ߶߆㧚ᓟᣇ㑐▵൮ᒆ✭ߦࠃࠆ෻ᒛ⤒ߦኻߒߡⷰⴊ⊛ᴦ≮(Piriou ᴺ)ࠍᣉⴕ
ߒߚ 1 ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦447㧙448㧚
72㧕 ㉿⷗๺ᒾ㧘⍹ฬ↰ᵗ৻㧘ᦸ᦬৻↵㧘દ⮮⧐Პ㧘Ꮉ਄♿᣿㧘ICD ᡷ⸓ߣᢛᒻᄖ⑼ක≮(ᐳ⺣ળ)㧘⥃ᐥᢛᒻᄖ⑼ 2008 ᐕ㧧43 Ꮞ㧦581㧙589㧚
73㧕 ዊᎹኡᕶ㧘દ⮮⧐Პ߶߆㧚Vancouver type B3 ࠬ࠹ࡓ๟࿐㛽᛬ߦኻߒ allograft㧙stem composite ࠍ૶↪
ߒߚੱᎿ⢆㑐▵ౣ⟎឵ⴚߩ 1 ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦1151㧙1152㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Hosoe H, Miyamoto K, Wada E, Shimizu K. A surgical treatment of scoliosis in Larsen's syndrome withbilateral hip dislocation: A case report. Spine. 2006;31:E302-306.
2㧕 Futani H, Minamizaki T, Nishimoto Y, Abe S, Yabe H, Ueda T. Long-Term Follow-up After Limb
Salvage in Skeletally Immature Children with a Primary Malignant Tumor of the Distal End of the
Femur. J Bone Joint Surg AM. 2006;88:595-603.
3㧕 Morita M, Banno Y, Dohjima T, Nozawa S, Fushimi K , Fan D, Ohno T, Miyazawa K, Liu N, Shimizu K.
Ǵ-Calpain is involved in the regulation of TNF--induced matrix metalloproteinase-3 release in arheumatoid synovial cell line. Biochem Bioph Res Commun. 2006;343:937-942.
4㧕 Ohnishi K, Miyamoto K, Hashimoto K, Hosoe H, Shimizu K. Surgical Treatment for Atlantoaxial
Subluxation Associated With Mixed Connective Tissue Disease. Orthopedics. 2006;29:369-370.
5㧕 Masuda T, Miyamoto K, Shimizu K. Intramuscular hemodynamics in bilateral erector spinase muscles
in symmetrical and asymmetrical postures with and without loading. Clin Biomecha. 2006;21:245-253.

㧙㧙

IF 2.499

IF 2.487

IF 2.749
IF 0.581
IF 1.642

6㧕 Matsumoto K, Kamiya N, Suwan K, Atsumi F, Shimizu K, Shinomura T, Yamada Y, Kimata K,
Watanabe H. Identification and Characterization of Versican/PG-M Aggregates in Cartilage. J Biol
Chem. 2006;281:18257-18263.
7㧕 Yoshida M, Kida K, Kodama H, Itokazu M, Shimizu K. Calcitonin treatment for calcifying tendinitis of
the shoulder. J Orthopaed Traumatol. 2006;7:6-11.
8㧕 Masuda T, Miyamoto K, Hosoe H, Sakaeda H, Tanaka M, Shimizu K. Surgical treatment with spinal
instrumentation for pyogenic spondylodiscitis due to menthicillin-resistant Staphylococcus
aureus(MRSA): a report of five cases. Arch Orthop Trauma Surg. 2006;126:339-349.
9㧕 Kamiya N, Watanabe H, Habuchi H, Takagi H, Shinomura T, Shimizu K, Kimata K. Versican/PG-M
Regulates Chondrogenesis as an Extracellular Matrix Molecule Crucial for Mesenchymal
Condensation. J Biol Chem. 2006;281:2390-2400.
10㧕 Wakahara K, Matsumoto K, Sumi H, Sumi Y, Shimizu K. Traumatic Spinal Cord Injuries From
Snowboarding. Am J Sports Med. 2006;34:1670-1674.
11㧕 Matsumoto K, Wakahara K, Sumi H, Shimizu K. Central Cord Syndrome in Patients With Klippel-Feil
Syndrome Resulting From Winter Sports. Am J Sports Med. 2006;34:1685-1689.
12㧕 Ogawa H, Itokazu M, Ito Y, Fukuta M, Shimizu K. The therapeutic outcome of minimally invasive
synovectomy assisted witharthroscopy in the rheumatoid knee. Mod Rheumatol. 2006;16:360-363.
13㧕 Matsumoto K, Itokazu M, Uemura S, Takigami I, Naganawa T, Shimizu K. Successful joint
arthroplasty after treatment of destructive MRSA arthritis of the knee using antibiotic-loadedhydroxyapatite blocks: a case report. Arch Orthop Trauma Surg. 2006;127:47-50.
14㧕 Ogawa H, Itokazu M, Ito Y, Fukuta M, Simizu K. An unusual meniscal ganglion cyst that triggered
recurrent hemarthrosis of the knee. Arthroscopy. 2006;22:455.e1-4.
15㧕 Akeda K, An HS, Okuma M, Attawia M, Miyamoto K, Thonar EJMA, Lenz ME, Sah RL, Masuda K.
Platelet-rich Plasma Stimulates Porcine Articular Chondrocyte Proliferation and Matrix Biosynthesis.
Osteoarthritis and Cartilage. 2006;14:1272-1280.
16㧕 Miyamoto K, Masuda K, Kim JG, Inoue N, Akeda K, Andersson GBJ, An HS. Intradiscal Injections ofOsteogenic Protein-1 Restore the Viscoelastic Properties of Degenerated Intervertebral Discs. Spine
Journal. 2006;6:692-703.
17㧕 Chujo T, An HS, Akeda K, Miyamoto K, Muehleman C, Attawia M, Andersson GBJ, Masuda K. Effects
of growth differentiation factor-5 (GDF-5) on the intervertebral disc - in vitro bovine study and in vivo
rabbit disc degeneration model study-. Spine. 2006;31:2909-2917.
18㧕 Ohara A, Miyamoto K, Naganawa T, Matsumoto K, Shimizu K. Sagittal alignment of the cervicalspine: comparison of five standard methods of measurement. Spine. 2006;31:2585-2591.
19㧕 Fushimi K, Miyamoto K, Nishimoto H, Hosoe H, Kodama H, Shimizu K. Clinical outcomes ofmultilevel anterior corpectomy and fusion as a revision surgery of the cervical spine. Report of sevencases. Spinal Cord. 2006;44:449-456.
20㧕 Miyamoto K, Masuda K, Inoue N, Okuma M, Meuhlmam C, An HS. Anti-adhesion properties ofthrombin-based hemostatic gelatin in a canine laminectomy model. –a biomechanical, biochemical,
and histological study. Spine. 2006;31:E91-E97.
21㧕 Sasaki T, Miyamoto K, Hosoe H, Shimizu K. Transoral Anterior Approach Used for Extensive Anterior
Decompression of C3 Vertebrae Level in a Patient with Severe Atlantoaxial Vertical Subluxation andRheumatoid Arthritis - A Case Report - Spinal Cord. 2006;44:52-55.
22㧕 Shimizu T, Miyamoto K, Masuda K, Miyata T, Hori H, Shimizu K, Maeda M. The clinical significanceof impaction at the femoral neck fracture site in the elderly. Arch Orthop Trauma Surg.
2007;127:515-521.
23㧕 Hosoe H, Shimizu K, Miyamoto K, Fukuta S, Iwai C. Cantilever-TLIF for patients with degenerative
scoliosis. Eur Spine J. 2007;16:S51.
24㧕 Aoki T, Terashima H, Itokazu M, Miyamoto K, Shimizu K. Stimulation of Music Prolonged
Disturbance of Consciousness Patients in Early Rehabilitation. J Saitama Kenou Rehabilitation.
2007;7:50-53.
25㧕 Ogawa H, Nishimoto H, Hosoe H, Suzuki N, Kanamori Y, Shimizu K. Clinical outcome aftersegmental wire fixation and bone grafting for repair of the defects in multiple level lumbar
spondylolysis. J Spinal Disord Tech. 2007;20:521-525.
26㧕 Ogawa H, Akaike A, Ishimaru D, Yamada K, Shimizu T, Koyama Y, Hori H. Posterior interosseous
nerve palsy related to rheumatoid synovitis of the elbow. Mod Rheumatol. 2007;17:327-329.
27㧕 Nagano A, Miyamoto K, Fushimi K, Hosoe H and Shimizu K. Failure of reconstruction surgery using
anterior fibular strut grafting for postlaminectomy kyphosis A case report. J Clin Neurosci.
2007;14:376-379.
28㧕 Inoue T, Miyamoto K, Kodama H, Hosoe H and Shimizu K. Total spondylectomy for treatment of asymptomatic hemangioma of the lumbar spine - A case report. J Clin Neurosci. 2007;14:806-809.
29㧕 Yamada K, Miyamoto K, Hosoe H, Mizutani M and Shimizu K. Scoliosis associated with Prader-Willi
syndrome A case report. Spine J. 2007;7:345-348.
30㧕 Miyamoto K, Shimizu K, Matsumoto S, Sumida H, Iida H, Hosoe H. Surgical treatment of scoliosis㧙㧙

IF 5.581

IF 0.913

IF 5.581
IF 3.397
IF 3.397

IF 0.913
IF 2.296

IF 3.793

IF 2.499
IF 2.499

IF 1.578

IF 2.499

IF 1.578

IF 0.913
IF 2.021

IF 1.303

IF 0.801
IF 0.801

associated with central core disease: Minimizing the effects of malignant hyperthermia withprovocation tests - Report of a case -. J Pediatr Orthoped B. 2007;16:239-242.
31㧕 Shimizu T, Miyamoto K, Masuda K, Miyata Y, Hori H, Shimizu K, Maeda M. The clinical significanceof impaction at the femoral neck fracture site in the elderly. Arch Orthop Trauma Surg.
2007;127:515-521.
32㧕 Fushimi K, Nakashima S, You F, Takigawa M, Shimizu K. Prostaglandin E2 Downregulates TNF-ǩ
-Induced Production of Matrix Metalloproteinase-1 in HCS-2/8 Chondrocytes by Inhibiting
Raf-1/MEK/ERK Cascade Through EP4 Prostanoid Receptor Activation. J Cell Biochem.
2007;100:783-793.
33㧕 Maehara H, Suzuki K, Sasaki T, Oshita H, Wada E, Inoue T , Shimizu K. G1-G2 Aggrecan Productthat can be Generated by M-calpain on Truncationat 709-Ala710 is Present Abundantly in Human
Articular Cartilage. J Biochem. 2007;141:469-477.
34㧕 Takeuchi A, Yamamoto Y, Tsuneyama K, Cheng C, Yonekura H, Watanabe T, Shimizu K, Tomita K,
Yamomoto H, Tsuchiya H. Endogenous secretory receptor for advanced glycation endproducts as anovel prognostic marker in chondrosarcoma. Cancer. 2007;9:2532-2540.
35㧕 Ogawa H, Nishimoto H, Hosoe H, Suzuki N, Kanamori Y, Shimizu K. Clinical outcome aftersegmental wire fixation and bone grafting for repair of the defects in multiple level lumbar
spondylolysis. J Spinal Disord Tech. 2007;20:521-525.
36㧕 Matsumoto K, Itokazu M, Uemura S, Takigami I, Naganawa T, Shimizu K. Successful joint
arthroplasty after treatment of destructive MRSA arthritis of the knee using antibiotic-loadedhydroxyapatite blocks -a case report-. Arch Orthop Trauma Surg. 2007;127:47-50.
37㧕 Hioki A, Miyamoto K, Hosoe H, Shimizu K. Two-staged decompression for thoracic paraparesis due tothe combined ossification of the posterior longitudinal ligament and the ligamentum flavum a casereport. Arch Orthop Trauma Surg. 2008;128:175-177.
38㧕 Yamamoto T,Inoue N, Miyamoto K, Sugiyama S, Nozawa S, Hosoe H, Shimizu K. Segmental wire
fixation for lumbar spondylolysis associated with spina bifida occulta. Arch Orthop Trauma Surg.
2008;128:1177-1182.
39㧕 Hashimoto K, Miyamoto K, Hosoe H, Kawai G, Kikuike K, Shimokawa K, Suzuki N, Matsuo M,
Kodama H, Shimizu K. Solitary fibrous tumor in the cervical spine with destructive vertebral
involvement:A case report and review of the literature. Arch Orthop Trauma Surg. 2008;128:1111-1116.
40㧕 Takigami I, Itoh Y, Itokazu M, Shimizu K. Radio-opaque marker of a surgical sponge appearing as an
intra-articular foreign body after total hip arthroplasty.
Arch
Orthop Trauma Surg.
2008;128:1167-1168.
41㧕 Chi D, Miyamoto K, Hosoe H, Kawai G, Ohnishi K, Suzuki N, Sumi H, Shimizu K. Symptomatic
lumbar mobile segment with spinal canal stenosis in fused spine associated with diffused idiopathic
skeletal hyperostosis A case report. Spine J. 2008;8:1019-1023.
42㧕 Hioki A, Ohnishi K, Miyamoto K, Hosoe H and Shimizu K. Spondylolysis of the second lumbar
vertebra treated with segmental wiring and bone grafting:a case report. Orthopaedics. 2008;31:287.
43㧕 Terabayashi N, Miyamoto K, Sasaki H, Hosoe H, Shimizu K. Multiple steroid-induced vertebral
fracture with paraparesis associated with Wegener’s granulomatosis treated with posterior spinal
instrumentation. Journal of Neurological Sciences(Turkish). 2008;25:67-71.
44㧕 Hioki A, Miyamoto K, Hosoe H, Fukuta S, Shimizu K. Two-stage decompression for combined epiconus
and cauda equina syndrome due to multilevel spinal canal stenosis of the thoracolumbar spine-a casereport. Arch Orthop Trauma Surg. 2008;128:955-958.
45㧕 Kawaguchi A, Chiba K, Tanimura Y, Motohashi T, Aoki H, Takeda T, Hayashi S, Shimizu K and
Kunisada T. Isolation and characterization of Kit-independent melanocyte precursors induced in theskin of Steel factor transgenic mice. Dev Growth Differ. 2008;50:63-69.
46㧕 Shinohe R. Sato M, Takemura M, Shimizu K, Koishi H, Tanaka R, Saito K, Seishima M. Cytokine
profiles in mice with arthritis induced by anti-type Τ collagen monoclonal antibody plus
lipopolysaccharide. Japanese Journal of Clinical Chemistry. 2008;37:53-62.
47㧕 Hirakawa A, Miyamoto K, Ohno Y, Hioki A, Ogawa H, Nishimoto H, Yokoi H, Shimizu K. Two-stage(posterior and anterior) surgical treatment of spinal osteomyelitis due to antypical mycobacteria andassociated thoracolumbar kyphoscoliosis in a nonimmunocompromised patient. Spine.
2008;33:E221-224.
48㧕 Matsumoto M, Chiba K, Toyama Y, Takeshita K, Seichi A, Nkamura K, Arimizu J, Fujibayashi S,
Hirabayashi S, Hirano T, Iwasaki M, Kaneoka K, Kawaguchi Y, Ijiri K, Maeda T, Matsuyama
Y,Mikami Y, Murakami H, Nagashima H, Nagata K, Nakahara S, Nohara Y, Oka S, Sakamoto K,
Saruhashi Y, Sasao Y, Shimizu K, Taguchi T, Takahashi M, Tanaka Y, Tani T, Tokuhashi Y, Uchida K,
Yamamoto K, Yamazaki M, Yokoyama T, Yoshida M,and Nishiwaki Y: Surgical results and related
factors for ossification of prosterior longitudinal ligament of the thoracic spinea multi-institutional
retrospective study. Spine. 2008;33:1034-1041.
49㧕 Hayashi Y, Sakurai T, Kimura A, Ikeda T, Masuyama Z, Suzuki Y, Tanaka Y, Hozumi I, Hosoe H,
Takahashi H, Inuzuka T. Selective cauda equina hypertrophy with ideiopathic inflammation, Muscle

㧙㧙

IF 0.619

IF 0.913

IF 3.381

IF 2.020

IF 4.632

IF 1.303

IF 0.913

IF 0.913

IF 0.913

IF 0.913

IF 0.913

IF 0.581

IF 0.913

IF 1.908

IF 2.499

IF 2.499

Nerve. 2008;38:105-1069.
IF 2.424
50㧕 Wakahara K, Ohno T, Kimura M, Masuda T, Nozawa S, Dohjima T, Yamamoto T, Nagano A, Kawai G,
Matsuhashi A, Saitoh M, Takigami I, Okano Y, Shimizu K. EWS-Fli1 up-regulates expression of the
Aurora A and Aurora B kinases. Mol. Cancer Res. 2008;6:1937-1945.
IF 7.672
51㧕 Takigami I, Itokazu M, Itoh Y, Matsumoto K, Yamamoto T, Shimizu K. Limb-length measurement in
total hip arthroplasty using a calipers dual pin retractor. Bull NYU Hosp Jt Dis. 2008;66:107-110.
52㧕 Ogawa H, Ito Y, Itokazu M, Mori N, Shimizu T, Terabayashi N, Ishimaru D, Shimizu K. Morcellized
Bone Grafting for Acetabular Deficiency in Cementless Total Hip Arthroplasty. Orthopedics.
2008;31:986.
IF 0.581

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛⠹ਃ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦⣄ᬁᩇ㕢Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧1,300 ජ౞(500㧦800 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦⷏ᧄ ⵨㧧ᐔᚑ 18 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⎇ⓥ⾌㧦⣖᪪Ⴇᓟߩ⵬ഥᚻߦኻߔࠆࡃ࡯࠴ࡖ࡞
࡝ࠕ࡝࠹ࠖࠍ೑↪ߒߚࠗࡔ࡯ࠫ࠻࡟࡯࠾ࡦࠣߩ᦭↪ᕈ㧧770 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦⚦ᳯ⧷ᄦ㧘⎇ⓥಽᜂ⠪㧦ᄢ㊁⾆ᢅ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦࡙࡯ࠗࡦࠣ⡺⣲ࡑ࠙ࠬࡕ࠺࡞ߩ᮸┙ߣ⸃ᨆ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,300 ජ౞(2,600㧦700 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᄢ㊁⾆ᢅ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌㧦߇ࠎ⚦⢩ߦኻߔࠆ᛫߇
ࠎ೷ᴦ≮⮎ߣ⚦⢩ᱫ-EWS/Fli-1 Ⲣวㆮવሶߦࠃࠆ Aurora kinase ߩォ౮ᵴᕈൻᯏ᭴-㧧ᐔᚑ 19 ᐕᐲ㧧
500 ජ౞
5㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛⠹ਃ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦⣄ᩇ㕢Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,000 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ᄢ㊁⾆ᢅ㧘⎇ⓥಽᜂ⠪㧦ᧁ᧛ᱜᔒ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦㛽エㇱ⣲≌ߦ߅ߌࠆࠝ࡯ࡠ࡜ࠠ࠽࡯࠯ߩ⸃ᨆ㧧ᐔᚑ 18 ᐕ㧙20 ᐕᐲ㧧3,600 ජ౞(2,600㧦500㧦500 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ᚭጊ⧐ᤘ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧ᐔᚑ 20 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧦⣄ᩇ㕤Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓సᤨ㧧2008 ᐕᣣᧄ⣄ᬁ⣄㜑∛ቇળ Visiting Scholar Program㧧1,000 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦ᄢ㊁⾆ᢅ㧘⎇ⓥಽᜂ⠪㧦ᚻႦᑪ৻㧘ේ ᣿㧧ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇ⎇ⓥ⑼㐳ⵙ㊂⚻⾌ ᄙ
ಽ㊁౒ห⎇ⓥ‫ޠࡓ࡯࠴࠻ࠢࠚࠫࡠࡊޟ‬㧦ᱤ㜑⚦⢩ߦࠃࠆ㛽ౣ↢ࡊࡠࠫࠚࠢ࠻ ࡅ࠻ᱤ㜑⚦⢩ࠍ↪޿ߚ఺∉ਇో࡜࠶࠻ᄢ⣽㛽㛽ன㑐▵ࡕ࠺࡞ߦ߅ߌࠆ㛽ౣ↢㧦ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞
2㧕ฃ⸤⎇ⓥ
1㧕 ⎇ⓥઍ⴫⠪㧦⮮ᳯᱜస㧘Ꮉ㦮᥍ਭ㧘⎇ⓥಽᜂ⠪㧦㊁↰ඳ㧘ਅ᧛ዏਯ㧘ᩕᨑ⵨ᢥ㧘⷏ᧄ⵨㧘቟୚ၮᐘ㧚ᣂࠛࡀ࡞ࠡ࡯࡮↥ᬺᛛⴚ✚ว㐿⊒ᯏ᭴ ੱ㑆ᡰេဳࡠࡏ࠶࠻ታ↪ൻၮ⋚ᛛⴚ㐿⊒੐ᬺ㧘ࠗࡔ࡯ࠫ࠻
࡟࡯࠾ࡦࠣᯏ⢻ઃ߈ᚻᜰ਄⢇࡝ࡂࡆ࡝ᡰេࠪࠬ࠹ࡓߩ⎇ⓥ㐿⊒㧧ᐔᚑ 17㧙19 ᐕᐲ㧧7,580 ජ౞(328㧦
4,854㧦2,398)㧦ਣን♖Ꮏ(ᩣ)
2㧕 ⎇ⓥઍ⴫⠪㧦㕍ᧁ㓉᣿㧚ࡑࠗࠢࡠࡃࡉ࡞ߩり૕߳ߩലᨐߦߟ޿ߡߩ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧1,000ජ౞㧦ᦺᣣ⥝ᬺ(ᩣ)
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 㕍ᧁ㓉᣿㧦೨⣨࿁ౝᄖㆇേ↪ⵝౕߩ㐿⊒㧧ᐔᚑ 19 ᐕᐲ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᷡ᳓సᤨ㧦
1㧕 ᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪⃻࿷)2㧕 ᣣᧄᚻߩᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪⃻࿷)
3㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╙ 19 ࿁ኾ㐷ක⹜㛎ญ㗡⹜㛎ᆔຬ(ᐔᚑ 18 ᐕ 10 ᦬㨪⃻࿷)
4㧕 ╙ 5 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓઍ⴫਎⹤ੱ(ᐔᚑ 19 ᐕ 1 ᦬㨪⃻࿷)
5㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)㧙㧙6㧕 ᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 5 ᦬㨪⃻࿷)7㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળᜰዉක೙ᐲᬌ⸛ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)8㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ࿖㓙ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)9㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)10㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ⽷ോᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)11㧕 Fighting Vascular Events in Gifu 2007 ਎⹤ੱ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)12㧕 ╙ 37 ࿁ᣣᧄ⣄ᬁ⣄㜑∛ቇળࡊࡠࠣ࡜ࡓᆔຬ(ᐔᚑ 19 ᐕ 10 ᦬㨪⃻࿷)13㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╙ 20 ࿁ኾ㐷ක⹜㛎ญ㗡⹜㛎ᆔຬ(ᐔᚑ 19 ᐕ 10 ᦬ 24 ᣣ)
14㧕 ╙ 1 ࿁᧲ᶏ㕒⣂ⴊᩖႧᩖ∝(VTE)੍㒐ࡀ࠶࠻ࡢ࡯ࠢࠪࡦࡐࠫ࠙ࡓ਎⹤ੱ(ᐔᚑ 19 ᐕ 12 ᦬ 8 ᣣ)
15㧕 ᐔᚑ 20 ᐕᐲᣣᧄᚻߩᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)16㧕 ᐔᚑ 20 ᐕᐲᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)17㧕 ╙ 21 ࿁ኾ㐷ක⹜㛎ญ㗡⹜㛎ᆔຬ(ᐔᚑ 20 ᐕ 10 ᦬ 22 ᣣ)
18㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ 2009 SAS scientific program reviewer(ᐔᚑ 20 ᐕ 10 ᦬ 24 ᣣ)
19㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╭㛽ᩰ♽ TAG ⚵❱ᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 11 ᦬㨪⃻࿷)ᄢ㊁⾆ᢅ㧦
1㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᧲ᶏ㛽エㇱ⣲≌⎇ⓥળᐙ੐(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)3㧕 㛽エㇱ⣲≌ᴦ≮ᬌ⸛ળᐙ੐(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)
4㧕 ᣣᧄㆇേེ⒖ᬀ࡮ౣ↢කቇ⎇ⓥળᐙ੐(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)⚦ᳯ⧷ᄦ㧦
1㧕 ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷කญ㗡⹜㛎⹜㛎ቭ(ᐔᚑ 18 ᐕ 1 ᦬ 20 ᣣ)
2㧕 ᣣᧄᢛᒻᄖ⑼ቇળ⣄ᬁౝⷞ㏜ਅᚻⴚࠗࡦࠪ࠺ࡦ࠻࡮ࡢ࡯ࠠࡦࠣࠣ࡞࡯ࡊ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)
3㧕 ᣣᧄ஥ᒭ∝ቇળ 2010 SRS ታⴕᆔຬળᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)
4㧕 ᣣᧄ⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪࡦቇળᐙ੐(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)5㧕 ጘ㒂⋵␠ળ⑔␩ክ⼏ળᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)6㧕 ጘ㒂Ꮢ␠ળ⑔␩ክ⼏ળᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)7㧕 ࿖᳃ஜᐽ଻㒾ክᩏຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)8㧕 㓚ኂᐕ㊄ክᩏຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)9㧕 ஥ᒗ∝ቇળᐙ੐(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)10㧕 ᣣᧄᢛᒻᄖ⑼ቇળઍ⼏ຬㆬ᜼▤ℂᆔຬળᆔຬ(㨪⃻࿷)11㧕 ᣣᧄ⣄ᬁ࡮⣄㜑∛ቇળ⹏⼏ຬ(㨪⃻࿷)12㧕 ᣣᧄ੃࡮ᐜఽ஥ᒗ∝⎇ⓥળ਎⹤ੱ(㨪⃻࿷)13㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)14㧕 ᧲ᶏ⣄ᬁᄖ⑼⎇ⓥળᏱછᐙ੐(㨪⃻࿷)⷏ᧄ ⵨㧦
1㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᢛᒻᄖ⑼ቇળઍ⼏ຬ(㨪⃻࿷)ᄢ㊁⟵ᐘ㧦1㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)દ⮮⧐Პ㧦1㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄੱᎿ㑐▵ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)
3㧕 ᣣᧄ⢆㑐▵ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)
4㧕 ᧲ᶏ㑐▵ᄖ⑼⎇ⓥળᐙ੐(㨪⃻࿷)5㧕 ᧲ᶏዊఽᢛᒻᄖ⑼ᙣ⹤ળᏱછᐙ੐(㨪⃻࿷)6㧕 ᧲ᶏੱᎿ㑐▵⎇ⓥળᏱછ਎⹤ੱ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)7㧕 㑐⷏⤒㑐▵㏜⎇ⓥળᐙ੐(㨪⃻࿷)8㧕 ╙ 11 ࿁᧲ᶏ⿷ߣ㕦ߩ⎇ⓥળᐙ੐(ᐔᚑ 19 ᐕ 10 ᦬ 20 ᣣ)㧙㧙9㧕 ᧲ᶏ⢆㑐▵⎇ⓥળઍ⴫ᐙ੐(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)10㧕 ጘ㒂ੱᎿ㑐▵ࡈࠜ࡯࡜ࡓᐙ੐(㨪⃻࿷)11㧕 ᣣᧄᢛᒻᄖ⑼ቇળ ICD-11 ᬌ⸛ᆔຬળᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)㕍ᧁ㓉᣿㧦
1㧕 ᣣᧄ⟵⢇ⵝౕቇળળೣᬌ⸛ᆔຬ(ᐔᚑ 18 ᐕ 10 ᦬ 20 ᣣ)
2㧕 ᣣᧄ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦࡀ࠶࠻ࡢ࡯ࠢ⎇ⓥળℂ੐(ᐔᚑ 18 ᐕ 12 ᦬ 3 ᣣ)
3㧕 ᢛᒻᄖ⑼࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦቇળ㘈໧(ᐔᚑ 18 ᐕ 12 ᦬㨪⃻࿷)
4㧕 ᣣᧄ⟵⢇ⵝౕቇળળೣᆔຬ(㨪⃻࿷)5㧕 ᣣᧄ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦࡀ࠶࠻ࡢ࡯ࠢቇળℂ੐(㨪⃻࿷)6㧕 ᣣᧄ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦකቇળ᧲ᶏਛㇱ࿾ᣇળᐙ੐(㨪⃻࿷)7㧕 ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ⹏⼏ຬ(㨪⃻࿷)ኹᨋિᄦ㧦1㧕 ᧲ᶏ㑐▵㏜⎇ⓥળᐙ੐(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)2㧕ቇળ㐿௅ᷡ᳓సᤨ㧦
1㧕 ╙ 8 ࿁ጘ㒂ᢛᒻᄖ⑼තᓟᄐᦼ࠮ࡒ࠽࡯2006(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂)2㧕 ╙ 9 ࿁ጘ㒂ᢛᒻᄖ⑼තᓟᄐᦼ࠮ࡒ࠽࡯2007(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂)
3㧕 ╙ 10 ࿁ጘ㒂ᢛᒻᄖ⑼තᓟᄐᦼ࠮ࡒ࠽࡯2008(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)દ⮮⧐Პ㧦
1㧕 ╙ 11 ࿁᧲ᶏ⿷ߣ㕦ߩ⎇ⓥળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂)㕍ᧁ㓉᣿㧦
1㧕 ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂)2㧕 ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹ᷡ᳓సᤨ㧦
1㧕 ᩣᑼળ␠කቇᦠ㒮‫⥃ޟ‬ᐥᢛᒻᄖ⑼‫ޠ‬㧧✬㓸ᆔຬ(㨪⃻࿷)
2㧕 Orthopaedic International: Editor(㨪⃻࿷)
3㧕 Orthopaedic Today: Editor(㨪⃻࿷)4㧕 ᩣᑼળ␠ࡔ࠺ࠖࠞ಴ ‫ޟ‬ᢛᒻᄖ⑼⋴⼔‫ޠ‬㧦✬㓸หੱ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᷡ᳓సᤨ㧦
1㧕 ࡌࡀ࠶࠻㛽☻㝃∝ቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߪᤃߒߊߥ޿㧙․ߦ㛽☻㝃∝߆ࠄ⿠ߎࠆᄌᒻᕈ⣄ᬁ∝㧙‫ޠ‬ᐳ㐳)2㧕 ጘ㒂⋵කᏧળஜᐽࠬࡐ࡯࠷කቇ⎇ୃળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫࠷࡯ࡐࠬޟ‬ㆬᚻߦ߅ߌࠆ⣶ᬁಽ㔌∝‫ޠ‬Ṷ⠪)3㧕 ጘ㒂⋵ᄖ்ᢇ๮ᢇᕆ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⃻ޟ‬ઍߩ㜞ᐲᄖ்ක≮‫ޠ‬ᐳ㐳)4㧕 ᴒ✽⣶∩࡮ਅ⢇∩ࡈࠜ࡯࡜ࡓ 2006(ᐔᚑ 18 ᐕ 1 ᦬㧘ᴒ✽㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ
⠪)
5㧕 කᏧળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 2 ᦬㧘ਃ㊀㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)
6㧕 ችፒ⋵⣶ㇱ⣄ᩇ▤⁜⓰∝ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 2 ᦬㧘ችፒ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)7㧕 ╙ 16 ࿁⑔ፉ⋵ᢛᒻᄖ⑼කߩ㓸޿(ᐔᚑ 18 ᐕ 2 ᦬㧘⑔ፉ㧘․೎⻠Ṷ‫ޟ‬⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪ
ࡦߦࠃࠆᄌᒻ⍶ᱜ‫ޠ‬Ṷ⠪)
8㧕 ⣶∩࡮ਅ⢇∩∔ᖚࡈࠜ࡯࡜ࡓ in ᾢᧄ(ᐔᚑ 18 ᐕ 2 ᦬㧘ᾢᧄ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)9㧕 ጘ㒂⋵⥃ᐥᢛᒻᄖ⑼කળ⻠Ṷળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ዊఽߩ⣄ᩇᄌᒻ‫ޠ‬Ṷ⠪)10㧕 ᧻ᳯᏒකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 3 ᦬㧘㠽ข㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)㧙㧙

11㧕 ╙ 392 ࿁ጤᚻᢛᒻἴኂᄖ⑼ᙣ⺣ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጤᚻ㧘․೎⻠Ṷ‫࠷࡯ࡐࠬޟ‬ㆬᚻߦ߅ߌࠆ⣶ᬁಽ㔌∝ߩᚻⴚ‫ޠ‬Ṷ⠪)12㧕 ╙ 35 ࿁㐿᡼ဳ∛ᐥࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)
13㧕 ᕺ㇊කᏧળᤐᦼቇળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)
14㧕 ࡕ࡯࡜ࠬ࠹࡯ࡊ⊒ᄁ 10 ๟ᐕ⸥ᔨቇⴚᢥൻ⻠Ṷળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ߩ⑳ޟ‬ข᧚ᚻᏭ߆
ࠄ㨪ࠊߚߒ߇಴ળߞߚ⚛ᢜߥੱߚߜ㨪‫ޠ‬ᐳ㐳)15㧕 ╙ 79 ࿁ᣣᧄᢛᒻᄖ⑼ቇળቇⴚ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘␹ᄹᎹ㧘ᢎ⢒⎇ୃ⻠Ṷ‫ޟ‬⢋ߎࠅߩකቇ‫ޠ‬ᐳ㐳)16㧕 㠽ข⋵᧲ㇱකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 5 ᦬㧘㠽ข㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)17㧕 ╙ 8 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄌᒻᕈ㑐▵∝ߩ∛ᘒߣᴦ≮‫ޠ‬ᐳ㐳)18㧕 ⣶∩࠮ࡒ࠽࡯in ၔධ(ᐔᚑ 18 ᐕ 6 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)
19㧕 ⟲㚍⋵⣶࡮⿷ߩߒ߮ࠇ∩ߺ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 6 ᦬㧘⟲㚍㧘․೎⻠Ṷ‫ޟ‬⣶ㇱᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)20㧕 ጘ㒂⋵කᏧળᄖ⑼කㇱળ࡮ഭἴᜰቯකㇱળ✚ળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ᧃޟ‬᪳␹⚻㓚ኂߩᴦ≮ߣ࡝ࡂࡆ࡝‫ޠ‬ᐳ㐳)21㧕 ╳ᓟ⥃ᐥᢛᒻᄖ⑼කળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 7 ᦬㧘⑔ጟ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)22㧕 ╙ 33 ࿁ࠬࡐ࡯࠷කቇ⎇ୃળ(ᐔᚑ 18 ᐕ 8 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣄ᩇ㧘⢷࡮⣶ᬁߩᄖ்ߣ㓚ኂ‫ޠ‬Ṷ⠪)23㧕 ⣶∩࡮ਅ⢇∩∔ᖚࡈࠜ࡯࡜ࡓᾢᧄ(ᐔᚑ 18 ᐕ 9 ᦬㧘ᾢᧄ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)24㧕 ࠝࠬ࠹ࠝࡐࡠ࡯ࠪࠬ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ᕈ⣄ᬁ㛽᛬ߩᴦ≹ㆊ⒟߆
ࠄߺߚᚢ⇛⊛଻ሽ࡮ᚻⴚᴦ≮ߩታ㓙ߣዷᦸ‫ޠ‬ᐳ㐳)25㧕 㛽☻㝃∝ᦨᣂ⻠Ṷળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߩࠣࡠ࡯ࡃ࡞ࠬ࠲ࡦ࠳࡯࠼ߣᚒ࿖
ߩ⃻⁁‫ޠ‬ᐳ㐳)26㧕 ጘ㒂⋵⣶∩ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)27㧕 ╙ 107 ࿁ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ(ᐔᚑ 18 ᐕ 10 ᦬㧘౓ᐶ㧘‫ޟ‬㛽☻㝃∝ᕈ࿶ㄼ㛽᛬ߦኻߔࠆᴦ
≮‫ޠ‬ᐳ㐳)28㧕 㒋␹ LCS ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 10 ᦬㧘౓ᐶ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)29㧕 ╙ 5 ࿁ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫╭ޟ‬ജჇᒝലᨐߩࠛࡆ࠺ࡦ
ࠬ‫ޠ‬ᐳ㐳)30㧕 ╙ 87 ࿁๺᱌ጊ⥃ᐥᢛᒻᄖ⑼කળ⎇ୃળ(ᐔᚑ 18 ᐕ 11 ᦬㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ
⠪)31㧕 ࠕ࡞ࡈࠔࡠ࡯࡞⊒ᄁ 25 ๟ᐕ⸥ᔨ⻠Ṷળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽᛬੍㒐ߩⷰὐߦၮߠ
ߊᦨᣂߩ㛽☻㝃∝ᴦ≮ᜰ㊎‫ޠ‬ᐳ㐳)32㧕 ╙ 34 ࿁᧲ᶏ࿾඙ᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᗲ⍮㧘․೎⻠Ṷ‫ޟ‬⢆㑐▵ߣ⣄ᬁߦ߅ߌࠆᚻ
ⴚᚻᛛߩᎿᄦߣታ㓙‫ޠ‬ᐳ㐳)33㧕 ࡊ࡜ࠗࡑ࡝࡮ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 12 ᦬㧘੩ㇺ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒ㧘⸻ᢿߣᴦ≮㧙⸻ᢿࠨࡐ࡯࠻࠷࡯࡞ࠍ฽߼ߡ㧙‫ޠ‬Ṷ⠪)34㧕 ⣶∩∔ᖚ࠮ࡒ࠽࡯2006(ᐔᚑ 18 ᐕ 12 ᦬㧘ṑ⾐㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)35㧕 ╙ 8 ࿁ Latest Orthopedics ⎇ⓥળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ጟጊ㧘․೎⻠Ṷ‫ޟ‬⣄ᬁ㛽㜑Ἳߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)36㧕 ╙ 166 ࿁⑔ጊᄖ⑼ળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)37㧕 ╙ 5 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ߦ࡞࡯ࡎ࠻࠶ࡇޟ‬፰ࠄߥ޿⿷∔ᖚ࡮ᄖ்ߩ⷗ᣇ‫ޠ‬ᐳ㐳)38㧕 ╙ 6 ࿁ጘ㒂㛽☻㝃∝ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㜞㦂⠪ߦ߅ߌࠆ᦯⮎ᜰዉߩታ〣㨪㛽☻㝃∝ᴦ≮⮎ࠍਛᔃߦ㨪‫ޠ‬ᐳ㐳)39㧕 㖧ᣣ⣄ᬁᄖ⑼ᙣ⹤ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㖧࿖ߦ߅ߌࠆ⣄ᬁᄖ⑼࠻ࡇ࠶ࠢࠬ‫ޠ‬ᐳ㐳)40㧕 2 ᦬ౝ⑼ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥸৻ޟ‬ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⣶∩ߩ⸻ᢿᴦ≮‫ޠ‬Ṷ⠪)41㧕 ╙ 5 ࿁৾㓊 LCS ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘⑔ጟ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)42㧕 ╙ 3 ࿁ጘ㒂ㆇേེ㩖ࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᣣᏱㆣㆄߔࠆエㇱ⣲≌㧙⸻≮ߩⷐὐߣ⋤ὐ㧙‫ޠ‬ᐳ㐳)43㧕 ವ㙚ᢛᒻᄖ⑼ળቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ವ㙚㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)44㧕 ╙ 10 ࿁ጘ㒂⣄ᬁ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣄ᬁ㛽㜑Ἳߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)45㧕 Medical Tribune ࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒ㧘⸻ᢿߣᴦ≮㧙⸻ᢿࠨࡐ࡯࠻࠷࡯࡞ࠍ฽߼ߡ㧙‫ޠ‬Ṷ⠪)㧙㧙

46㧕 ࡊ࡜ࠗࡑ࡝࡮ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒ㧘⸻ᢿߣᴦ≮㧙⸻ᢿࠨࡐ࡯࠻࠷࡯࡞ࠍ฽߼ߡ㧙‫ޠ‬Ṷ⠪)47㧕 ⥄ォゞߦࠃࠆஜᐽߠߊࠅ⻠Ṷળ(ᐔᚑ 19 ᐕ 3 ᦬㧘⟤Ớ㧘․೎⻠Ṷ‫⥄ޟ‬ォゞߣஜᐽ‫ޠ‬Ṷ⠪)48㧕 ╙ 4 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㗖ᬁ∔ᖚߩ∛⸻ㅪ៤㧙ߚ߆߇⢋ߎࠅ㧘ߐࠇߤ⢋ߎࠅ㧙‫ޠ‬ᐳ㐳)49㧕 ╙ 4 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩⸻ᢿߩ⪭ߣߒⓣ‫ޠ‬ᐳ㐳)50㧕 ╙ 108 ࿁ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫ޟ‬਄૏㗖ᬁㇱ்∛ߩ⸻≮ߩⷐὐ‫ޠ‬ᐳ㐳)51㧕 ⠀ፉ㇭ࡔ࠺ࠖࠞ࡞࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 4 ᦬㧘⠀ፉ㇭㧘․೎⻠Ṷ‫⥸৻ޟ‬ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⣶∩ߩ⸻ᢿᴦ≮‫ޠ‬Ṷ⠪)52㧕 ╙ 6 ࿁߮ࠊߎࠬࡐ࡯࠷㓚ኂࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢᵤ㧘․೎⻠Ṷ‫ޟ‬⣶ߩ∩ߺߣࠬࡐ࡯࠷㓚ኂ‫ޠ‬Ṷ⠪)53㧕 ࠪࠞࠧ㨯ጘ㒂 ⣄ᬁ⣄㜑∛࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄌᕈᬁ㑆᧼ߩᴦ≮ ☨࿖ߢߩᦨㄭߩ⹤㗴߆ࠄ‫ޠ‬ᐳ㐳)54㧕 ╙ 9 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫࠷࡯ࡐࠬ⤒ޟ‬㓚ኂᴦ≮ߩ࠻ࡇ࠶ࠢࠬ‫ޠ‬ᐳ㐳)55㧕 Inspiration Asia(2007.06㧘Bali㧘Long term complications after cervical fusion; chairperson)
56㧕 Fighting Vascular Events in Gifu 2007(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝⸻ᢿߩⷞὐ߆ࠄߺߚ㧘ABI ߩᝒ߃ᣇ‫ޠ‬ᐳ㐳)57㧕 Fighting Vascular Events in Gifu 2007(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬PAD ߦኻߔࠆᄖ⑼ᴦ≮ᚢ⇛㧙ઁ⑼ߣߩㅪ៤ߦࠃࠆ integrated therapy㧙‫ޠ‬ᐳ㐳)58㧕 ╙ 63 ࿁⷏ᣣᧄ⣄ᬁ⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘⑔ጟ㧘․೎⻠Ṷ‫ޟ‬⣶ᬁᄌᕈ஥ᒭ∝ߩᚻⴚ‫ޠ‬Ṷ⠪)59㧕 ጘ㒂 biological ⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᣂߒ޿ RA ᴦ≮ߩน⢻ᕈ㧙↢‛ቇ⊛⵾೷ߣエ㛽⎕უ㧙‫ޠ‬ᐳ㐳)60㧕 ࡌࡀ࠶࠻ Weeklyjy ㍤ᣂ⊒ᄁ⸥ᔨ⻠Ṷળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߩ⮎‛≮ᴺ㧦2006
ᐕ ࠟࠗ࠼࡜ࠗࡦࠍ〯߹߃ߡ‫ޠ‬ᐳ㐳)61㧕 ╙ 7 ࿁ ATST ࡒ࡯࠹ࠖࡦࠣ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣶ᬁᄌᕈ∔ᖚ߳ߩࡠ࡯ࡊࡠࡈࠔࠗ࡞
ࠪࠬ࠹ࡓߦߟ޿ߡ‫ޠ‬ᐳ㐳)62㧕 The 17th Korean-Japanese Combined Orthpaedic Symposium(2007.07, Soul, Free paper
12:Spine 1; chairperson)
63㧕 ᄢಽ⣶ㇱ⣄ᩇ▤⁜⓰∝ࡈࠜ࡯࡜ࡓ 2007(ᐔᚑ 19 ᐕ 7 ᦬㧘ᄢಽ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)64㧕 ጘ㒂㛽☻㝃∝ᴦ≮⎇ⓥળ․೎⻠Ṷળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ਛਅ૏㗖ᬁߩ೨ᣇᚻⴚ‫ޠ‬Ṷ⠪)65㧕 ࡔ࠼࠻ࡠ࠾࠶ࠢࠬࡄࠗࡦ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 8 ᦬㧘␹ᚭ㧘․೎⻠Ṷ‫ޟ‬MINI-OPEN TLIF‫ޠ‬ᐳ㐳)66㧕 ࡔ࠼࠻ࡠ࠾࠶ࠢࠬࡄࠗࡦ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 8 ᦬㧘␹ᚭ㧘․೎⻠Ṷ‫ޟ‬TLIF ߦࠃࠆ⣶ᬁᄌᕈ஥ᒗߩᴦ
≮‫⻠ޠ‬Ṷ)67㧕 SICOT ࿖㓙ᢛᒻᄖ⑼ቇળ(2007.08-09, Morocco, SURGICAL TREATMENT FOR SPONDYLOLYSISIN YOUNG ATHLETES; Lecturer)
68㧕 SICOT ࿖㓙ᢛᒻᄖ⑼ቇળ(2007.08-09, Morocco, Session 05: Spine degenerative; chairperson)
69㧕 ╙ 14 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬㜞㦂⠪㗖㜑∝ߩ∛ᘒ߅ࠃ߮೨ᣇ㒰࿶࿕ቯⴚߩᚑ❣-dynamic plate ߩ᦭↪ᕈߦߟ޿ߡ-‫ޠ‬ᐳ㐳)70㧕 ╙ 14 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬ABC 㗖ᬁ࠳ࠗ࠽ࡒ
࠶ࠢࡊ࡟࡯࠻ߩᚻⴚᚻᛛߩ⚫੺ߣᵈᗧὐ(ࡂࡦ࠭ࠝࡦ࠮࠶࡚ࠪࡦ B)‫ޠ‬ᐳ㐳)71㧕 ࠝࠬ࠹ࠝࡐࡠ࡯ࠪࠬ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߦ઻߁㛽᛬ߩ੍㒐‫ޠ‬ᐳ㐳)72㧕 ╙ 109 ࿁ᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄹ⦟㧘․೎⻠Ṷ‫ޟ‬ᄢ੽࠮ࡒ࠽࡯9 ⣶∩ᴦ≮ Up to Date㧙⣶ㇱ⣄ᩇ▤⁜⓰∝ࠍਛᔃߦ㧙‫ޠ‬ᐳ㐳)73㧕 ၯ₹⣶∩ࡈࠜ࡯࡜ࡓ 2007(ᐔᚑ 19 ᐕ 10 ᦬㧘ᎹญᏒ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)74㧕 6th Combined Meeting of Orthopaedic Reseach Societies(2007.10, Hawaii, Session 22:
Intervertebral Disc; chairperson)75㧕 ╙ 36 ࿁᧲ᶏ࿾඙ᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣶ᬁᬁ㑆᧼㓚ኂߩၮ␆ߣ⥃ᐥ‫ޠ‬ᐳ㐳)㧙㧙

76㧕 㛽☻㝃∝ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 11 ᦬㧘⑔੗㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ᕈᬁ૕㛽᛬ߩᚻⴚ‫ޠ‬ᐳ㐳)77㧕 ዊ’ᏒකᏧળ↢ᶦᢎ⢒⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ዊ’㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)78㧕 ᐔᚑ 19 ᐕᐲ╙ 4 ࿁᧲੩ㇺ⥃ᐥᢛᒻᄖ⑼කળ⛔ว⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)79㧕 ASEAN OA27 VOA06 SSHV12(2007.12, Vietnam, Two staged(posterior and anterior) surgicaltreatment for pyogenic abd tuberculotic spondylitis; Lecturer)
80㧕 ␹ᄹᎹ LCS ࡈࠜ࡯࡜ࡓ 2008(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿᏒ㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)81㧕 ╙ 110 ࿁ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᄢᵤᏒ㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒߣᴦ≮‫ޠ‬ᐳ㐳)82㧕 ⼾↰ട⨃ᢛᒻᄖ⑼ቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 4 ᦬㧘⼾↰Ꮢ㧘⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)83㧕 ዊᵿᏒකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ዊᵿᏒ㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ᕈᬁ૕㛽᛬ߩᚻⴚ‫ޠ‬Ṷ⠪)84㧕 ╙ 14 ࿁ጊญ⋵⣶∩⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጊญᏒ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᚻⴚ⊛ᴦ≮‫ޠ‬Ṷ
⠪)85㧕 ╙ 10 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂Ꮢ㧘․೎⻠Ṷ‫ޟ‬਄⢇ߩ⛉ᛗᕈᧃ᪳␹⚻㓚ኂߦߟ޿ߡ‫ޠ‬ᐳ㐳)86㧕 APOA,the Spine and Pediatric Sections 2008(2008.06, Jeju Island, Symposium 2㧦Cervicalspondylotic myelopethy; chairperson)
87㧕 APOA,the Spine and Pediatric Sections 2008(2008.06, Jeju Island, Surgical treatment forspondylolysis in young Athletes. Lecture)88㧕 ጘ㒂㛽☻㝃∝࡝ࡃ࡯ࠨࠗ࠼ࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬㜞㦂⠪ߩ㛽᛬੍㒐ߣォୟ੍‫ޠ‬ᐳ㐳)89㧕 ጘ㒂⋵ VTE ੍㒐࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘‫ޟ‬ᒰ㒮ߦ߅ߌࠆࡈࠜࡦ࠳ࡄ࡝࠿ࠢࠬߩ૶↪⚻㛎‫ޠ‬‫ޟ‬ਅ⢇ᢛᒻᄖ⑼๟ⴚᦼ੍㒐ߩᦨᣂࠬ࠻࡜࠹ࠫ࡯‫ޠ‬ᐳ㐳)90㧕 ᄖ⑼කㇱળ࡮ഭἴᜰቯකㇱળวห⻠Ṷળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⣄ᬁߩࠬࡐ࡯࠷㓚ኂ‫ޠ‬Ṷ⠪)91㧕 ╙ 41 ࿁ᣣᧄᢛᒻᄖ⑼ቇળ㛽࡮エㇱ⣲≌ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ᵿ᧻㧘ᢎ⢒⎇ୃ⻠Ṷ
‫ޟ‬Current statusof spinal tumors in the USA‫ޠ‬ᐳ㐳)92㧕 ᢛᒻᄖ⑼ቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 7 ᦬㧘㇊ⷓᏒ㧘⻠Ṷ‫ޟ‬⣄ᬁᗵᨴ∝ߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)93㧕 The 18th Japanese-Korean Combined Orthopaedic Symposium(2008.07-08, Nagasaki,
Symposium 1:spondyloarthropathy following hemodialysis. chairperson)
94㧕 ╙ 7 ࿁የᒛ↢ᵴ⠌ᘠ∛⎇ⓥળ(ᐔᚑ 20 ᐕ 8 ᦬㧘ฬฎደᏒ㧘⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)95㧕 ጘ㒂⋵࿖᳃ஜᐽ଻㒾ㆇ༡ද⼏ળળ㐳ㅪ⛊ද⼏ળ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩㧙ㆇേེߩ↢ᵴ⠌ᘠ∛‫ޠ‬Ṷ⠪)96㧕 ᄢ↰⣶ㇱ⣄ᩇ▤⁜⓰∝࠮ࡒ࠽࡯2008(2008.08, ᄢ↰Ꮢ(Korea), Hospital-clinic partership in low
back pain practice. Lecture)97㧕 SICOT/SIROT2008 XX Φ
Triennial World Congress(2008.08, Hong Kong, Free
Papers-Spine:Cervical Spine Τ. chairperson)
98㧕 ∩ߺߩᴦ≮ࡈࠜ࡜ࡓ in ጘ㒂(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⣶∩ߩ∛ᘒߣᴦ≮㧙ᣂߒ޿᭎ᔨߣᚢ⇛㧙‫ޠ‬Ṷ⠪)99㧕 ߉߰㊄⪇ጊᢛᒻᄖ⑼࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ᢛᒻᄖ⑼කߩ⍮ߞߡ߅ߊߴ߈ක≮⸷⸩ߣ࡝ࠬࠢࡑࡀࠫࡔࡦ࠻ߩ⍮⼂㧙ᢛᒻᄖ⑼කߣᖚ⠪ߩ቟ోߣ቟ᔃߩߚ߼ߦ㧙‫ޠ‬ᐳ㐳)100㧕 ╙ 6 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⢋↲Ꮺ⣲≌ߩౣᑪߣᯏ
⢻‫ޠ‬ᐳ㐳)101㧕 ╙ 15 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᄢᵤᏒ㧘․೎⻠Ṷ‫ޟ‬Percutaneousvertebroplasty‫ޠ‬ᐳ㐳)102㧕 ࡕ࡯࡜ࠬࡄ࠶ࡊ⊒ᄁ 20 ๟ᐕ⸥ᔨ⻠Ṷળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂Ꮢ㧘ᵤᎹ㓷ᒾ⻠Ṷ‫ޟ‬ᓎ⠪↢ᵴࠍᡰ߃ࠆᔃߣ૕ߩஜᐽ‫ޠ‬ᐳ㐳)103㧕 ST360° Surgical Technique Seminar(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደᏒ㧘⽸Ꮉᢛᒻᄖ⑼∛㒮㒮㐳ᳰ਄ੳᔒ⻠Ṷ ᐳ㐳)
104㧕 ╙ 42 ࿁ᣣᧄ஥ᒭ∝ቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ᄹ⦟㧘⻠Ṷ‫ޟ‬஥ᒗ∝ᴦ≮ߩࠦ࠷ ᚻⴚ(೨ᣇᴺ)‫ޠ‬Ṷ⠪)105㧕 ╙ 23 ࿁ᣣᧄᢛᒻᄖ⑼ቇળၮ␆ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘੩ㇺ㧘⻠Ṷ‫ޟ‬㗖ᬁ೨ᣇᚻⴚߦᓎ┙ߟᯏ⢻⸃೬‫ޠ‬Ṷ⠪)106㧕 8th Inspiration Meeting(2008.10, Rome, Round-table discussionn of clinical cases : Anteriorstabilization of degenerative cervical spinal lesions. chairperson )㧙㧙107㧕 ╙ 43 ࿁᧲ᶏធ㛽ቇળ࡮╙ 90 ࿁ਛㇱធ㛽ቇળ(ᐔᚑ 20 ᐕ 11 ᦬㧘⠀ፉᏒ㧘․೎⻠Ṷ‫ޟ‬㗖ᬁ∝㧘OPLLߩᚻⴚᴦ≮‫ޠ‬Ṷ⠪)108㧕 ⣶ㇱ⣄ᩇ▤⁜⓰∝ߣⴊ▤∔ᖚቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂Ꮢ㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒߣᴦ≮‫ޠ‬ᐳ㐳)109㧕 ฬᏒᄢᢛᒻᄖ⑼࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደᏒ㧘․೎⻠Ṷ‫࠷࡯ࡐࠬޟ‬ㆬᚻߩ⣶ᬁಽ㔌∝‫ޠ‬Ṷ⠪)110㧕 ଻㒾⸻≮ߦ㑐ߔࠆ⻠⠌ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጘ㒂㧘⻠Ṷ‫଻ޟ‬㒾කߣ⸻≮ႎ㈽ߩክᩏ‫ޠ‬ᐳ㐳)ᄢ㊁⾆ᢅ㧦
1㧕 ╙ 8 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ᦨޟ‬ㄭⴕߞߡ޿ࠆ⣲≌ౣᑪⴚ‫ޠ‬ᐳ㐳)2㧕 ጘ㒂⋵⥃ᐥᢛᒻᄖ⑼කળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽エㇱ⣲≌ߩ⸻≮‫ޠ‬Ṷ⠪)3㧕 ጘ㒂⥃ᐥ⣲≌⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽エㇱ⣲≌ߦߟ޿ߡ‫ޠ‬Ṷ⠪)
4㧕 ╙ 3 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᣣᏱㆣㆄߔࠆ㛽⣲≌㧙⸻≮ߩⷐὐߣ⋤ὐ㧙‫ޠ‬ᐳ㐳)
5㧕 ╙ 6 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘᜗ᓙ⻠Ṷ‫ޟ‬⢋↲Ꮺ⣲≌ߩౣᑪߣᯏ⢻‫ޠ‬ᐳ㐳)
6㧕 ╙ 32 ࿁ᄢ၂Ꮢᄖ⑼ㅪวળቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ᄢ၂㧘․೎⻠Ṷ‫ޟ‬㛽エㇱ⣲≌ߩ⸻≮‫ޠ‬Ṷ⠪)7㧕 ╙ 23 ࿁ᣣᧄᢛᒻᄖ⑼ቇળၮ␆ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘੩ㇺ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㛽エㇱ⣲≌ߩᴦ≮㧦
Future perspecrives‫ ࠻ࠬࠫࡐࡦࠪޠ‬ಽሶᮡ⊛ߣߒߡߩ EWS Ⲣวㆮવሶ)8㧕 ╙ 2 ࿁઻ଛേ‛ߩ⥃ᐥකቇ⎇ⓥળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㛽エ㛽⣲≌ߩ⥃ᐥ⹜㛎ߣකቇ₞කቇㅪ៤‫ޠ‬Ṷ⠪)9㧕 ╙ 2 ࿁઻ଛേ‛ߩ⥃ᐥකቇ⎇ⓥળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㛽エ㛽⣲≌ߩ⺖㗴‫ޠ‬ᐳ㐳)10㧕 ጘ㒂ᄖ⑼ᙣ⺣ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬エㇱ⣲≌ߩⷐὐ࡮⋤ὐ‫ޠ‬Ṷ⠪)⚦ᳯ⧷ᄦ㧦
1㧕 ᐔᚑ 17 ᐕᐲዊఽᢛᒻᄖ⑼࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ዊఽ⣄ᬁ∔ᖚ㧦ቇᩞ଻ஜ߿ᴦ
≮਄ߩ⻉໧㗴ߣߘߩኻ╷‫ޠ‬ᐳ㐳)2㧕 ╙ 5 ࿁᧲Ớ࡮ട⨃⣄ᬁᄖ⑼࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ᄙᴦ⷗㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)3㧕 ╙ 4 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⣶∩⸻ᢿߩ⪭ߣߒⓣ‫ޠ‬Ṷ⠪)4㧕 ╙ 80 ࿁ਅํᏒකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ਅํ㧘⻠Ṷ‫ޟ‬⣶∩⸻≮ߩ⪭ߣߒⓣ‫ޠ‬Ṷ⠪
5㧕 ╙ 19 ࿁ጤᚻ⣄ᬁ⣄㜑ᄖ⑼ᙣ⹤ળ㧘╙ 407 ࿁ጤᚻᢛᒻἴኂᄖ⑼ᙣ⹤ળ(ᐔᚑ 19 ᐕ 10 ᦬ 20 ᣣ㧘⋓ጟ㧘⻠Ṷ‫ޟ‬㛽☻㝃∝ᕈ⣄ᬁ㛽᛬ߦኻߔࠆ⣄ᬁ⍴❗ⴚ‫ޠ‬Ṷ⠪)
6㧕 ╙ 6 ࿁ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޡ‬㓚ኂస᦯ߩߚ߼ߩ࠾ࡘ࡯
ࡠࡃࠗࠝ࠾ࠢࠬ‫ޢ‬ᐳ㐳)7㧕 ᐔᚑ 19 ᐕᐲጘ㒂⣄ᬁ․೎⻠Ṷળ(ᐔᚑ 20 ᐕ 1 ᦬㧘ጘ㒂Ꮢ㧘⻠Ṷ‫ޟ‬⣄ᬁᄖ⑼㧙⑳ߩᎿᄦߣⴚਛ MRIᚻⴚ㧙‫ޠ‬ᐳ㐳)8㧕 ᢛᒻᄖ⑼࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 1 ᦬㧘ጘ㒂㧘⻠Ṷ‫⚻ޟ‬ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ TLIFߩታ㓙‫ޠ‬ᐳ㐳)9㧕 KAPSS ᔕ↪⣄ᩇౣᑪ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 4 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬⣄ᩇ஥ᒭ∝⍶ᱜ࿕ቯ߳ߩᔕ↪‫ޠ‬Ṷ⠪)10㧕 ࡂࠗࡍࡦ⻠Ṷળ(ᐔᚑ 20 ᐕ 9 ᦬㧘⻠Ṷ‫ޟ‬ᢛᒻᄖ⑼ߢᛒ߁⣄㜑∔ᖚߩ⸻ᢿߣᴦ≮‫ޠ‬ᐳ㐳)11㧕 ╙ 15 ࿁⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛ⎇ⓥળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᄢᵤᏒ㧘Spine Leader's lecture‫ޟ‬ᣂߒ޿᭎ᔨߩ㗖ᬁ೨ᣇ Dynamic Plate ߣߘߩ᦭↪ᕈ‫ޠ‬Ṷ⠪㧘⻠Ṷ‫ޟ‬ᣂߒ޿᭎ᔨߩ㗖ᬁ೨ᣇ Dynamic Plate㨪ߘߩ᦭↪ᕈߣᚻⴚᚻᛛ㨪‫ޠ‬Ṷ⠪)12㧕 ╙ 7 ࿁ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂Ꮢ㧘․೎⻠Ṷ‫ᧃޟ‬᪳␹⚻ᄖ⑼ߩ࡝ࡂࡆ
࡝࠹࡯࡚ࠪࡦ‫ޠ‬ᐳ㐳)13㧕 ⣶ㇱ⣄ᩇ▤⁜⓰∝ߣⴊ▤∔ᖚቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂Ꮢ㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߣ PADߩว૬ߪ޽ࠆߩ߆㧫‫ޠ‬ᐳ㐳)⷏ᧄ ⵨㧦
1㧕 ⷏Ớ⥃ᐥᢛᒻᄖ⑼කળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᄢ၂㧘ᢎ⢒⎇ୃ⻠Ṷ‫ޟ‬㛽㨯エㇱ⣲≌ᴦ≮ߩࠦ࠷ߣ⪭ߣߒⓣ‫ޠ‬
Ṷ⠪)

㧙㧙

2㧕 ╙ 115 ࿁஻ᓟᢛᒻᄖ⑼කળ(ᐔᚑ 20 ᐕ 4 ᦬㧘⑔ጊ㧘⻠Ṷ‫ޟ‬㛽㨯エㇱ⣲≌㧙⸻ᢿ߆ࠄ㓚ኂ⠪ࠬࡐ࡯࠷߹
ߢ㧙‫ޠ‬Ṷ⠪)ᄢ㊁⟵ᐘ㧦
1㧕 ╙ 2 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ᧃޟ‬᪳␹⚻៊்ߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)દ⮮⧐Პ㧦
1㧕 ╙ 1 ࿁᧲ᶏ⢆㑐▵ᄖ⑼⎇ⓥળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ᗲ⍮㧘․೎⻠Ṷ‫ޟ‬1.㛽⋚㛽᛬ߩᴦ≮࡮ᣇ㊎㧘2.⢆㑐▵∔ᖚ⸻ᢿߩࠦ࠷‫ޠ‬ᐳ㐳)2㧕 ╙ 8 ࿁ฬฎደ⢆㑐▵࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⢆㑐▵∔ᖚߦኻߔࠆ THA‫ޠ‬Ṷ⠪)
3㧕 ╙ 9 ࿁ฬฎደ⢆㑐▵࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 6 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬ᄌᒻᕈ⢆㑐▵∝ߦኻߔࠆ㛽㗡᷷ሽᚻⴚ(✚⺰)‫ޠ‬Ṷ⠪)
4㧕 ╙ 11 ࿁ฬฎደ⢆㑐▵࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 2 ᦬㧘ฬฎደ㧘⻠Ṷ‫⬄⥓ߚ޿↪ࠍ࡯࠲࡯ࡐࠨࡊ࠶ࠞޟ‬ౣᑪⴚ‫ޠ‬Ṷ⠪)
5㧕 ╙ 12 ࿁ฬฎደ⢆㑐▵࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 6 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬ᄌᒻᕈ⢆㑐▵∝ߦኻߔࠆ㛽㗡᷷ሽᚻⴚ(✚⺰)‫ޠ‬Ṷ⠪)㕍ᧁ㓉᣿㧦
1㧕 ጘ㒂⋵ធ㛽ቇળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫∔⚻␹ޟ‬ᖚߩ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ‫ޠ‬Ṷ⠪)
2㧕 ╙ 3 ࿁ጘ㒂࿁ᓳᦼ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘‫ߩࡦ࡚ࠪ࡯࠹࡝ࡆࡂ࡝ޟ‬࿾ၞㅪ៤‫)࠻ࠬࠫࡐࡦࠪޠ‬3㧕 ጘ㒂⥃ᐥᢛᒻᄖ⑼(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄖ்ᕈ㗪ㇱ∝୥⟲ߩ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ‫ޠ‬Ṷ
⠪)
4㧕 㜞㦂⠪ォୟࠍ⠨߃ࠆ⻠Ṷળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㜞㦂⠪ߩォୟ࡮㛽᛬੍㒐ߦߟ޿ߡ‫ޠ‬
ᐳ㐳)
ᄢፉᐽม㧦
1㧕 ᐔᚑ 20 ᐕᐲ↢ℂቇ⎇ⓥᚲ⎇ⓥળ‫ ╙ޟ‬2 ࿁઻ଛേ‛ߩ⥃ᐥකቇ⎇ⓥળ‫ࡑ࡯࠹ޠ‬㧦Ყセ⣲≌ቇ㧧㛽エ㛽⣲≌ࠍస᦯ߔࠆ-㛽⡺⣲ࠍਛᔃߦ-(ᐔᚑ 20 ᐕ 12 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ 4‫ޟ‬㛽エ㛽⣲≌ߩ⺖㗴‫ޠ‬Ṷ⠪)᫪ ᢕᐘ㧦
1㧕 LCS ⸥ᔨ⻠Ṷ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᒰ⑼ߦ߅ߌࠆ LCS ߩ૶↪⚻㛎‫ޠ‬Ṷ⠪)2㧕 ጘ㒂Ꮢ᳃ஜᐽ⻠ᐳ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⤒ޟ‬㑐▵∩ߦߟ޿ߡ(ᄌᒻᕈ⤒㑐▵∝ࠍਛᔃߦ)‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ⚦ᳯ⧷ᄦ㧦╙ 15 ࿁⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛ⎇ⓥળࡌࠬ࠻࡮ࡍ࡯ࡄ࡯⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേᷡ᳓సᤨ㧦
1㧕 ⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌ᆔຬળኾ㐷ᆔຬ(ᐔᚑ 18 ᐕ 1 ᦬㨪ᐔᚑ 19 ᐕ 12 ᦬)
2㧕 ᣣᧄࠬ࠻࡜ࠗࠞ࡯ᩣᑼળ␠⥃ᐥ㐿⊒ㇱ⥃ᐥᴦ㛎ߦ㑐ߔࠆකቇኾ㐷ኅ(ᐔᚑ 18 ᐕ 4 ᦬㨪ᐔᚑ 19 ᐕ 3 ᦬)
3㧕 ㆇേེߩ 10 ᐕᣣᧄᆔຬળ࿖㓙ᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 9 ᦬)
4㧕 ⥃ᐥᴦ㛎ߦ㑐ߔࠆකቇኾ㐷ኅ(㨪⃻࿷)5㧕 ᢛᒻἴኂᄖ⑼ቇ⎇ⓥഥᚑ⽷࿅ㆬ⠨ᆔຬ(㨪⃻࿷)6㧕 ᢛᒻἴኂᄖ⑼⑼ቇ⎇ⓥഥᚑ⽷࿅ડ↹㨯൐㊄ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 5 ᦬ 23 ᣣ)
7㧕 ⽷࿅ᴺੱᢛᒻἴኂ⑼ቇ⎇ⓥഥᚑ⽷࿅ℂ੐(ᐔᚑ 19 ᐕ 5 ᦬㨪⃻࿷)8㧕 ጘ㒂㔍∛ㅪ㔍∛ක≮⑔␩⋧⺣ળ⋧⺣ຬ(ᐔᚑ 20 ᐕ 10 ᦬ 5 ᣣ)
9㧕 ╙ 10 ࿁࿖㓙࠹࠾ࠬ࡮ࠬࡐ࡯࠷කቇળ⼏⚵❱ᆔຬ(ᐔᚑ 20 ᐕ 10 ᦬ 2 ᣣ㧙4 ᣣ)㧙㧙⚦ᳯ⧷ᄦ㧦
1㧕 ᣣᧄᢛᒻᄖ⑼ቇળኾ㐷කญ㗡⹜㛎(ᐔᚑ 19 ᐕ 1 ᦬ 19 ᣣ)દ⮮⧐Პ㧦1㧕 ⽷࿅ᴺੱᗲ⍮㛽エㇱ⚵❱⒖ᬀᝄ⥝⽷࿅⹏⼏ຬ(㨪⃻࿷)㕍ᧁ㓉᣿㧦1㧕 ࠫࡖࡄࡦࡄ࡜࡝ࡦࡇ࠶ࠢ᳓ᵒ ࡔ࠺ࠖࠞ࡞࠼࡯ࡇࡦࠣࠝࡈࠖࠨ࡯(ᐔᚑ 18 ᐕ 7 ᦬ 16 ᣣ㧙17 ᣣ)
2㧕 ࡈࠚࠪࡇ࠶ࠢ 2006 㓚ኂ⠪ࠬࡐ࡯࠷ࠕࠫࠕᄢળᏪห࠼ࠢ࠲࡯(ᐔᚑ 18 ᐕ 11 ᦬ 21 ᣣ㧙12 ᦬ 3 ᣣ)
3㧕 ࡗࡑࡂ⊒േᯏ㧙IPC 㓚ኂ⠪ࠕ࡞ࡍࡦࠬࠠ࡯ࡢ࡯࡞࠼ࠞ࠶ࡊ ࡔ࠺ࠖࠞ࡞࡮࠼࡯ࡇࡦࠣ࡮ࠝࡈࠖࠨ࡯(ᐔᚑ 18 ᐕ 1 ᦬ 28 ᣣ㧙2 ᦬ 1 ᣣ)
4㧕 㓚ኂ⠪ࠬࡐ࡯࠷ᜰዉຬ⻠⠌ળ⻠⟵(ᐔᚑ 19 ᐕ 3 ᦬ 10 ᣣ)
5㧕 CP ࠨ࠶ࠞ࡯ో࿖ㆬᚻᮭᄢળᄢળක(ᐔᚑ 19 ᐕ 6 ᦬ 16㧙17 ᣣ)
6㧕 㑐᧲り૕㓚ኂ⠪㒽਄┹ᛛㆬᚻᮭᄢળ࠼࡯ࡇࡦࠣකᏧ(ᐔᚑ 19 ᐕ 7 ᦬ 1 ᣣ)
7㧕 ࠫࡖࡄࡦࡄ࡜࡝ࡦࡇ࠶ࠢࠕ࡯࠴ࠚ࡝࡯࠼࡯ࡇࡦࠣකᏧ(ᐔᚑ 19 ᐕ 7 ᦬ 22 ᣣ)
8㧕 ᄢಽゞ᫹ሶࡑ࡜࠰ࡦ࠼࡯ࡇࡦࠣකᏧ(ᐔᚑ 19 ᐕ 10 ᦬ 28 ᣣ)
9㧕 US ࠝ࡯ࡊࡦ㓚ኂ⠪᳓ᵒ࿖㓙ᄢળᏪหක(ᐔᚑ 19 ᐕ 12 ᦬ 3 ᣣ㧙10 ᣣ)
10㧕 ᣣᧄࠕࡦ࠴࠼࡯ࡇࡦࠣදળ DCO(㨪⃻࿷)ᄢ㊁⟵ᐘ㧦1㧕 ᧲ᶏࡑࠗࠢࡠࠨ࡯ࠫࡖ࡝࡯⎇ⓥળ਎⹤ੱ(㨪⃻࿷)2㧕 ጘ㒂ᚻߩᄖ⑼∝଀ᬌ⸛ળᐙ੐(㨪⃻࿷)⷏ᧄ⵨㧦1㧕 ጘ㒂⋵␠ળ଻㒾⸻≮ႎ㈽⺧᳞ᦠክᩏᆔຬળክᩏᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵૕⢒දળක⑼ቇᆔຬ(ᐔᚑ 19 ᐕᐲ㨪ᐔᚑ 20 ᐕᐲ)
3㧕 ጘ㒂⋵૕⢒දળක⑼ቇᆔຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)4㧕 ጘ㒂ഭ௛ዪഭἴ଻㒾⸻≮ද⼏ળᆔຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᷡ᳓సᤨ㧚㗖ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦ㑐ߔࠆᩮᴦ⊛ᴦ≮ߦ㑐ߔࠆ⎇ⓥ ╙ 2 ႎ ᣂߒ޿ゲᬁㇱᓟᣇ㒰࿶
ᴺ㧦ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ⣄ᩇ㕤Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔ
ᚑ 18 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦129(2007 ᐕ 3 ᦬)
2㧕 ᷡ᳓సᤨ㧚㗖ᬁ੝ో៰೨ᣇ࿕ቯⴚᓟߩ⣦㛽ቯ⌕ߣౝ࿕ቯ᧚ᢱߩᄌൻߦ㑐ߔࠆ⎇ⓥ㧦ෘ↢ഭ௛⋭⑼ቇ
⎇ⓥ⾌⵬ഥ㊄㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ⣄ᩇ㕤Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 19 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦106㧙107(2008 ᐕ 3 ᦬)11㧚ႎ㆏1㧕 ᄢ㊁⾆ᢅ㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬㛽⡺⣲ߩቢᴦࠍ⋡ᜰߒߡ㧦ጘ㒂ᣂ⡞(2006 ᐕ 5 ᦬ 16 ᣣ)
2㧕 ⷏ᧄ⵨㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬ᄢಾߥᕆᕈᦼߩ࡝ࡂࡆ࡝㧦ጘ㒂ᣂ⡞(2006 ᐕ 6 ᦬ 20 ᣣ)
3㧕 ᷡ᳓సᤨ㧦⥄ォゞߢᔃ߽ஜᐽߦ ࠷ࠕ࡯࡮ࠝࡉ࡮ࠫࡖࡄࡦ㐿௅⸥ᔨ㧦ጘ㒂ᣂ⡞(2007 ᐕ 3 ᦬ 2 ᣣ)
4㧕 㕍ᧁ㓉᣿㧘⷏ᧄ⵨㧘Ꮉፒ᥍ਭ㧦ᚻᜰ਄⢇࡝ࡂࡆ࡝ᡰេࠪࠬ࠹ࡓ㧦ᢛᒻῥẂ(2007 ᐕ 12 ᦬)
5㧕 ᷡ᳓సᤨ㧦ࡑ࡞ࡎᢛᒻᄖ⑼࠮ࡒ࠽࡯㧦࡜ࠫࠝ NIKKEI ᧄ␠ࠬ࠲ࠫࠝ(2008 ᐕ 9 ᦬ 3 ᣣ᡼ㅍ)12㧚⥄Ꮖ⹏ଔ
⹏ଔ޿ߕࠇߩ⎇ⓥࠣ࡞࡯ࡊߣ߽㧘ᓢ‫ߦޘ‬లታߒߚ⎇ⓥᚑᨐࠍ᜼ߍߟߟ޽ࠆ߇㧘వㅴᕈࠍ㆐ᚑߔࠆߚ߼㧘ࠃࠅ৻ጀߩദജࠍⷐߔࠆ‫ޕ‬㆏ߩࠅ߇㐳ߊ㧘ߔߋߦߪᚑᨐ߇⃻ࠇߥ޿⺖㗴߽޽ࠆ߇㧘࿾㆏ߥദജࠍ⛮⛯ߒߡ߅ࠅ㧘੹ᓟߩዷ㐿߇ᦼᓙߢ߈ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ੱຬਇ⿷߇ᦨ߽ᄢ߈ߥ໧㗴ߢ޽ࠅ㧘ᣂ⥃ᐥ⎇ୃࠪࠬ࠹ࡓߦ⒖ⴕߒߡએ᧪⛯޿ߡ޿ࠆ‫੹ޕ‬ᓟߘߩᓇ㗀߇ߐࠄߦ㗼⪺ߣߥࠅ㧘ᄢቇ㒮↢ߩ⏕଻߇࿎㔍ߣߥࠆߎߣ߇੍ᗐߐࠇࠆ‫ߦࠇߘޕ‬෻ߒࠬ࠲࠶ࡈߩ⥃ᐥ㕙ߢߩ㧙㧙

duty ߇Ⴧടߒߡ߅ࠅ㧘৻ጀߩല₸ൻ߇ᦸ߹ࠇࠆ߇㧘හല⊛ߥ⸃᳿╷ߪߥ޿ߩ߇⃻⁁ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸవߩ໧㗴ὐߪ޽ࠆ߇㧘੹ᓟ߽⾰ߩ㜞޿⎇ⓥࠍ⋡ᜰߒߡ޿߈ߚ޿‫ޕ‬ᢛᒻᄖ⑼߇ᜂ߁㗔ၞߪ㕖Ᏹߦᐢߊ㧘᣿ࠄ߆ߦߔߴ߈໧㗴ὐ߇ᢙᄙߊሽ࿷ߔࠆ‫ࠍࠄࠇߘޕ‬ਤᔨߦ♖ᩏߒߡ㧘ᖚ⠪ߩ QOL ะ਄ߦ❬߇ࠆᣂߚߥࡔ
࠶࠮࡯ࠫࠍ㧘਎⇇ߦะߌߡ⊒ାߒߚ޿ߣ⠨߃ࠆ‫ޕ‬㧙㧙㧔5㧕⊹⤏∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
1㧕ർፉᐽ㓶ᢎ᝼ߪෘ↢ഭ௛⋭․ቯ∔ᖚᏗዋ㔍ᴦᕈ∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ਥછ⎇ⓥ⠪ߣߒߡ㧘ᄤ∊≙㧘వᄤᕈ⴫⊹᳓∊∝㧘⤥∊ᕈੇ⊈㧘᳓∊ဳ㝼㠦⊈᭽⚃⊹∝ߩ 4 ∔ᖚߦߟ޿ߡ 2002 ᐕ߆ࠄ 2004 ᐕߩ 3 ᐕ㑆ߦᒁ߈⛯߈㧘2005 ᐕ߆ࠄ 2007 ᐕߩ 3 ᐕ㑆ߦ߅޿ߡ߽⸻ᢿၮḰ㧘⊒∝ᯏᐨ㧘ᴦ≮ᴺߩ㐿⊒ߦߟ޿ߡߩ⎇ⓥࠍⴕߥߞߚ‫ߚ߹ޕ‬᳗੗⟤⾆⥃ᐥ⻠Ꮷ߇කቇ⎇ⓥ⑼㐳ࡊ࡯࡞ഥᚻߩ㊀ὐൻഥᚻߣߒߡ 2006 ᐕ 2 ᦬߆ࠄណ↪ߐࠇᧄ⎇ⓥߩਥⷐࡔࡦࡃ࡯ߣߒߡෳടߒߚ‫ޕ‬
2㧕ᄤ∊≙ߦ㑐ߔࠆ⎇ⓥᄤ∊≙࡮㘃ᄤ∊≙ߪోりߦ߮ࠄࠎ᳓∊ࠍᒻᚑߔࠆ⥄Ꮖ఺∉᳓∊∝ߢ޽ࠆ‫⚦ޕ‬⢩㑆ធ⌕᭴ㅧ㧔࠺ࠬࡕ࠰࡯
ࡓ㧕᭴ᚑᚑಽ߿㧘⴫⊹⌀⊹Ⴚ⇇ធว᭴ㅧ㧔ࡋࡒ࠺ࠬࡕ࠰࡯ࡓ㧕ߦኻߔࠆ⥄Ꮖ᛫૕ߦࠃࠅ⊒∝ߔࠆ‫ޕ‬ᒰ⑼ߢ
ߪ⥄Ꮖ఺∉ᕈ᳓∊∝ߩ⊒∝ࡔࠞ࠾࠭ࡓߩ⸃᣿ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬㘃ᄤ∊≙ߦߟ޿ߡߪർፉᐽ㓶ᢎ᝼ࠍਛᔃ
ߦ␹የዏሶ㧔⎇ⓥ⵬૒ຬ 2008 ᐕ߹ߢ࿷☋㧕㧘ጤ↰ᶈ᣿ഥᢎ߇㘃ᄤ∊≙ߩ∛ᘒ⎇ⓥࠍⴕߞߡ߅ࠅ㧘㘃ᄤ∊≙᛫૕ߦࠃࠅ᛫ේߢ޽ࠆ BP180 ᛫ේ߇ಽ⸃ߔࠆߎߣࠍ↢ൻቇ⊛ߦ⸽᣿ߒߚ‫ޕ‬ᄤ∊≙⎇ⓥߢߪ㧘ർፉᐽ㓶ᢎ᝼ߣ㕍ጊ⵨⟤⻠Ꮷࠍਛᔃߦદ૒଻㚅㧔⎇ⓥ⵬૒ຬ㧕᧛ἑ㚅ᄹ㧔ᄢቇ㒮㧕߇⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬ਥߥ⎇ⓥ࠹࡯ࡑߪᄤ∊≙᛫૕ߦࠃࠆ p120catenin 㑐ㅪ࠺ࠬࡕࠣ࡟ࠗࡦ 3 ߩಽ⸃⺃ዉࠪࠣ࠽࡞ߩ⸃ᨆߢ޽ࠆ‫ޕ‬๟౞
ഥᢎ߇ 2007 ᐕ߆ࠄ৻ᐕ㑆ࠗ࠲࡝ࠕࡕ࠺࠽ᄢቇ⊹⤏⑼㧔Carlo Pincelli ඳ჻㧕ߦࡐࠬ࠼ࠢߣߒߡ⇐ቇߒᄤ∊≙᛫૕ߦࠃࠆࠕࡐ࠻࡯ࠪࠬ⺃ዉᯏ᭴ߩ⸃ᨆߩ౒ห⎇ⓥࠍⴕߞߚ‫ޕ‬2008 ᐕ 5 ᦬࿖㓙⎇ⓥ⊹⤏⑼ቇળࠨ࠹
࡜ࠗ࠻ࠪࡦࡐࠫ࠙ࡓ‫ޡ‬Post IID 5th Joint Meeting of SSSR and SCUR, and International Meeting on
Autoimmune Bullous Disease 2008‫ࠍޢ‬ᄢᵤߢਥ௅ߒߚ‫ᧄޕ‬ቇળߪᣣᧄ㧘☨࿖㧘࡛࡯ࡠ࠶ࡄࠍਛᔃߦ⥄Ꮖ఺∉ᕈ᳓∊∝ߩ⎇ⓥ⠪߇ෳടߒᚒ‫⎇ߩߢ߹ࠇߎ߽ޘ‬ⓥᚑᨐࠍႎ๔ߒߚ‫ޕ‬
3㧕వᄤᕈ⴫⊹᳓∊∝ർፉᐽ㓶ᢎ᝼ࠍਛᔃߦᄢ㒋ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ㆮવሶᴦ≮ቇᢎቶ₹੗సੱಎᢎ᝼߅ࠃ߮ጘ㒂ᄢቇ⊹⤏∛ᘒቇᄢቇ㒮↢ߩ⍮㊁೰⋥ߣߩ౒หߢㆮવሶᴦ≮ߩၮ␆⎇ⓥࠍⴕߞߚ‫ߦ․ޕ‬⢝ఽᦼߦ఺∉ኡኈࠍ⺃ዉߔࠆߎߣߦᚑഞߒߚ‫ޕ‬
4㧕ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳߦ㑐ߔࠆ⎇ⓥ㜞ᧁ⡸೨ഥᢎ᝼㧘㓶ጊℰᩕ⥃ᐥ⻠Ꮷࠍਛᔃߦᴦ≮ᴺ㧘଻Ḩ⢻ߥߤߩ⥃ᐥ⊛⎇ⓥࠍⴕߥߞߚ‫ޕ‬
5㧕⊹⤏ᖡᕈ⣲≌ߦ㑐ߔࠆ⎇ⓥෘ↢ഭ௛⋭≸⎇ⓥࡔ࡜ࡁ࡯ࡑ⃰ળ⼏ߩ⎇ⓥදജ⠪㧔ർፉᐽ㓶ᢎ᝼㧕ߣߒߡෳടߒ㧘␹⼱⑲༑⻠Ꮷ㧘ጤ↰ᶈ᣿⥃ᐥ⻠Ꮷ㧘㕍ጊ⵨⟤⻠Ꮷࠍਛᔃߦᖡᕈ⣲≌ߦ㑐ߔࠆၮ␆⊛߅ࠃ߮⥃ᐥ⊛⎇ⓥࠍⴕߥߞߚ‫ޕ‬
6㧕ੇ⊈ߦ㑐ߔࠆ⎇ⓥ
㓶ጊℰᩕഥᢎࠍਛᔃߦ㧘⊹∐ㇱߩⷺጀߦ߅ߌࠆ࠺ࠬࡕࠣ࡟ࠗࡦ 1 ߩಽᏓߦߟ޿ߡ࠹࡯ࡊࠬ࠻࡝࠶ࡇࡦࠣ
ᴺࠍ↪޿ߡⷰኤߒ㧘ੇ⊈ߩ⸻ᢿ࡮ᴦ≮ߩ⹏ଔߥߤߦߟ޿ߡ᳃㑆ߩൻ♆ຠ㑐ㅪળ␠ߣ౒ห⎇ⓥࠍⴕߞߚ‫ޕ‬㧔ർፉᐽ㓶ᢎ᝼ߪᣣᧄੇ⊈ቇળߩℂ੐㧕7㧕⊹⤏⌀⩶∝ߦ㑐ߔࠆ⎇ⓥ㕍ጊ⵨⟤⻠Ꮷࠍਛᔃߦ⸻ᢿߣᴦ≮ᴺߩ㐿⊒⎇ⓥࠍⴕߥߞߚ‫ޕ‬㧔ർፉᢎ᝼ߪᣣᧄක⌀⩶ቇળߩℂ੐㧕
8㧕ᒝ⊹∝ߦ㑐ߔࠆ⎇ⓥᏒૼༀ㇢ಎᢎ᝼ࠍਛᔃߦ㧘ᒝ⊹∝ߦ߅ߌࠆᧃ᪳ᓴⅣ㓚ኂߩ∛ᘒ⸃᣿ߩ⎇ⓥࠍⴕߥߞߚ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

ർፉᐽ㓶
Ꮢ᧪ༀ㇢
␹⼱⑲༑
㕍ጊ⵨⟤
᳗੗⟤⾆
㓶ጊℰᩕ
ጤ↰ᶈ᣿
๟ ౞
ᄥ๺↰⍮㉿
᧻ጊ߆ߥߎ
ᐔశ⵨ሶ
⮮ដ⌀ℂሶ
ᄢᯅఝᢥ
቞ደᥓᨑ

Yasuo Kitajima
Yoshiro Ichiki
Hideki Kamiya
Yumi Aoyama
Miki Nagai
Zuiei Oyama
Hiroaki Iwata
En ShuChisato Tawada
Kanako Matsuyama
Yuuko Hiramitsu
Mariko Fujikake
Masafumi Ohhashi
Chie Moriya㧙㧙3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ർፉᐽ㓶㧘⷏ጟ ᷡ✬㧚ࠤ࡞ࠬࠬ⑱≙ߣߩ㐓೎߇㔍ߒ޿଀࡯⚦⩶࡮⌀⩶ᗵᨴ∝࡯㧦⊹⤏⑼⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦48㧙49.
2㧕 ർፉᐽ㓶㧚ṚᎹ㓷ᶈ࡮ᷰㄝ᤯৻✬㧚㘃ᄤ∊≙࡯᳓∊∝࡯㧦⊹⤏∔ᖚᦨᣂߩᴦ≮ 2007-2008㧘᧲੩㧦ධᳯၴ㧧
2006 ᐕ㧦115㧙117.
3㧕 Ꮢૼༀ㇢㧘⷏ጟ ᷡ✬㧚SLE ᄖ᧪⸻≮ߢߩ⪭ߣߒⓣ࡯∛ᘒᄌൻࠍ⷗ㅏߐߥ޿ߚ߼ߦ࡯㧦⊹⤏⑼⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦29㧙31.
4㧕 ␹⼱⑲༑㧘ᷡේ␽ᄦ࡮ጊፒ⋥਽✬㧚㒶⢆ㇱ㧦Visual Dermatology࡯ᚻⴚߦᓎ┙ߟ࡝ࡦࡄᵹࠕ࠻࡜ࠬ࡯㧘᧲੩㧦⑲Ả␠㧧2006 ᐕ㧦148㧙149.
5㧕 ␹⼱⑲༑㧘 ጊ৻ᦶ࡮࿯↰ື਽࡮ᯅᧄ 㓉࡮ฎᳯჇ㓉࡮ᷰㄝ᤯৻✬㧚‛ℂൻቇ⊛㓚ኂ࡯╙ 7 ┨࡯㧦⊹⤏⑼
ቇᢎ⑼ᦠ㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦281㧙295.
6㧕 㕍ጊ⵨⟤㧘⷏ጟ ᷡ✬㧚ᄤ∊≙ߩ⪭ߣߒⓣ࡯㕖ౖဳ଀ࠍ⷗ㅏߐߥ޿࡯㧦⊹⤏⑼⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦142㧙143.
7㧕 ጤ↰ᶈ᣿㧘ᷡේ␽ᄦ࡮ጊፒ⋥਽✬㧚⢛⣶⤦ㇱ㧦Visual Dermatology࡯ᚻⴚߦᓎ┙ߟ࡝ࡦࡄᵹࠕ࠻࡜ࠬ࡯᧲
੩㧦⑲Ả␠㧧2006 ᐕ 128㧙129.
8㧕 ␹⼱⑲༑ઁ 16 ฬ㧘⑼ቇ⊛ᩮ᜚ߦၮߠߊ⊹⤏ᖡᕈ⣲≌⸻≮ࠟࠗ࠼࡜ࠗࡦ ╙ 1 㧘᧲੩㧦㊄ේ಴ 㧧2007ᐕ
9㧕 㕍ጊ⵨⟤㧚⪭⪲⁁ᄤ∊≙㧦⋡ߢ⷗ࠆࠕ࡟࡞ࠡ࡯ᕈ⊹⤏∔ᖚ㧘᧲੩㧦ධᳯၴ㧧2007 ᐕ㧦267㧙275㧚
10㧕 Ꮢૼༀ㇢㧘ጊญ ᔀ✬㧚⊕⊈㧘⊹⤏♻⁁⩶∝㧦੹ᣣߩᴦ≮ᜰ㊎ 2008 ᐕ 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦898㧚
11㧕 Ꮢૼༀ㇢㧘ർፉᐽ㓶㧚Ḵญ᣽ሶઁ✬㧚⊹⤏ߩߒߊߺ㧦⊹⤏ߩ੐ౖ㧘᧲੩㧦ᦺୖᦠᐫ㧧2008 ᐕ㧦4㧙15㧚
12㧕 Ꮢૼༀ㇢㧘Ỉ᧛ᴦ᮸㧘ർፉᐽ㓶㧚ᄥ↰೑ሶઁ✬㧚૕⴫ㇱᗵᨴ∝㧦ᓸ↢‛ᬌᩏቇ㧘᧲੩㧦ㄭઍ಴ 㧧2008 ᐕ㧦
269㧙279㧚
13㧕 ጤ↰ᶈ᣿㧚₹⟎㇌ᒾ✚✬㧚Primary dermal melanoma㧦ᦨᣂ⊹⤏⑼ቇ૕♽㧘᧲੩㧦ਛጊᦠᐫ㧧2008 ᐕ㧦
205㧙210.
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ർፉᐽ㓶㧚᳓∊ဳవᄤᕈ㝼ῂ⊈᭽⚃⊹∝࡯᳓∊ࠍ๒ߔࠆవᄤᕈ⊹⤏∔ᖚ㧘Visual Dermatology 2008 ᐕ㧧
798㧙799㧚
2㧕 ർፉᐽ㓶㧘㕍ጊ⵨⟤㧚⴫⊹ߩ᭴ㅧߣᯏ⢻㧘Visual Dermatology 2006 ᐕ㧧2 Ꮞ㧦56㧙63㧚
3㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧚⌀⊹ߩ᭴ㅧߣᯏ⢻㧘Visual Dermatology 2006 ᐕ㧧2 Ꮞ㧦341㧙345㧚
4㧕 ർፉᐽ㓶㧚⊹⤏ࡃ࡝ࠕᯏ⢻ߣߘߩ೙ᓮ㧦⴫⊹᭴ㅧߩⷰὐ߆ࠄ࡯․㓸 ⊹⤏ࡃ࡝ࠕᯏ⢻ߣ⊹⤏ࠍ੺ߔࠆ DDS
ߩㅴᱠ㧙㧘Drug Delivery System 2007 ᐕ㧧22 Ꮞ㧦424㧙432㧚
5㧕 ർፉᐽ㓶㧚⥄Ꮖ఺∉ᕈ᳓∊∝ߩᴦ≮ߣታ㓙㧘ᣣᧄ⊹⤏⑼ቇળ㔀⹹ 2007 ᐕ㧧117 Ꮞ㧦2099㧙2101㧚
6㧕 ർፉᐽ㓶࡮ἏᎹ㓷ᶈ࡮દ⮮㓷┨࡮દ⮮ 㓉㧚⊹⤏⑼ኾ㐷ක೙ᐲߩ໧㗴ߣ੹ᓟߩᣇะᕈ㧘ᣣᧄ⊹⤏⑼ቇળ㔀⹹ 2007 ᐕ㧧117 Ꮞ㧦2229㧙2235㧚
7㧕 ർፉᐽ㓶࡮㕍ጊ⵨⟤㧚⥄Ꮖ఺∉ᕈ᳓∊∝㧘Ἳ∝ߣ఺∉ 2007 ᐕ㧧5 Ꮞ㧦633㧙638㧚
8㧕 ർፉᐽ㓶㧚⭄㤗∐࡮ⴊ▤ᕈᶋ⣲ߩᴦ≮ࠟࠗ࠼࡜ࠗࡦ࡯ᣣᧄ⊹⤏⑼ቇળ 2005 ᐕ ߩ⑳ߩ⸃㉼ߣ૶↪࡯㧘ዊఽ⑼⥃ᐥ 2007 ᐕ㧧Ⴧೀ 60 ภ㧦1437㧙1445㧚
9㧕 ␹⼱⑲༑㧚⊹⤏ᄖ⑼ߢ૗߇ߢ߈ࠆ߆࡯ᬀ⊹ߩߎߟ࡯㧔ᢎ⢒⻠Ṷᛞ㍳㓸㧕
㧘ᣣᧄ⊹⤏⑼ቇળ㔀⹹ 2007 ᐕ㧧
117 Ꮞ㧦2206㧙2207㧚
10㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧚Structure and function of hair follicle, sebaceous gland, and sweat grand㧙Ძ൮ઃዻེ♽ߩ᭴ㅧߣᯏ⢻㧘Visual Dermatology 2007 ᐕ㧧3 Ꮞ㧦51㧙55㧚
11㧕 ർፉᐽ㓶㧚✬㓸ડ↹㧘᳓∊∝ߩ⸻ᢿߣᴦ≮㧘Monthly Book Derma㧦ోᣣᧄ∛㒮಴ ળ 2008 ᐕ㧧137 ภ㧦
1㧙69㧚
12㧕 ർፉᐽ㓶㧘㕍ጊ⵨⟤㧚᳓∊∝ߩ⸻ᢿߣᴦ≮㧦⥄Ꮖ఺∉ᕈ᳓∊∝㧙዆Ᏹᕈᄤ∊≙ߣ⪭⪲⁁ᄤ∊≙ߩ⸻ᢿߣᴦ
≮㧙㧘Monthly Book Derma 2008 ᐕ㧧137 ภ㧦27㧙34.
13㧕 ർፉᐽ㓶㧚⊹⤏⑼කߦᔅⷐߥ዆Ᏹᕈੇ⊈ߩ⍮⼂㧙ੇ⊈⴫⊹∛ᘒߩ⠨߃ᣇ㧦⴫⊹ࡎࡔࠝࠬ࠲࡯ࠪࠬੇ⊈ࠪࡈ࠻㧙㧘ᣣᧄ⊹⤏⑼ቇળ㔀⹹ 2008 ᐕ㧧118㧦2527㧙2530.
14㧕 ർፉᐽ㓶㧚කቇᢎ⢒ߦ߅ߌࠆ⊹⤏⑼ቇ㧦⊹⤏⑼ቇߩකቇᢎ⢒ߣ⸻≮ߦ߅ߌࠆၮ⋚᜛ᄢߩߚ߼ߦ㧙ጘ㒂ᄢቇߢߩ⊹⤏⑼࠴ࡘ࡯࠻࡝ࠕ࡞ᢎ⢒ߣࠢ࡝࠾ࠞ࡞ࠢ࡜࡯ࠢࠪ࠶ࡊ⊹⤏⑼ᢎ⢒㧙㧘ᣣᧄ⊹⤏⑼ቇળ㔀⹹ 2008ᐕ㧧118㧦3004㧙3005.
15㧕 ർፉᐽ㓶㧚᳓∊∝ߣ᳓∊ߩߢ߈ࠆ⊹⤏∔ᖚ㧘ஜᐽᢎቶ 2008 ᐕ㧧59 Ꮞ㧦77㧙80㧚
16㧕 ␹⼱⑲༑㧚⊹⤏ᖡᕈ⣲≌ࠟࠗ࠼࡜ࠗࡦ㧦ၮᐩ⚦⢩≸ߩ⸻≮ࠟࠗ࠼࡜ࠗࡦ㧘Skin Cancer 2008 ᐕ㧧22 Ꮞ㧦
233㧙238.
17㧕 ␹⼱⑲༑㧚ၮᐩ⚦⢩≸㧘ᣣశⷺൻ∝ߦ 5-FU ᄖ↪ߪ᦭↪߆㧙ᖡᕈ⣲≌㧙㧘EBM ⊹⤏∔ᖚߩᴦ≮ 2008-2009㧧
253㧙256.
18㧕 ␹⼱⑲༑㧚੃ᚱᄖ Paget ∛ߩ⥃ᐥ⊛․㐳ߣಾ㒰▸࿐㧙⊹⤏ᖡᕈ⣲≌㧦⸻≮ࠟࠗ࠼࡜ࠗࡦߣ࠻ࡇ࠶ࠢࠬ㧙㧘කቇߩ޽ࠁߺ 2008 ᐕ㧧226 Ꮞ㧦219㧙222.

㧙㧙

19㧕 ␹⼱⑲༑㧘ᄢේ࿡┨㧚59. Tumoral calcinosis㧙♖ㆬ Clonicolor ࡌࠬ࠻ 180㧙㧘⊹⤏⑼ߩ⥃ᐥ೎ౠ 2008
ᐕ㧦116㧙117.
20㧕 ␹⼱⑲༑㧘ᄢේ࿡┨㧚119. Blepharochalasis㧙♖ㆬ Clonicolor ࡌࠬ࠻ 180㧙㧘⊹⤏⑼ߩ⥃ᐥ೎ౠ 2008ᐕ㧦232㧙233.
21㧕 ␹⼱⑲༑㧚࡝ࡦࡄ▵ㇳᷡߩ᦭ήߢ↢ሽ₸ߦᏅߥߒ㧙੃ᚱᄖࡄࠫࠚ࠶࠻∛㧙㧘Medical Tribune 2008 ᐕ㧧
41 Ꮞ㧦21.
22㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧚᳓∊∝ߩ⸻ᢿߣᴦ≮㧦⥄Ꮖ఺∉ᕈ᳓∊∝㧙ᅧᆼᕈ∊∐ߣᣂ↢ఽ㘃ᄤ∊≙ߩ⸻ᢿߣᴦ
≮㧙㧘Monthly Book Derma 2008 ᐕ㧧137 ภ㧦49㧙54.
23㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧘ⷺൻ∝⸻≮ࡑ࠾ࡘࠕ࡞㧙᳓∊ဳవᄤᕈ㝼ῂ⊈᭽⚃⦡∝㧙㧘Monthly Book Derma
2008 ᐕ㧧142 ภ㧦21㧙29.
✚⺑㧔᰷ᢥ㧕
1㧕 Kitajima Y. New perspective of autoimmune bullous diseases : Molecular cell biology of blistering
mechanisms and logical treatment. Dermatologica Sinica. 2008;26:52-64.
2㧕 Kitajima Y. Desmoglein 3 as a crucial component for investigating the regulation of desmosome
remodelling. J Stomatol Invest. 2008;1:3-5.
ේ⪺㧔๺ᢥ㧕
1㧕 Ꮢૼༀ㇢㧚∣ߺࠍ઻߁⊹⤏∔ᖚ㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦47㧙50.
2㧕 ␹⼱⑲༑㧘ጤ↰ᶈ᣿㧘ർፉᐽ㓶㧘Ꮷ੗ᵗ৻㧚੃ᚱᄖ Paget ∛ࠣ࡞࡯ࡊࠬ࠲࠺ࠖ 2005 ᐕᐲႎ๔㧘ᣣᧄ⊹⤏
ᄖ⑼ቇળ⹹ 2006 ᐕ㧧10 Ꮞ㧦24㧙27.
3㧕 㕍ጊ⵨⟤㧘ዊ↰⌀༑ሶ㧘๟ ౞㧘᳓⼱㓁ሶ㧘ർፉᐽ㓶㧚ోりᕈᒻ⾰⚦⢩Ⴧᄙ∝ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2006
ᐕ㧧48 Ꮞ㧦691㧙696.
4㧕 ᳗੗⟤⾆㧘㕍ጊ⵨⟤㧚ᄤ∊≙ߣ᳓∊ᕈ㘃ᄤ∊≙ߩ⸻ᢿߦ߅ߌࠆ ELISA ᴺ㧘කቇߩ޽ࠁߺ 2006 ᐕ㧧218
Ꮞ㧦937㧙940.
5㧕 ጤ↰ᶈ᣿㧘ട⮮ఝ૫㧘㓶ጊℰᩕ㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚ᕆㅦߦㅴⴕߒߚ㜞㦂⊒∝ߩ⩶⁁ᕷ⡺∝ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2006 ᐕ㧧48 Ꮞ㧦581㧙584.
6㧕 ᧖㊁૫ᄹ㧘㓶ጊℰᩕ㧘␹⼱⑲༑㧘Ꮢ᧪ༀ㇢㧘㜞ᧁ ⡸㧘ർፉᐽ㓶㧘ᄢ㊁ ᐽ㧚ᴦ≮⚻ㆊਛߦ⢖ࠕࠬࡍ࡞ࠡ
࡞ࠬ∝ࠍว૬ߒߚ⊹⤏╭Ἳߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2006 ᐕ㧧48 Ꮞ㧦877㧙881.
7㧕 ᧖㊁૫ᄹ㧘␹⼱⑲༑㧘ർፉᐽ㓶㧘ဈ ᣽▸㧚㜞㦂⠪ߦ⊒∝ߒߚ malignant trichilemmoma ߩ 2 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2006 ᐕ㧧48 Ꮞ㧦1641㧙1645.
8㧕 ᵻᎹ⛗ℂ㧘␹⼱⑲༑㧘๟ ౞㧘ᳯፒᥓ㚅ሶ㧘Ꮢ᧪ༀ㇢㧘㜞ᧁ ⡸㧘ർፉᐽ㓶㧘⮮ᐢḩᥓሶ㧚ળ㒶ㇱ߅ࠃ߮ਔ⣠┃ߦ∛ᄌࠍ⹺߼ߚ Triple Paget ∛ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2006 ᐕ㧧48 Ꮞ㧦437㧙440.
9㧕 ဈ ⟵⚻㧘ᷡ᳓⧷᮸㧘␹⼱⑲༑㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚⚵❱ቇ⊛ߦᄙᢙߩ balloon cell ࠍ⹺߼ߚ Superficial
Spreading Melanoma(SSM)ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ(ࡒ࠾࡟ࡐ࡯࠻) 2006 ᐕ㧧48 Ꮞ㧦598㧙599.
10㧕 ဈ ⟵⚻㧘␹⼱⑲༑㧘ർፉᐽ㓶㧚ᐢ▸࿐ߩㅒⴕᕈ⊹⤏ォ⒖ࠍ᧪ߒߚ eccrine porocarcinoma(EPC)ߩ 1 ଀㧘Skin Cancer 2006 ᐕ㧧21 Ꮞ㧦81㧙84.
11㧕 Ꮢ᧪ༀ㇢㧚⤔ේ∛ᄖ᧪㧘⊹⤏⑼ߩ⥃ᐥ 2007 ᐕ㧧49 Ꮞ㧦999㧙1000.
12㧕 ␹⼱⑲༑㧘ጤ↰ᶈ᣿㧘ർፉᐽ㓶㧘Ꮷ੗ᵗ৻㧚੃ᚱᄖ Paget ∛ࠣ࡞࡯ࡊࠬ࠲࠺ࠖ㧙2006 ᐕᐲႎ๔㧘ᣣᧄ⊹⤏
ᄖ⑼ቇળ⹹ 2007 ᐕ㧧11 Ꮞ㧦18㧙21.
13㧕 ␹⼱⑲༑㧘ᣣ⟎ടᄹ㧘ർፉᐽ㓶㧚ᖡᕈ㤥⦡⣲࡯․㓸㧦⤯ㇱߩ⊹⤏∛࡯㧘⊹⤏∛⸻≮ 2007 ᐕ㧧29 Ꮞ㧦833
㧙836.
14㧕 ᢪ↰ବ᣿㧘ᐘ㊁ ஜ㧘⌀㍿ ᳞㧘࿯↰ື਽㧘ጊᧄ᣿ผ㧘ጊፒ⋥਽㧘ᷡේ␽ᄦ㧘┻ਯౝㄖ਽㧘౎↰ዏੱ㧘␹
⼱⑲༑㧘ᷡේ㓉ብ㧘Ꮷ੗ᵗ৻㧘㣮㑆⋥ੱ㧘㜞↰ ታ㧘ቝේ ਭ㧘ฎ⾐ᒄᔒ㧚ᣣᧄ⊹⤏⑼ቇળࠟࠗ࠼࡜ࠗࡦ࡮
⊹⤏ᖡᕈ⣲≌⸻≮ࠟࠗ࠼࡜ࠗࡦ㧘ᣣᧄ⤏⑼ቇળ㔀⹹ 2007 ᐕ㧧117 Ꮞ㧦1855㧙1925.
15㧕 ጤ↰ᶈ᣿㧘ዊ᎑ਃ૫㧘ᵻᎹ⛗ℂ㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚⚃⊹∝ࠍ߈ߚߒߚ⊹⤏╭Ἳߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ
2007 ᐕ㧧49 Ꮞ㧦165㧙169.
16㧕 ጤ↰ᶈ᣿㧘␹⼱⑲༑㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚ᒰ⑼ߦ߅ߌࠆࡑࠗࡏ࡯ࡓ⣼≸ߩ߹ߣ߼㧘⊹⤏⑼ߩ⥃ᐥ 2007
ᐕ㧧49 Ꮞ㧦567㧙570.
17㧕 ᵻ੗߆ߥߎ㧘ጤ↰ᶈ᣿㧘␹⼱⑲༑㧘ർፉᐽ㓶㧚㆙㓒ォ⒖ࠍ᧪ߒߚ⎕უဳၮᐩ⚦⢩≸ߩ 1 ଀㧘Skin Cancer
2007 ᐕ㧧22 Ꮞ㧦57㧙61.
18㧕 ㋈ᧁᥓሶ㧘ጤ↰ᶈ᣿㧘㓶ጊℰᩕ㧘␹⼱⑲༑㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚ⴊ▤⡺⣲ߩ 2 ଀ߣᒰ⑼ߦ߅ߌࠆᴦ≮ߩᄌㆫ㧘Skin Cancer 2007 ᐕ㧧22 Ꮞ㧦130㧙135.
19㧕 㘸㊁ ᓀ㧘ᵻ੗߆ߥߎ㧘ጤ↰ᶈ᣿㧘␹⼱⑲༑㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚23 ᐕᓟߦ⢖ォ⒖ࠍ᧪ߒߚ ultra-laterecurrence ߣ⠨߃ߚᖡᕈ㤥⦡⣲ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2007 ᐕ㧧49 Ꮞ㧦633㧙636.
20㧕 ␹⼱⑲༑㧘ጤ↰ᶈ᣿㧘ർፉᐽ㓶㧘Ꮷ੗ᵗ৻㧚੃ᚱᄖ Paget ∛ࠣ࡞࡯ࡊࠬ࠲࠺ࠖ-2007 ᐕᐲႎ๔㧘ᣣᧄ⊹⤏
ᄖ⑼ቇળ⹹ 2008 ᐕ㧧12 Ꮞ㧦140㧙143.
21㧕 㘸㊁ ᓀ㧘ᏒᎹ⵨ሶ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧘ᴡౝ㓉ᒄ㧘ጊ↰ବ᮸㧘᫪⣁ਭ㓉㧚B ⚦⢩࡝ࡦࡄ⣲ߦ઻ߞߚ⣲≌㓐઻ᕈᄤ∊≙ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦31㧙34.
22㧕 㘸㊁ ᓀ㧘ᏒᎹ⵨ሶ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧘ේ ᱞᔒ㧘᫪⣁ਭ㓉㧚Narrow-Band UVB ≮ᴺߦࠃࠆᴦ≮ߢ৻ᤨ⊛ߥലᨐࠍᓧࠄࠇߚᚑੱ T ⚦⢩⊕ⴊ∛/࡝ࡦࡄ⣲ߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦133㧙136.
23㧕 ૒⮮ਃ૫㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧚ࠨ࡝࠴࡞㉄ࠣ࡝ࠦ࡯࡞߅ࠃ߮ 1-ࡔࡦ࠻࡯࡞ߦࠃࠆὐ⁁⚡᢬ࠍ઻ߞߚធ⸅
ᕈ⊹⤏Ἳߩ 1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦727㧙731.

㧙㧙24㧕 ᵻ੗߆ߥߎ㧘ᣣ⟎ടᄹ㧘ᨋ ⟤Ⓞ㧘☨↰๺ผ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧚ᓟᄤᕈ⴫⊹᳓∊∝ߩ 1 ଀㧘⊹⤏⑼ߩ
⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦1613㧙1616.
25㧕 ᳰ↰ᔒᢦ㧘㤥ᴛ⟤ᥓሶ㧘ጊᧄ᣿⟤㧘₹੗సੱ㧘☨↰⠹ㅧ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧔ᣣᧄ⊹⤏⑼ቇળࠟࠗ࠼࡜
ࠗࡦ૞ᚑᆔຬળ㧕㧚ᣣᧄ⊹⤏⑼ቇળ⸻≮ࠟࠗ࠼࡜ࠗࡦ㧙᳓∊ဳవᄤᕈ㝼ῂ⊈᭽⚃⦡∝㧘ᣣᧄ⊹⤏⑼ቇળ㔀⹹
2008 ᐕ㧧118 Ꮞ㧦343㧙346.
26㧕 ᵻᎹ⛗ℂ㧘⨹ᧁ㤗㉿㧘᳗੗⟤⾆㧘␹⼱⑲༑㧘ർፉᐽ㓶㧘ဈ ᣽▸㧚਄⣨ߦ↢ߓߚ⊹ਅဳࡔ࡞ࠤ࡞⚦⢩≸ߩ
1 ଀㧘⊹⤏⑼ߩ⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦405㧙408.
27㧕 ጤ↰ᶈ᣿㧘૒⮮ਃ૫㧘㕍ጊ⵨⟤㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚BCG ធ⒳ㇱ૏ߦ⊹⤏ẩ≌ࠍ↢ߓߚ 1 ଀㧘⊹⤏⑼ߩ
⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦420㧙421.
28㧕 ጤ↰ᶈ᣿㧘㕍ጊ⵨⟤㧘␹⼱⑲༑㧘Ꮢ᧪ༀ㇢㧘ർፉᐽ㓶㧚ᒰ⑼ߦ߅ߌࠆญໃ≸㧔᦭᫚⚦⢩≸㧕ߩ߹ߣ߼㧘⊹⤏⑼ߩ⥃ᐥ 2008 ᐕ㧧50 Ꮞ㧦1139㧙1142.
ේ⪺㧔᰷ᢥ㧕
1㧕 Amagai M, Ahmed AR, Kitajima Y, Bystryn JC, Milner Y, Gniadecki R, Hertl M, Pincelli C, Kurzen H,
Fridkis-Hareli M, Aoyama Y, Frusic-Zlotkin M, Muller E, David M, Mimouni D, Vind-Kezunovic D,
Michel B, Mahoney M, Grando S. Are desmoglein autoantibodies essential for the
immunopathogenesis of pemphigus vulgaris, or just “witnesses of disease” ?. Exp Dermatol.
2006;15:815-831.
2㧕 Kamiya H, Kitajima Y, Ban M. Bowen’s disease with invasive adnexal carcinoma: the pluripotential
nature of Bowen’s disease cells. J Dermatol. 2006;33:858-864.
3㧕 Kawasaki Y, Aoyama Y, Tsunoda K, Amagai M, Kitajima Y. Pathogenic monoclonal antibody against
desmoglein3 augments desmoglein 3 and p38 MARK phosphorylation in human squamous carcinoma
cell line. Autoimmunity. 2006;39:587-590.
4㧕 Tosaki H, Kunisada T, Motohashi T, Aoki H, Yoshida H, Kitajima Y. Mice transgenic for kitV620A:
recapitulation of piebaldism but not progressive depigmentation seen in humans with this mutation. J
Invest Dermatol. 2006;126:1111-1118.
5㧕 Chernyavsky AI, Arredondo J, Kitajima Y, Sato-Nagai M, Grando SA. Desmoglein vs non-desmoglein
signailing in pemphigus acantholysis: characterization of novel signaling pathways downstream of
pemphigus vulgaris antigens. J Biol Chem. 2007;282:13804-11382.
6㧕 Kitajima Y, Aoyama Y. A perspective of pemphigus from bedside and laboratory-bench. Clin Rev Allerg
Immu. 2007;33:57-66.
7㧕 Ichiki Y, Kitajima Y. Thrombotic thrombocytopenic purpura associated with systemic lupus
erythematosus. EurJDermatol. 2007;17:548-549.
8㧕 Aoyama Y, Asai K, Hioki K, Funato M, Kondo N, Kitajima Y. Herpes gestationis in a mother andnewborn: immunoclinical perspectives based on a weekly follow-up the enzyme-linked immunosorbent
assay index of a bullous pemphigoid antigen noncollageous domain. Arch Dermatol.
2007;143:1168-1172.
9㧕 Suzuki N, Suzuki T, Inagaki K, Ito S, Kono M, Horikawa T, Fujiwara S, Ishiko A, Matsunaga K,
Aoyama Y, Tosaki-Ichikawa H, Tomita Y. Ten novel mutations of the ADARI gene in Japanese patientswith dyschromatosis symmetrica hereditaria. J Invest Dermatol. 2007;127:309-311.
10㧕 Iwata H, Aoyama Y, Esaki C, Kitajima Y. Cicatricial pemphigoid with prominent alopecia. Eur J
Dermatol. 2007;17:338-339.
11㧕 Shu E, Yamamoto Y, Aoyama Y, Kitajima Y. Intraperitoneal injection of pemphigus vulgaris-IgG into
mouse depletes epidermal keratinocytes of desmoglein 3 associated with generation of acantholysis.
Arch Dermatol Res. 2007;299:165-167.
12㧕 Yamamoto Y, Aoyama Y, Shu E, Tsunoda K, Amagai M, Kitajima Y. Anti-desmoglein3(Dsg3)
monoclonal antibodies deplete desmosomes of Dsg3 and differ in their Dsg3-depleting activities
related to pathogenicity. J Biol Chem. 2007;282:17866-17876.
13㧕 Yamamoto Y, Aoyama Y, Shu E, Tsunoda Y, Amagai M, Kitajima Y. No activation of urokinase
plasminogen activator by anti-desmoglein 3 monoclonal IgG antibodies in cultured humankeratinocytes. J Dermatol Sci. 2007;47:119-125.
14㧕 Ichiki Y, Kato Y, Kitajima Y. Assessment of burn area: most objective method. Burns. 2008;34:425-426.
15㧕 Ichiki Y, Kitajima Y. Ulcerative sarcoidosis; case report and review of Japanese literature. Acta Derm
Venereol. 2008;88:526-528.
16㧕 Ichiki Y, Kitajima Y. Successful treatment of scleroderma-related cutaneous ulcer with suction blistergrafting. Rheumatol Int. 2008;28:299-301.
17㧕 Kato Y, Ichiki Y, Kitajima Y. A case of systemic lupus erythematosus presenting as hypoglycemia due
to anti-insulin receptor antibodies Rheumatol Int. 2008;29:103-105.
18㧕 Aoyama Y, Nagasawa C, Nagai M, Kitajima Y. Severe pemphigus vulgaris: successful combination
therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent reboundincrease in pathogenic IgG. Eur J Dermatol. 2008;18:557-560.
19㧕 Kanno M, Aoyama Y. Yamoto Y, Kitajima Y. p120 catenin is associated with desmogleins when
desmosomes are assembled in high-Ca2+ medium but not when disassembled in low- Ca2+medium in㧙㧙

IF 2.951
IF 0.694

IF 2.887

IF 4.829

IF 5.581
IF 2.077
IF 1.294

IF 2.845

IF 4.829
IF 1.294

IF 1.596

IF 5.581

IF 2.500
IF 1.220
IF 1.927
IF 1.270
IF 1.270

IF 1.294

DJM-1 cells. J Dermatol. 2008;35:317-324.
IF 0.694
20㧕 Kanno M, Isa Y, Aoyama Y, Yamamoto Y, Nagai M, Ozawa M, Kitajima Y. p120-catenin is a novel
desmoglein 3 interacting partner: identification of p120-catenin association site of desmoglein 3. Exp
Cell Res. 2008;314:1683-1692.
IF 3.6954㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ർፉᐽ㓶㧘⎇ⓥಽᜂ⠪㧦Ꮢ᧪ༀ㇢㧘㕍ጊ⵨⟤㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦
⴫⊹⚦⢩㑆ធ⌕࡮⚦⢩㛽ᩰಽሶ㑆⚿ว೙ᓮߣฦ⒳᳓∊∝⊒∝ᯏᐨߩಽሶ↢‛ቇ⊛⎇ⓥ㧧ᐔᚑ 16㧙18
ᐕᐲ㧧14,500 ජ౞(10,100㧦2,300㧦2,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ർፉᐽ㓶㧘⎇ⓥಽᜂ⠪㧦ᯅᧄ 㓉㧘ᄤ⼱㓷ⴕ㧘ጤ᦬໪᳁㧘⸵ ධᶈ㧘ዊችᩮ⌀ᑿ㧘ᷡ᳓ ብ㧘ᯅᧄ౏ੑ㧘㊄↰቟ผ㧘ᳰ↰ᔒᢦ㧘ጊᧄ᣿⟤㧘㤥ᴛ⟤ᥓሶ㧘ዊỈ ᣿㧘ፉ↰⋿〝㧘ᾖ੗ ᱜ㧘ᣂ㑐ኡᓼ㧘₹੗సੱ㧘☨↰᭴ㅧ㧘㕍ጊ⵨⟤㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ∔ᖚኻ╷⎇ⓥ੐ᬺ㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧154,700 ජ౞(39,000㧦57,200㧦58,500
ජ౞)3㧕 ⎇ⓥઍ⴫⠪㧦ᢪ↰ବ᣿㧘⎇ⓥಽᜂ⠪㧦ർፉᐽ㓶㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦ᖡᕈ㤥⦡⣲ߩᴦ≮㧧
ᐔᚑ 18 ᐕᐲ㧧200 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦Ꮢ᧪ༀ㇢㧘⎇ⓥಽᜂ⠪㧦㜞ᧁ ⡸㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ㆆ⿛
ᕈⅣ⁁⚃᢬㓍઻ᕈవᄤᕈ⴫⊹᳓∊∝ࠍࡕ࠺࡞ߣߒߚࠤ࡜࠴ࡦ∛ߩಽሶ↢‛ቇ⊛⸃ᨆ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,600 ජ౞(3,000㧦600 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᄤ∊≙ߦ߅ߌࠆ∛ේᕈࠪࠣ࠽
࡞વ㆐⚻〝ߩᬌ⸛㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,700 ජ౞(3,200㧦500 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ጘ㒂ᄢቇකቇㇱ㐳ⵙ㊂⚻⾌㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ጘ㒂ᄢቇ∛㒮㐳ⵙ㊂⚻⾌㧦ᖚ⠪ⴊᷡਛߩ᛫ BP180 ᛫૕ߩ᷹ቯ㧘⥄Ꮖ᛫૕ߩ᛫ේ᳿ቯ㧧ᐔᚑ 18 ᐕᐲ㧧2,100 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ർፉᐽ㓶㧘⎇ⓥදജ⠪㧦㕍ጊ⵨⟤㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ∔ᖚኻ╷⎇ⓥ੐
ᬺ㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧1,000 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦᳗੗⟤⾆㧧ጘ㒂ᄢቇකቇㇱ㐳ⵙ㊂⚻⾌㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞
10㧕 ⎇ⓥઍ⴫⠪㧦ጤ↰ᶈ᣿㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦੃ᚱᄖࡄࠫࠚ࠶࠻∛ߣ⴫⊹ౝ≸ߩᶐẢ࡮ォ⒖₪ᓧᯏᐨߩ MIA ⊒⃻ߣᯏ⢻߆ࠄ⷗ߚ⸃ᨆ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,600 ජ౞(3,100㧦500ජ౞)11㧕 ⎇ⓥઍ⴫⠪㧦ጊፒ⋥਽㧘⎇ⓥಽᜂ⠪㧦ർፉᐽ㓶㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦ᖡᕈ㤥⦡⣲ߩᴦ≮㧧
ᐔᚑ 19 ᐕᐲ㧧200 ජ౞
12㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᄤ∊≙᛫૕ߦࠃࠆ࠺ࠬࡕࠣ࡟ࠗ
ࡦ 3 ⚿วဳ p120ctn 㑐ㅪࠪࠣ࠽࡞વ㆐ᯏ᭴ߩ⸃ᨆ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,700 ජ౞(3,200㧦500 ජ౞)
13㧕 ⎇ⓥઍ⴫⠪㧦ർፉᐽ㓶㧘⎇ⓥදജ⠪㧦㕍ጊ⵨⟤㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ∔ᖚኻ╷⎇ⓥ੐
ᬺ㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,500 ජ౞
14㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ጘ㒂ᄢቇකቇㇱ㐳ⵙ㊂⚻⾌㧧ᐔᚑ 19 ᐕᐲ㧧500 ජ౞
15㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ጘ㒂ᄢቇ∛㒮㐳ⵙ㊂⚻⾌㧦ᖚ⠪ⴊᷡਛߩ᛫ BP180 ᛫૕ߩ᷹ቯ㧘⥄Ꮖ᛫૕ߩ᛫ේ᳿ቯ㧧ᐔᚑ 19 ᐕᐲ㧧2,100 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦ጊፒ⋥਽㧘⎇ⓥಽᜂ⠪㧦ർፉᐽ㓶㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦ᖡᕈ㤥⦡⣲ߩᴦ≮㧧
ᐔᚑ 20 ᐕᐲ㧧200 ජ౞
17㧕 ⎇ⓥઍ⴫⠪㧦ጤ᦬໪᳁㧘⃰ຬ㧦㕍ጊ⵨⟤㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ∔ᖚኻ╷⎇ⓥ੐ᬺ㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞
18㧕 ⎇ⓥઍ⴫⠪㧦㕍ጊ⵨⟤㧧ጘ㒂ᄢቇ∛㒮㐳ⵙ㊂⚻⾌㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚ㧔⥄Ꮖ఺∉ᕈ᳓∊∝࡮వᄤᕈ㝼㠦⊈᭽⚃⊹∝࡮వᄤᕈ⴫⊹ធ⌕ಽሶ⇣Ᏹ∝㧕ߩಽሶቇ⊛⸻ᢿ㧧ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞
19㧕 ⎇ⓥઍ⴫⠪㧦ጤ↰ᶈ᣿㧧ጘ㒂ᄢቇකቇㇱ㐳ⵙ㊂⚻⾌㧦᳓∊ᕈ㘃ᄤ∊≙ߩ᳓∊ᒻᚑᯏᐨ⸃᣿ߩታ㛎㧧ᐔᚑ 20 ᐕᐲ㧧500 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ㧙㧙5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬർፉᐽ㓶㧦
1㧕 ᣣᧄ⊹⤏⑼ቇળℂ੐࡮೽ℂ੐㐳(㨪ᐔᚑ 18 ᐕ 4 ᦬)
2㧕 ᣣᧄ⊹⤏⑼ቇળਛㇱᡰㇱ㐳(㨪ᐔᚑ 19 ᐕ 3 ᦬)
3㧕 ᣣᧄකቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄੇ⊈ቇળℂ੐(㨪⃻࿷)5㧕 㖧࿖⎇ⓥ⊹⤏⑼ቇળฬ⹷ળຬ(㨪⃻࿷)6㧕 ᣣᧄක⌀⩶ቇળℂ੐(㨪⃻࿷)7㧕 ᣣᧄᖡᕈ⣲≌ቇળℂ੐(㨪⃻࿷)8㧕 ᣣᧄ⎇ⓥ⊹⤏⑼ቇળ⹏⼏ຬ(㨪⃻࿷)9㧕 ᣣᧄ⚿ว❱ቇળ⹏⼏ຬ(㨪⃻࿷)10㧕 ᣣᧄ㔚㗼⊹⤏↢‛ቇળㆇ༡ᆔຬ(㨪⃻࿷)11㧕 ⷺൻ∝⎇ⓥળℂ੐㧘᳓∊∝⎇ⓥળળ㐳࡮਎⹤ੱᐙ੐(㨪⃻࿷)Ꮢૼༀ㇢㧦1㧕 ᣣᧄ⥃ᐥ⊹⤏⑼කળ᧲ᶏർ㒽ᡰㇱㆇ༡ᆔຬ(㨪⃻࿷)␹⼱⑲༑㧦
1㧕 ╙ 24 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ੐ോዪ㐳(㨪ᐔᚑ 20 ᐕ 7 ᦬)
2㧕 ᣣᧄ⊹⤏ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⊹⤏⑼ቇળ࡮⊹⤏ᖡᕈ⣲≌ᜰዉኾ㐷කᆔຬ(㨪⃻࿷)5㧕 ੃ᚱᄖ Paget ∛⎇ⓥળ਎⹤ੱ(㨪⃻࿷)㕍ጊ⵨⟤㧦1㧕 Post IID 5th Joint Meeting of SSSR & SCUR, and International Meeting on Autoimmune Bullous
Disease 2008 ੐ോዪ㐳(㨪ᐔᚑ 20 ᐕ 5 ᦬)
2㧕 ᣣᧄ⎇ⓥ⊹⤏⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⊹⤏⑼ቇળ᧲ᶏ࿾ᣇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᳓∊∝⎇ⓥળ੐ോዪ(㨪⃻࿷)2㧕ቇળ㐿௅ർፉᐽ㓶㧦
1㧕 ╙ 235 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ)2㧕 ╙ 237 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ฬฎደ)3㧕 ╙ 51 ࿁ᣣᧄක⌀⩶ቇળ✚ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘㜞ጊ)4㧕 SSSR & SCUR Joint Meeting2008 as a post IID 2008(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢᵤ)5㧕 Post IID Autoimmune Bullous Disease 2008(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢᵤ)6㧕 ╙ 24 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ✚ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)7㧕 ╙ 246 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደ)
3㧕ቇⴚ㔀⹹ർፉᐽ㓶㧦
1㧕 ᣣᧄ⊹⤏⑼ቇળ㔀⹹㧧✬㓸ᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
2㧕 Journal of Dermatology㧧Editor(㨪⃻࿷)␹⼱⑲༑㧦
1㧕 ᣣᧄ⊹⤏⑼ቇળ࡮⊹⤏ᖡᕈ⣲≌⸻≮ࠟࠗ࠼࡜ࠗࡦ૞ᚑᆔຬ(㨪ᐔᚑ 20 ᐕ 3 ᦬)㧙㧙㕍ጊ⵨⟤㧦
1㧕 Journal of Dermatology㧧Section Editor, Faculty of 1000 Medicine(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ർፉᐽ㓶㧦
1㧕 ╙ 69 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲੩ᡰㇱቇળ(ᐔᚑ 18 ᐕ 2 ᦬㧘᧲੩㧘․೎࠮࠶࡚ࠪࡦ‫⑼⤏⊹ޟ‬ᢎ⢒࡮⎇ୃߩ⃻⁁ߣ዁᧪‫ޠ‬Ṷ⠪)
2㧕 ╙ 31 ࿁ᣣᧄ⎇ⓥ⊹⤏⑼ቇળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘Concurrent Oral Session‫ޟ‬Carcinogenesis, Gene
Expression, Transaction Regulation‫ޠ‬ᐳ㐳)
3㧕 ╙ 105 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 18 ᐕ 6 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ 5‫ޟ‬᳓∊∝㧦ᦨㄭߩㅴᱠ‫ޠ‬ᐳ㐳)4㧕 33rd Annual Meeting of the Society for Cutaneous Ultrastructurrer Research(2006 ᐕ 6 ᦬㧘Warszawa, Porland㧘․೎⻠Ṷ‫ޟ‬Blistering mechanisms of pemphigus vulgaris: biochemical andultrastractual studies‫ޠ‬Ṷ⠪)
5㧕 ⊹⤏ၮ␆⎇ⓥᚲࠢ࡜ࠬ࠲࡯ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 7 ᦬㧘᧲੩㧘․೎⻠Ṷ‫⚦࠻ࠗࠨࡁ࠴࡜ࠤ⊹⴫ޟ‬⢩㑆ធ⌕ߩᯏ᭴‫ޠ‬Ṷ⠪)
6㧕 ╙ 21 ࿁ⷺൻ∝⎇ⓥળ(ᐔᚑ 18 ᐕ 8 ᦬㧘᧲੩㧘․೎⻠Ṷ‫⊹⴫ޟ‬ጀ᧼㗰☸ࠍ߼ߋࠆᦨㄭߩ⍮⷗‫ޠ‬ᐳ㐳)7㧕 ᣣᧄ⊹⤏⑼ቇળ╙ 338 ࿁⑔ጟ࿾ᣇળ(ᐔᚑ 18 ᐕ 9 ᦬㧘౎ᐈ㧘․೎⻠Ṷ‫ޟ‬ᄤ∊≙ߩ⊒∝ᯏᐨߣᴦ≮ߩታ㓙㧦ⴊẏ੤឵㧘ࠬ࠹ࡠࠗ࠼ࡄ࡞ࠬ㧘఺∉ᛥ೙೷‫ޠ‬Ṷ⠪)8㧕 ╙ 56 ࿁ᣣᧄ⊹⤏⑼ቇળਛㇱᡰㇱቇળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘ᢎ⢒⻠Ṷ‫ޟ‬㘃ᄤ∊≙ߣߘߩ㘃∝ߩ∛ᘒߣᴦ≮‫ޠ‬ᐳ㐳)9㧕 ╙ 70 ࿁ቇળᣣᧄ⊹⤏⑼ቇળ᧲੩ᡰㇱቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘᧲੩㧘․೎⻠Ṷ‫∛ޟ‬㒮߆ࠄ⷗ߚ⊹⤏⑼ߩක≮⚻ᷣቇ㧦⃻⁁ߣኻ╷㧙ጘ㒂ᄢቇ∛㒮ࠍ଀ߦߒߡ‫ޠ‬Ṷ⠪㧕10㧕 ╙ 106 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ‫⥄ޟ‬Ꮖ఺∉᳓∊∝ߩᴦ≮ߩታ㓙㧦᳓∊∝ߩၮ␆⍮⼂‫ޠ‬Ṷ⠪)11㧕 ╙ 106 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ‫⑼⤏⊹ޟ‬ኾ㐷ක೙ᐲߩ໧㗴ߣ੹ᓟߩᣇะᕈ‫ޠ‬ᐳ㐳)12㧕 ╙ 58 ࿁ᣣᧄ⊹⤏⑼ቇળਛㇱᡰㇱቇⴚᄢળ(ᐔᚑ 19 ᐕ 10 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ‫⸻࡯ࡇࠦࠬࡕ࡯࠳ޟ‬ᢿṶ⠌‫ޠ‬ᐳ㐳㧕13㧕 33rd Annual Meeting of the Taiwanese Dermatological ssociation(2007 ᐕ 11 ᦬㧘Taipei,Taiwan㧘
Professor Lu Yau-Chin Memorial Lectureship ฃ⾨⻠Ṷ‫ޟ‬A new perspective of autoimmune
bullous diseases: molecular cell biology of blistering mechanisms and logical treatments‫ޠ‬Ṷ⠪㧕
14㧕 ╙ 71 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲੩ᡰㇱቇળ(ᐔᚑ 20 ᐕ 2 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 5‫ޟ‬ක≮⚻ᷣߣක≮⚻ℂߩ㆑޿ߦߟ޿ߡ㧙ᖚ⠪ߩߚ߼ߩක≮⚻ᷣߣක≮⚻༡ߩ㆑޿‫ޠ‬Ṷ⠪)
15㧕 ╙ 90 ࿁ᣣᧄ⊹⤏⑼ቇળ㕒ጟ࿾ᣇળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ᵿ᧻㧘․೎⻠Ṷ‫ޟ‬ᄤ∊≙ߩ᳓∊ᒻᚑᯏᐨߣᴦ≮㧦ᄤ∊≙ߪ࠺ࠬࡕ࠰࡯ࡓ࡝ࡕ࠺࡝ࡦࠣ∛ߩⷞὐ߆ࠄ‫ޠ‬Ṷ⠪)
16㧕 ╙ 60 ࿁ᣣᧄ⊹⤏⑼ቇળጊ᪸࿾ᣇળ(ᐔᚑ 20 ᐕ 4 ᦬㧘↲ᐭ㧘․೎⻠Ṷ 1.‫ޟ‬ᄤ∊≙ߣ㘃ᄤ∊≙ߪ࠺ࠬࡕ࠰࡯ࡓ࡮ࡋࡒ࠺ࠬࡕ࠰࡯ࡓ࡝ࡕ࠺࡝ࡦࠣ∛‫ޠ‬2.‫ޟ‬ක≮⚻ᷣߣක≮ㆇ༡㧦∛㒮ߣ⊹⤏⑼㧙ጘ㒂ᄢቇ∛㒮㐳⚻㛎߆ࠄቇࠎߛߎߣ‫ޠ‬Ṷ⠪)17㧕 ╙ 60 ࿁ᣣᧄ⊹⤏⑼ቇળጊ᪸࿾ᣇળ(ᐔᚑ 20 ᐕ 4 ᦬㧘↲ᐭ㧘․೎⻠Ṷ 2.‫ޟ‬ක≮⚻ᷣߣක≮ㆇ༡㧦∛㒮ߣ⊹⤏⑼㧙ጘ㒂ᄢቇ∛㒮㐳⚻㛎߆ࠄቇࠎߛߎߣ‫ޠ‬Ṷ⠪)18㧕 ╙ 107 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ 1-1‫∛⊹⴫⊈ੇޟ‬ᘒߩ⠨߃ᣇ㧦⴫⊹ࡎࡔࠝࠬ࠲࡯ࠪࠬੇ⊈ࠪࡈ࠻‫ޠ‬Ṷ⠪)
19㧕 ╙ 107 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ 40‫ޟ‬කቇᢎ⢒ߦ߅ߌࠆ⊹⤏⑼ቇ㧦⊹⤏⑼ቇߩකቇᢎ⢒ߣ⸻≮ߦ߅ߌࠆၮ␆᜛ᄢߩߚ߼ߦ‫ޠ‬ᐳ㐳)20㧕 ╙ 107 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ 40-2‫ޟ‬තᓟᢎ⢒㧦ጘ㒂ᄢቇߢߩ࠴ࡘ
࡯࠻࡝ࠕ࡞ߣࠢ࡝࠾ࠞ࡞ࠢ࡜࡯࡚ࠢࠪ࠶ࡊ⊹⤏⑼ᢎ⢒‫ޠ‬Ṷ⠪)
21㧕 ⊹⤏ၮ␆⎇ⓥࠢ࡜ࠬ࠲࡯ࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘․೎⻠Ṷ‫⚦⊹⴫ޟ‬⢩ߩⷺൻߣ⊹⤏∔ᖚ‫ޠ‬ᐳ㐳)22㧕 ╙ 23 ࿁ᣣᧄੇ⊈ቇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᣩᎹ㧘ࠪࡦࡐࠫ࠙ࡓ‫⎇ߩ⊈ੇޟ‬ⓥߣᴦ≮ߩዷ㐿‫ޠ‬ᐳ㐳)23㧕 ╙ 18 ࿁ᣣᧄญ⣧☼⤑ቇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘᧲੩㧘․೎⻠Ṷ‫࠺ࡕ࡝ࡓ࡯࠰ࡕࠬ࠺ߩ࠻ࠗࠨࡁ࠴࡜ࠤޟ‬࡝ࡦࠣ㓚ኂߦࠃࠆ਄⊹∔ᖚ㧦᳓∊∝࡮ⷺൻ⇣Ᏹ∝࡮ಽൻ⇣Ᏹ∝‫ޠ‬Ṷ⠪)24㧕 ╙ 72 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲ㇱᡰㇱቇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘⑺↰㧘ࠬࡐࡦࠨ࡯࠼ࠪࡦࡐࠫ࠙ࡓ 8‫ޟ‬᳓⯻㧔⿷⊕⊈)⸻ᢿ࡮ᴦ≮ᴺߩᭂᗧ㧦⌀⩶ᗵᨴ∝‫ޠ‬Ṷ⠪㧕㧙㧙

25㧕 ╙ 59 ࿁ᣣᧄ⊹⤏⑼ቇળਛㇱᡰㇱቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ㧘ᢎ⢒⻠Ṷ 8‫ޟ‬዆Ᏹᕈੇ⊈ߩ∛ᘒߣᴦ≮㧦ᣂߒ޿᭎ᔨߣᣂⷙߩᴦ≮ᴺ‫ޠ‬ᐳ㐳)26㧕 ᄤ∊≙ Forum(ᐔᚑ 20 ᐕ 10 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ޟ‬ᄤ∊≙ߩ∛࿃ߣᴦ≮‫ޠ‬Ṷ⠪)␹⼱⑲༑㧦
1㧕 ╙ 106 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ‫ޟ‬ᬀ⊹ߩߎߟ㧦⊹⤏ᄖ⑼ߢ૗߇ߢ߈
ࠆ߆‫ޠ‬Ṷ⠪)2㧕 ╙ 23 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ᣂẟ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ၮᐩ⚦⢩≸ߩ⸻≮ࠟࠗ࠼࡜ࠗ
ࡦ㧦⊹⤏ᖡᕈ⣲≌ࠟࠗ࠼࡜ࠗࡦ‫ޠ‬Ṷ⠪)
3㧕 ╙ 24 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓΤ‫੃ޟ‬ᚱᄖ Paget ∛ߩ∛ᦼಽ㘃ߩቯ⌕ߣㅴⴕ଀ߦኻߔࠆᴦ≮ᣇ㊎ߩᬌ⸛‫)࡯ࠩࠗ࠽ࠟ࡯ࠝޠ‬4㧕 ╙ 24 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ࠎ߇ޟ‬ᕈ−∩ߣߘߩኻ╷‫ޠ‬ᐳ㐳)
5㧕 ╙ 59 ࿁ᣣᧄ⊹⤏⑼ቇળਛㇱᡰㇱቇⴚᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓΣ‫ޟ‬ᖡᕈ㤥⦡⣲㧦⥃ᐥߩᦨ೨✢‫)࡯ࠩࠗ࠽ࠟ࡯ࠝޠ‬㕍ጊ⵨⟤㧦
1㧕 ╙ 31 ࿁ᣣᧄ⎇ⓥ⊹⤏⑼ቇળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘Concurrent Oral Session‫ޟ‬Bullous Disease,
Regeneration, Extracellular Matrix‫ޠ‬ᐳ㐳)2㧕 ╙ 106 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ‫ޟ‬ᄤ∊≙ߩ∛ᘒ UP-TO-DATE㧦᳓∊∝ߩᦨవ┵‫ޠ‬Ṷ⠪)
3㧕 ╙ 71 ࿁ᣣᧄ⊹⤏⑼ቇળ᧲੩ᡰㇱ✚ળ(ᐔᚑ 20 ᐕ 2 ᦬㧘᧲੩㧘ᢎ⢒⻠Ṷ‫⥄ޟ‬Ꮖ఺∉ᕈ᳓∊∝㧦⥄Ꮖ᛫૕ߩ᛫ේߩหቯߣ᛫૕ଔࠍࡕ࠾࠲࡝ࡦࠣߒߚᴦ≮ߩታ㓙଀‫ޠ‬Ṷ⠪)
4㧕 Post IID 2008 Satellite International Meeting on Autoimmune Bullous Disease(2008 ᐕ 5 ᦬㧘ᄢᵤ 㧘 ࠪ ࡦ ࡐ ࠫ ࠙ ࡓ ‫ ޟ‬p120-catenin, a possible new intracellular signal mediator in
pemphigus-acantholysis‫ޠ‬Ṷ⠪)
5㧕 ᐔᚑ 20 ᐕᐲᣣᧄ⊹⤏⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደ㧘↢ᶦᢎ⢒⻠Ṷ‫ޟ‬ᄤ∊≙ߩ∛࿃ߩᦨᣂߩ⍮⷗ߣ⥄Ꮖ఺∉ᕈ᳓∊∝ߩ⸻ᢿᴺ㧦ELISA ᴺߢ㒶ᕈߩᤨߦߎ߁⠨߃ࠆ‫ޠ‬Ṷ⠪)᳗੗⟤⾆㧦
1㧕 ╙ 106 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮᵿ㧘ᢎ⢒⻠Ṷ‫ޟ‬㔚㗼߇ߥߊߡ߽⷗ࠄࠇࠆ㔚㗼౮⌀㧦
∛ℂᮡᧄࠍḰ஻ߔࠆߚ߼ߩࠦ࠷‫ޠ‬Ṷ⠪)
2㧕 ╙ 107 ࿁ᣣᧄ⊹⤏⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ‫ޟ‬㔚㗼߇ߥߊߡ߽⷗ࠄࠇࠆ㔚㗼౮⌀‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ർፉᐽ㓶㧦╙ 21 ࿁቟↰࡮㒋ᧄ⸥ᔨ⾨(ᐔᚑ 19 ᐕᐲ)
2㧕 ർፉᐽ㓶㧦Prof. Lu Yau-Chin Memorial Lectureship(ᐔᚑ 19 ᐕᐲ)
9㧚␠ળᵴേർፉᐽ㓶㧦
1㧕 ጘ㒂⋵଻ஜක≮ផㅴද⼏ળᆔຬ෸߮ක≮⸘↹ㇱળᆔຬ(㨪ᐔᚑ 18 ᐕ 3 ᦬)
2㧕 ጘ㒂⋵ක≮ኻ╷ද⼏ળᆔຬ(㨪ᐔᚑ 18 ᐕ 3 ᦬)
3㧕 ਛㇱේሶജᙣ⺣ળᓎຬ(㨪ᐔᚑ 18 ᐕ 3 ᦬)
4㧕 ጘ㒂⋵ක≮ࠕࠢ࠮ࠬኾ㐷ᆔຬ(㨪ᐔᚑ 18 ᐕ 3 ᦬)
5㧕 ጘ㒂⋵ᖱႎࠪࠬ࠹ࡓኾ㐷ᆔຬ(㨪ᐔᚑ 18 ᐕ 3 ᦬)
6㧕 ෘ↢ഭ௛⋭㔍∛ኻ╷⎇ⓥ⃰࡮⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰⃰㐳(㨪ᐔᚑ 20 ᐕ 3 ᦬)
7㧕 ෘ↢ഭ௛⋭․ቯ∔ᖚኻ╷ᙣ⺣ળᆔຬ(㨪⃻࿷)8㧕 ౏⋉ା⸤Ⓑේ⸥ᔨක࡮ᱤቇ⇐ቇ↢េഥၮ㊄ㆇ༡ᆔຬ(㨪⃻࿷)9㧕 ጘ㒂Ꮢ᳃∛㒮ᡷ▽ၮᧄ⸘↹㊀ὐ㗄⋡ᬌ⸛ᆔຬળᆔຬ(㨪⃻࿷)10㧕 JICA ╙ਃ࿖㓸࿅⎇ୃ⍴ᦼ୘೎ኾ㐷ኅᵷ㆜ຬ(㨪⃻࿷)11㧕 A Chair Professor, Kaohsiung Medical University(Taiwan)(ᐔᚑ 20 ᐕ 7 ᦬㨪⃻࿷)㧙㧙Ꮢૼༀ㇢㧦
1㧕 ጘ㒂⋵․ቯ∔ᖚ╬ኻ╷ද⼏ળᆔຬ(㨪⃻࿷)㕍ጊ⵨⟤㧦1㧕 ෘ↢ഭ௛⋭㔍∛ኻ╷⎇ⓥ⃰࡮⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰⎇ⓥදജ⠪߅ࠃ߮੐ോዪ(㨪ᐔᚑ 20 ᐕ 3 ᦬)
2㧕 ෘ↢ഭ௛⋭㔍∛ኻ╷⎇ⓥ⃰࡮⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰⃰ຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ർፉᐽ㓶㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ ✚᜝⎇ⓥႎ๔ᦠ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌
⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕㧦3㧙13(2006 ᐕ 3 ᦬)
2㧕 ർፉᐽ㓶㧘ጊᧄࠁ߆ࠅ㧘㕍ጊ⵨⟤㧦ᄤ∊≙᛫૕㧘᛫࠺ࠬࡕࠣ࡟ࠗࡦ(Dsg)3 ࡕࡁࠢࡠ࡯࠽࡞᛫૕ೝỗߦࠃࠆ DJM-1 ⚦⢩ߦ߅ߌࠆ Dsg3 ಽሶߩᷫዋ₸ߣ⚦⢩㑆⚿วജߩᷫᒙ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕㧦15㧙19(2006 ᐕ 3 ᦬)
3㧕 ർፉᐽ㓶㧦⴫⊹⚦⢩㑆ធ⌕࡮⚦⢩㛽ᩰಽሶ㑆⚿ว೙ᓮߣฦ⒳᳓∊∝ᯏᐨߩಽሶ↢‛ቇ⊛⎇ⓥ㧦ᐔᚑ
16 ᐕᐲ㧙18 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙79(2006 ᐕ 3 ᦬)
4㧕 ᢪ↰ବ᣿㧘ᐘ㊁ ஜ㧘⌀㍿ ᳞㧘࿯↰ື਽㧘ጊᧄ᣿ผ㧘ጊፒ⋥਽㧘ᷡේ␽ᄦ㧘┻ਯౝㄖ਽㧘౎↰ዏੱ㧘␹⼱⑲༑㧘ᷡේ㓉ብ㧘Ꮷ੗ᵗ৻㧘㣮㑆⋥ੱ㧘㜞↰ ታ㧘ቝේ ਭ㧘ฎ⾐ᒄᔒ㧦⊹⤏ᖡᕈ⣲≌⸻≮ࠟࠗ࠼࡜ࠗࡦߩ૞ᚑߣ Web ൻߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ಽᜂ⎇ⓥႎ๔ᦠ㧔ᢪ↰⃰㧕㧦242㧙248(2006 ᐕ 1 ᦬)
5㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧘ᴡፒఝᏗ㧘ᄤ⼱㓷ⴕ㧘ⷺ↰๺ਯ㧦ᄤ∊≙᛫૕㧘᛫࠺ࠬࡕࠣ࡟ࠗࡦ 3 ࡕࡁࠢࡠ࡯࠽࡞᛫૕ߦࠃࠆ⚦⢩ౝࠪࠣ࠽࡞વ㆐⚻〝ߩ⸃ᨆ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕
㧦67㧙71(2006 ᐕ 3 ᦬)
6㧕 ർፉᐽ㓶㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝⎇ⓥႎ
㧦3㧙13(2007 ᐕ 3 ᦬)๔ᦠ㧔ർፉ⃰㧕7㧕 ർፉᐽ㓶㧘ጊᧄࠁ߆ࠅ㧘㕍ጊ⵨⟤㧘ᄤ⼱㓷ⴕ㧘ⷺ↰๺ਯ㧦ฦ⒳ Dsg3 ࡕࡁࠢࡠ࡯࠽࡞᛫૕ᷙวೝỗߦࠃࠆࠤ࡜࠴ࡁࠨࠗ࠻ߦ߅ߌࠆ Dsg3 ಽሶߩᷫዋ₸ߣ⚦⢩㑆ធ⌕ജᷫዋ(Dissociation assay)㧦ᐔᚑ 18ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧔ർፉ⃰㧕㧦15㧙23(2007 ᐕ 3 ᦬)
8㧕 ർፉᐽ㓶㧦⴫⊹⚦⢩㑆ធ⌕࡮⚦⢩㛽ᩰಽሶ㑆⚿ว೙ᓮߣฦ⒳᳓∊∝ᯏᐨߩಽሶ↢‛ቇ⊛⎇ⓥ㧦ᐔᚑ
16 ᐕᐲ㧙18 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙79(2007 ᐕ 3 ᦬)
9㧕 ᢪ↰ବ᣿㧘ᐘ㊁ ஜ㧘⌀㍿ ᳞㧘࿯↰ື਽㧘ጊᧄ᣿ผ㧘ጊፒ⋥਽㧘ᷡේ␽ᄦ㧘┻ਯౝㄖ਽㧘౎↰ዏੱ㧘␹⼱⑲༑㧘ᷡේ㓉ብ㧘Ꮷ੗ᵗ৻㧘㣮㑆⋥ੱ㧘㜞↰ ታ㧘ቝේ ਭ㧘ฎ⾐ᒄᔒ㧦⊹⤏ᖡᕈ⣲≌⸻≮ࠟࠗ࠼࡜ࠗࡦߩ૞ᚑߣ Web ൻߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲ㧙18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚ว⎇ⓥႎ๔ᦠ㧔ᢪ↰⃰㧕㧦1141㧙1695(2007 ᐕ 3 ᦬)
10㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧘ᴡፒఝᏗ㧦᛫࠺ࠬࡕࠣ࡟ࠗࡦ 3 ࡕࡁࠢࡠ࡯࠽࡞᛫૕ߦࠃࠆ⚦⢩ౝࠪࠣ࠽࡞વ
㆐ᯏ᭴ߩᬌ⸛㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄✚᜝⎇ⓥႎ๔ᦠ㧔ർፉ⃰㧕
㧦71㧙75(2007 ᐕ 3 ᦬)
11㧕 ർፉᐽ㓶㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲ㧙19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚ว⎇ⓥႎ๔ᦠ㧔ർፉ⃰㧕㧦1㧙77(2008 ᐕ 3 ᦬)
12㧕 ർፉᐽ㓶㧦⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝⎇ⓥႎ๔ᦠ㧔ർፉ⃰㧕㧦3㧙12(2008 ᐕ 3 ᦬)
13㧕 ർፉᐽ㓶㧘㕍ጊ⵨⟤㧘ጊᧄࠁ߆ࠅ㧘␹የዏሶ㧦዆Ᏹᕈᄤ∊≙ߪ࠺ࠬࡕ࠰࡯ࡓ࡝ࡕ࠺࡝ࡦࠣ∛ߣ޿߁ⷞὐ߆ࠄߩ᳓∊ᒻᚑᯏᐨߩ⸃᣿㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕㧦31㧙39(2008 ᐕ 3 ᦬)
14㧕 ㊄↰቟ผ㧘₹੗సੱ㧘⍮㊁೰⋥㧘ർፉᐽ㓶㧦⴫⊹᳓∊∝ߦኻߔࠆㆮવሶᴦ≮ߩ㐿⊒㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕㧦128㧙130(2008 ᐕ 3 ᦬)
15㧕 ㊄↰቟ผ㧘₹੗సੱ㧘⍮㊁೰⋥㧘ർፉᐽ㓶㧦⴫⊹᳓∊∝ߦኻߔࠆ⚦⢩≮ᴺߩน⢻ᕈߩᬌ⸛㧦ᐔᚑ 19ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕
㧦131㧙132(2008 ᐕ 3 ᦬)
16㧕 ₹੗సੱ㧘㊄↰቟ผ㧘⍮㊁೰⋥㧘ർፉᐽ㓶㧦㛽㜑⚦⢩ߦࠃࠆ⴫⊹ౣ↢ᯏᐨ⸃᣿ߣ⴫⊹᳓∊∝ᴦ≮߳ߩᔕ↪㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕
㧦133㧙136(2008 ᐕ 3 ᦬)
17㧕 㕍ጊ⵨⟤㧘ർፉᐽ㓶㧘દ૒଻㚅㧦∛ේᕈ᛫࠺ࠬࡕࠣ࡟ࠗࡦ 3 ࡕࡁࠢࡠ࡯࠽࡞᛫૕ߦࠃࠆ࠺ࠬࡕࠣ࡟
㧦88㧙92(2008ࠗࡦߩಽ⸃ߩᬌ⸛㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕
ᐕ 3 ᦬)
18㧕 ᾖ੗ ᱜ㧘ᮮጊ ᗲ㧘ේ ᒄਯ㧘᭱ፉ ⺈㧘㕍ጊ⵨⟤㧦⤥∊ᕈੇ⊈ߩ∛࿃ߣᴦ≮㧙⾗⾰ઍ⻢ߦ㑐ߔ㧙㧙ࠆ⸃ᨆ㧙㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂႎ๔ᦠ㧔ർፉ⃰㧕㧦99㧙105(2008 ᐕ 3᦬)19㧕 ᄤ⼱㓷ⴕ㧘⼱Ꮉℭሶ㧘ᷡ᳓ᥓሶ㧘ᯅᧄ 㓉㧘ᳰ↰ᔒᢦ㧘ᣂ㑐ኡᓼ㧘㤥ᴛ⟤ᥓሶ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧦ᄤ∊≙ߩ⸻ᢿߣᴦ≮ࠟࠗ࠼࡜ࠗࡦ㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ႎ๔ᦠ㧔ർፉ⃰㧕೎ᷝ⾗ᢱ 1㧦1㧙14(2008 ᐕ 3 ᦬)
20㧕 ᯅᧄ 㓉㧘ự↰ዏብ㧘ᳰ↰ᔒᢦ㧘ᄤ⼱㓷ⴕ㧘ᣂ㑐ኡᓼ㧘㤥ᴛ⟤ᥓሶ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧦᳓∊∝㘃ᄤ∊≙ࠟࠗ࠼࡜ࠗࡦ㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ႎ๔ᦠ㧔ർፉ⃰㧕೎ᷝ⾗ᢱ 1㧦15㧙34(2008ᐕ 3 ᦬)
21㧕 ጤ↰໪᳁㧘ᾖ੗ ᱜ㧘ዊỈ ᣿㧘ዊችᩮ⌀ᑿ㧘᪢Ỉᘮ♿㧘ਛ⷏ ర㧘ේ ᒄਯ㧘㚍ᷨᥓ↢㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧦⤥∊ᕈੇ⊈㧔᳢⊒ဳ㧕⸻≮ࠟࠗ࠼࡜ࠗࡦ㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ႎ๔ᦠ㧔ർፉ⃰㧕೎ᷝ⾗ᢱ 1㧦35㧙92(2008 ᐕ 3 ᦬)
22㧕 ᷡ᳓ ብ㧘ᯅᧄ౏ੑ㧘₹੗సੱ㧘㤥ᴛ⟤ᥓሶ㧘㕍ጊ⵨⟤㧘ർፉᐽ㓶㧦⴫⊹᳓∊∝⸻ᢿߣᴦ≮ߩࠟࠗ࠼࡜ࠗࡦ㧦ᐔᚑ 19 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ႎ๔ᦠ㧔ർፉ⃰㧕೎ᷝ⾗ᢱ 1㧦93㧙103(2008 ᐕ 3 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ1㧕ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ߪ⛮⛯ࠍ฽߼ 5 ઙ㧔ၮ⋚ B1 ઙ㧘C3 ઙ㧘⧯ᚻ B1 ઙ㧕㊄㗵ߪ 1050 ౞ߢ޽ߞߚ‫ޕ‬
2㧕ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ߪ⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߩ⃰㐳ࠍߒߡ޿ߚߚ߼ᐔᚑ 17 ᐕ߆ࠄ 19 ᐕߦ✚㗵 1 ం 5470 ਁ౞㧘18 ᐕ߆ࠄ 19 ᐕߛߌߢ߽ 1 ం 1570 ਁ౞ࠍ₪ᓧߒߚ‫┹ߩ߆ߟߊ޿ઁߩߘޕ‬੎⊛⎇ⓥ⾌
ࠍ⸘ 1270 ਁ౞ᓧߡ޿ࠆ‫ߪࠇߎޕ‬ᚒ‫ߩޘ‬ᢎቶߩ⎇ⓥ⾌ࠍߎߩಽ㊁ߢ₪ᓧߢ߈ࠆ࡟ࡌ࡞ߢ޽ߞߚߎߣࠍ␜
ߒߡ޿ࠆ‫ޕ‬3㧕⺰ᢥ⊒⴫ᢙߦߟ޿ߡߪ㧘⧷ᢥ࿖㓙⹹ߪ৻ᦼ೨ 3 ᐕ㑆㧔ᐔᚑ 15 ᐕ㨪17 ᐕ㧕ߩ 20 ႎ߆ࠄ 22 ႎߦჇടߒߚ‫ޕ‬ᣣᧄ⺆⺰ᢥ߿∝଀ႎ๔ߪ 48 ႎ߆ࠄ 64 ႎߦჇടߒߡ޿ࠆߩߢ⎇ⓥᚑᨐ߽లಽߦ᜼ߍߡ޿ࠆߎߣࠍ
␜ߒߡ޿ࠆ‫ޕ‬4㧕ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⒘ዋ㔍ᴦᕈ⊹⤏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰⃰㐳ߣߒߡ2 ᦼ⋡3 ᐕ㑆ߩ⛮⛯੍▚ࠍ੤ઃߐࠇࠆᚑ❣ࠍ᜼ߍߚߩߢ৻ቯߩ⹏ଔߣ⠨߃ࠄࠇࠆ‫ޕ‬
5㧕ർፉᢎ᝼߇࿖㓙⎇ⓥ⊹⤏⑼ቇળࠨ࠹࡜ࠗ࠻ࠪࡦࡐࠫ࠙ࡓ‫ޡ‬Post IID 5th Joint Meeting of SSSR and
SCUR, and International Meeting on Autoimmune Bullous Disease 2008‫ߩޢ‬ળ㐳ࠍോ߼㧘ቇળࠍਥቿ
ߒߚߎߣߪ⹏ଔߐࠇࠆ‫ޕ‬
6㧕ർፉᢎ᝼߇╙ 51 ࿁ᣣᧄක⌀⩶ቇળ✚ળ㧔ᐔᚑ 19 ᐕ 11 ᦬㧘㜞ጊ㧕ߩળ㐳ࠍോ߼㧘ቇળࠍਥቿߒߚߎ
ߣߪ⹏ଔߐࠇࠆ‫ޕ‬7㧕ർፉᢎ᝼߇╙ 24 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળ✚ળ㧔ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧕ߩળ㐳ࠍോ߼㧘ቇળࠍਥቿ
ߒߚߎߣߪ⹏ଔߐࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᴺੱൻᓟߪ⥃ᐥ߳ߩᤨ㑆㈩ಽߣ♖␹⊛㈩ಽ߇ᄙߊߥࠅ㧘⎇ⓥታⴕߩⅣႺߪᖡൻߒߚ‫ߪߡ޿ߟߦࠇߎޕ‬ኻ╷߇ᔅⷐߢ޽ࠆ‫ޕ‬තᓟ⥃ᐥ⎇ୃᔅୃൻߦࠃࠅ 3 ᐕ⋡ߩ⊹⤏⑼ᧂ⚻㛎⠪߇౉ዪߔࠆߎߣߦߥࠅᜰዉ⊛කᏧߩᢙ߇ᷫዋߒߚ‫ޕ‬ᓟᦼ⎇ୃࠍ㒮ᄖߣදജߒߡᢎ⢒ߔࠆᔅⷐ߇޽ࠆ‫ޕ‬੹ᓟߩዷᦸጘ㒂ᄢቇකቇㇱߪᄢቇ㒮ൻߐࠇߚߚ߼㧘੹߹ߢએ਄ߦ⎇ⓥታ❣ࠍ਄ߍࠆᔅⷐ߇޽ࠆ‫ߟ߆ޕ‬ᴺੱൻߐࠇߚ∛㒮ߢߪක≮෼⋉ߩჇ෼ߣߣ߽ߦ㜞ᐲవㅴක≮ߩ㐿⊒㧘කቇㇱ↢㧘⎇ୃක㧘කຬߩᢎ⢒ࠍⴕߥ߁ᔅⷐ
߇޽ࠆ‫੹ޕ‬ᓟߪߎࠇࠄߦ․ൻߒߚ⋡⊛ࠍ⸳ቯߔࠆᔅⷐ߇޽ࠆ‫ޕ‬㧙㧙㧔6㧕ᴲዩེ⑼ቇಽ㊁1㧚 ⎇ⓥߩ᭎ⷐ
1㧕ዩ〝↢ᱺེ⣲≌ߩᴦ≮ߣ੍ᓟߦ㑐ߔࠆၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ
Ԙ᛫≸೷ᗵฃᕈ㧘᛫≸೷⠴ᕈ࿃ሶߦ㑐ߔࠆ⎇ⓥ⥃ᐥ᧚ᢱࠍ↪޿ߡ㧘ATP ᵴᕈࠍ↪޿ߚ᛫≸೷ᗵฃᕈ⹜㛎ᚑ❣ߣ㧘⠴ᕈㆮવሶ⊒⃻㊂ߣߩ㑐ㅪࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬
ԙዩ〝↢ᱺེ≸ߩ੍ᓟ੍᷹࿃ሶߦ㑐ߔࠆ∛ℂቇ⊛⎇ⓥ≸⚵❱ߦ߅ߌࠆ․ቯߩㆮવሶ㧘⧯ߒߊߪㆮવሶ↥‛ߩ⊒⃻ߩ㧘੍ᓟ੍᷹࿃ሶߣߒߡߩน⢻ᕈࠍ⎇ⓥߒ㧘୘‫ߩߢ଀∝ߩޘ‬ᴦ≮ᣇ㊎᳿ቯߦ߅޿ߡߩߘߩ᦭↪ᕈࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬Ԛ೨┙⣼≸ߩ᛫≸೷⠴ᕈᯏᐨߩၮ␆⊛⎇ⓥ
ࡎ࡞ࡕࡦ≮ᴺ⠴ᕈ೨┙⣼≸ߦኻߔࠆ᛫≸೷ᴦ≮ߩ⏕┙ࠍ⋡ᜰߒ㧘ၭ㙃⚦⢩෸߮ታ㛎േ‛ࠍ↪޿ߚ᛫≸೷⠴ᕈߦ㑐ㅪߒߚㆮવሶߩหቯߣ㧘ߘߩ⊒⃻㒖ᱛߦߟ޿ߡߩၮ␆⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬ԛ೨┙⣼≸ᴦ≮ߦ㑐ߔࠆ⥃ᐥ⊛⎇ⓥᣣᧄߦ߅ߌࠆ೨┙⣼≸ߦኻߔࠆ࡛࠙⚛ 125 ኒኽዊ✢Ḯ᳗ਭᝌ౉≮ᴺߦ㑐ߔࠆ೨ะ߈ࠦࡎ࡯࠻⎇ⓥ߅ࠃ߮㒢ዪᕈ೨┙⣼≸ߦኻߔࠆࡎ࡞ࡕࡦ≮ᴺߩ᦭ലᕈߦ㑐ߔࠆⷰኤ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧕ዩ〝ᗵᨴ∝ߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ
Ԙᄢⷙᮨ⺞ᩏߦࠃࠆ⿠࿃⩶ߩ⥃ᐥ⊛⎇ⓥ
㑐ㅪᣉ⸳ࠍ฽߼ߡᲤᐕⶄ㔀ᕈዩ〝ᗵᨴ∝ߩ⿠࿃⩶ࠍ෼㓸ߒ㧘߹ߚ㧘⥃ᐥ⢛᥊߿⥃ᐥ∛⁁ߣߩ㑐ㅪࠍ⎇ⓥ
ߒߡ޿ࠆ‫ ߦࠄߐޕ‬4 ᐕᲤߦᅚሶᕆᕈන⚐ᕈ⣾⢲Ἳߩ✚ว⺞ᩏࠍ⛮⛯ਛߢ޽ࠆ‫ޕ‬ԙ⮎೷⠴ᕈ⩶ߩ಴⃻⁁ᴫ㧘⠴ᕈᯏᐨߩ⸃᣿
⥃ᐥ଀ࠃࠅᓧࠄࠇߚ⿠࿃⩶ࠍ↪޿ߡ㧘⓭ὼᄌ⇣ߥߤߩㆮવሶ࡟ࡌ࡞ߢߩ⮎೷⠴ᕈᯏᐨࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬߹ߚ㧘᛫⩶೷ߩ૶↪ߣㆮવሶᄌ⇣ߣߩ㑐ㅪ߽⎇ⓥߒߡ޿ࠆ‫ޕ‬Ԛዩ〝ᗵᨴ∝ߦኻߔࠆ⮎‛≮ᴺߦߟ޿ߡߩ⥃ᐥ⊛⎇ⓥ㑐ㅪ∛㒮ߣදജߒዩ〝ᗵᨴ∝ߦኻߔࠆฦ⒳᛫⩶೷ߩ᦭ലᕈߦߟ޿ߡᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬
3㧕↵ሶዩ㆏Ἳߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ
Ԙಽሶ↢‛ቇ⊛ᚻᴺࠍ↪޿ߚ⿠Ἳ⩶ߩᬌ಴ᴺߩ㐿⊒⃻࿷߹ߢߦ⸃᣿ߐࠇߡ޿ߥ޿㕖ᶷ⩶ᕈዩ㆏Ἳߩ⿠Ἳ⩶ߩหቯߣ㧘ߘߩ⸻ᢿᴺߩ㐿⊒㧘․ߦᩭ㉄Ⴧ᏷ࠍ↪
޿ߚᚻᴺࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬ԙ⮎೷⠴ᕈ⩶ᶷ⩶ߩ∉ቇ⎇ⓥ㑐ㅪᣉ⸳ࠍ฽߼ߡᐕᰴ⊛ߦ⥃ᐥಽ㔌ᩣࠍ෼㓸ߒ㧘ߘࠇࠄߩ᛫⩶೷ᗵฃᕈࠍ᷹ቯߒ㧘ᐕᰴ⊛ߥᄌ⒖ࠍ⎇ⓥ
ߒߡ޿ࠆ‫ޕ‬Ԛ⮎೷⠴ᕈ⩶ᶷ⩶ߩ⮎೷⠴ᕈᯏᐨߩ⸃᣿
⮎೷⠴ᕈ⩶ᶷ⩶ߩౝߢ⚻ญ࠮ࡈࠚࡓ೷⠴ᕈᶷ⩶ߦ⌕⋡ߒ㧘ߘߩ⠴ᕈᯏᐨࠍㆮવሶ࡟ࡌ࡞ߢ⎇ⓥߒߡ޿ࠆ‫ޕ‬ԛ↵ሶዩ㆏Ἳߦኻߔࠆ⮎‛≮ᴺߦߟ޿ߡߩ⥃ᐥ⊛⎇ⓥ㑐ㅪ∛㒮ߣදജߒ↵ሶዩ㆏Ἳߦኻߔࠆฦ⒳᛫⩶೷ߩ᦭ലᕈߦߟ޿ߡᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬4㧕⣢⒖ᬀߦ߅ߌࠆ⥃ᐥ⊛⎇ⓥ
Ԙ఺∉ᛥ೙೷ߩㆡᱜൻ
ᜎ⛘෻ᔕࠍ㒐߉㧘ᣣ๺⷗ᗵᨴ∝ࠍᒁ߈⿠ߎߐߥ޿ㆡᱜߥ఺∉ᛥ೙೷ߩᛩਈᣇᴺߦ㑐ߔࠆ⥃ᐥ⊛⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬ԙ⒖ᬀ⣢ߩ∛ℂቇ⊛⎇ⓥ⒖ᬀ⣢ߦኻߒߡቯᦼ⊛ߥ↢ᬌࠍᣉⴕߒߡ㧘⒖ᬀ⣢ᯏ⢻ߦ෸߷ߔẜ࿷⊛ߥᜎ⛘෻ᔕ㧘࠙ࠗ࡞ࠬᗵᨴࠍ∛ℂ
௝߆ࠄ⎇ⓥߒߡ޿ࠆ‫ߦࠄߐޕ‬㧘∛ℂ⚵❱௝߆ࠄ⒖ᬀ⣢ߩ㐳ᦼ↢⌕ࠍ⋡ᜰߒߚ࠹࡯࡜࡯ࡔࠗ࠼ߥ఺∉ᛥ೙≮ᴺࠍⴕߞߡ޿ࠆ‫ޕ‬
5㧕㏜ⷞਅᚻⴚᚻᛛߩ㐿⊒⎇ⓥ⣻⣧㏜ਅ೽⣢៰಴ⴚ㧘⣻⣧㏜ਅ⣢៰಴ⴚߪ㧘ߔߢߦᮡḰⴚᑼߣߥࠅߟߟ޽ࠆ߇㧘⋵ਅߢታᣉߒߡ޿ࠆᣉ
⸳ߪዋߥ޿‫ᧄޕ‬ᚻᛛࠍ቟ో߆ߟ⏕ታߦⴕ߁ߚ߼ߩᚻᛛ߅ࠃ߮ᧄⴚᑼࠍᔕ↪ߒߚᣂߚߥⴚᑼߩ㐿⊒㧘ߥࠄ߮ߦౕེ㧘ེ᧚ߩ㐿⊒⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
6㧕ឃዩ㓚ኂಽ㊁ߦ߅ߌࠆ⥃ᐥ⊛⎇ⓥԘ↵ᕈ೨┙⣼⢈ᄢ∝ᖚ⠪ߩਅㇱዩ〝∝⁁ߦኻߔࠆ⮎೷ߩലᨐߦߟ޿ߡ㧘೨┙⣼⢈ᄢ∝ߦ઻߁ㆊᵴേ⣾⢲∝⁁㧘೨┙⣼⢈ᄢ∝ᖚ⠪ߦว૬ߔࠆᄛ㑆㗫ዩ㧘೨┙⣼⢈ᄢ∝ߦኻߔࠆᴦ≮ᛶ᛫ᕈߩਇቯᗜ⸷ߦኻߔࠆ⮎‛≮ᴺࠍ⥄ⷡ⊛㧘ઁⷡ⊛ߦ⹏ଔߒ㧘ᦨㆡߥᛩਈᣇᴺࠍᬌ⸛ߒߡ޿ࠆ‫ޕ‬ԙᄛ㑆㗫ዩߩේ࿃ߪᄙ࿃ሶߢ޽ࠅ㧘ਅㇱዩ〝ߩ⇣Ᏹએᄖߦ߽ోり⊛ߥ໧㗴߇ᓇ㗀ߒߡ޿ࠆ‫ᤨ⌁⌧ޕ‬ή๭㧙㧙ๆ∝୥⟲㧔SAS㧕߽ߘߩේ࿃ߩ 1 ߟߣߐࠇߡ߅ࠅ㧘ߘࠇࠍ⥃ᐥ⊛ߦ⸽᣿ߔࠆߚ߼ SAS ⇼޿ߩᖚ⠪ߦኻߒឃዩࡄ࡜ࡔ࡯࠲࡯ߩ⹏ଔࠍⴕ޿㧘SAS ᴦ≮ᓟߦ߽⹏ଔࠍߒ㑐ㅪࠍ⺞ߴߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

಴ญ 㓉
ᳯේ⧷ବ
દ⮮ᘕ৻
ખ㊁ᱜඳ
ᮮ੗❥᣿
቟↰ ḩ
ධ⥪ ⻞
ጊᧄ⋥᮸
ਃベᅢ↢
࿯ደ᦮ᄢ
Ⴧᩕቁሶ
⩵࿾⟤ᄹ
᳗੗⌀๋
ၳᳯᙗ๋

Takashi Deguchi
Hidetoshi Ehara
Shin-ichi Ito
Masahiro Nakano
Shigeaki Yokoi
Mitsuru Yasuda
Yuzuru Minamidate
Naoki Yamamoto
Kousei Miwa
Tomohiro Tsuchiya
Takako Masue
Mina Kikuchi
Shingo Nagai
Kengo Horie

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ಴ญ 㓉㧚൮⨍㧘੉㗡൮⊹Ἳ㧦ጊญ ᔀ㧘ർේశᄦ㧘⑔੗ᰴ⍫✚✬㓸㧚 TODAY’S THERAPY 2006 ੹ᣣߩᴦ≮ᜰ㊎㧘᧲੩㧦කቇᦠ㒮㧧2006 ᐕ㧦815㧚
2㧕 ಴ญ 㓉㧘ᮮ੗❥᣿㧘቟↰ ḩ㧚⣾⢲Ἳ㧔⚦⩶ᕈ߅ࠃ߮㕖⚦⩶ᕈ⣾⢲Ἳ㧕㧦ർጟᑪ᮸㧘㘵㊁㕏ᒾ㧘੖ච፲ 㓉㧘ᧁ᧛ஜੑ㇢㧘ၳᳯ㊀㇢✬㓸㧚⣢࡮ዩ〝∔ᖚߩ⸻≮ᜰ㊎‘06㧘᧲੩㧦᧲੩කቇ␠㧧2006 ᐕ㧦403㧙405㧚
3㧕 ಴ญ 㓉㧚ዩ〝ᕈེᗵᨴ∝ ̆᛫⩶⮎૶↪ࠟࠗ࠼࡜ࠗࡦߦᴪߞߚ᛫⩶⮎ߩ૶޿ᣇ̆ ߪߓ߼ߦ㧦ᣣᧄᴲዩེ⑼ቇળ 2007 ᐕ තᓟ࡮↢ᶦᢎ⢒࠹ࠠࠬ࠻㧘᧲੩㧦ᣣᧄᴲዩེ⑼ቇળ㧧2007 ᐕ㧦69㧚
4㧕 ಴ญ 㓉㧚ዩ〝ᕈེᗵᨴ∝ ̆᛫⩶⮎૶↪ࠟࠗ࠼࡜ࠗࡦߦᴪߞߚ᛫⩶⮎ߩ૶޿ᣇ̆ ᕈེᗵᨴ∝㧦ᣣᧄᴲዩེ⑼ቇળ 2007 ᐕ තᓟ࡮↢ᶦᢎ⢒࠹ࠠࠬ࠻㧘᧲੩㧦ᣣᧄᴲዩེ⑼ቇળ㧧2007 ᐕ㧦75㧙81㧚
5㧕 ቟↰ ḩ㧚ዩ〝ᕈེᗵᨴ∝ ̆᛫⩶⮎૶↪ࠟࠗ࠼࡜ࠗࡦߦᴪߞߚ᛫⩶⮎ߩ૶޿ᣇ̆ ዩ〝ᕈེᗵᨴ∝㧦ᣣᧄᴲዩེ⑼ቇળ 2007 ᐕ තᓟ࡮↢ᶦᢎ⢒࠹ࠠࠬ࠻㧘᧲੩㧦ᣣᧄᴲዩེ⑼ቇળ㧧2007 ᐕ㧦70㧙74㧚
6㧕 ಴ญ 㓉㧚ጊญ ᔀ㧘ർේశᄦ㧘⑔੗ᰴ⍫✚✬㓸㧚⣾⢲Ἳ㧦TODAY’S THERAPY 2008 ੹ᣣߩᴦ≮ᜰ㊎㧘᧲੩㧦කቇᦠ㒮㧧2008㧦834㧙835㧚
7㧕 ಴ญ 㓉㧚࿯⢈⟵⢬㧘ጊᧄኈᱜ㧘ቝ⾐ᤘੑ✬㧚ᴲዩ↢ᱺེᗵᨴ∝㧦ࠬ࠲ࡦ࠳࡯࠼ ᓸ↢‛ቇ ╙ 2 㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦172㧙182㧚
8㧕 ಴ญ 㓉㧘቟↰ ḩ㧘೨↰⌀৻㧚↰ਛᱜ೑✬㓸㧚ࡑࠗࠦࡊ࡜࠭ࡑ㧦ᕈᗵᨴ∝ STD ᡷ⸓ 2 㧘᧲੩㧦ධጊၴ㧧2008 ᐕ㧦179㧙186㧚
9㧕 ಴ญ 㓉㧚ࡑࠗࠦࡊ࡜࠭ࡑ㧦቟రᘕ৻㇢✬㓸㧚STD㧔ᕈᗵᨴ∝㧕ࠕ࠻࡜ࠬ㧘᧲੩㧦⑲Ả␠㧧2008 ᐕ㧦133.
10㧕 ಴ญ 㓉㧚࠙࡟ࠕࡊ࡜࠭ࡑ㧦቟రᘕ৻㇢✬㓸㧚STD㧔ᕈᗵᨴ∝㧕ࠕ࠻࡜ࠬ㧘᧲੩㧦⑲Ả␠㧧2008 ᐕ㧦133㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ಴ญ 㓉㧚↵ሶዩ㆏Ἳߩ⸻ᢿߣᴦ≮ߩᦨㄭߩ⹤㗴㧘ᴲዩེ⑼ቇߩᦨㄭߩㅴᱠ 2006 ᐕ㧧22 Ꮞ㧦1㧙5㧚
2㧕 㜞ᯅ⟵ੱ㧘ᮮ੗❥᣿, ੉੗ା๋, ಴ญ 㓉㧚ᚻⴚᚻᛛ ዩ〝ౝⷞ㏜ᚻⴚ ⚻ዩ㆏⊛⣾⢲⚿⍹៰಴ⴚ ⚻⊹⊛⣾⢲⚿⍹៰಴ⴚ㧘⥃ᐥᴲዩེ⑼ 2006 ᐕ㧧60 Ꮞ㧦361㧙367㧚
3㧕 ಴ญ 㓉㧚೨┙⣼∔ᖚ ᣂߒ޿ᴦ≮ᴺࠍℂ⸃ߔࠆߚ߼ߦ-೨┙⣼Ἳ ᕆᕈ೨┙⣼Ἳߩ⸻ᢿߣᴦ≮㧘Modern
Physician 2006 ᐕ㧧26 Ꮞ㧦1007㧙1010㧚
4㧕 ᳯේ⧷ବ㧘ખ㊁ᱜඳ, ಴ญ 㓉㧚ዪᚲᶐẢ೨┙⣼≸ߩᴦ≮ᚢ⇛ ࡎ࡞ࡕࡦ≮ᴺߩ૏⟎ઃߌ㧘ᴲዩེ⑼♿ⷐ2006 ᐕ㧧52 Ꮞ㧦473㧙477㧚
5㧕 ಴ญ 㓉, ⪤ේᓼᐽ, દ⮮ᘕ৻㧚ᴲዩེ⑼⥃ᐥߩ㔍໧ࠍ⸃ߊ EBM ࠍ⠨ᘦߒߚ⸃⺑-ᘟᕈ೨┙⣼Ἳߩᴦ≮㧘⥃ᐥᴲዩེ⑼ 2006 ᐕ㧧60 Ꮞ㧦549㧙554㧚
6㧕 ಴ญ 㓉㧚ዩ〝ᗵᨴ∝ߩ∛ᘒߣ⸻ᢿ࡮ᴦ≮ߣ੍㒐 ⇐⟎ࠞ࠹࡯࠹࡞߽฽߼ߡ㧚ᗵᨴ㒐ᱛ 2007 ᐕ㧧17 Ꮞ㧦
9㧙15㧚
7㧕 ಴ญ 㓉㧚∛᳇ߣ⮎ߩ⺑᣿ࠟࠗ࠼ 2007㧘ᗵᨴᕈ∔ᖚ ⮎‛≮ᴺ✬ ක⮎ຠᖱႎ✬ ᕈེᗵᨴ∝㧚⮎ዪ 2007
ᐕ㧧58 Ꮞ㧦1563㧙1569㧚
8㧕 ᮮ੗❥᣿㧘಴ญ 㓉㧚ᴲዩེ⑼−∩ኻ╷㧘ዩ〝ᕈེᗵᨴ∝࡮㛽⋚ౝ−∩∝୥⟲ߦኻߔࠆ−∩ኻ╷㧚Urology
View 2007 ᐕ㧧5 Ꮞ㧦30㧙33㧚㧙㧙9㧕 㜞ᯅ⟵ੱ, ਛᩮᘮᄥ, ᮮ੗❥᣿㧚ᚻⴚᚻᛛ ⣻⣧㏜ਅᚻⴚᤨઍߦ߅ߌࠆ㐿᡼ᚻⴚ න⚐⣢៰㒰ⴚ㧚⥃ᐥᴲዩ
ེ⑼ 2007 ᐕ㧧61 Ꮞ㧦117㧙124㧚
10㧕 ቟↰ ḩ㧚ᕈᗵᨴ∝ߩ⃻⁁㧘ਥⷐ∔ᖚߩࡊ࡜ࠗࡑ࡝ࠤࠕ⸻≮ ᶷ⩶ᗵᨴ∝ߩ⸻ᢿߣᴦ≮ ࠢ࡝࠾ࠞ࡞ࡊ࡜
ࠢ࠹ࠖࠬ 2007 ᐕ㧧26 Ꮞ㧦304㧙307㧚
11㧕 દ⮮ᘕ৻, ࿯ደ᦮ᄢ, ቞ጊᵗม, Ⓑ၂ാᄦ, ಴ญ 㓉㧚⣢⒖ᬀᓟ BK ࠙ࠗ࡞ࠬ⣢∝ߣ࠺ࠦࠗ࠮࡞ߩᗧ⟵㧘ᬌᩏߣᛛⴚ 2007 ᐕ㧧35 Ꮞ㧦407㧙410㧚
12㧕 ಴ญ 㓉, ⪤ේᓼᐽ, ቟↰ ḩ, ೨↰⌀৻㧚ᕈᗵᨴ∝ ੹㧘ߥߦ߇໧㗴߆㧘ᕈᗵᨴ∝ ⸻ᢿ࡮ᴦ≮ 㕖ࠢ࡜ࡒࠫࠕᕈ㕖ᶷ⩶ᕈዩ㆏Ἳ㧚⥃ῼߣ⎇ⓥ 2007 ᐕ㧧84 Ꮞ㧦673㧙676㧚
13㧕 ቟↰ ḩ㧚ᕈᗵᨴ∝ߩ⃻⁁㧘ᄙ೷⠴ᕈᶷ⩶ᗵᨴ∝ߩᴦ≮ ⥃ᐥᴲዩེ⑼ 2007 ᐕ㧧61 Ꮞ㧦773㧙779㧚
14㧕 ጤਅ᣿ሶ, ಴ญ 㓉㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞᵺ࡮⣢⋃ᵞᵺ Do Not 㐽㎮ᑼ⇐⟎ࠞ࠹࡯࠹࡞ߢߪ߻߿ߺ߿ߚࠄߦ⣾⢲ᵞᵺࠍߒߡߪ޿ߌߥ޿! ࠞ࠹࡯࠹࡞⇐⟎ᤨ㧘ࠞ࠹࡯࠹࡞㐽Ⴇᤨߥߤ․ᱶߥ႐วࠍ㒰޿ߡߪ⣾⢲ᵞᵺߔߴ߈ߢߪߥ޿㧚ᴲዩེࠤࠕ 2007 ᐕ㧧౻ቄჇೀ㧦128㧙130㧚
15㧕 ጟ↰ᒄ⟤, ಴ญ 㓉㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞᵺ࡮⣢⋃ᵞᵺ Do ⣾⢲ᵞᵺ߇࿎㔍ߥ႐ว㧘ߘߩℂ↱ࠍ⠨߃ߥߌࠇ߫ߥࠄߥ޿! ᴲዩེࠤࠕ 2007 ᐕ㧧౻ቄჇೀ㧦131㧙134㧚
16㧕 ጟ↰ᒄ⟤, ಴ญ 㓉㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞᵺ࡮⣢⋃ᵞᵺ Do Not ᗵᨴ㒐ᱛ⋡⊛ߢࠗ࠰ࠫࡦᶧߢ⣾⢲ᵞᵺࠍߒߡߪ޿ߌߥ޿! ᴲዩེࠤࠕ 2007 ᐕ㧧౻ቄჇೀ㧦135㧙137㧚
17㧕 ᐔጟ૒❱, ખ㊁ᱜඳ㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞᵺ࡮⣢⋃ᵞᵺ Do Not ⴊዩ߇Ớ޿ߣ߈ߦᜬ⛯⣾⢲ᵞᵺߩㅦᐲࠍㆃߊߒߡߪ޿ߌߥ޿! ᴲዩེࠤࠕ 2007ᐕ㧧౻ቄჇೀ㧦138㧙141㧚
18㧕 ᐔጟ૒❱, ખ㊁ᱜඳ㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞᵺ࡮⣢⋃ᵞᵺ Do ᜬ⛯⣾⢲ᵞᵺᤨߪࠗࡦࠕ࠙࠻㊂㧘ਅ⣻ㇱߩ⁁ᘒߦᵈᗧߒߥߌࠇ߫ߥࠄߥ޿! ᴲዩེࠤࠕ
2007 ᐕ㧧౻ቄჇೀ㧦142㧙145㧚
19㧕 ੹੗⟤๺ሶ, ખ㊁ᱜඳ㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞ
ᵺ࡮⣢⋃ᵞᵺ Do Not ⣢≪ㅧ⸳ᓟ㧘ಝⴊ႙ߢ⣢≪߇㐽Ⴇߒߡ߽ᵞᵺߒߡߪ޿ߌߥ޿! ᴲዩེࠤࠕ 2007ᐕ㧧౻ቄჇೀ㧦146㧙150㧚
20㧕 ੹੗⟤๺ሶ, ખ㊁ᱜඳ㧚ᴲዩེࠤࠕߩ Do & Do Not㧘ᴲዩེ⑼ߩࠞ࠹࡯࠹࡞▤ℂߩ Do & Do Not ⣾⢲ᵞ
ᵺ࡮⣢⋃ᵞᵺ Do Not ⣢⋃ᵞᵺᤨߦ㧘⣾⢲ᵞᵺߣหߓࠃ߁ߦ 30㨪50mL ߩ↢ℂ㘩Ⴎ᳓ࠍᵈ౉ߒߡߪ޿ߌ
ߥ޿! ᴲዩེࠤࠕ 2007 ᐕ㧧౻ቄჇೀ㧦151㧙153㧚
21㧕 ┻ౝᢅⷞ, ಴ญ 㓉㧚ᴲዩེ⑼ᢇᕆ㧘ዩ〝ᗵᨴ∝࡮ࡈ࡞࠾ࠛუ∓㧚⥃ᐥᴲዩེ⑼ 2007 ᐕ㧧61 Ꮞ㧦1079
㧙1085㧚
22㧕 ᳯේ⧷ବ, ಴ญ 㓉㧚ᄖ⑼⊛ಣ⟎ࠍⷐߔࠆᴲዩེ⑼㗔ၞߩ㊀∝ᗵᨴ∝㧘೨┙⣼⤥≌㧘♖Ꮍ਄૕⤥≌㧘㒶⨍⤥≌㧚ᴲዩེᄖ⑼ 2008 ᐕ㧧21 Ꮞ㧦453㧙459㧚
23㧕 ቟↰ ḩ㧚ᴲዩེ⑼ᄖ᧪ࡌࠬ࠻࠽ࡆࠥ࡯࡚ࠪࡦ㧘ዩ〝࡮ᕈེߩἻ∝ᕈ∔ᖚ 㕖ᶷ⩶ᕈዩ㆏Ἳ㧘ࠢ࡜ࡒࠫࠕ
ᗵᨴ∝߇⇼ࠊࠇࠆᖚ⠪ߢߔ‫ޕ‬ኻಣߣಣᣇߦߟ޿ߡᢎ߃ߡߊߛߐ޿‫ޕ‬2008 ᐕ㧧62 Ꮞ㧦95㧙97㧚
24㧕 ቟↰ ḩ㧚ᴲዩེ⑼ᄖ᧪ࡌࠬ࠻࠽ࡆࠥ࡯࡚ࠪࡦ㧘〝࡮ᕈེߩἻ∝ᕈ∔ᖚ ࠻࡝ࠦࡕ࠽ࠬ㧘‫࠻߇࡯࠽࠻࡯ࡄޟ‬࡝ࠦࡕ࠽ࠬ⣪Ἳߢᴦ≮߇㐿ᆎߐࠇߚ‫߁޿ߣޠ‬ᖚ⠪ߢߔ‫ޕ‬ኻಣߣಣᣇߦߟ޿ߡᢎ߃ߡߊߛߐ޿‫⥃ޕ‬ᐥᴲዩེ⑼ 2008 ᐕ㧧62 Ꮞ㧦98㧙100㧚
25㧕 ቟↰ ḩ㧚ᴲዩེ⑼ᄖ᧪ࡌࠬ࠻࠽ࡆࠥ࡯࡚ࠪࡦ㧘ዩ〝࡮ᕈེߩἻ∝ᕈ∔ᖚ ೨┙⣼∩㧘㗎࿕ߥ೨┙⣼∩ߩ⥄ⷡ∝⁁ࠍ⸷߃ࠆᖚ⠪ߢߔ‫ޕ‬ኻಣߣಣᣇߦߟ޿ߡᢎ߃ߡߊߛߐ޿‫⥃ޕ‬ᐥᴲዩེ⑼ 2008 ᐕ㧧62 Ꮞ㧦101
㧙104㧚
26㧕 ቟↰ ḩ㧚ᕈᗵᨴ∝ߦ߅ߌࠆᲣሶᗵᨴኻ╷㧘ᶷ⩶ᗵᨴ∝㧚ᣣᧄᕈᗵᨴ∝ቇળ⹹ 2008 ᐕ㧧19 Ꮞ㧦43㧙49㧚
27㧕 ቟↰ ḩ, ಴ญ 㓉㧚ᕈᗵᨴ∝㧘߅߽ߥᕈᗵᨴ∝ 㕖ࠢ࡜ࡒࠫࠕ࡮㕖ᶷ⩶ᗵᨴ㧘ߘߩઁ HB㧘⿒∯ࠕࡔ࡯ࡃ㧘᪢Ქߥߤ㧚ዊఽ⑼⸻≮ 2008 ᐕ㧧71 Ꮞ㧦1301㧙1310㧚
28㧕 ቟↰ ḩ㧚ᗵᨴ∝ߩᴦ≮ ᛫⩶⮎ࠍ૶޿ߎߥߘ߁㧘ᣣᏱ⊛ߥ⸻≮ߦ߅ߌࠆ᛫⩶⮎ߩ૶޿ᣇ ࠛࡦࡇ࡝࠶ࠢ
ߥ᛫⩶⮎ߩ૶޿ᣇߣ⪭ߣߒⓣ ዩ〝ᗵᨴ∝ߦ߅ߌࠆ᛫⩶⮎㧚ౝ⑼ 2008 ᐕ㧧102 Ꮞ㧦878㧙883㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ጊ↰ ᔀ㧘࿯ደ᦮ᄢ㧘੉੗ା๋㧘ᬢ ⌬ᱜ㧘⷏㊁ᅢೣ㧘⷏↰ᵏᐘ㧘⼱ญశብ㧘᳗੗ ม㧘┻ౝᢅⷞ㧘ᳯේ⧷ବ㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧘ጘ㒂ዩ〝਄⊹≸⎇ⓥࠣ࡞࡯ࡊ㧚⴫࿷ᕈ⣾⢲≸ߩౣ⊒࿃ሶ㧘੍ᓟ࿃ሶߩᬌ⸛ 800
଀ߩᬌ⸛㧘ᣣᧄᴲዩེ⑼ቇળ㔀⹹ 2006 ᐕ㧧97 Ꮞ㧦33㧙41㧚
2㧕 Ⴧᩕቁሶ㧘ട⮮ ථ㧘⪤ේᓼᐽ㧘ᮮ੗❥᣿㧘ᳯේ⧷ବ㧘಴ญ 㓉㧚ዩ㆏ᄖ⣕಴ࠍ઻ߞߚዩ▤≜ߩකේᕈ⎕ⵚ㧘⥃ᐥᴲዩེ⑼ 2006 ᐕ㧧60 Ꮞ㧦143㧙145㧚
3㧕 ቝ㊁⵨Ꮘ㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧚Gray zone ∝଀ߦ߅ߌࠆ⚻⋥⣺ᑼ೨┙⣼ᄙᢙ▎ᚲ↢ᬌߩㆡᔕߦ㑐ߔࠆᬌ⸛㧘ᣣᧄ߇ࠎᬌ⸻࡮⸻ᢿቇળ⹹ 2006 ᐕ㧧13 Ꮞ㧦179㧙182㧚
4㧕 ਭ଻↰ᕺ┨㧘࿯ደ᦮ᄢ㧘੉੗ା๋㧘ᳯේ⧷ବ㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧘੖ፉ ⡡㧘౗᧻㓷ਯ㧚Ⴇᩖⴚ߇᦭ല
ߢ޽ߞߚ⣢േ⣂≜ಾㄼ⎕ⵚߩ 1 ଀㧘ᴲዩེ⑼♿ⷐ 2006 ᐕ㧧52 Ꮞ㧦349㧙352㧚
5㧕 ᾢᧄᖝ᣿㧘Ⴆᧄᵏม㧘᧻Ꮉ㓷ೣ㧘࿖ፉᐽ᥍㧘ᐢἑፏ⥝㧘⨃↰჻㇢㧘ጊญ ⣑㧘⍹ᯅ ໪㧘㍯⼱㆐ᄦ㧘ศ↰㧙㧙ᶈ㧘੹⑔⵨ม㧘᧛੗ ൎ㧘ᷰㄝᷡ᣿㧘ዊᨋ⧐ᄦ㧘ౝ↰ ඳ㧘᧻↰㕒ᴦ㧘૒⮮ᣂ৻㧘⮮⋡ ⌀㧘⮮↰๺ᒾ㧘ⁿ⁚ ᷕ㧘ዊᩙ⼾ሶ㧘ጊญᗆਃ㧘ฎ⼱ାᒾ㧘಴ญ 㓉㧘⍹ේ ື㧘ᄢᳯ ብ㧘ጟ ⡛ᰴ㧘ർ᧛㓷຦㧘⑔ේศౖ㧘቞Ლ⽵ᄦ㧘⨹Ꮉഃ৻㧘౏ᢥ⵨Ꮘ㧘㐷↰ᤩ৻㧚ዩ〝ᗵᨴ∝ಽ㔌⩶ߦኻߔࠆ⚻ญߥࠄ߮ߦᵈ኿↪᛫⩶⮎
ߩ᛫⩶ജᲧセ(╙ 26 ႎ 2004 ᐕ) (ߘߩ 1.) ᗵฃᕈߦߟ޿ߡ㧘The Japanese Journal of Antibiotics
2006 ᐕ㧧59 Ꮞ㧦177㧙200㧚
6㧕 ᾢᧄᖝ᣿㧘Ⴆᧄᵏม㧘᧻Ꮉ㓷ೣ㧘࿖ፉᐽ᥍㧘ᐢἑፏ⥝㧘⨃↰჻㇢㧘ጊญ ⣑㧘⍹ᯅ ໪㧘㍯⼱㆐ᄦ㧘ศ↰ᶈ㧘੹⑔⵨ม㧘᧛੗ ൎ㧘ᷰㄝᷡ᣿㧘ዊᨋ⧐ᄦ㧘ౝ↰ ඳ㧘᧻↰㕒ᴦ㧘૒⮮ᣂ৻㧘⮮⋡ ⌀㧘⮮↰๺ᒾ㧘ⁿ⁚ ᷕ㧘ዊᩙ⼾ሶ㧘ጊญᗆਃ㧘ฎ⼱ାᒾ㧘಴ญ 㓉㧘⍹ේ ື㧘ᄢᳯ ብ㧘ጟ ⡛ᰴ㧘ർ᧛㓷຦㧘⑔ේศౖ㧘቞Ლ⽵ᄦ㧘⨹Ꮉഃ৻㧘౏ᢥ⵨Ꮘ㧘㐷↰ᤩ৻㧚ዩ〝ᗵᨴ∝ಽ㔌⩶ߦኻߔࠆ⚻ญߥࠄ߮ߦᵈ኿↪᛫⩶⮎
ߩ᛫⩶ജᲧセ(╙ 26 ႎ 2004 ᐕ) (ߘߩ 2.) ᖚ⠪⢛᥊㧘The Japanese Journal of Antibiotics 2006 ᐕ㧧
59 Ꮞ㧦201㧙213㧚
7㧕 ᾢᧄᖝ᣿㧘Ⴆᧄᵏม㧘᧻Ꮉ㓷ೣ㧘࿖ፉᐽ᥍㧘ᐢἑፏ⥝㧘⨃↰჻㇢㧘ጊญ ⣑㧘⍹ᯅ ໪㧘㍯⼱㆐ᄦ㧘ศ↰ᶈ㧘੹⑔⵨ม㧘᧛੗ ൎ㧘ᷰㄝᷡ᣿㧘ዊᨋ⧐ᄦ㧘ౝ↰ ඳ㧘᧻↰㕒ᴦ㧘૒⮮ᣂ৻㧘⮮⋡ ⌀㧘⮮↰๺ᒾ㧘ⁿ⁚ ᷕ㧘ዊᩙ⼾ሶ㧘ጊญᗆਃ㧘ฎ⼱ାᒾ㧘಴ญ 㓉㧘⍹ේ ື㧘ᄢᳯ ብ㧘ጟ ⡛ᰴ㧘ർ᧛㓷຦㧘⑔ේศౖ㧘቞Ლ⽵ᄦ㧘⨹Ꮉഃ৻㧘౏ᢥ⵨Ꮘ㧘㐷↰ᤩ৻㧘᧻ᧄືᦶ㧘᧛⼱ື㇢㧘ౝ⮮⺈ੑ㧘ᳯ㗡⒤ਭ㧘ዊ⷏㜞ବ㧘
ᴡ㊁ ⨃㧘ᐔẟᵗ৻㧘ㄭ⮮ ᤩ㧘᧻↰ᷕ৻㧘ਛ㊁〝ሶ㧚ዩ〝ᗵᨴ∝ಽ㔌⩶ߦኻߔࠆ⚻ญߥࠄ߮ߦᵈ኿↪᛫⩶⮎ߩ᛫⩶ജᲧセ(╙ 26 ႎ 2004 ᐕ) (ߘߩ 3.) ᗵฃᕈߩផ⒖㧘The Japanese Journal of Antibiotics
2006 ᐕ㧧59 Ꮞ㧦217㧙315㧚
8㧕 ᨋ ⟤૫㧘቟↰ ḩ㧘಴ญ 㓉㧚㜑⤑Ἳ⩶ߦࠃࠆ↵ሶዩ㆏Ἳߩ৻଀㧘ᣣᧄᕈᗵᨴ∝ቇળ⹹ 2006 ᐕ㧧17
Ꮞ㧦78㧙81㧚
9㧕 Ⴧᩕᚑᵏ㧘቟⮮౏㓉㧘⼾↰ ᴰ㧘᫪ ⟵㓶㧘ዊୖ⌀ᴦ㧘ਛᩮᘮᄥ㧘⪤ේᓼᐽ㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧚వᄤᕈ⣢⋃ዩ▤⒖ⴕㇱ⁜⓰∝ߦว૬ߒߚᄖ்ᕈ⣢៊்ߩ 1 ଀㧘ᢇᕆකቇ 2007 ᐕ㧧31 Ꮞ㧦111㧙113㧚
10㧕 㜞ᯅ⟵ੱ㧘ਛᩮᘮᄥ㧘⼱ญశብ㧘ᄙ↰ᤩม㧘ᮮ੗❥᣿㧘ખ㊁ᱜඳ㧘᳓⼱ᤩテ㧘಴ญ 㓉㧘┻ౝᢅⷞ㧚ᴲዩེ⣻⣧㏜ᚻⴚߩ⥃ᐥ⊛ᬌ⸛ ጘ㒂ᄢቇ߅ࠃ߮㑐ㅪᣉ⸳ߦ߅ߌࠆ 9 ᐕ㑆ߩ⚻㛎㧘ጘ㒂⋵කᏧળකቇ㔀⹹
2007 ᐕ㧧20 Ꮞ㧦93㧙99㧚
11㧕 ੉੗ା๋㧘ᮮ੗❥᣿㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧘┻ౝᢅⷞ㧘Ⳝᧄ㓶ฝ㧘⮮ᧄ૫ೣ㧚⣻⣧㏜ਅ೽⣢៰㒰ⴚ ೋᦼ
50 ∝଀ߩ⚻㛎㧘ᴲዩེ⑼♿ⷐ 2007 ᐕ㧧53 Ꮞ㧦107㧙112㧚
12㧕 ട⮮ ථ, 㜞ᯅ⟵ੱ㧘ਛᩮᘮᄥ㧘ᮮ੗❥᣿㧘ᳯේ⧷ବ㧘◉↰⢒↵㧘಴ญ 㓉㧚ᄙ⊒ᕈྙ⢩⣢ߦว૬ߒߚਔ
஥⣢⚦⢩≸ߩ 1 ଀㧘ᴲዩེ⑼♿ⷐ 2007 ᐕ㧧53 Ꮞ㧦117㧙119㧚
13㧕 ਭ଻↰ᕺ┨㧘࿯ደ᦮ᄢ㧘੉੗ା๋㧘ᳯේ⧷ବ㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧘੖ፉ ⡡㧘౗᧻㓷ਯ㧚N-butyl2-cyanoacrylate(hystoacryl)ߦߡ 2 ᦼ⊛ߦႧᩖⴚࠍⷐߒߚᏂᄢ⣢േ㕒⣂ᄸᒻߩ 1 ଀㧘ᴲዩེ⑼♿ⷐ 2007
ᐕ㧧53 Ꮞ㧦307㧙310㧚
14㧕 ☨↰ዏ↢㧘⮮ᧄ૫ೣ㧘ቝ㊁㓷ඳ㧘Ⴧᩕቁሶ㧘᦯ㇱᘅ৻㧚ᩮᴦ⊛೨┙⣼ో៰಴ⴚᓟౣ⊒ߦߟ޿ߡߩᬌ⸛㧘ో࿖⥄ᴦ૕∛㒮ද⼏ળ㔀⹹ 2007 ᐕ㧧46 Ꮞ㧦395㧙396㧚
15㧕 ቝ㊁㓷ඳ㧘ጊ↰૫ノ㧘Ⴧᩕቁሶ㧘☨↰ዏ↢㧘⮮ᧄ૫ೣ㧚࠮ࡒࡁ࡯ࡑ stage I ߩ㐳ᦼᴦ≮ᚑ❣㧘ᴲዩེᄖ⑼ 2007
ᐕ㧧20 Ꮞ㧦179㧙182㧚
16㧕 Ⴧᩕቁሶ㧘ጊ↰૫ノ㧘᦯ㇱᘅ৻㧘ቝ㊁㓷ඳ㧘☨↰ዏ↢㧘⮮ᧄ૫ೣ㧚ዊఽዊ㒶ໃ≹⌕∝ߩ 1 ଀㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2007 ᐕ㧧20 Ꮞ㧦133㧙134㧚
17㧕 ⍹↰ஜ৻㇢㧘ේ↰ศ዁㧘㈕ ṽᓃ㧘᳓⼱ᤩテ㧘ᮮ੗❥᣿㧘಴ญ 㓉㧘㜞ᯅ⟵ੱ㧘ᨹේ৻຦㧘Ⳝᧄ㓶ฝ㧚㕖⸅⍮♖Ꮍߦኻߔࠆ⣻⣧㏜ᬌᩏߩ⚻㛎㧘ᴲዩེ⑼♿ⷐ 2007 ᐕ㧧53 Ꮞ㧦795㧙799㧚
18㧕 ቟↰ ḩ㧘ᄢᬮᷡᢥ㧘ਃ㡞ᑝ❥㧘ᓟ⮮ජኼ㧘Ỉ᧛ᴦ᮸㧘᧛਄໪㓶㧘಴ญ 㓉㧘᫪⣁ਭ㓉㧚ጘ㒂ᄢቇ㒝ዻ∛㒮ߢಽ㔌ߐࠇߚ✛⤥⩶ߩ⮎೷ᗵฃᕈߩᐕᰴផ⒖ߦߟ޿ߡ㧘✛⤥⩶ᗵᨴ∝⎇ⓥળ⻠Ṷ⸥㍳ 2007 ᐕ㧧41 Ꮞ㧦
47㧙51㧚
19㧕 ⩲ේ ፏ㧘᳗੗⌀๋㧘቞ጊᵗม㧘⮮ᐢ ⨃㧚2,8-dihydroxyadenine ⚿⍹ߩ 1 ଀㧘ጘ㒂⿒චሼ∛㒮කቇ㔀⹹
2007 ᐕ㧧19 Ꮞ㧦11㧙14㧚
20㧕 ᦯ㇱᘅ৻㧘⮮ᧄ૫ೣ㧘☨↰ዏ↢㧘ቝ㊁㓷ඳ㧘Ⴧᩕቁሶ㧚12 ᱦ↵ሶߦ⊒↢ߒߚ♖ሶ⡺⧘⣲ߩ 1 ଀㧘⷏ᣣᧄᴲ
ዩེ⑼ 2007 ᐕ㧧69 Ꮞ㧦640㧙643㧚
21㧕 ₹ᧁᱜ⟵㧘ᷡኅஜ૞㧘⷏↰ᵏᐘ㧘೨↰⌀৻㧘ਭ଻↰ᕺ┨㧘಴ญ 㓉㧚࠻࡛࠲⸥ᔨ∛㒮ߦ߅ߌࠆ೨┙⣼≸ߦኻߔࠆ೨┙⣼ో៰㒰ⴚߩ⥃ᐥ⊛ᬌ⸛㧘࠻࡛࠲කႎ 2007 ᐕ㧧17 Ꮞ㧦23㧙28㧚
22㧕 ᴡ↰ᐘ㆏㧘቟↰ ḩ㧘↰ਛ৻ᔒ㧘㐷↰ᤩ৻㧘⿒ဈ⡡৻㇢㧘ᳯ㗡⒤ਭ㧘⾐᧪ḩᄦ㧘ၳ ⺈ᴦ㧚ⶄ㔀ᕈዩ〝ᗵᨴ∝ࠍኻ⽎ߣߒߚ sitafloxacin ߩ↪㊂Ყセ⹜㛎㧘ᣣᧄൻቇ≮ᴺቇળ㔀⹹ 2008 ᐕ㧧56 Ꮞ㧔Ⴧೀ 1 ภ㧕
㧦92
㧙102㧚
23㧕 ቝ㊁㓷ඳ㧘☨↰ዏ↢㧘᦯ㇱᘅ৻㧘ᩮ╣ା৻㧘⮮ᧄ૫ೣ㧘Ⴧᩕቁሶ㧚Stone cone ዉ౉ߦࠃࠆ⚻ዩ㆏⊛ዩ▤⎈⍹ⴚߩ⥃ᐥ⊛ᬌ⸛㧘Japanese Journal of Endourology and ESWL 2008 ᐕ㧧21 Ꮞ㧦209㧙213㧚
24㧕 ਃベᅢ↢㧘቞ጊᵗม㧘Ⴧᩕቁሶ㧘⷏㊁ᅢೣ㧘᦯ㇱᘅ৻㧘ട⮮ᚑ৻㧘⍹↰ஜ৻㇢㧘Ⴧᩕᚑᵏ㧘቟↰ ḩ㧘ቝ㊁㓷ඳ㧘⼱ญశብ㧘₹ᧁᱜ⟵㧘ᳯේ⧷ବ㧘☨↰ዏ↢㧘ጟ㊁ ቇ㧘┻ౝᢅⷞ㧘ᄙ↰ᤩม㧘⮮ᧄ૫ೣ㧘೨↰⌀৻㧘㐳⼱Ꮉ⟵๺㧘⮮ᐢ ⨃㧘㈬੗ବഥ㧘ဈ ⟵ੱ㧘಴ญ 㓉㧚೨┙⣼⢈ᄢ∝ᖚ⠪ߦߺࠄࠇࠆ㛽⋚ㇱਇᔟᗵߦኻߔࠆࠛࡆࡊࡠࠬ࠲࠶࠻ߩ᦭ലᕈߩᬌ⸛㧘ᴲዩེᄖ⑼ 2008 ᐕ㧧21 Ꮞ㧦807㧙814㧚
25㧕 ⷏㊁ᅢೣ㧘಴ญ 㓉㧚ᅚᕈߩㆊᵴേ⣾⢲ߦኻߔࠆ᛫ࠦ࡝ࡦ⮎ࠗࡒ࠳ࡈࠚ࠽ࠪࡦߣ࠰࡝ࡈࠚ࠽ࠪࡦߩή૞ὑ
ഀઃߦࠃࠆᲧセᬌ⸛㧘ᴲዩེᄖ⑼ 2008 ᐕ㧧21 Ꮞ㧦815㧙822㧚
26㧕 ᳓⼱ᤩテ㧘⩵࿾⟤ᄹ㧘ㄭ⮮ᶈผ㧘቞ጊᵗม㧘࿯ደ᦮ᄢ㧘ખ㊁ᱜඳ㧘ᳯේ⧷ବ㧘಴ญ 㓉㧘◉↰⢒↵㧚ಽ▵ᕈേ⣂ਛ⤑Ⲣ⸃߇⇼ࠊࠇߚ⣢઒ᕈേ⣂≜⎕ⵚߩ 1 ଀㧘ᴲዩེ⑼♿ⷐ 2008 ᐕ 54 Ꮞ㧦489㧙491㧚
27㧕 ⩵࿾⟤ᄹ㧘੉੗ା๋㧘቞ጊᵗม㧘࿯ደ᦮ᄢ㧘ਃベᅢ↢㧘ᮮ੗❥᣿㧘ખ㊁ᱜඳ㧘ᳯේ⧷ବ㧘಴ญ 㓉㧘ᑝἑ㧙㧙ༀା㧚FOLFOX4(ࠝࠠࠨ࡝ࡊ࡜࠴ࡦ㧘ࡠࠗࠦࡏ࡝ࡦ㧘5-FU)ࠍⴚ೨᛫≸ൻቇ≮ᴺߦ↪޿ߚዩ⤑▤≸ߩ 1 ଀㧘ᴲዩེ⑼♿ⷐ 2008 ᐕ㧧54 Ꮞ㧦557㧙559㧚
28㧕 Ⴧᩕቁሶ㧘᦯ㇱᘅ৻㧘㜞ᧁ౏ᥙ㧘ቝ㊁㓷ඳ㧘☨↰ዏ↢㧘⮮ᧄ૫ೣ㧚⢷᳓⾂⇐ߦߡ⊒⷗ߐࠇߚ೨┙⣼≸ߩ 2଀㧘ᴲዩེ⑼♿ⷐ 2008 ᐕ㧧54 Ꮞ㧦565㧙568㧚
29㧕 ⷏↰ᵏᐘ㧘ᷡኅஜ૞㧘ጊᧄ⋥᮸㧘೨↰⌀৻㧘㜞᪀ᐽᚑ㧘↰ઍ๺ᒄ㧘₹ᧁᱜ⟵㧚ᓟ⣢ᕈ⣼⣲ߩ 1 ଀㧘࠻࡛࠲
කႎ 2008 ᐕ㧧18 Ꮞ㧦100㧙104㧚
30㧕 ട⮮ ථ㧘ખ㊁ᱜඳ㧘ቝ㊁⵨Ꮘ㧘ᷡኅஜ૞㧘ዊፉ࿻ᄥ㇢㧘ਭ଻↰ᕺ┨㧘ᓟ⮮㜞ᐢ㧘ጊᧄ⋥᮸㧘ᳯේ⧷ବ㧘Ⳝᧄ㓶ฝ㧘㜞ᯅ⟵ੱ㧘಴ญ 㓉㧘ጘ㒂೨┙⣼≸⎇ⓥࠣ࡞࡯ࡊ㧚೨┙⣼㊎↢ᬌᮡᧄߣ೨┙⣼ో៰ᮡᧄߦ߅ߌ
ࠆࠣ࡝࠰ࡦࠬࠦࠕߩਵ㔌ߦߟ޿ߡߩᬌ⸛ ৻⥸∛ℂකߩ⃻⁁㧘ᴲዩེ⑼♿ⷐ 2008 ᐕ㧧54 Ꮞ㧦641㧙645㧚
31㧕 ᳯේ⧷ବ㧘દ⮮ᘕ৻㧘㜞↰ବᒾ㧘࿯ደ᦮ᄢ㧘቞ጊᵗม㧘੉੗ା๋㧘Ⴧᩕᚑᵏ㧘ጊ↰ ᔀ㧘⬉ፉ⻞৻㧘᳗੗ม㧘☨↰ዏ↢㧘ᨋ ⑲ᴦ㧘⍹ේ ື㧘ၳᳯᱜት㧘಴ญ 㓉㧚ੑᰴᕈ೽↲⁁⣼ᯏ⢻੣ㅴ∝ߦኻߔࠆࡑࠠࠨࠞ
࡞ࠪ࠻࡯࡞㐳ᦼ૶↪ߩ੍ᓟ⺞ᩏ㧘ᣣᧄㅘᨆකቇળ㔀⹹ 2008 ᐕ㧧41 Ꮞ㧦717㧙722㧚
32㧕 ᷡኅஜ૞㧘⷏↰ᵏᐘ㧘ጊᧄ⋥᮸㧘೨↰⌀৻㧚㉄ᕈዩ㉄ࠕࡦࡕ࠾࠙ࡓ⚿⍹ߩ 1 ଀㧘ᴲዩེ⑼♿ⷐ 2008 ᐕ㧧
54 Ꮞ㧦689㧙692㧚
33㧕 ዊፉ࿻ᄥ㇢㧘੉੗ା๋㧘಴ญ 㓉㧚ⴚ೨ᬌᩏߦߡ⣾⢲⣲≌߇⇼ࠊࠇߚ TUR ᓟߩ೨┙⣼ౣ⢈ᄢ㧘⥃ᐥᴲዩ
ེ⑼ 2008 ᐕ㧧62 Ꮞ㧦1088㧙1090㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Hasegawa N, Mizutani K, Suzuki T, Deguchi T, Nozawa Y. A comparative study of protein profiling byproteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostatecancer cells. Urol Int. 2006;77:347-354.
2㧕 Nakano M, Uno H, Gotoh T, Kubota Y, Ishihara S, Deguchi T, Hayashi S, Matsuo M, Tanaka O, Hoshi
H. Migration of prostate brachytherapy seeds to the vertebral venous plexus. Brachytherapy.
2006:127-130.
3㧕 Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of twoalpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower
urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int.
2006;97:747-751, discussion 751.
4㧕 Mizutani K, Matsumoto K, Hasegawa N, Deguchi T, Nozawa Y. Expression of clusterin, XIAP andsurvivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and
CPT-sensitive LNCaP cells. Exp Oncol. 2006;28:209-215.
5㧕 Ito H, Iwamoto I, Mizutani K, Morishita R, Deguchi T, Nozawa Y, Asano T, Nagata K. Possible
interaction of a Rho effector, Rhotekin, with a PDZ-protein, PIST, at synapses of hippocampal neurons.
Neurosci Res. 2006;56:165-171.
6㧕 Tanaka O, Hayashi S, Matsuo M, Sakurai K, Nakano M, Maeda S, Kajita K, Deguchi T, Hoshi H.
Comparison of MRI-based and CT/MRI fusion-based postimplant dosimetric analysis of prostatebrachytherapy. Int J Radiat Oncol Biol Phys. 2006;66:597-602.
7㧕 Maeda S, Kubota Y, Senda Y, Tamaki M, Yasuda M, Deguchi T. Failure to detect urethral Trichomonas
vaginalis in Japanese men with or without urethritis. Int J Urol. 2006;13:1418-1420.
8㧕 Tanaka O, Hayashi S, Sakurai K, Matsuo M, Nakano M, Maeda S, Hoshi H, Deguchi T. Importance of
the CT/MRI fusion method as a learning tool for CT-based postimplant dosimetry in prostatebrachytherapy. Radiother Oncol. 2006;81:303-308.
9㧕 Masue N, Deguchi, Yokoi S, Yamada T, Ohkusu K, Ezaki T. System for simultaneous detection of 16
pathogens related to urethritis to diagnose mixed infection. Int J Urol. 2007;14:39-42.
10㧕 Masue N, Hasegawa Y, Moriyama Y, Ikeda Y, Gotoh T, Deguchi T. Spontaneous disappearance ofmultiple lung metastases after nephroureterectomy from sarcomatoid carcinoma of the renal pelvis:
a case report. Int J Urol. 2007;14:75-78.
11㧕 Tanaka O, Hayashi S, Kanematsu M, Matsuo M, Nakano M, Maeda S, Deguchi T, Hoshi H. CT-based
postimplant dosimetry of prostate brachytherapy: comparison of 1-mm and 5-mm section CT. Radiat
Med. 2007;25:22-26.
12㧕 Ito H, Usuda N, Atsuzawa K, Iwamoto I, Sudo K, Katoh-Semba R, Mizutani K, Morishita R, Deguchi T,
Nozawa Y, Asano T, Nagata K. Phosphorylation by extracellular signal-regulated kinase of amultidomain adaptor protein, vinexin, at synapses. J Neurochem. 2007;100:545-554.
13㧕 Ehara H, KojimaK, Hagiwara N, Phuoc NB, Deguchi T. Abscess of the corpus cavernosum. Int J InfectDis. 2007;11:553-554.
14㧕 Phuoc NB, Ehara H, Gotoh T, Nakano M, Yokoi S, Deguchi T, Hirose Y. Immunohistochemical analysis
with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma. Urology.
2007;69:843-848.
15㧕 Mizutani K, Ito H, Iwamoto I, Morishita R, Deguchi T, Nozawa Y, Asano T, Nagata KI. Essential rolesof ERK-mediated phosphorylation of vinexin in cell spreading, migration and anchorage-independent
growth. Oncogene. 2007;26:7122-7131.
16㧕 Maeda S, Tamaki M, Kubota Y, Nguyen PB, Yasuda M, Deguchi T. Treatment of men with urethritis
negative for Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Mycoplasma㧙㧙

IF 0.820

IF 2.751

IF 2.121

IF 4.290
IF 0.769

IF 4.074
IF 0.769

IF 0.769

IF 4.451
IF 2.250

IF 2.134

IF 6.440hominis, Ureaplasma parvum and Ureaplasma urealyticum. Int J Urol. 2007;14:422-425.
17㧕 Yoshida T, Deguchi T, Maeda S, Kubota Y, Tamaki M, Yokoi S, Yasuda M, Ishiko H. Quantitative
detection of Ureaplasma parvum (biovar 1) and Ureaplasma urealyticum (biovar 2) in urine specimensfrom men with and without urethritis by real-time polymerase chain reaction. Sex Transm Dis.
2007;34:416-419.
18㧕 Ochiai S, Sekiguchi Y, Hayashi A, Shimadzu M, Ishiko H, Matsushima-Nishiwaki R, Kozawa O,
Yasuda M, Deguchi T. Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2
for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother. 2007;60:54-60.
19㧕 Goto T, Nakano M, Ito S, Ehara H, Yamamoto N, Deguchi T. Significance of an E-cadherin genepromoter polymorphism for risk and disease severity of prostate cancer in a Japanese population.
Urology. 2007;70:127-130.
20㧕 Tanaka O, Hayashi S, Matsuo M, Nakano M, Kubota Y, Maeda S, Ohtakara K, Deguchi T, Hoshi H.
Comparison of urethral diameters for calculating the urethral dose after permanent prostatebrachytherapy. Radiat Med. 2007;25:329-334.
21㧕 Yokoi S, Maeda S, Kubota Y, Tamaki M, Mizutani K, Yasuda M, Ito S, Nakano M, Ehara H, Deguchi T.
The role of Mycoplasma genitalium and Ureaplasma urealyticum biovar 2 in postgonococcal urethritis.
Clin Infect Dis. 2007;45:866-871.
22㧕 Tanaka O, Hayashi S, Matsuo M, Nakano M, Uno H, Ohtakara K, Miyoshi T, Deguchi T, Hoshi H.
Effect of edema on postimplant dosimetry in prostate brachytherapy using CT/MRI fusion. Int J
Radiat Oncol Biol Phys. 2007;69:614-618.
23㧕 Tanaka O, Hayashi S, Matsuo M, Nakano M, Kubota Y, Maeda S, Ohtakara K, Deguchi T, Hoshi H.
MRI-based preplanning in low-dose-rate prostate brachytherapy. Radiother Oncol. 2008;88:115-120.
24㧕 Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, Tamaki M, Maeda S. Threat to cefixime
treatment for gonorrhea. Emerg Infect Dis. 2007;13:1275-1277.
25㧕 Mizutani K, Nagata KI, Ito H, Ehara H, Nozawa Y, Deguchi T. Possible Roles of Vinexinbeta in Growthand Paclitaxel Sensitivity in Human Prostate Cancer PC-3 Cells. Cancer Biol Ther. 2007;6:1800-1804.
26㧕 Mizutani K, Ehara H, Yokoi S, Phuoc NB, Deguchi T, Hirose Y. Treatment-related ureteral cancer
following stage II testicular seminoma. Int J Clin Oncol. 2007;12:469-471.
27㧕 Kubota Y, Kawai A, Tsuchiya T, Kozima K, Yokoi S, Deguchi T. Bilateral primary malignant lymphomaof the ureter. Int J Clin Oncol. 2007;12:482-484.
28㧕 Mizokami A, Ueno S, Fukagai T, Ito K, Ehara H, Kinbara H, Origasa H, Usami M, Namiki M, Akaza H.
Global update on defining and treating high-risk localized prostate cancer with leuprorelin: an Asian
perspective. BJU Int. 2007;99 Suppl 1:6-9.
29㧕 Kubota Y, Kamei S, Ehara H, Takahashi Y, Deguchi T. Anterior urethral valve in the fossa navicularispresenting as a sprit urinary stream in a child. Hinyokika Kiyo. 2008;54:135-138.
30㧕 Uno H, Nakano M, Ehara H, Deguchi T. Indications for extended 14-core transrectal
ultrasound-guided prostate biopsy. Urology. 2008;71:23-27.
31㧕 Ochiai S, Ishiko H, Yasuda M, Deguchi T. Rapid detection of the mosaic structure of the Neisseria
gonorrhoeae penA Gene, which is associated with decreased susceptibilities to oral cephalosporins. J
Clin Microbiol. 2008;46:1804-1810.
32㧕 Kubota Y, Kamei S, Nakano M, Ehara H, Deguchi T, Tanaka O. The potential role of prebiopsy
magnetic resonance imaging combined with prostate-specific antigen density in the detection of
prostate cancer. Int J Urol. 2008;15:322-326; discussion 327.
33㧕 Goto T, Nguyen BP, Nakano M, Ehara H, Yamamoto N, Deguchi T. Utility of Bcl-2, P53, Ki-67, andcaveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a
Japanese population. Urology. 2008;72:167-171.
34㧕 Moriyama Y, Miwa K, Tanaka H, Fujihiro S, Nishino Y, Deguchi T. Nocturia in men less than 50 yearsof age may be associated with obstructive sleep apnea syndrome. Urology. 2008;71:1096-1098.
35㧕 Kojima K, Ohhashi R, Fujita Y, Hamada N, Akao Y, Nozawa Y, Deguchi T, Ito M. A role for SIRT1 incell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res
Commun. 2008;373:423-428.
36㧕 Moriyama Y, Minamidate Y, Yasuda M, Ehara H, Kikuchi M, Tsuchiya T, Deguchi T, Tsurumi H. Acuterenal failure due to bilateral ureteral stone impaction in an HIV-positive patient. Urol Res.
2008;36:275-277.
37㧕 Phuoc NB, Ehara H, Gotoh T, Nakano M, Kamei S, Deguchi T, Hirose Y. Prognostic value of theco-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear
cell renal cell carcinoma. Oncol Rep. 2008;20:525-530.
38㧕 Deguchi T, Yasuda M, Maeda S. Lack of nationwide surveillance of antimicrobial resistance of
Neisseria gonorrhoeae in Japan. Ann Intern Med. 2008;149:363-364.
39㧕 Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, Deguchi T, Ito M. Effects of miR-34a on
cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun.
2008;377:114-119.

㧙㧙

IF 0.769

IF 2.928

IF 4.038

IF 2.134

IF 6.750

IF 4.290
IF 4.074
IF 5.755
IF 2.873

IF 2.751

IF 2.134

IF 3.708

IF 0.769

IF 2.134
IF 2.134

IF 2.749

IF 1.385

IF 1.597
IF 15.516

IF 2.749

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦દ⮮ᘕ৻㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦⣢⒖ᬀߦ߅ߌࠆᕆᕈᜎ⛘෻ᔕߩ࡝ࠕ࡞࠲ࠗࡓቯ㊂⊛ PCR ᴺࠍ↪޿ߚᣧᦼ⸻ᢿᴺߩ⏕┙㧧ᐔᚑ 16㧙18 ᐕᐲ㧧2,500 ජ౞(1,400㧦800㧦
300 ජ౞)2㧕 ⎇ⓥઍ⴫⠪㧦દ⮮ᘕ৻㧘⎇ⓥಽᜂ⠪㧦಴ญ 㓉㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦CD8 KOࡑ࠙ࠬߢߩห⒳⊹⤏⒖ᬀ ߩᜎ⛘෻ᔕߩࠛࡈࠚࠢ࠲࡯⚦⢩ߩหቯ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧5,000 ජ౞(2,800㧦2,200 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ዊፉ࿻ᄥ㇢㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦೨┙⣼≸⚦⢩ߦ߅ߌࠆ⮎೷⠴ᕈᯏᐨߩ⸃᣿㧧ᐔᚑ 20㧙21 ᐕᐲ㧧3,900 ජ౞(2,600㧦1,300 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ಴ญ 㓉㧦DU-6859a ╙Υ⋧⥃ᐥ⹜㛎㧙ⶄ㔀ᕈዩ〝ᗵᨴ∝ࠍኻ⽎ߣߒߚੑ㊀⋤ᬌ↪㊂Ყセ⹜㛎㧙㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,806,712 ౞㧦╙৻⵾⮎㧔ᩣ㧕
2㧕 ಴ญ 㓉㧦YM617 ╙Υ⋧⹜㛎㧔↵ᕈ㧕㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,036,384 ౞㧦ࠕࠬ࠹࡜ࠬ⵾⮎㧔ᩣ㧕
3㧕 ಴ญ 㓉㧦YM617 ╙Υ⋧⹜㛎㧔ᅚᕈ㧕㧧ᐔᚑ 17㧙18 ᐕᐲ㧧4,956,120 ౞㧦ࠕࠬ࠹࡜ࠬ⵾⮎㧔ᩣ㧕
4㧕 ಴ญ 㓉㧦YP-18 ߩⶄ㔀ᕈዩ〝ᗵᨴ∝ࠍኻ⽎ߣߒߚ⥃ᐥ╙Υ⋧⹜㛎㧙ࠝ࡯ࡊࡦ࡜ࡌ࡞ᄙᣉ⸳౒ห⹜
㛎㧙㧧ᐔᚑ 17㧙18 ᐕᐲ㧧2,895,984 ౞㧦ᄢᱜንጊක⮎ຠ㧔ᩣ㧕
5㧕 ಴ญ 㓉㧦YP-18 ߩᢌⴊ∝࡮ᗵᨴᕈᔃౝ⤑Ἳࠍኻ⽎ߣߒߚ⥃ᐥ╙Υ⋧⹜㛎㧙ࠝ࡯ࡊࡦ࡜ࡌ࡞ᄙᣉ⸳
౒ห⹜㛎㧙㧧ᐔᚑ 17㧙18 ᐕᐲ㧧1,998,360 ౞㧦ᄢᱜንጊක⮎ຠ㧔ᩣ㧕
6㧕 ಴ญ 㓉㧦CS-023 ╙Τ⋧⹜㛎-ⶄ㔀ᕈዩ〝ᗵᨴ∝ࠍኻ∝ߣߒߚ৻⥸⹜㛎-㧧ᐔᚑ 18 ᐕᐲ㧧1,260,000౞㧦ਃ౒㧔ᩣ㧕7㧕 ಴ญ 㓉㧦ࡊࡠࠣ࡜ࡈࠞࡊ࠮࡞᦭ኂ੐⽎⹦⚦⺞ᩏ㧧ᐔᚑ 18 ᐕᐲ㧧42,000 ౞㧦ࠕࠬ࠹࡜ࠬ⵾⮎㧔ᩣ㧕8㧕 ಴ญ 㓉㧦DR-3355 ߩⶄ㔀ᕈዩ〝ᗵᨴ∝ࠍኻ∝ߣߒߚ৻⥸⹜㛎㧔╙Υ⋧㧕㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
1,486,800 ౞㧦╙৻⵾⮎㧔ᩣ㧕
9㧕 ಴ญ 㓉㧦ࡃ࠶ࡊࡈࠜ࡯․ቯ૶↪ᚑ❣⺞ᩏ㧔ᱷዩ㊂ࠍᜰᮡߣߒߚ᦭↪ᕈߩᬌ⸛㧕㧧ᐔᚑ 18㧙19 ᐕᐲ㧧
315,000 ౞㧦ᄢ㢈⮎ຠᎿᬺ㧔ᩣ㧕
10㧕 ಴ญ 㓉㧦ࡊࡠࠣ࡜ࡈࠞࡊ࠮࡞᦭ኂ੐⽎⹦⚦⺞ᩏ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧21,000 ౞㧦ࠕࠬ࠹࡜ࠬ⵾⮎㧔ᩣ㧕11㧕 ಴ญ 㓉㧦࡝ࡘ࡯ࡊ࡝ࡦ SR ᵈ኿↪ 11.25mg ․ቯ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧945,000 ౞㧦ᱞ↰⮎ຠᎿᬺ㧔ᩣ㧕12㧕 ಴ญ 㓉㧦ࡃࠪ࡝ࠠࠪࡑࡉ෸߮ࠬ࠹ࡠࠗ࠼೷ࠍ૬↪ߔࠆᣂⷙᚑੱ⣢⒖ᬀᖚ⠪ࠍኻ⽎ߣߒߡᷫ㊂ࡀࠝ࡯࡜࡞ߣ૬↪ߒߚࠛࡌࡠ࡝ࡓࠬ㧔ⴊਛỚᐲߦၮߠ߈ᛩਈ㊂ࠍ⺞ᢛߔࠆ㧕ߣᮡḰ㊂ࡀࠝ࡯࡜࡞ߣ૬↪
ߒߚࡒࠦࡈࠚࡁ࡯࡞㉄ࡕࡈࠚ࠴࡞ߩ᦭ലᕈ෸߮቟ోᕈࠍᲧセߔࠆ㧘12 ࡩ᦬㧘ᄙᣉ⸳౒ห㧘࡜ࡦ࠳ࡓൻ㧘ࠝ࡯ࡊࡦ࡜ࡌ࡞⹜㛎㧧ᐔᚑ 19㧙22 ᐕᐲ㧧1,990,800 ౞㧦ࡁࡃ࡞࠹ࠖࠬࡈࠔ࡯ࡑ㧔ᩣ㧕
13㧕 ಴ญ 㓉㧦ࡌࠪࠤࠕ㍤૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧105,000 ౞㧦ࠕࠬ࠹࡜ࠬ⵾⮎㧔ᩣ㧕
14㧕 ಴ญ 㓉㧦࡝ࠩࡌࡦ೽૞↪⹦⚦⺞ᩏ㧧ᐔᚑ 20 ᐕᐲ㧧21,000 ౞㧦ࠠ࠶࠮ࠗ⮎ຠᎿᬺ㧔ᩣ㧕
15㧕 ಴ญ 㓉㧦ࡃ࠶ࡊࡈࠜ࡯․ቯ૶↪ᚑ❣⺞ᩏ гૐኈ㊂ 10 mg/ᣣ 㐿ᆎ଀ߦ߅ߌࠆ᦭↪ᕈߩᬌ⸛г㧧ᐔᚑ 19㧙20 ᐕᐲ㧧 315,000 ౞㧦ᄢ㢈⮎ຠᎿᬺ㧔ᩣ㧕
16㧕 ಴ญ 㓉㧦ࠝ࡯ࠕࠗࠛࡈ․ቯ૶↪ᚑ❣⺞ᩏ㧔⊹ਅᵈ㧕㧧ᐔᚑ 19㧙20 ᐕᐲ㧧94,500 ౞㧦ᄢႦ⵾⮎㧔ᩣ㧕
17㧕 ಴ญ 㓉㧦DC-159a ߩ Mycoplasma genitalium ߦኻߔࠆ᛫⩶ᵴᕈߩ⹏ଔ㧧ᐔᚑ 20㧙21 ᐕᐲ㧧
2,310,000 ౞㧦╙৻ਃ౒㧔ᩣ㧕
18㧕 ಴ญ 㓉㧦ࠢ࡜ࡆ࠶࠻㍤࡮⚦☸ ․ቯ૶↪ᚑ❣⺞ᩏ‫ޟ‬ዩ〝ᗵᨴ∝ߩਥⷐේ࿃⩶ߩฦ⒳᛫⩶⮎ߦኻߔࠆᗵฃᕈᬌ⸛‫ޠ‬㧧ᐔᚑ 20 ᐕᐲ㧧315,000 ౞㧦╙৻ਃ౒㧔ᩣ㧕
19㧕 ಴ญ 㓉㧦ࡀࠢࠨࡃ࡯࡞㍤ ․ቯ૶↪ᚑ❣⺞ᩏ㧔㐳ᦼ૶↪㧕㧧ᐔᚑ 20㧙22 ᐕᐲ㧧157,500 ౞㧦ࡃࠗࠛ࡞⮎ຠ㧔ᩣ㧕
20㧕 ಴ญ 㓉㧦ࠬ࡯࠹ࡦ࠻ࠞࡊ࠮࡞ 12.5 mg ․ቯ૶↪ᚑ❣⺞ᩏ г‫ޟ‬⣢⚦⢩≸ߦኻߔࠆ⺞ᩏ‫ޠ‬г㧧ᐔᚑ
20㧙24 ᐕᐲ㧧378,000 ౞㧦ࡈࠔࠗࠩ࡯㧔ᩣ㧕
3㧕౒ห⎇ⓥߥߒ㧙㧙5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ಴ญ 㓉㧦
1㧕 ᣣᧄᴲዩེ⑼ቇળ⋙੐(㨪⃻࿷)2㧕 ᣣᧄൻቇ≮ᴺቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄൻቇ≮ᴺቇળ⷏ᣣᧄᡰㇱᐙ੐(㨪⃻࿷)4㧕 ᣣᧄᕈᗵᨴ∝ቇળℂ੐(㨪⃻࿷)5㧕 ᣣᧄᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ዩ〝ᗵᨴ∝⎇ⓥળᐙ੐(㨪⃻࿷)7㧕 ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળㆇ༡ᆔຬ㐳(㨪⃻࿷)8㧕 ᴲዩེ⑼ಽሶ࡮⚦⢩⎇ⓥળ਎⹤ੱ(㨪⃻࿷)9㧕 ᧲ᶏࠬ࠻࡯ࡑ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)10㧕 J-POPS ㆇ༡ᆔຬ(㨪⃻࿷)ᳯේ⧷ବ㧦1㧕 ᣣᧄᴲዩེ⑼ቇળࡏ࡯࠺ࠖࡦࠣࡔࡦࡃ࡯(㨪⃻࿷)2㧕 ᧲ᶏ⣻⤑ㅘᨆ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)3㧕 ᴲዩེಽሶ࡮⚦⢩⎇ⓥળ⹏⼏ຬ(㨪⃻࿷)4㧕 ጘ㒂⋵ㅘᨆ≮ᴺ⎇ⓥળቇⴚᆔຬ(㨪⃻࿷)5㧕 ᧲ᶏࠬ࠻࡯ࡑ࡮࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)દ⮮ᘕ৻㧦1㧕 ᣣᧄᴲዩེ⑼ቇળࡏ࡯࠺ࠖࡦࠣࡔࡦࡃ࡯(㨪⃻࿷)2㧕 ᣣᧄ⒖ᬀቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ⣢⒖ᬀⴊ▤ᄖ⑼⎇ⓥળ਎⹤ੱ(㨪⃻࿷)ખ㊁ᱜඳ㧦
1㧕 ᣣᧄᴲዩེ⑼ቇળࡏ࡯࠺ࠖࡦࠣࡔࡦࡃ࡯(㨪⃻࿷)2㧕 ᣣᧄ Endourology࡮ESWL ቇળ⹏⼏ຬ(㨪⃻࿷)ᮮ੗❥᣿㧦1㧕 ᣣᧄᴲዩེ⑼ቇળࡏ࡯࠺ࠖࡦࠣࡔࡦࡃ࡯(㨪⃻࿷)2㧕 ᣣᧄ Endourology࡮ESWL ቇળ⹏⼏ຬ(㨪⃻࿷)቟↰ ḩ㧦
1㧕 ᣣᧄᴲዩེ⑼ቇળࡏ࡯࠺ࠖࡦࠣࡔࡦࡃ࡯(㨪⃻࿷)2㧕 ᣣᧄൻቇ≮ᴺቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᕈᗵᨴ∝ቇળ⹏⼏ຬ(ᐔᚑ 17 ᐕ 12 ᦬㨪⃻࿷)
4㧕 ᣣᧄൻቇ≮ᴺቇળ᛫⩶⮎⥃ᐥ⹏ଔࠟࠗ࠼࡜ࠗࡦᡷቯᆔຬળᆔຬ(㨪⃻࿷)5㧕 ᣣᧄൻቇ≮ᴺቇળࠨ࡯ࡌࠗ࡜ࡦࠬᆔຬળᆔຬ(㨪⃻࿷)6㧕 ᣣᧄൻቇ≮ᴺቇળ UTI ⮎ല⹏ଔၮḰ⷗⋥ߒߩߚ߼ߩᆔຬળᆔຬ(㨪⃻࿷)2㧕ቇળ㐿௅಴ญ 㓉㧦
1㧕 ╙ 234 ࿁ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ฬฎደ)2㧕 ╙ 241 ࿁ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ฬฎደ)
3㧕ቇⴚ㔀⹹಴ญ 㓉㧦
1㧕 ᴲዩེ⑼♿ⷐ㧧✬㓸ᆔຬ(㨪⃻࿷)㧙㧙2㧕 Int. J. Urol.㧦Editor(㨪⃻࿷)቟↰ ḩ㧦
1㧕 ᣣᧄᕈᗵᨴ∝ቇળ㧧✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄൻቇ≮ᴺቇળ㧧✬㓸ᆔຬ(ᐔᚑ 20 ᐕ㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳಴ญ 㓉㧦
1㧕 ╙ 56 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬අߩᚻⴚ࡮ᧂ᧪ߩ   ᛛ‫ޠ‬ᐳ㐳)
2㧕 ╙ 56 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘ࠨ࠹࡜ࠗ࠻ࠪࡦࡐࠫ࠙ࡓ 2‫ޟ‬ㄭᧂ᧪⊛೨┙⣼≸ኻ╷‫ޠ‬ᐳ㐳)
3㧕 ╙ 341 ࿁ᣣᧄᴲዩེ⑼ቇળᣂẟ࿾ᣇળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ᣂẟ㧘․೎⻠Ṷ‫⮎ޟ‬೷⠴ᕈ⩶ߪߎ߁ߒߡ಴
⃻ߔࠆ㧙ዩ〝ᕈེᗵᨴ∝ߩ႐ว㧙‫ޠ‬Ṷ⠪)
4㧕 ╙ 95 ࿁ᣣᧄᴲዩེ⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘තᓟᢎ⢒ࡊࡠࠣ࡜ࡓ‫ޟ‬ዩ〝ᕈེᗵᨴ∝—᛫⩶೷૶↪ࠟࠗ࠼࡜ࠗࡦߦᴪߞߚ᛫⩶೷ߩ૶޿ᣇ- ᕈེᗵᨴ∝‫ޠ‬Ṷ⠪)
5㧕 ╙ 111 ࿁ᣣᧄ⌒⑼ቇળ✚ળ ኾ㐷೎⎇ⓥળ ╙ 8 ࿁⌒⑼ DNA ࠴࠶ࡊ⎇ⓥળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ޟ‬ᗵᨴ∝ߩㆮવሶ⸻ᢿ —ዩ〝ᕈེᗵᨴ∝ߢߩᔕ↪—‫ޠ‬Ṷ⠪)
6㧕 ᣣᧄᕈᗵᨴ∝ቇળ╙ 20 ࿁ቇⴚᄢળ(ᐔᚑ 19 ᐕ 12 ᦬㧘᧲੩㧘ᢎ⢒࠮ࡒ࠽࡯‫ޟ‬Mycoplasma genitaliumᗵᨴ∝ߩ update‫ޠ‬Ṷ⠪)7㧕 ╙ 58 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ṑ⾐㧘․೎⻠Ṷ‫ޟ‬ᴲዩེ⑼⣲≌ߦ߅ߌࠆ PET↹௝⸻ᢿߩᓎഀ‫ޠ‬ᐳ㐳)દ⮮ᘕ৻㧦
1㧕 ╙ 56 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘⎇ୃක࡮කቇ↢ߩߚ߼ߩᢎ⢒࠮ࡒ࠽࡯‫৻╙ޣ‬ㇱ‫ޟޤ‬ノߊ⥄ಽࠍ⷗ߟߌࠃ߁‫ޠ‬Ṷ⠪)
ખ㊁ᱜඳ㧦
1㧕 ╙ 56 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘⎇ୃක࡮කቇ↢ߩߚ߼ߩᢎ⢒࠮ࡒ࠽࡯‫৻╙ޣ‬ㇱ‫ޟޤ‬ノߊ⥄ಽࠍ⷗ߟߌࠃ߁‫ޠ‬Ṷ⠪)
2㧕 ╙ 235 ࿁ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ㧘․೎ડ↹‫ޟ‬㒢ዪᕈ೨┙⣼≸㧔T1c orT2)࡛࠙⚛ 125 ኒኽዊ✢Ḯ᳗ਭᝌ౉≮ᴺ‫ޠ‬Ṷ⠪㧕
3㧕 ╙ 236 ࿁ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ฬฎደ㧘․೎ડ↹‫ޟ‬ૐ࡝ࠬࠢ⟲ߦኻߔࠆኒ
ኽዊ✢Ḯ᳗ਭᝌ౉≮ᴺߩᚑ❣‫ޠ‬Ṷ⠪)
4㧕 ╙ 242 ࿁ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደ㧘․೎ડ↹‫ޟ‬ಽሶᮡ⊛ᴦ≮ᤨઍߩㅴⴕᕈ⣢≸ᴦ≮ ࠰࡜ࡈࠚ࠾ࡉ߇᦭ലߢ޽ߞߚᄙ⊒ォ⒖ߩ 1 ଀‫ޠ‬Ṷ⠪)ᮮ੗❥᣿㧦
1㧕 ╙ 56 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬අߩᚻⴚ࡮ᧂ᧪ߩ
ᛛ‫ޠ‬‫ޟ‬HoLEP ዉ౉ߦ㓙ߒߡߩᛛ‫ޠ‬Ṷ⠪)
2㧕 ╙ 95 ࿁ᣣᧄᴲዩེቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ ⣻⣧㏜ᚻⴚ⧯ᚻ⸛⺰ળ‫ޟ‬⣻⣧㏜࠻࡟࡯࠾ࡦࠣ‫ޠ‬Ṷ⠪)቟↰ ḩ㧦
1㧕 ᣣᧄᕈᗵᨴ∝ቇળ ╙ 19 ࿁ቇⴚᄢળ(ᐔᚑ 18 ᐕ 12 ᦬㧘㊄ᴛ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᕈᗵᨴ∝೙࿶ߦะߌ
ߡ㧦⥃ᐥකቇ߆ࠄߩࠕࡊࡠ࡯࠴‫ޟޠ‬ᕈᗵᨴ∝೙࿶ߦะߌߡߩࠊࠇࠊࠇߩขࠅ⚵ߺߦߟ޿ߡ‫✼ޠ‬⠪)2㧕 ╙ 95 ࿁ᣣᧄᴲዩེ⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘තᓟᢎ⢒ࡊࡠࠣ࡜ࡓ‫ޟ‬ዩ〝ᕈེᗵᨴ∝㧙᛫⩶೷૶↪ࠟࠗ࠼࡜ࠗࡦߦᴪߞߚ᛫⩶೷ߩ૶޿ᣇ㧙 ዩ〝ᕈེᗵᨴ∝‫ޠ‬Ṷ⠪)
3㧕 ᣣᧄᕈᗵᨴ∝ቇળ╙ 20 ࿁ቇⴚᄢળ(ᐔᚑ 19 ᐕ 12 ᦬㧘᧲੩㧘ᢎ⢒࠮ࡒ࠽࡯‫ޟ‬ᶷ⩶㧘ࠢ࡜ࡒࠫࠕ㧘ࡑࠗࠦࡊ࡜࠭ࡑߩ᜛ᄢ㒐ᱛ╷‫ޠ‬Ṷ⠪)
4㧕 ᣣᧄᕈᗵᨴ∝ቇળ╙ 20 ࿁ቇⴚᄢળ(ᐔᚑ 19 ᐕ 12 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Უሶု⋥ᗵᨴߩ੍㒐 ᶷ⩶ᗵᨴ∝‫ޠ‬Ṷ⠪)
5㧕 ╙ 241 ࿁ᣣᧄᴲዩེ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ฬฎደ㧘․೎ડ↹‫♧ޟ‬ዩ∛ߣᴲዩེ⑼∔ᖚ㧙㧙೨┙⣼↢ᬌߣ♧ዩ∛‫ޠ‬Ṷ⠪)
6㧕 ╙ 49 ࿁ᄢ㖧⸻ᢿකቇᬌᩏቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘Korea㧘Industry-Sponsored Lecture & Dinner‫ޟ‬The criteria for evaluation of clinical efficacy of antimicrobial agents on urinary tract infection– The diagnosis of urinary tract infections -‫ޠ‬Speaker)
7㧕 ╙ 26 ࿁ᣣᧄࠢ࡜ࡒࠫࠕ⎇ⓥળ㧘╙ 15 ࿁࡝ࠤ࠶࠴ࠕ⎇ⓥળวห⎇ⓥ⊒⴫ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂㧘ࡕ࡯࠾ࡦࠣ࠮ࡒ࠽࡯‫⥃ޟ‬ᐥߦ߅ߌࠆࠢ࡜ࡒࠫࠕᕈዩ㆏Ἳߩ⸻ᢿ࡮ᴦ≮ߩታ㓙‫ޠ‬Ṷ⠪)8㧕 ╙ 58 ࿁ᣣᧄᴲዩེ⑼ቇળਛㇱ✚ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ṑ⾐㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬ዩ㆏Ἳᴦ≮ߦ߅ߌࠆ໧㗴ὐߣߘߩ⸃᳿╷ г㕖ᶷ⩶ᕈዩ㆏Ἳࠍਛᔃߣߒߡ‫ޠ‬Ṷ⠪)9㧕 11th Western Pacific Congress on Chemotherapy and Infectious Disease(ᐔᚑ 20 ᐕ 12 ᦬, Taiwan,
Symposium: Management of Complicated UTI, Complex Renal Infection; Symposist)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ಴ญ 㓉㧦
1㧕 ጘ㒂⋵り૕㓚ኂ⠪කቇ⊛್ቯབྷ⸤කᏧ(㨪⃻࿷)2㧕 ጘ㒂⋵ᗵᨴ∝੍㒐ኻ╷ࠛࠗ࠭ኻ╷ㇱળᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⋵೨┙⣼߇ࠎᬌ⸻ኾ㐷ᆔຬળᆔຬ㐳(㨪⃻࿷)4㧕 ጘ㒂⋵ࠫࡦ࡮ࠕࠗࡃࡦࠢදળ೽ℂ੐㐳(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ಴ญ 㓉㧦ዩ〝࡮ᕈེᗵᨴ∝∛ේᓸ↢‛ߩㄦㅦ߆ߟ൮᜝⊛ㆮવሶ⸻ᢿࠪࠬ࠹ࡓߩ㐿⊒㧦ᐔᚑ 16 ᐕᐲ㧙ᐔᚑ 17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙45(2006 ᐕ 3 ᦬)
11㧚ႎ㆏
1㧕 ಴ญ 㓉㧘⷏㊁ᅢೣ㧘Ⴧᩕቁሶ㧘㜞ᧁኡᴦ㧦ㆊᵴേ⣾⢲ߩ⸻ᢿߣᴦ≮㧦Medical Tribune(2007 ᐕ 1
᦬)2㧕 ಴ญ 㓉㧦⚕਄⸻ኤቶ PSA 㜞ߊ೨┙⣼೥ࠆᬌᩏ൘߼ࠄࠇ㧦ਛᣣᣂ⡞(2007 ᐕ 2 ᦬ 16 ᣣ)
3㧕 ಴ญ 㓉㧦ឃዩ㓚ኂኻ╷ࠍ⚫੺㧦ጘ㒂ᣂ⡞(2007 ᐕ 6 ᦬ 12 ᣣ)
4㧕 ⩵ᳰ ⾫㧘Ỉ᧛ᱜਯ㧘಴ญ 㓉㧘ự⍾⦟৻㧘ዊᨋኑ༁㧦ᐳ⺣ળ ᕈᗵᨴ∝ߩ໧㗴ὐߣᬌᩏቶߩኻᔕ㧦
BioScan (2008 ᐕ)
5㧕 ᚭႦᕶ৻㧘᧻ᧄືᦶ㧘಴ญ 㓉㧦ᐳ⺣ળ ᴲዩེ⑼㗔ၞߦ߅ߌࠆࠠࡁࡠࡦ♽⮎ߩᦨㆡߥᛩਈᴺߣߪ㧦
Medical Tribune (2008 ᐕ 8 ᦬ 14 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔዩ〝ᕈེᗵᨴ∝ߩಽ㊁ߢߪ㧘వㅴ⊛ߥ⎇ⓥᚑᨐࠍ޽ߍࠆߎߣ߇ߢ߈ߡ߅ࠅ⹏ଔࠍฃߌߡ޿ࠆ‫ߒ߆ߒޕ‬ߥ߇ࠄ㧘ઁߩ⎇ⓥ⺖㗴ߦ߅޿ߡߪ⌕ታߦ⎇ⓥߪㅴⴕߒߡ޿ࠆ߽ߩߩ㧘ᚑᨐߣߒߡߪ޽ࠄࠊࠇߡ߅ࠄߕࠃ
ࠅ৻ጀߩദജࠍⷐߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᦨᄢߩ໧㗴ὐߪ㑐ㅪᣉ⸳߽฽߼ߚੱຬਇ⿷ߢ޽ࠆ‫ߦࠄߐޕ‬㧘ᣂ∛㒮߳ߩ⒖ォᓟߩ⥃ᐥᵴേߩ࠙ࠚࠗ࠻
߇Ⴧߒߚߎߣߦ઻ߞߡ㧘⋉‫⎇ޘ‬ⓥߦഀߌࠆຬᢙߣᤨ㑆ߦᓇ㗀߇಴ߡ޿ࠆ‫ޕ‬හലᕈߩ޽ࠆኻᔕ╷ߪߥߊ㧘߹ߚ㧘ᒰಽ㊁ߛߌߩ໧㗴ߢߪߥ޿ߣ⠨߃ߡ޿ࠆ‫ޕ‬ᒰಽ㊁ߣߒߡߪ㧘એ೨ߦ߽Ⴧߒߡᧄቇකቇㇱ↢෸߮ઁᄢቇߩቇ↢ߦⓍᭂ⊛ߦࠕࡇ࡯࡞ߒ㧘⇐ቇ↢߿ቇᄖડᬺ߆ࠄߩ␠ળੱᄢቇ
㒮↢ࠍⓍᭂ⊛ߦฃ౉ࠍⴕߞߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ
1㧕ዩ〝↢ᱺེ⣲≌ߩᴦ≮ߣ੍ᓟߦ㑐ߔࠆၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ
ዩ〝↢ᱺེ≸ߦ߅ߌࠆㆮવሶᄌ⇣ߩ൮᜝⊛ߥ⹏ଔߣߘߩ⥃ᐥᔕ↪ࠍ⋡ᜰߔ‫ޕ‬
2㧕ዩ〝ᗵᨴ∝ߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ⃻࿷ߩ⎇ⓥࠍㅴ߼㧘߹ߚ㧘ㆮવሶ⸃ᨆߦࠃࠆ⮎೷ᗵฃᕈ್ቯᴺߩ㐿⊒ࠍ⋡ᜰߔ‫ߩࠄࠇߎޕ‬ၮ␆⊛⎇ⓥ㧙㧙ᚑᨐߦၮߠ޿ߚㆡᱜߥ᛫⩶ൻቇ≮ᴺߩ⏕┙ࠍ⋡ᜰߔ‫ޕ‬
3㧕↵ሶዩ㆏Ἳߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ
ዩ㆏Ἳߩ∛ේᓸ↢‛ߩ⸃᣿ࠍߐࠄߦㅴ߼ࠆߣߣ߽ߦ㧘ዩ㆏Ἳߦኻߔࠆㆡᱜߥ᛫⩶ൻቇ≮ᴺߩ⏕┙ࠍ⋡ᜰߔ‫ޕ‬4㧕⣢⒖ᬀߦ߅ߌࠆ⥃ᐥ⊛⎇ⓥ
఺∉ᛥ೙೷ߩㆡᱜ૶↪ߩ⏕┙ߣ⒖ᬀ⣢ߩ㐳ᦼᯏ⢻⛽ᜬࠍ⋡ᜰߔ‫ޕ‬
5㧕㏜ⷞਅᚻⴚᚻᛛߩ㐿⊒⎇ⓥᣂߚߥᛛⴚ߅ࠃౕེ߮㧘ེ᧚ߩ㐿⊒ߦࠃࠅ㧘㏜ⷞਅᚻⴚߩㆡᔕߩ᜛ᄢࠍ⋡ᜰߔ‫ޕ‬㧙㧙㧔7㧕㤗㈮࡮−∩೙ᓮቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
㤗㈮࡮−∩೙ᓮቇಽ㊁ߩਥߥ⎇ⓥ⺖㗴ߪ㧘⥃ᐥ㤗㈮ߩ቟ోᕈߣ㔍ᴦᕈ−∩ᴦ≮ߩ㐿⊒ߣࠍਥ⌒ߦ⟎޿ߚ
⎇ⓥߢ޽ࠆ‫ޕ‬෻኿ᕈߩ๭ๆᓴⅣ෻ᔕߣ⣖⣄㜑ߩᓸዊᓴⅣ߆ࠄ๟ⴚᦼߩ⣖଻⼔ߦ㑐ߔࠆ⍮⷗ߩ෼㓸߿㧘㤗㈮ߣ−∩ߩࠪࠣ࠽࡞વ㆐ᯏ᭴ߣߘߩ೙ᓮ㧘㔍ᴦᕈ−∩ߩࡔࠞ࠾࠭ࡓࠍࠝࡇࠝࠗ࠼㧘ǩ2 ࠕࠧ࠾ࠬ࠻㧘Ion
transporter ╬ߩ⣄㜑㎾∩ᯏ᭴ࠍ⸃᣿ߔࠆၮ␆⊛⎇ⓥࠍⴕߞߡ߅ࠅ㧘એਅߩࠃ߁ߦ߹ߣ߼ࠆߎߣ߇ߢ߈ࠆ‫ޕ‬
1㧕㤗㈮࡮ଚⷅਛߩ๭ๆ࡮ᓴⅣ෻ᔕᕈ෻ᔕߦ㑐ߔࠆ⥃ᐥ⊛⎇ⓥ
2㧕⣖࡮⣄㜑ᓴⅣߦኻߔࠆ㤗㈮෸߮ߘߩ㑐ㅪ⮎ߦ㑐ߔࠆ⎇ⓥ
3㧕−∩೙ᓮᯏ᭴ߩ␹⚻ൻቇ⊛⎇ⓥߣ㤗㈮⮎㧘ࠝࡇࠝࠗ࠼㧘ǩ2 ࠕࠧ࠾ࠬ࠻ K+࠴ࡖࡀ࡞㐿ญ⮎㧘ࠗࠝࡦ࠻࡜ࡦࠬࡐ࡯࠲࡯㧘NSAIDs ߥߤߩ૞↪ᯏᐨߦ㑐ߔࠆ⎇ⓥ
ㆊ෰ 10 ᐕ㑆㧘⑼ቇ⎇ⓥ⾌ߩ㈩ಽࠍฃߌ㧘㗡⬄ౝ෸߮⣄㜑⣧ౝ᦭⓹ᴺࠍ↪޿ߡ㧘⣖෸߮⣄㜑ߩᓸዊᓴⅣ
ߦኻߔࠆ㤗㈮⮎ߘߩઁߩ૞↪ᯏᐨߦ㑐ߔࠆᵴ⊒ߥ⎇ⓥࠍⴕ޿㧘ᦨㄭߪ⥃ᐥ߹ߢ઀੐ߩ᏷ࠍᐢߍߡ߈ߚ‫ࠝޕ‬ࡇࠝࠗ࠼㧘ǩ2 ࠕࠧ࠾ࠬ࠻ K+࠴ࡖࡀ࡞㐿ญ⮎㧘ࠗࠝࡦ࠻࡜ࡦࠬࡐ࡯࠲࡯ߥߤߩ⣄㜑㎾∩ᯏ᭴߳ߩᓇ㗀ߦኻߔࠆᣂߒ޿⍮⷗߽ᄙߊߥߞߡ߈ߚ‫ߚ߹ޕ‬㧘ࡄ࠶࠴ࠢ࡜ࡦࡊᴺࠍ↪޿ߡ㧘⣄㜑ᓟᩮ⚦⢩ߩ Na+࠴ࡖࡀ࡞߳
ߩ૞↪㧘K+࠴ࡖࡀ࡞㧘޽ࠆ޿ߪዪᚲ㤗㈮⮎߿㎾∩⵬ഥ⮎ߩࠪࠣ࠽࡞ಽሶᯏ᭴߳ߩ૞↪߽ᬌ⸛ߒ㧘ࠕࡐ࠻࡯ࠪࠬࠍ⺃⊒ߔࠆߎߣ߽᣿ࠄ߆ߦߒߚ‫ޕ‬2㧚ฬ★
࿯⢈ ୃมᢎ᝼㧦㘵↰ ብ᮸ಎᢎ᝼㧦┻ਛ రᐽ⻠Ꮷ㧦ᄢ⇗ ඳੱ
⻠Ꮷ㧦
㐳ἑ ᷡ
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦 ↰ㄝ ਭ⟤ሶ⥃ᐥ⻠Ꮷ㧦 ㆏㊁ ᦮ᵗ⥃ᐥ⻠Ꮷ㧦 ᧖ጊ 㓁ሶ⥃ᐥ⻠Ꮷ㧦 ᾢỈ ᣽ᒾ⥃ᐥ⻠Ꮷ㧦 ᩉ⥪ ን⟤㣐⷗ ๺ⴕ
කຬ㧦
ጊญ ᔋ
කຬ㧦
㘵↰ ⟤♿
කຬ㧦⑔ጟ ዏ๺කຬ㧦ችᧄ ⌀♿
කຬ㧦
ධ ౏ੱ
කຬ㧦
㋈ᧁ ෹Ꮧකຬ㧦ਛ᧛ ᅢ⟤
කຬ㧦

Shuji Dohi
Hiroki Iida
Motoyasu Takenaka
Hiroto Ohata
Kiyoshi Nagase
Kumiko Tanabe
Tomohiro Michino
Yoko Sugiyama
Masahiko Kumazawa
Fumi Yanagidate
Kazuyuki Sumi
Shinobu Yamaguchi
Miki Iida
Naokazu Fukuoka
Maki Miyamoto
Kimito Minami
Yuki Suzuki
Yoshimi Nakamura

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ࿯⢈ୃม㧘ઁ౒⪺㧚8. 㤗㈮ߣ⣖␹⚻ᯏ⢻㧦ᄤ⠀ᢘ␭⋙ୃ㧚㤗㈮⑼ቇ࡟ࡆࡘ࡯2006ᦨᣂਥⷐᢥ₂㓸㧘᧲੩㧦✚วකቇ␠㧧2006 ᐕ㧦46㧙55㧚
2㧕 ࿯⢈ୃม㧘ઁ౒⪺㧚9. 㤗⮎㧛ⷡ㉕೷㧛⣕ᴺ࠼࡜࠶ࠣ ࡔ࠲ࡦࡈࠚ࠲ࡒࡦ㧦㤥Ꮉ㗼✬㧚ਛᲥ∝ߩߔߴߡ޿
ߑߣ޿߁ᤨߦᓎ┙ߟ‫ߥ⏕⊛ޔ‬ᴦ≮ߩߚ߼ߦ㧘᧲੩㧦᳗੗ᦠᐫ㧧2006 ᐕ㧦385㧚
3㧕 ࿯⢈ୃม✬⪺㧚Σ-01 㤗㈮⑼࠹ࠢ࠾࠶ࠢߩ቟ోߥᣉⴕߩߚ߼ߩේೣ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦14㧙15㧚
4㧕 ࿯⢈ୃม✬⪺㧚Σ-03 㤗㈮⑼⸘↹ߩታ㓙㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006ᐕ㧦18㧙19㧚
5㧕 ࿯⢈ୃม✬⪺㧚Σ-04 ᖚ⠪࡮ኅᣖ߳ߩ⺑᣿࡮หᗧᦠขᓧ㧔ࠗࡦࡈࠜ࡯ࡓ࠼ࠦࡦ࠮ࡦ࠻㧕ߩ࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦20㧙21㧚
6㧕 ࿯⢈ୃม✬⪺㧚Σ-05 㤗㈮ེߩၮᧄ᭴ㅧߣ㤗㈮ߩḰ஻㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦22㧙23㧚
7㧕 ࿯⢈ୃม✬⪺㧚Σ-09 㤗㈮ਛߩ૕ᶧ࡮ઍ⻢▤ℂߩ࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦30㧙31㧚
8㧕 ࿯⢈ୃม✬⪺㧚Σ-10 ∝଀ࡊ࡟࠯ࡦ࠹࡯࡚ࠪࡦߩ࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦32㧙33㧚㧙㧙

9㧕 ࿯⢈ୃม✬⪺㧚Τ-01 ࡑࠬࠢ࡮ࡃ࠶ࠢ↪ᚻ឵᳇ߩࠦ࠷㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦34㧙35㧚
10㧕 ࿯⢈ୃม✬⪺㧚Τ-09 ᗧ⼂ൻᝌ▤㧔awake intubation㧕,᳇㆏㤗㈮㧘TTI㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦50㧙51㧚
11㧕 ࿯⢈ୃม✬⪺㧚Υ-01 ㉄⚛ᛩਈ㧔⚻ญ㧘⚻㥦㧘⚻᳇▤㧕ߩᣇᴺ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦56㧙57㧚
12㧕 ࿯⢈ୃม✬⪺㧚Υ-09 NG ࠴ࡘ࡯ࡉߩᝌ౉࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦74㧙75.
13㧕 ࿯⢈ୃม✬⪺㧚Υ-11 㤗㈮࿁ᓳߩ⹏ଔ㧔࡝ࠞࡃ࡝࡯ࠬࠦࠕ‫ࠢ࠶ࠚ࠴ޔ‬㗄⋡㧘ౣᝌ▤ߩㆡᔕ㧕㧦ࠗ࡜ࠬ࠻ߢ
ࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦78㧙79.
14㧕 ࿯⢈ୃม✬⪺㧚Φ-01 ᧃ᪳㕒⣂ࠞ࠹࡯࠹࡞ߩ⇐⟎㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦80㧙81.
15㧕 ࿯⢈ୃม✬⪺㧚Φ-02 ౝ㗪㕒⣂ࠞ࠹࡯࠹࡞ᝌ౉㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦84㧙85.
16㧕 ࿯⢈ୃม✬⪺㧚Χ-01 ࡞࡯࠴ࡦࡕ࠾࠲࡯㧔ᔃ㔚࿑㧘SpO2㧘ⴊ࿶㧕㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦94㧙95.
17㧕 ࿯⢈ୃม✬⪺㧚Χ-04 ᳇㆏ౝ࿶㧘๭᳇ੑ㉄ൻ὇⚛Ớᐲ㧔ETCO2㧕ߩ⹏ଔ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦100㧙101.
18㧕 ࿯⢈ୃม✬⪺㧚Χ-05 േ࡮㕒⣂ⴊࠟࠬᖱႎߩ⹏ଔ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦102㧙103.
19㧕 ࿯⢈ୃม✬⪺㧚Χ-10 㤗㈮ਛߩ⣖࡮␹⚻ᯏ⢻ߩࡕ࠾࠲࡯ D)⥄ᓞ␹⚻ᵴേ⹏ଔߩ࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢ
ࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦126㧙127.
20㧕 ࿯⢈ୃม✬⪺㧚Ω-02 ⎬⤑ᄖ㤗㈮㧦⓫ೝߣࠞ࠹࠹࡝ࠩ࡯࡚ࠪࡦާࡄ࡜ࡔ࠺ࠕࡦ‫ޔ‬ᄖ஥ᴺ‫ޔ‬ᱜਛᴺ㧔ᛶ᛫‫ޔ‬ࡃ࡞࡯ࡦ‫ޔ‬᳓Ṣ㧕ި㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦154㧙155㧚
21㧕 ࿯⢈ୃม✬⪺㧚Ω-03 㗪ㇱ⎬⤑ᄖ⣧⓫ೝߣࠞ࠹࡯࠹࡞ߩᝌ౉㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦156㧙157㧚
22㧕 ࿯⢈ୃม✬⪺㧚Ϊ-01 ∩ߺߩቯ⟵ߣ−∩વ㆐⚻〝㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦168㧙169.
23㧕 ࿯⢈ୃม✬⪺㧚Ϊ-02 ∩ߺߩ⹏ଔߣㆬᛯ⊛␹⚻ࡉࡠ࠶ࠢߦࠃࠆ⹏ଔ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦170㧙171.
24㧕 ࿯⢈ୃม✬⪺㧚Ϊ-09 ߇ࠎᖚ⠪ߩ−∩▤ℂ࠹ࠢ࠾࠶ࠢ A)ၮᧄ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦186㧙187.
25㧕 ࿯⢈ୃม✬⪺㧚Ϊ-12 ᤊ⁁␹⚻▵ࡉࡠ࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006
ᐕ㧦194㧙195.
26㧕 ࿯⢈ୃม✬⪺㧚Ϊ-29 ࠗࠝࡦ࠻ࡈࠜ࡟࡯ࠪࠬ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦228㧙229.
27㧕 ࿯⢈ୃม✬⪺㧚Ϋ-02 ᖡᔃ࡮ཌྷฯߩ੍㒐ߣᴦ≮㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦234㧙235.
28㧕 ࿯⢈ୃม✬⪺㧚Ϋ-03 ⴚᓟૐ㉄⚛ⴊ∝㧔᳇㆏㐽Ⴇ㧘╭ᒆ✭⮎ߩᱷሽ㧕㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦236㧙237.
29㧕 ࿯⢈ୃม✬⪺㧚Ϋ-10 ⢖ⴊᩖႧᩖ∝ߩ੍㒐ߩ࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦252㧙253㧚
30㧕 ࿯⢈ୃม✬⪺㧚ά-06 ૕ᶧ࡮㔚⸃⾰⇣Ᏹߩ⵬ᱜ࠹ࠢ࠾࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦270㧙271㧚
31㧕 ࿯⢈ୃม✬⪺㧚ά 㤗㈮ਛ߿✕ᕆᤨߩᬌᩏߩၮḰ୯ߣࡄ࠾࠶ࠢ୯৻ⷩ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦277㧚
32㧕 㘵↰ብ᮸㧚Σ-07 ๆ౉㤗㈮ᴺߩ࠹ࠢ࠾࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦26㧙27㧚
33㧕 㘵↰ብ᮸㧚Ω-05 ㅘⷞਅࠞ࠹࡯࠹࡝࠯࡯࡚ࠪࡦߩ࠹ࠢ࠾࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦160㧙161㧚
34㧕 㘵↰ብ᮸㧚Ϊ-11 ␹⚻ࡉࡠ࠶ࠢߩዪᚲ㤗㈮࡮ࠬ࠹ࡠࠗ࠼࡮␹⚻⎕უ⮎࡮ಝ࿕ᾲ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢ
ࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦192㧙193.
35㧕 㘵↰ብ᮸㧚Ϊ-15 ਃ෷␹⚻ࡉࡠ࠶ࠢ㧔ࠟ࠶࠮࡞␹⚻▵ࡉࡠ࠶ࠢ㧕㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦200㧙201.
36㧕 㘵↰ብ᮸㧚Ϊ-15 ਃ෷␹⚻ࡉࡠ࠶ࠢ㧔਄࡮ਅ㗶␹⚻ࡉࡠ࠶ࠢ㧕㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ
㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦202㧙203.
37㧕 㘵↰ብ᮸㧚Ϊ-22 ᬁ㑆㑐▵㧔ࡈࠔ࠮࠶࠻㧕ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦214㧙215.
38㧕 㘵↰ብ᮸㧚Ϋ-11 Anticoagulant ᖚ⠪߳ߩᴦ≮࠹ࠢ࠾࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦254㧙255㧚
39㧕 㘵↰ብ᮸㧘ጊญᔋ㧚╙ 3 ┨㧚⎬⤑ᄖ㤗㈮ B.4.⎬⤑ᄖ㤗㈮ᓟ⣶⢛ㇱ∩ߩ․ᓽߣኻ╷㧦ጤፒኡઁ✬㧚ߎߎ߇ࡐࠗࡦ࠻ 㤗㈮ᚻᛛ਄㆐ߩࠦ࠷㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦237㧙239㧚
40㧕 㘵↰ብ᮸㧚╙ 3 ┨㧚⎬⤑ᄖ㤗㈮ B.5.⎬⤑ᄖ㤗㈮ᓟߩ⎬⤑ᄖ⣧ߩⴊ⣲࡮⤥≌ᒻᚑᤨߩ∝⁁ߣኻ╷㧦ጤፒኡ㧙㧙ઁ✬㧚ߎߎ߇ࡐࠗࡦ࠻ 㤗㈮ᚻᛛ਄㆐ߩࠦ࠷㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦240㧙243㧚
41㧕 㘵↰ብ᮸㧚20.⥃ᐥ㤗㈮ߩ⇼໧ߦ╵߃ࠆ↢ℂቇ I㧚⣖␹⚻ 7.㤗㈮ߢ⣖ⴊᵹߣ⣖ઍ⻢ࠍࠦࡦ࠻ࡠ࡯࡞ߢ߈ࠆ
߆㧦㜞ᯅ⌀ᑿ✬㧚㤗㈮⑼⸻≮ࡊ࡜ࠢ࠹ࠖࠬ㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦48㧙51㧚
42㧕 ┻ਛరᐽ㧚Τ-07 ༄㗡㏜ߩ⒳㘃㧘࠻࡜ࠠ࡜ࠗߩㆡᔕ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦46㧙47.
43㧕 ┻ਛరᐽ㧚Ϊ-24 ⢷ㇱற⣄ᬁࡉࡠ࠶ࠢ㧔thoracic paravertebral block㧕㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ
㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦218㧙219.
44㧕 ┻ਛరᐽ㧚Ϊ-25 ⢷ㇱ੤ᗵ␹⚻ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦220㧙221.
45㧕 ┻ਛరᐽ㧚Ϊ-26 ⣶ㇱ੤ᗵ␹⚻▵ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦222㧙223.
46㧕 ᄢ⇗ඳੱ㧚Σ-02 ᖚ⠪⹏ଔߣ㤗㈮⸘↹㧦࿯⢈ୃม✬⪺㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦16㧙17㧚
47㧕 ᄢ⇗ඳੱ㧚Υ-08
⢖឵᳇ߩ࠹ࠢ࠾࠶ࠢ㧔ಽ㔌⢖឵᳇ߩ࠹ࠢ࠾࠶ࠢ㧕㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦70㧙71.
48㧕 ᄢ⇗ඳੱ㧚Ϋ-06 ᔃ╭⯯ⴊ⊒૞㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦242㧙243.
49㧕 ↰ㄝਭ⟤ሶ㧚Υ-03 㤗㈮⮎ߩㆬᛯ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦60㧙61.
50㧕 㐳ἑ ᷡ㧚Χ-08 ⚻㘩㆏ᔃࠛࠦ࡯ࡊࡠ࡯ࡉߩᝌ౉ߣᔃᯏ⢻ߩ⹏ଔߩ࠹ࠢ࠾࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢ
ࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦1114㧙1115.
51㧕 㐳ἑ ᷡ㧚Χ-09 ௯ᚱᑯ‫ޔ‬ᄢേ⣂ᑯ‫ޔ‬Ꮐቶ‫ޔ‬ᄢേ⣂ߩᯏ⢻⹏ଔ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ
㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦1116㧙117.
52㧕 ㆏㊁᦮ᵗ㧚Χ-03 ૕᷷ߩ᷹ቯߣ૕᷷⛽ᜬߩ࠹ࠢ࠾࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦98㧙99.
53㧕 ᄢỈ㓁ሶ㧚Τ-08 ㄦㅦ᳇▤ౝᝌ▤㧔with cricoid pressure Columbia㧕㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦48㧙49.
54㧕 ᄢỈ㓁ሶ㧚Ψ-02 ⢈ḩᖚ⠪ߩ㤗㈮㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦132㧚
55㧕 ᾢᴛ᣽ᒾ㧚Τ-04 ⚻㥦ᝌ▤㧦࿯⢈ୃม✬⪺㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006ᐕ㧦40㧙41㧚
56㧕 ᩉ⥪౷⟤㧚Σ-06 㤗㈮೨ᛩ⮎ߣߘߩ⹏ଔ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦24㧙25㧚
57㧕 ᫜ᯅ㊀⡡㧚Ψ-07 ᔃ⤳∔ᖚ㧔㐿ᔃⴚ㧕㧦࿯⢈ୃม✬⪺㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦142㧙144㧚
58㧕 ᧻ᧄ⨃⟤㧚Ϊ-20 ⢋↲⁁␹⚻ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦210㧙211.
59㧕 ᧻ᧄ⨃⟤㧚Ϊ-21 ⡻㑆␹⚻ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬⪺㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦212㧙213.
60㧕 ጊญ ᔋ㧚Ω-08 㐽㎮␹⚻ࡉࡠ࠶ࠢ‫ޔ‬ᄢ⣽␹⚻ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬⪺㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦166㧙167㧚
61㧕 ጊญᔋ㧚Ϊ-18 ᓟ㗡␹⚻ࡉࡠ࠶ࠢ㧦࿯⢈ୃม✬㧚ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧
2006 ᐕ㧦206㧙207.
62㧕 㣐⷗๺ⴕ㧚࿯⢈ୃม✬⪺㧚Ϊ-17 ᵻㇱ࡮ᷓㇱ㗪␹⚻ฌࡉࡠ࠶ࠢ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦204㧙205.
63㧕 㘵↰⟤♿㧚࿯⢈ୃม✬⪺㧚Φ-02 േ⣂ౝࠞ࠹࡯࠹࡞ߩ⇐⟎ߣ࡜ࠗࡦߩ▤ℂ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦82㧙83.
64㧕 ⑔ጟዏ๺㧚࿯⢈ୃม✬⪺㧚Τ-10 ࠳ࡉ࡞࡞࡯ࡔࡦ࠴ࡘ࡯ࡉߩᝌ౉㧔ฝ࡮Ꮐ㧕㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ
㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦52㧙53.
65㧕 ⑔ጟዏ๺㧚࿯⢈ୃม✬⪺㧚Ϋ-01 ༄㗡∨ᡨ࡮᳇▤ᡰ∨ᡨ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦232㧙233.
66㧕 ᳗ဈ↱♿ሶ㧚࿯⢈ୃม✬⪺㧚Ϋ-04 ᧃ᪳␹⚻㓚ኂ㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦238㧙239.
67㧕 ↰ญ૫ᐢ㧚࿯⢈ୃม✬⪺㧚Τ-03 ⚻ญᝌ▤ (฽߻࠴ࡘ࡯ࡉߩㆬᛯ) 㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦38㧙39.
68㧕 ᴡ᧛ਃජ㚅㧚࿯⢈ୃม✬⪺㧚Τ-02 ࠛࠕ࠙ࠛࠗ㧔⚻ญ‫⚻ޔ‬㥦㧕ߩᝌ౉㧦ࠗ࡜ࠬ࠻ߢࠊ߆ࠆ㤗㈮⑼ᔅ㗇࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦36㧙37.
69㧕 ࿯⢈ୃม㧚1.ᘟᕈ∩ߪߥߗ⿠ߎࠆߩ߆㧦⷏ጟਭኼ᮸✬㧚✢⛽╭∩∝ࡂࡦ࠼ࡉ࠶ࠢ 2 ┨ ၮ␆㧘᧲੩㧦ᣣᧄක੐ᣂႎ␠㧧2007 ᐕ㧦14㧙25㧚
70㧕 㘵↰ብ᮸㧘㣐⷗๺ⴕ㧚ࡍࠗࡦࠢ࡝࠾ࠪࡖࡦߩߚ߼ߩ∩ߺ⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧦ችፒ᧲ᵗ✬㧚቟ోߢ⧰∩ߩዋߥ޿⣶ㇱ␹⚻ᩮࡉࡠ࠶ࠢߩᎿᄦ,᧲੩㧦ਛጊᦠᐫ㧧2007 ᐕ㧦146㧙148.
71㧕 㐳ἑᷡ㧘㜞Ⴆ⋥⢻㧘♿ࡁቯ଻⤿㧘ጊᧄ⋿↱⟤㧚ᕆᕈᦼ∛㒮⚻༡ߦ߅ߌࠆᚻⴚㇱࡑࡀࠫࡔࡦ࠻․ቯᯏ⢻∛㒮ᚻⴚቶߩࠤ࡯ࠬ㧘᧲੩㧦⚻ᷣ↥ᬺ⋭ක≮⚻༡ੱ᧚⢒ᚑࠤ࡯ࠬᢎ᧚㐿⊒ࡊࡠࠫࠚࠢ࠻㧧2007 ᐕ㧦1㧙58㧚㧙㧙72㧕 ࿯⢈ୃม㧚․㓸ߦ޽ߚߞߡߪߓ߼ߡߩ㤗㈮⑼⎇ୃ㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦5.
73㧕 ᄢ⇗ඳੱ㧚ᚻⴚᖚ⠪ߩ⹏ଔߣ㤗㈮ࡊ࡜ࡦߩ૞ᚑߩࡐࠗࡦ࠻㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦6㧙14.
74㧕 ᄢ⇗ඳੱ㧚ᚻⴚᖚ⠪ߩ⹏ଔߣ㤗㈮ࡊ࡜ࡦߩ૞ᚑߩࡐࠗࡦ࠻㧙ࡒ࠾࡟ࠢ࠴ࡖ࡯ ᵈᗧߔߴ߈∔ᖚ࡮ᖚ⠪㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦15㧚
75㧕 ᄢ⇗ඳੱ㧚ᚻⴚᖚ⠪ߩ⹏ଔߣ㤗㈮ࡊ࡜ࡦߩ૞ᚑߩࡐࠗࡦ࠻㧙ࡒ࠾࡟ࠢ࠴ࡖ࡯ ✕ᕆᚻⴚߩ㤗㈮ࠍᚻવ߁
㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦16㧙17㧚
76㧕 㘵↰⟤♿㧚㕒⣂〝࡮േ⣂〝ߩ⏕଻㧦ࠬࡑ࡯࠻ߥࠕࡊࡠ࡯࠴㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦28㧙33㧚
77㧕 ࿯⢈ୃม㧚᳇㆏࡮๭ๆ▤ℂߩታ㓙ߣࠦ࠷㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008ᐕ㧦36㧙46㧚78㧕 ㆏㊁᦮ᵗ㧚ች૕૏ߪߤ߁ߔࠆ㧫㧦࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦49㧙
51㧚
79㧕 Ⴧᳯ㆐ᒾ㧚ᓴⅣ▤ℂ㧔ⴊ࿶ૐਅ‫ޔ‬ഥ⣂߳ߩኻᔕ㧕ߩታ㓙㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦52㧙55㧚
80㧕 ᾢỈ᣽ᒾ㧚૕ᶧ࡮ઍ⻢▤ℂߩታ㓙ߣࠦ࠷㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008ᐕ㧦58㧙61㧚81㧕 㣐⷗๺ⴕ㧚⎬⤑ᄖ㤗㈮ߩታ㓙ߣࠦ࠷㧦ች࿾⦟᮸✬㧚⥃ᐥ⎇ୃࡊ࡜ࠢ࠹ࠖࠬ 5 Ꮞ㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦
76㧙79㧚
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ࿯⢈ୃม㧚−∩ࠪࠣ࠽࡞વ㆐ߣ೙ᓮᯏ᭴㧘Pharma Medica 2006 ᐕ㧧6 Ꮞ㧦25㧙30㧚
2㧕 ࿯⢈ୃม㧚ߪߓ߼ߦ㧘කቇߩ޽ࠁߺ 2008 ᐕ㧧225 Ꮞ㧦985㧚
3㧕 ࿯⢈ୃม㧚㤗㈮ਛߩⷡ㉕ߣᄞ㧘කቇߩ޽ࠁߺ 2008 ᐕ㧧225 Ꮞ㧦1023㧙1028㧚
4㧕 ࿯⢈ୃม㧚㤗㈮⑼ቇߩㆊ෰࡮⃻࿷࡮ㄭᧂ᧪́ቇⴚߩㅴᱠߣ㤗㈮⑼ක≮ߩዷ㐿́㧘㤗㈮ 2008 ᐕ㧧57 Ꮞ㧔Ⴧೀ㧕
㧦S1㧙S7㧚
5㧕 㘵↰ብ᮸㧘ઁ౒⪺㧚᧻ᨐ૕∛ᄌߦኻߔࠆ infratentorial supracerebellar approach, No Shinkei Geka 2007
ᐕ㧧35 Ꮞ㧦453㧙466㧚
6㧕 㘵↰ብ᮸㧚⣖㧔⣄㜑㧕⯯ⴊߩᴦ≮ߣ㤗㈮́㤗㈮⮎߅ࠃ߮㤗㈮㑐ㅪ⮎ߣ⣖⣄㜑ⴊ▤́㧘⯃↢㧘᧲੩ 2008 ᐕ㧧
27 Ꮞ㧧106㧙117㧚
7㧕 㘵↰ඳ᮸㧚㤗㈮⑼කߪߤߎ߹ߢ⤳ེ଻⼔ߦ㑐ਈߢ߈ࠆ߆㧫́⣄㜑଻⼔ߦ㑐ߒߡ́㧘ᣣᧄ⥃ᐥ㤗㈮ቇળ⹹
2008 ᐕ㧧೎ౠ㧦599㧙607㧚
✚⺑㧔᰷ᢥ㧕
1㧕 Iida H, Iida M. Effects of spinal analgesics on spinal circulation the safety standpoint. J Neurosurg
Anesthesiol Rev. 2008;20:180-187.
ේ⪺㧔๺ᢥ㧕
1㧕 ጊญᔋ㧘┻ਛరᐽ㧘⑔ጟዏ๺㧘᫜ᯅ㊀⡡㧘㘵↰ብ᮸㧘࿯⢈ୃม㧚ਛᔃ㕒⣂ࠞ࠹࡯࠹࡞⇐ᗧଐ㗬∝଀ߢ⿠߈ߚࠗࡦࠪ࠺ࡦ࠻ߦኻߔࠆ㤗㈮⑼ᄖ᧪ߢߩኻᔕ㧘ᣣᧄ⥃ᐥ㤗㈮ቇળ⹹ 2006 ᐕ㧧26 Ꮞ㧦713㧙717㧚
2㧕 ↰ญ૫ᐢ㧘㘵↰ብ᮸㧘ጊญᔋ㧘㣐⷗๺ⴕ㧘᫜ᯅ㊀⡡㧘┻ਛరᐽ㧘࿯⢈ୃม㧚ᄖ்ᕈ㗪ㇱ∝୥⟲ߦ઻߁㗡ߦ⎬⤑ᄖ⥄Ꮖⴊࡄ࠶࠴߇᦭ലߢ޽ߞߚ 1 ∝଀́⣖⣄㜑ᶧᷫዋ∝ߩ⸻ᢿߦ߅ߌࠆ⎬⤑ᄖ↢ℂ㘩Ⴎ᳓ᵈ౉ߩ᦭ലᕈ́㧘ࡍࠗࡦࠢ࡝࠾࠶ࠢ 2006 ᐕ㧧27 Ꮞ㧦1451㧙1455㧚
3㧕 ᬀᧁ໪ᢥ㧘ዊᎹ⋥ᔒ㧘㘵↰ብ᮸㧚߁ߟ∛ߩᱷㆮ∝⁁ߦኻߒߡ ECT ߇⪺ലߒߚ 1 ଀㧘⥃ᐥ♖␹කቇ 2006
ᐕ㧦35 Ꮞ㧦1195㧙1200.
4㧕 ᄢ⇗ඳੱ㧘࿯⢈ୃม㧚Ⴎ㉄࡜ࠫࠝࡠ࡯࡞㧘ࠢ࡝࠾ࠞ࡞ࡊ࡜ࠢ࠹ࠖࠬ 2007 ᐕ㧧26 Ꮞ㧦62㧙64㧚
5㧕 ᄢ⇗ඳੱ㧘࿯⢈ୃม㧚౰േ⣂∔ᖚᖚ⠪ߦ߅ߌࠆ╭ᒆ✭⮎ߩᜟ᛫㧘Lisa 2007 ᐕ㧧14 Ꮞ㧦460㧙466㧚
6㧕 ᄢ⇗ඳੱ㧘⒳᧛⴩㉿ሶ㧘࿯⢈ୃม㧚㜞↪㊂࠺ࠢࠬࡔ࠺࠻ࡒࠫࡦࠍ↪޿ߚ㕖ᝌ▤࡮⥄⊒๭ๆਅߢߩ࡜࡝ࡦࠧ
ࡑࠗࠢࡠᚻⴚߩ㤗㈮⚻㛎㧘㤗㈮ 2008 ᐕ㧧57 Ꮞ㧦427㧙432㧚
7㧕 ᄢ⇗ඳੱ㧘ጊ↰ᔘೣ㧘࿯⢈ୃม㧚߽߿߽߿∛ᖚ⠪ߩᵻ஥㗡േ⣂́ਛᄢേ⣂่วਛⴚਛߦᕆᕈ⎬⤑ᄖⴊ⣲ࠍ↢ߓߚ 1 ଀㧘㤗㈮ 2008 ᐕ㧧57 Ꮞ㧦755㧙760㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Yanagidate F, Dohi S. Modified nasal cannula for simultaneous oxygen delivery and end-tidal CO 2
monitoring during spontaneous breathing. Eur J Anaesthesiol. 2006;23:257-260.
IF 1.4352㧕 Iida H, Iida M, Takenaka M, Fujiwara H, Dohi S. Angiotensin II type 1 (AT1)-receptor blocker
prevents impairment of endothelium-dependent cerebral vasodilation by acute cigarette smoking inrats. Life Sci. 2006;78:1310-1316.
IF 2.257
3㧕 Tanahashi S,Iida H,Dohi S. An anaphy lactoid reaction after administration of fluorescein sodium㧙㧙during neurosurgery. Anesth Analg. 2006;103:503.
4㧕 Yamakawa H, Yamada K, Sumi K, Iida H, Iwama T. Preoperative assessment of microvascularcompression of cranial nerve IX and X using 3D fast imaging employing steady-state acquisition
resonance imaging in glossopharyngeal neuralgia. Neurosurg Q. 2006;16:166-168.
5㧕 Iida H㧘Iida M㧘Ohata H, Michino T, Dohi S. Effect of dexmedetomidine on cerebral circulation andsystemic hemodynamics after cardiopulmonary resuscitation in dogs. J Anesth. 2006;20:202-207.
6㧕 Tanemura E, Masue T, Sugimoto J, Dohi S. Repetitive acute shock following tracheal extubations after
neurosurgery for a cerebellar tumor. J Anesth. 2006;20:255-256.
7㧕 Tanabe K, Tokuda H, Takai S, Matsushima-Nishiwaki R, Hanai Y, Hirade K, Katagiri Y, Dohi S,
Kozawa O. Modulation by the steroid/thyroid hormone superfamily of TGF-E-stimulated VEGF releasefrom vascular smooth muscle cells. J Cell Biochem. 2006;99:187-195.
8㧕 Oshima T, Kasuya Y, Okumura Y, Murakami T, Dohi S. Identification of independent risk factors forfentany-induced cough. Can J Anesth. 2006;53:753-758.
9㧕 Zeng W, Chen X, Dohi S. Antinociceptive Synergisic Interaction Between Clonidine and Ouabain On
thermal Nociceptive tests in the Rat. J Pain. 2007;8:983-988.
10㧕 Dohi S, Iida M, Iida H, Nagase K, Nagata C. Implementation of smoke-free policy in university
hospital decreases carboxyhemoglobin level in inpatients undergoing surgery. Anesthesiology.
2007;106:406-407.
11㧕 Kumazawa M, Iida H, Uchida M, Iida M, Takenaka M, Dohi S. The comparative effects of intravenous
nicardipine and prostaglandin E1 on the cerebral pial arteriolar constriction seen after unclamping ofan aortic cross-clamp in rabbits. Anesth Analg. 2007;104:659-665.
12㧕 Tanahashi S, Iida H, Oda A, osawa Y, Uchida M, Dohi S. Effects of ifenprodil on valtage-gatedtetrodtoxin-resistant Na+ Channels in rat sensory neurons. Eur J Anaesth. 2007;24:782-788.
13㧕 Miyamoto K, Shimizu K, Matsumoto S, Sumida H, Iida H, Hosoe H. Surgical treatment of scoliosis
assiciated with central core disease: minimizing the effects of malignant hyperthermia withprovocation tests. J Pediatric Orthopaedics B. 2007;16:239-242.
14㧕 Oshima T, Utsunomiya H, Kasuya Y, Sugimoto J, Maruyama K, Dohi S. Identification of independent
predictors for intravenous thiopental-induced yawning. J Anesth. 2007;21:131-135.
15㧕 Takada M, Dohi S, Akamatsu S, Suzuki A. Effects of pericardial lidocaine on hemodynamic
parameters and responses in dogs anesthetized with midazolam and fentanyl. J Cardiothorac vasc
Anesth. 2007;21:393-399.
16㧕 Oda A, Iida H, Tanahashi S, Osawa Y, Yamaguchi S, Dohi S. Effects of alph2 adrenoceptor agonists on
tetrodotoxin-resistant Na channels in rat dorsal root ganglion neurons. Eur J Anaesthesiol.
2007;24:934-941.
17㧕 Tanabe K, Takai S, Matsushima-Nishiwaki, Kato K, Dohi S, Kozawa O. 2 adrenoreceptor agonist
regulates protein kinase C-induced heat shock protein 27 phosphorylation in C6 glioma cells. J
Neurochem. 2008;106:519-528.
18㧕 Iida H, Iida M, Takenaka M, Fukuoka N, Dohi S. Rho-kinase inhibitor and nicotinamide adenine
dinucleotide phosphate oxidase inhibitor prevent impairment of endothelium-dependent cerebral
vasodilation by acute cigarette smoking in rats. J Renin Angiotensin Aldosterone Syst. 2008;9:89-94.
19㧕 Iida H, Iida M, Dohi S, Fukuoka N, Iida M. Preoperative smoking cessation and smoke-free policy in auniversity hospital in Japan. Can J Anaesth. 2008;55:316-318.
20㧕 Sumi K, Iida H, Yamaguchi S, Fukuoka N, Shimabukuro K, Dohi S. Human atrial natriuretic peptide
prevents the increase in pulmonary artery pressure associated with aortic unclamping during
abdominal aortic aneurysmectomy. J Cardiothorac Vasc Anesth. 2008;22:204-209.
21㧕 Kumazawa M, Iida H, Uchida M, Iida M, Fukuoka N, Michino T, Dohi S. The effects of transientcerebral ischemia on vasopressin-induced vasoconstriction in rabbit cerebral vessels. Anesth Analg.
2008;106:910-915.
22㧕 Niinomi K, Banno Y, Iida H, Dohi S. Nicorandil, an Adenosine Triphate-Sensitive Potassium Channel
Opener, Inhibits Muscarinic Acetylcholine Receptor-Mediated Activation of Extracellular
Signal-Regulated Kinases in PC12 Cell. Anesth Analg. 2008;107:1892-1898.
23㧕 Mizuta K, Osawa Y, Mizuta F, Xu D, Emala CW. Functional expression of GABAB receptors in airway
epithelium. Am J Respir Cell Mol Biol. 2008;39:296-304.

IF 2.214

IF 0.073

IF 3.381
IF 1.808
IF 3.578

IF 4.596

IF 2.214
IF 1.435

IF 0.937

IF 1.435

IF 4.451

IF 0.851
IF 1.808

IF 0.937

IF 2.214

IF 2.214
IF 1.1544㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦⿒᧻ ❥(᧻ᵄ✚ว∛㒮)㧘⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧘࿯⢈ୃม㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦෼ฃߟ߈๟ⴚᦼᔃ╭⯯ⴊᓟߩᔃߩ࡝ࡕ࠺࡝ࡦࠣߦ߅ߌࠆ✢ṁ♽࿃ሶߩᓎഀߣ⥃ᐥ⊛ᗧ⟵㧧ᐔ
ᚑ 17㧙18 ᐕᐲ㧧3,800 ජ౞(2,700㧦1,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦㘵↰ብ᮸㧘⎇ⓥಽᜂ⠪㧦㘵↰⌀⟤㧘࿯⢈ୃม㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦࡝ࡕ࡯࠻ࡊ࡟ࠦࡦ࠺࡚ࠖࠪ࠾ࡦࠣߦࠃࠆ⣄㜑଻⼔ᴺߩ⚦⢩ౝࡔࠞ࠾࠭ࡓߣ㑐ㅪ࿃ሶߩ⸃ᨆ㧧ᐔᚑ 18㧙19 ᐕ㧙㧙ᐲ㧧3,100 ජ౞(1,600㧦1,500 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦㐳ἑ ᷡ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ(B)㧦৻ㆊᕈో⣖⯯ⴊᓟߩ⣖ᓸዊᓴⅣ෻ᔕߦኻߔࠆ⣖ૐ૕᷷≮ᴺߩᓇ㗀㧧ᐔᚑ 16㧙17 ᐕᐲ㧧1,800 ජ౞(1,100㧦700 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦࿯⢈ୃม㧘⎇ⓥಽᜂ⠪㧦ᄢỈ㓁ሶ㧘ᩉ⥪ን⟤㧘↰ㄝਭ⟤ሶ㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(A)㧦
㤗㈮⮎ࠪࠣ࠽࡞વ㆐ᯏ᭴ߦ߅ߌࠆ࠽࠻࡝࠙ࡓࠞ࡝࠙ࡓࡐࡦࡊߩᓎഀߣߘߩ᭴ㅧᄌൻߩ⸃ᨆ㧧ᐔᚑ 19
㧙21 ᐕᐲ㧧21,760 ජ౞(8,660㧦6200㧦6900 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦㐳ἑ ᷡ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ(B)㧦৻ㆊᕈో⣖⯯ⴊࡕ࠺࡞ߦ߅ߌࠆ Rho ࠠ࠽࡯࠯㒖ኂ⮎ࡈࠔࠬࠫ࡞ߩ⣖ᓸዊᓴⅣ߳ߩᓇ㗀㧧ᐔᚑ 19㧙21 ᐕᐲ㧧3,650 ජ౞(1,750㧦1,000㧦900 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ᩉ⥪ን⟤㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ(B)㧦ዪᚲ㤗㈮⮎ߣࠝࡇࠝࠗ࠼ߩ⣄㜑−∩೙ᓮᯏ᭴ߦ
߅ߌࠆ⋧੕૞↪ߩᯏᐨߩ⸃᣿㧧ᐔᚑ 19 ᐕᐲ㧧800 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⌀↱⟤㧘⎇ⓥಽᜂ⠪㧦㐳ἑ ᷡ㧘㜞Ⴆ⋥⢻㧘♿ࡁቯ଻⤿㧧⚻ᷣ↥ᬺ⋭ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺߦ߅ߌࠆࠤ࡯ࠬࠬ࠲࠺ࠖᢎ᧚㐿⊒ࡊࡠࠫࠚࠢ࠻㧧ᐔᚑ 19 ᐕᐲ㧧238 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦㘵↰⌀⟤㧘⎇ⓥಽᜂ⠪㧦㘵↰ብ᮸㧘࿯⢈ୃม㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ᔃ⢖⯃↢ᤨߩ⣖଻⼔ߦ߅ߌࠆᕈࡎ࡞ࡕࡦߩᗧ⟵ߣᓎഀ㧙৻ㆊᕈో⣖⯯ⴊࡕ࠺࡞ߢߩᬌ⸛㧙㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,914 ජ౞(1,814㧦1,100㧦1,000 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦ᄢ⇗ඳੱ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)ࠣ࡞࠲ࡒࡦ㉄ฃኈ૕૞േ⮎ߩ⣖ᓸዊⴊ▤߅ࠃ
߮ AQP-4 ߦਈ߃ࠆᓇ㗀ߦ㑐ߔࠆᬌ⸛㧧ᐔᚑ 20㧙22 ᐕᐲ㧧2,450 ජ౞(1,050㧦700㧦700 ජ౞)
10㧕 ⎇ⓥઍ⴫⠪㧦↰ㄝਭ⟤ሶ㧘⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ਛᨔ␹⚻♽ߦ߅ߌࠆ␹⚻଻⼔૞↪ߩಽሶၮ⋚ߩ⸃ᨆ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧4,200 ජ౞(2,500㧦1,000㧦700 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 㘵↰ብ᮸㧦ⴊ▤ౝ⊹ᯏ⢻᷹ቯⵝ⟎㧧ᐔᚑ 20 ᐕ(․㗿 2007́138493)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ࿯⢈ୃม㧦
1㧕 ᣣᧄ㤗㈮⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥࡕ࠾࠲࡯ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⥃ᐥ㤗㈮ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ㓸ਛᴦ≮ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ⯃↢ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄᓴⅣ೙ᓮකቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄࡍࠗࡦࠢ࡝࠾࠶ࠢቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄዪᚲ㤗㈮ቇળ⹏⼏ຬ(㨪⃻࿷)9㧕 ᣣᧄ−∩ቇળ⹏⼏ຬ(㨪⃻࿷)10㧕 ᣣᧄዊఽ㤗㈮ቇળ⹏⼏ຬ(㨪⃻࿷)㘵↰ብ᮸㧦1㧕 ᣣᧄ㤗㈮⑼ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄࡍࠗࡦࠢ࡝࠾࠶ࠢቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ−∩ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ␹⚻㤗㈮㓸ਛᴦ≮⎇ⓥળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅࿯⢈ୃม㧦
1㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 55 ࿁ቇⴚᄢળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ)
2㧕 ╙ 11 ࿁ᣣᧄ⣖ૐ᷷≮ᴺቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)㧙㧙┻ਛరᐽ㧦
1㧕 ╙ 19 ࿁᧲ᶏࡍࠗࡦࠢ࡝࠾࠶ࠢ⎇ⓥળ(ᣣᧄࡍࠗࡦࠢ࡝࠾࠶ࠢቇળ᧲ᶏ࿾ᣇળ)(ᐔᚑ 20 ᐕ 5 ᦬㧘ฬฎደ)3㧕ቇⴚ㔀⹹
࿯⢈ୃม㧦
1㧕 Jounal of Anesthesia(ᣣᧄ㤗㈮ቇળ⹹);Editor(㨪⃻࿷)2㧕 Regional Anesthesia & Pain Medicine;Editor(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳࿯⢈ୃม㧦
1㧕 ✢⛽╭∩∝ߩ∛࿃࡮∛ᘒ⸃᣿ߦ㑐ߔࠆಽ⑼ળ౏㐿ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 3 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬−∩ߩࠪࠣ࠽࡞વ㆐࡮೙ᓮᯏ᭴‫ޠ‬Ṷ⠪)
2㧕 ╙ 10 ࿁ᣣᧄ㤗㈮࡮㓸ਛᴦ≮⎇ⓥળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ᄢ㒋㧘ᐳ㐳)
3㧕 ╙ 13 ࿁‫⎇ߩߺ∩ޟ‬ⓥળ‫(ޠ‬ᐔᚑ 18 ᐕ 6 ᦬㧘ᗲ⍮㧘․೎⻠Ṷ‫⥃ߩߺ∩ޟ‬ᐥߣ⣄㜑ࡔࠞ࠾࠭ࡓ‫ޠ‬Ṷ⠪)
4㧕 ╙ 13 ࿁⑺↰−∩⎇ⓥળ(ᐔᚑ 18 ᐕ 6 ᦬㧘⑺↰㧘․೎⻠Ṷ‫ߩߺ∩ޟ‬⣄㜑ࡔࠞ࠾࠭ࡓߣߘߩᴦ≮‫⻠ޠ‬Ṷ⠪)
5㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 53 ࿁ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 6 ᦬㧘␹ᚭ㧘ቇⴚ⻠Ṷ ᐳ㐳)6㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 53 ࿁ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 6 ᦬㧘␹ᚭ㧘ࠪࡦࡐࠫ࠙ࡓ‫↢ޟ‬๮ߣ㉄⚛‫ޔ‬ᵴᕈ㉄⚛‫ޔ‬ᵴᕈ⓸⚛‫ޠ‬ᐳ㐳)7㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 53 ࿁ቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 6 ᦬㧘␹ᚭ㧘․೎⻠Ṷ ᐳ㐳)8㧕 ╙ 9 ࿁ᣣᧄ⣖ૐ᷷≮ᴺቇળ(ᐔᚑ 18 ᐕ 7 ᦬㧘᧲੩㧘࠮࠶࡚ࠪࡦ ᐳ㐳)
9㧕 ᣣᧄࡍࠗࡦࠢ࡝࠾࠶ࠢቇળ╙ 40 ࿁ᄢળ(ᐔᚑ 18 ᐕ 7 ᦬㧘␹ᚭ㧘․೎⻠Ṷ ᐳ㐳)10㧕 ╙ 5 ࿁᧲ᶏ㤗㈮ኾ㐷කળ‫ޟ‬ቇⴚ⻠Ṷળ‫(ޠ‬ᐔᚑ 18 ᐕ 8 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫㉄ࡁࡒࠕޟ‬ャᶧߦࠃࠆⴚਛ૕᷷⛽ᜬ‫ޠ‬Ṷ⠪)11㧕 ╙ 9 ࿁ጘ㒂ᕆᕈⴊᶧᵺൻ⎇ⓥળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)12㧕 ╙ 11 ࿁ᣣᧄᔃ⤳ⴊ▤㤗㈮ቇળቇⴚᄢળ(ᐔᚑ 18 ᐕ 9 ᦬㧘㐳ፒ㧘ᢎ⢒⻠Ṷ‫ᦨޟ‬ㄭߩᔃᚱ⚦േࡑࡀࠫࡔ
ࡦ࠻‫ޠ‬ᐳ㐳)13㧕 ╙ 73 ࿁ਅํᏒකᏧળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥃ߩߺ∩ޟ‬ᐥߣ⣄㜑−∩ฃኈᯏ᭴‫ޠ‬ᐳ㐳)14㧕 ᣣᧄ⥃ᐥ㤗㈮ቇળ╙ 26 ࿁ᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᣩᎹ㧘ࠪࡦࡐࠫ࠙ࡓ ᐳ㐳)15㧕 ᣣᧄ⥃ᐥ㤗㈮ቇળ╙ 26 ࿁ᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᣩᎹ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯ ᐳ㐳)16㧕 ᣣᧄ⯃↢ቇળ╙ 25 ࿁ᄢળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ᵿ᧻㧘․೎⻠Ṷ ᐳ㐳)17㧕 ╙ 10 ࿁ጘ㒂๟ⴚᦼᓴⅣ▤ℂ⎇ⓥળ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⍴ᤨ㑆૞↪E1 ㆤᢿ⮎ߩ⃻⁁ߣᣂߚߥㆡᔕ‫ޠ‬ᐳ㐳)18㧕 ᣣᧄ㤗㈮⑼ቇળ᧲ᶏ࡮ർ㒽ᡰㇱ╙ 4 ࿁ቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ฬฎደ㧘ᢎ⢒⻠Ṷ ᐳ㐳)19㧕 ╙ 11 ࿁ᣣᧄ␹⚻㤗㈮࡮㓸ਛᴦ≮⎇ⓥળ(ᐔᚑ 19 ᐕ 4 ᦬㧘⑺↰㧘ࠗࡉ࠾ࡦࠣ࠮ࡒ࠽࡯ ᐳ㐳)20㧕 ╙ 8 ࿁✭๺ࠤࠕ࡮ࡊ࡜ࠢ࠹ࠖࠬ(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)21㧕 ╙ 10 ࿁ጘ㒂ᕆᕈⴊᶧᵺൻ⎇ⓥળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)22㧕 ╙ 11 ࿁ጘ㒂๟ⴚᦼᓴⅣ▤ℂ⎇ⓥળ(ᐔᚑ 20 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬๟ⴚᦼ▤ℂߦ߅ߌࠆᔃࠛࠦ࡯
ߩ᦭↪ᕈ‫ޠ‬ᐳ㐳)23㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 55 ࿁ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ޟ‬කᏧߩຠᩰ‫ޠ‬ᐳ㐳)24㧕 ╙ 11 ࿁ᣣᧄ⣖ૐ᷷≮ᴺቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘᜗⺧⻠Ṷ‫↢ߩࠄ߆ࡦ࡜ࡉࡦࡕޟ‬ㆶ㧙⊓ጊߢ஧⊒ᕈૐ૕᷷∝㧙‫ޠ‬ᐳ㐳)25㧕 ╙ 16 ࿁ᣣᧄ㓸ਛᴦ≮කቇળ᧲ᶏർ㒽࿾ᣇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ળ㐳⻠Ṷ‫⑼ޟ‬ቇߒㅪ៤ߔࠆ㓸ਛᴦ≮‫ޠ‬ᐳ㐳)26㧕 ╙ 9 ࿁✭๺ࠤࠕ࡮ࡊ࡜ࠢ࠹ࠖࠬ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)27㧕 ᣣᧄ⥃ᐥ㤗㈮ቇળ╙ 28 ࿁ᄢળ(ᐔᚑ 20 ᐕ 11 ᦬㧘੩ㇺ㧘᜗⺧⻠Ṷ ᐳ㐳)㘵↰ብ᮸㧦1㧕 ጘ㒂๟ⴚᓴⅣ▤ℂ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ ᐳ㐳)2㧕 ᣣᧄ⥃ᐥ㤗㈮ቇળ╙ 26 ࿁ᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᣩᎹ㧘ࠪࡦࡐࠫ࠙ࡓ Ṷ⠪)
3㧕 ╙ 11 ࿁ᣣᧄ␹⚻㤗㈮࡮㓸ਛᴦ≮⎇ⓥળ(ᐔᚑ 19 ᐕ 4 ᦬㧘⑺↰㧘ࠪࡦࡐࠫ࠙ࡓ‫▤ⴊޟ‬૞േ⮎ߩ⣖⣄㜑㧙㧙ⴊᵹ(ⴊ▤)ߦਈ߃ࠆᓇ㗀‫ޠ‬Ṷ⠪)
4㧕 ᣣᧄ⯃↢ቇળ╙ 26 ࿁ᄢળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ጟጊ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㤗㈮⮎߅ࠃ߮㤗㈮㑐ㅪ⮎ߣ⣖⣄㜑ⴊ▤‫ޠ‬Ṷ⠪)
5㧕 ╙ 11 ࿁ጘ㒂๟ⴚᦼᓴⅣ▤ℂ⎇ⓥળ(ᐔᚑ 20 ᐕ 1 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬DPC ኻ⽎᳃㑆✚ว∛㒮ߦ߅ߌࠆ․ቯ㓸ਛᴦ≮ቶนേߦߟ޿ߡ‫ޠ‬ᐳ㐳)
6㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 55 ࿁ᄢળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㤗㈮࡮ᚻⴚ೨⑌ᾍ㧦ߘߩലᨐߣ
outcome‫ޠ‬Ṷ⠪)7㧕 ᣣᧄ㤗㈮⑼ቇળ╙ 55 ࿁ᄢળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬㤗㈮ኾ㐷කߩᔅୃ࠹ࠢ࠾࠶ࠢ
ࠪ࡝࡯࠭ 2‫ޠ‬ᐳ㐳)8㧕 ᣣᧄ㤗㈮⑼ቇળ᧲ᶏ࡮ർ㒽ᡰㇱ╙ 6 ࿁ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬๟ⴚᦼߩᗵᨴ▤ℂ 㨪☨࿖ߩ SCIP ߆ࠄቇ߱㨪‫ޠ‬ᐳ㐳)┻ਛరᐽ㧦
1㧕 ╙ 16 ࿁ᣣᧄࡎࠬࡇࠬ࡮࿷ቛࠤࠕ⎇ⓥળో࿖ᄢળ(ᐔᚑ 19 ᐕ 6 ᦬㧘㜞ጊ㧘․೎⻠Ṷ‫≸ޟ‬−∩ᴦ≮
update‫ޠ‬Ṷ⠪)
2㧕 ╙ 19 ࿁᧲ᶏࡍࠗࡦࠢ࡝࠾࠶ࠢ⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬ᘟᕈ∩ࡕ࠺࡞ߩ⥄ᓞ␹⚻ᯏ⢻ߣ᳇⽎ⷐ⚛ᄌൻߦኻߔࠆ෻ᔕᕈߦߟ޿ߡ‫ޠ‬ᐳ㐳)
3㧕 ╙ 24 ࿁ᣣᧄ⊹⤏ᖡᕈ⣲≌ቇળቇⴚᄢળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫≸ޟ‬ᕈ−∩ߣߘߩኻ╷‫ޠ‬Ṷ⠪)㐳ἑ ᷡ㧦
1㧕 ╙ 18 ࿁ᣣᧄ⥃ᐥࡕ࠾࠲࡯ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ฬฎደ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬ᰴ਎ઍߩ㤗㈮⸥
㍳ࠍ⋡ᜰߒߡ㨪⥃ᐥ⃻႐߆ࠄߩឭ᩺㨪‫ޠ‬Ṷ⠪)2㧕 ጘ㒂ᄢቇච౐㌁ⴕ↥ቇㅪ៤࡮ක≮⚻༡ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᚻⴚቶߩല₸⊛ߥㆇ༡ࠍ⋡ᜰߒߡ‫ޠ‬Ṷ⠪)
3㧕 ╙ 55 ࿁ᣣᧄ㤗㈮⑼ቇળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ቢో㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓࠍᵴ↪
ߒߚක≮ߩ⾰ߩะ਄‫ޔ‬ല₸ൻᮡḰൻߩᡷༀ㧘ක≮ㆊ⺋㒐ᱛߦะߌߚ 3 ᐕ㑆ߩขࠅ⚵ߺ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ㘵↰ብ᮸㧦
1㧕 ጘ㒂⋵ࡔ࠺ࠖࠞ࡞ࠦࡦ࠻ࡠ࡯࡞ᆔຬ(ᐔᚑ 20 ᐕᐲ)
10㧚ႎ๔ᦠ
1㧕 ࿯⢈ୃม㧦㤗㈮࡮−∩ࠪࠣ࠽࡞વ㆐ߦ߅ߌࠆࠗࠝࡦ࠴ࡖࡀ࡞ߣࠗࠝࡦ࡮࠻࡜ࡦࠬࡐ࡯࠲࡯ߩ೙ᓮᯏ
᭴㧦ᐔᚑ 14㧙17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(A)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙102(2006 ᐕ 3 ᦬)
2㧕 㘵↰ብ᮸㧦࡝ࡕ࡯࠻ࡊ࡟ࠦࡦ࠺࡚ࠖࠪ࠾ࡦࠣߦࠃࠆ⣄㜑଻⼔ᴺߩ⚦⢩ౝࡔࠞ࠾࠭ࡓߣ㑐ㅪ࿃ሶߩ⸃
ᨆ㧦ᐔᚑ 18㧙19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙60(2008 ᐕ 3 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ೨࿁ߩႎ๔ᦠ߆ࠄߩ⪺᣿ߥᄌൻߪ㧘ᄢቇ∛㒮ߪ߽ߣࠃࠅ㑐ㅪ∛㒮ߩ㤗㈮⑼ߩᬺോߩჇടߥߤߦࠃࠆੱ
ᚻਇ⿷ߢ㧘⎇ⓥߦㆱߌࠆᤨ㑆߇㕖Ᏹߦᷫߞߚߎߣ㧘ߥߤ߇㊀ߥߞߚ߇㧘޿ߊߟ߆ߩ㕙ߢߩ⺖㗴ߪలಽߦߣߪ޿߃ߥ޿߇㧘ࠕࡔ࡝ࠞ㤗㈮ቇળߢߩ⊒⴫㧘࡛࡯ࡠ࠶ࡄ㤗㈮ቇળ㧔Ṷ㗴ᔕ൐ਛ㧕ߘߒߡᣣᧄ㤗㈮⑼ቇ
ળ߳ߩ⊒⴫ࠍㅢߒߡ㧘㆐ᚑߢ߈ߚߣ⹏ଔߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷කቇㇱ߅ࠃ߮∛㒮ߩో㕙⒖ォ߆ࠄ 5 ᐕࠍ⚻ߡ㧘⸻≮૕೙ਗ߮ߦ⎇ⓥ૕೙߽ᢛ஻ߐࠇߡ߈ߚ‫߇ߛޕ‬㧘ੱ㧙㧙⊛໧㗴ߥߤ⎇ⓥࠍㆀⴕߒߡ޿ࠆ਄ߢߩታ㓙⊛ߥ໧㗴ߢ޽ࠆ‫⃻ޕ‬࿷⎇ⓥࠍᏗᦸߒߡᄢቇ㒮ߦ౉ቇߒߡ޿ࠆ
කᏧߦ߽㧘ቇ⾌ࠍᛄ޿ߥ߇ࠄ㧘⥃ᐥᬺോࠍ⟵ോൻߒߡㆀⴕߖߑࠆࠍᓧߥ޿ߎߣߢ޽ߞߚ߇㧘⃻࿷ߪᡷༀߒߡ޿ࠆ‫ߩߎޕ‬ኻᔕߦߪ㧘␠ળੱᄢቇ㒮↢߽ቯ⌕ߒ㧘∛㒮⸻≮ᬺോߣߩ౒ሽߥน⢻ߣߥߞߡ߈ߚߣ޿߃
ࠆ‫ޕ‬ᛮᧄ⊛ߥᡷ㕟ߪ੹ᓟߩ໧㗴ߣߒߡᱷߐࠇߡ޿ࠆ‫⎇ޕ‬ⓥ⾌ߪ㧘ᐘߦ߽⑼ቇ⎇ⓥ⾌ߩ㈩ಽࠍฃߌ㧘⎇ⓥቶߩᢛ஻߽ߥࠅ㧘ᒰ㕙ߪᵴ⊒ߥ⎇ⓥᵴേ߇ᦼᓙߢ߈ࠆ‫ޕ‬੹ᓟߩዷᦸ⃻࿷ߒߡ޿ࠆ⎇ⓥ࡟ࡌ࡞ࠍዋߥ޿⎇ⓥຬߢߤ߁⛽ᜬߒ㧘⊒ዷߐߖߡ޿ߊ߆㧘߇ᒁ߈⛯޿ߡߩ⺖㗴ߢ޽ࠆ‫ޕ‬ᄢቇ∛㒮ߩ␠ળ⊛૶๮ߩ৻ߟ㧘ఝࠇߚ⥃ᐥකࠍ㑐ㅪߔࠆක≮ᯏ㑐ߦᵷ㆜ߔࠆߣ޿߁⋡⊛߇޽ࠆߛߌ
ߦ㧘ᒰ㕙ߩࡑࡦࡄࡢ࡯ߩల⿷ߪᦼᓙߢ߈ߥ޿ߩߢ㧘ᣂߒ޿ᚻᛛࠍዉ౉ߒ㧘৻ㇱⴕߞߡ޿ࠆઁ⎇ⓥᯏ㑐ߣߩ౒ห⎇ⓥߦࠃߞߡ㧘ࠃࠅല₸⊛ߦ⎇ⓥࠍㆀⴕߔࠆߎߣߢ޽ࠆ‫⎇ޕ‬ⓥ⠪ߩ⣄㜑㎾∩ᯏ᭴߳ߩࠪࠣ࠽࡞વ
㆐ߦ㑐ߔࠆ⎇ⓥߩ┹੎߽ᵴ⊒ߦߥߞߡ߈ߚ‫⃻ޕ‬࿷㧘⣄㜑ᓟᩮ␹⚻࠾ࡘ࡯ࡠࡦߢዷ㐿ߒߡ߈ߚ⎇ⓥࠍࡒࠢࡠࠣ࡝ࠕ⚦⢩ߦ⊒ዷߐߖ㧘ᚑᨐ߽਄߇ߞߡ޿ࠆߩߢ㧘ߎߩಽ㊁ߢߩᵴ⊒ߥᚑᨐ߇ᦼᓙߐࠇࠆ‫ߚ߹ޕ‬㧘ࠞࡊࠨࠗࠪࡦ⺃⊒ߩ⣄㜑ᓟᩮ⚦⢩ߦ߅ߌࠆ⚦⢩ౝࠪࠣ࠽࡞વ㆐ ERK ߩ࡝ࡦ㉄ൻࠍ㧘ࡠࡇࡃࠞࠗࡦߥߤߩዪᚲ㤗㈮⮎㧘޽ࠆ޿ߪ Na+㧙K+㧙2Cl-࠻࡜ࡦࠬࡐ࡯࠲࡯ߩ㒖ኂ⮎ߢ޽ࠆࡈࡠ࠮ࡒ࠼߇ߤ߁ୃ㘼ߔࠆ߆ߩᬌ
⸛߳ߣㅴ߼ߡ޿ߊ‫ޕ‬⎇ⓥቶߢߩ⎇ⓥㆀⴕߩᛮᧄ⊛ߥ⸃᳿߇⷗಴ߐࠇߥ޿߹߹ߢ޽ࠆ߇㧘㤗㈮࡮ᚻⴚਛߩャᶧ㧔♧฽᦭ャᶧ㧕ߩ೑ὐߥߤࠍዩਛࠕࠢࠕࡐ࡝ࡦߩേᘒ߆ࠄ㧘ᄢⴊ▤ㆤᢿߦࠃࠆᧃ᪳⯯ⴊ໧㗴ࠍࡃ࠰ࡊ࡟࠶ࠪࡦߩേᘒ߿
⯯ⴊ⠴ᕈ㧔ischemic preconditioning㧕߆ࠄ⸃᣿ߔࠆߥߤߩ㧘⥃ᐥߩ቟ోᕈߩᬌ⸛ࠍᲤᣣߩ⥃ᐥᬺോߢ⸃
᳿ࠍ࿑ࠆߴ߈⎇ⓥࡊࡠࠫࠚࠢ࠻ࠍផㅴߒߡ޿ࠆ‫ޕ‬㧙㧙㧔8㧕⯃↢࡮㓸ਛᴦ≮ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ߎߩಽ㊁ߪ㧘‫ޟ‬㤗㈮⮎ߦࠃߞߡᛥ೙ߐࠇ↢๮ߩ᏷ࠍᭂ┵ߦ⁜ߊߒߡ޿ࠆ⁁ᘒ㧘߆ߟᚻⴚߣ޿߁ỗߒ޿ࠬ࠻࡟ࠬਅߦ޽ࠆᖚ⠪ߩ๭ๆ࡮ᓴⅣ࡮૕ᶧ࡮ઍ⻢▤ℂߢ޽ࠆ‫ߣ߽ߩ⼂⹺ࠆ޽ߢޠ‬㧘⯃↢ߩജ㊂߇ߥߊߡߪ቟
ోߦ㤗㈮ࠍ߆ߌࠆߎߣ߇ߢ߈ߥ޿ߣ޿߁ⷞὐ߆ࠄߩ⎇ⓥߢ޽ࠅ㧘⋡⊛ࠍᣂߒ޿ᔃ⢖⯃↢ᴺߣᔃ⤳ᯏ⢻ࡕ࠾࠲࡯ߩ㐿⊒ߣ޿߁ᓥ᧪⯃↢࡮㓸ਛᴦ≮ߦ߅ߌࠆਛᔃ⊛ߥ⺖㗴ߦ߅޿ߡ߈ߚ‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦 ࿯⢈ୃมShuji Dohi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ⪺ᦠ㧔᰷ᢥ㧕
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ✚⺑㧔๺ᢥ㧕
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ✚⺑㧔᰷ᢥ㧕
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖේ⪺㧔๺ᢥ㧕
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖේ⪺㧔᰷ᢥ㧕
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
2㧕ฃ⸤⎇ⓥ
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
3㧕౒ห⎇ⓥ
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
2㧕ቇળ㐿௅
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
3㧕ቇⴚ㔀⹹
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ㧙㧙8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
9㧚␠ળᵴേ
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ
10㧚ႎ๔ᦠ
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ11㧚ႎ㆏
㤗㈮࡮−∩೙ᓮቇಽ㊁ෳᾖ12㧚⥄Ꮖ⹏ଔ
⹏ଔቴຬ⥃ᐥᢎ᝼ߢ޽ࠆ೨࿁ߩ⿒᧻ࠍਛᔃߦ㧘⮎ℂ∛ᘒቇ㧔ዊỈᢎ᝼㧕ߩᜰዉࠍฃߌ㧘⎇ⓥࠍㆀⴕߒߡ޿
ࠆ‫ޕ‬ᄢቇ∛㒮ߪ߽ߣࠃࠅ㑐ㅪ∛㒮ߩ㤗㈮⑼ߩᬺോߩჇടߥߤߦࠃࠆੱᚻਇ⿷ߢ㧘⎇ⓥߦㆱߌࠆᤨ㑆߇㕖Ᏹߦᷫߞߚߎߣ㧘ߥߤ߇㊀ߥߞߡ㧘⺖㗴ߪలಽߦ㆐ᚑߢ߈ߥ߆ߞߚ߇㧘৻ㇱ㧘⥃ᐥ⊛ߥⷞὐߩ⎇ⓥ㧘ਗ߮ߦ⣖ૐ᷷≮ᴺߩ⎇ⓥߩᚑᨐ߇ߺࠄࠇߡ߈ߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⎇ⓥ਄ߩ໧㗴ߪᄙ޿‫⎇ޕ‬ⓥᣉ⸳ߣⅣႺ㧘ੱ⊛໧㗴ߥߤ⎇ⓥࠍㆀⴕߒߡ޿ࠆ਄ߢߩታ㓙⊛ߥ໧㗴ߢ޽ࠆ‫ޕ‬කቇㇱ߅ࠃ߮∛㒮ߩో㕙⒖ォ㧘ߐࠄߦ․ߦᴺੱൻᓟߩ৻ᤓᐕ㧘ᤓᐕߪ⥃ᐥᬺോ߇ᄙᔔࠍᭂ߼㧘ߎߩ㕙ߢ
⎇ⓥߪㆀⴕߢ߈ߥ߆ߞߚ‫ޕ‬ᐘ޿㧘ᣂߒߊടࠊߞߚᄢቇ㒮↢߇ߣ৻✜ߦ⎇ⓥࠍౣ㐿ߔࠆ‫ޕ‬੹ᓟߩዷᦸ⥃ᐥߦ߅ߌࠆ㊀ⷐߥࡕ࠾࠲࡯ᯏེߩᣂߒ޿⊒ዷߣߒߡ㧘േ⣂࿶ᦛ✢߆ࠄᔃ৻࿁ᜉ಴㊂ࠍផ᷹ߔࠆᣇᴺ
ࠍ㧘ߐ߹ߑ߹ߥⴊ▤∛ᘒߦ߅ߌࠆା㗬ᕈࠍ⹏ଔߒ㧘ߘࠇࠍ⥃ᐥߦ߅ߌࠆ቟ోᕈߦ❬ߍࠆ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ޕ‬㤗㈮࡮−∩೙ᓮቇಽ㊁ߣ৻✜ߦߔߔ߼ߡ޿ࠆ㧘⣖ᓸዊᓴⅣࠍ㗡⬄ౝ᦭⓹ᴺߦ↪޿ߡߩᔃ⢖⯃↢ਛߩ⣖
ᓴⅣߦᐢߍߡᬌ⸛ߔࠆߎߣߦട߃ߡ㧘ᔃ⢖⯃↢ᴺߢߩലᨐ߇⏕ታⷞߐࠇߡ߈ߚࡄ࠰ࡊ࡟࠶ࠪࡦߩ⣖エ⤑ⴊ▤߳ߩ૞↪㧘ᄢⴊ▤ㆤᢿ߅ࠃ߮ㆤᢿᓟߩࡄ࠰ࡊ࡟࠶ࠪࡦ߿ࠛࡦ࠼࠮࡟ࡦߩേᘒߦᵈ⋡ߒߡ⎇ⓥࠍ㐿ᆎߔࠆ‫ߩߎޕ‬ಽ㊁ߢ߽㧘ᓥ᧪એ਄ߦ⮎ℂ∛ᘒ㧔ዊỈᢎ᝼㧕ߥߤߩᧄቇၮ␆♽ಽ㊁ߩᜰዉࠍઔ߉㧘⎇ⓥߩ⾰ߩะ਄ߦദ߼ࠆ‫ޕ‬㧙㧙㧔9㧕ญ⣧∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
⃻࿷㧘ᒰಽ㊁ߦ߅޿ߡዷ㐿ਛߩ⎇ⓥ⺖㗴ࠍ⥃ᐥ⎇ⓥߣၮ␆⎇ⓥߦᄢ೎ߒߡㅀߴࠆ‫ޕ‬⥃ᐥ⎇ⓥ㧦ᦨㄭߩಽሶ↢‛ቇߩ⊒ዷߦࠃࠅ㧘ᄙߊߩ∔ᖚߦ߅޿ߡಽሶ↢‛ቇ⊛ᯏᐨ߇᣿ࠄ߆ߣߐࠇߡ᧪
ߡ޿ࠆ‫ߚ߹ޕ‬㧘ㄭᐕߩౣ↢ක≮⎇ⓥߩ⊒ዷ߽⪺ߒߊ㧘ญ⣧ක≮߳ߩᔕ↪߽᭽‫ߥޘ‬㕙ߢㅴዷߒߡ᧪ߡ޿ࠆ‫ޕ‬ߎߩ⃻⁁ࠍ㐓ߺ㧘ᒰಽ㊁ߢߪ㧘ญ⣧∛ᄌ㧔ญ⣧߇ࠎ㧘⊕᧼∝㧘ᚳᐔ⧡⊈㧘ߘߩઁᱤේᕈ⣲≌ߥߤ㧕ߩ⸃ᨆߣ㧘ౣ↢ක≮ߩ⥃ᐥዷ㐿ߦゲ⿷ࠍ⟎߈એਅߩ⎇ⓥ⺖㗴ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬1㧕ญ⣧∛ᄌߩಽሶ∉ቇ⊛⸃ᨆ
2㧕ญ⣧ᯏ⢻ౣᑪ㧔⒖ᬀ࡮ౣ↢ක≮㧕
3㧕ญ⣧ੇ῎∝ߩ∛ᘒߣᴦ≮4㧕ญ⣧߇ࠎߩ㓸ቇ⊛ᴦ≮5㧕ࡅ࠻ᱤ⢦࡮ᱤ㜑߆ࠄߩᐙ⚦⢩ណขߣ iPS ⚦⢩ൻ࡮ࡃࡦࠢൻ੐ᬺ
ၮ␆⎇ⓥ㧦ญ⣧߇ࠎߩᰴ਎ઍᴦ≮ᴺ㐿⊒ࠍ⋡ᜰߒ㧘⊒߇ࠎ࡮ᖡᕈൻㅴዷࡊࡠ࠮ࠬߦ߅ߌࠆ Initiation,
Promotion, Progression ߩฦ Phase ߦᣈߌࠆ೙ᓮߩน⢻ᕈߣ㗶࡮ญ⣧ᯏ⢻ߩᡷༀ࡮ౣ↢ߦኻߔࠆ⚦⢩Ꮏቇ⊛ᬌ⸛ࠍⷞ㊁ߦએਅߩᬌ⸛ࠍⴕߥߞߡ޿ࠆ‫ޕ‬1㧕߇ࠎᖡᕈൻㅴዷᯏᐨߩ⸃ᨆ
2㧕㛽ઍ⻢࡮ౣ↢ක≮ߩᣂᛛⴚ㐿⊒3㧕ญ⣧߇ࠎൻቇ੍㒐ᴺߩ㐿⊒
4㧕ࡅ࠻ᱤ⢦࡮ᱤ㜑߆ࠄߩᐙ⚦⢩ណขߣ iPS ⚦⢩ൻ࡮ࡃࡦࠢൻ੐ᬺ
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦

ᩊ↰ᢅਯ
࿯੗↰ ⺈
ጊਅ⍮Ꮘ
’↰ᶈ᮸
ട⮮ᕺਃ
☨ᧄ๺ᒄ
⇗ጊᄢੑ㇢
ᵻ㚅㓶৻㇢
ᱞ↰⍮ሶ
ችፒᐽ㓶

Toshiyuki Shibata
Makoto Toida
Tomomi Yamashita
Hiroki Makita
Keizo Kato
Kazuhiro Yonemoto
Daijiro Hatakeyama
Yuichiro Asaka
Tomoko Takeda
Yasuo Miyazaki3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⮮Ⴆ⑲᮸㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧚ᴡว㆐ᔒ㧘ᢪ⮮ ⺈㧘⼾ጊᵗテ✬㧚ߎߎ߹ߢ߈ߚ㔚⣖∛㒮ࠪࠬ࠹ࡓ㧦
Dental IT Navigation 2006㧘᧲੩㧦࠺ࡦ࠲࡞࠳ࠗࡗࡕࡦ࠼␠㧧2006 ᐕ㧘112㧙115㧚
2㧕 ᩊ↰ᢅਯ㧚ਛ᧛ᐽ↢(࠮ࠞࡦ࠼࡮ࠝࡇ࠾ࠝࡦࠍផㅴߐߖࠆળ)✬㧚ታജකߩጁᱧᦠ ᄖ⑼♽ III ⣖␹⚻ᄖ⑼ߩ∛᳇ 㗡㗪ㇱ࡮ญ⣧ߩ≸ ↲⁁⣼≸㧘᧲੩㧦࡜ࠗࡈડ↹㧧2008 ᐕ㧦409㧚
3㧕 ᩊ↰ᢅਯ㧚ਛ᧛ᐽ↢(࠮ࠞࡦ࠼࡮ࠝࡇ࠾ࠝࡦࠍផㅴߐߖࠆળ)✬㧚ක⠪߇ߔߔ߼ࠆኾ㐷∛㒮࡮᧲ᶏ 㧘᧲੩㧦࡜ࠗࡈડ↹㧧2008 ᐕ㧦423㧚
4㧕 ᩊ↰ᢅਯ㧚ᣣᧄญ⣧ࠤࠕቇળ✬㧚ญ⣧≸ߣญ⣧ࠤࠕ㧦ญ⣧ࠤࠕ ၮ␆⍮⼂ ญ⣧ࠤࠕ 4 ⚖࡮5 ⚖⹺ቯ⾗ᩰၮḰḰ᜚㧘᧲੩㧦᳗ᧃᦠᐫ㧧2008 ᐕ㧦27㧙28㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᩊ↰ᢅਯ㧚ࡆࠬࡈࠔࠬࡈࠜࡀ࡯࠻⵾೷ߣᱤ⑼ᴦ≮̆㗶㛽უᱫߩෂ㒾ᕈߣකᱤ⮎ㅪ៤ߩᔅⷐᕈ㧘ጘᱤᣂႎ
2007 ᐕ㧧742 ภ㧦30㧙36㧚
2㧕 ᩊ↰ᢅਯ㧚ࡆࠬࡈࠔࠬࡈࠜࡀ࡯࠻⵾೷ߦࠃࠆ㗶㛽უᱫߩෂ㒾ᕈߣකᱤ⮎ㅪ៤ߩᔅⷐᕈ㧘ጘ㒂⋵කᏧળႎ
2007 ᐕ㧧672 ภ㧦14㧙15㧚
3㧕 ࿯੗↰ ⺈㧚ᱤ⑼࡮ญ⣧ᄖ⑼ߦ߅ߌࠆᘟᕈ−∩̆․ߦ⥠∩∝ߦߟ޿ߡ㧘ࠕ࡞ࠞࡠࠗ࠼⎇ⓥળળ⹹ 2008 ᐕ㧧
34 Ꮞ㧦19㧙25㧚㧙㧙✚⺑㧔᰷ᢥ㧕ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ’↰ᶈ᮸㧘ችፒᐽ㓶㧘ጊਅ⍮Ꮘ㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧚㗠☼⤑ߦォ⒖ߒߚ⣢⚦⢩≸ߩ৻଀㧘ᣣᧄญ⣧⸻ᢿቇળ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦306㧙309㧚
2㧕 ࿯੗↰ ⺈㧘ട⮮ᕺਃ㧘☨ᧄ๺ᒄ㧘’↰ᶈ᮸㧘⇗ጊᄢੑ㇢㧘ᬮ ᐘඳ㧘ችᧄ ⻞㧘⮮Ⴆ⑲᮸㧘ጊਅ⍮Ꮘ㧘⍹ਣ⚐৻㧘ᩊ↰ᢅਯ㧚ࠪࠚ࡯ࠣ࡟ࡦ∝୥⟲ᖚ⠪ߩญ⣧ੇ῎∝ᴦ≮ߦ߅ߌࠆႮ㉄࠮ࡆࡔ࡝ࡦ᳓๺‛ߩ೽૞↪⊒⃻ߣߘߩ੍㒐ߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘ᣣᧄญ⣧⑼ቇળ㔀⹹ 2006 ᐕ㧧55 Ꮞ㧦246㧙252㧚
3㧕 ᄢਭ଻ᕡᱜ㧘↰ਛብผ㧘੹੗ ദ㧘⋉↰ᄢテ㧘ᩊ↰ᢅਯ㧚߁ߟ∛ߦ઻߁ญ⣧ౝ࠮ࡀࠬ࠻ࡄ࠴࡯㧘㜞ጊ⿒චሼ∛㒮♿ⷐ㧘2006 ᐕ㧧30 ภ㧦18㧙21㧚
4㧕 ੹੗ ദ㧘ᄢỈ዁਽㧘ᄢਭ଻ᕡᱜ㧘ጟᧄᷡዏ㧘ᩊ↰ᢅਯ㧚ฝ㗠ㇱߦ⊒∝ߒߚ㘃⴫⊹ྙ⢩ߩ 1 ଀㧘㜞ጊ⿒චሼ∛㒮♿ⷐ 2006 ᐕ㧧30 ภ㧦40㧙43㧚
5㧕 ᵻ㚅㓶৻㇢㧘ጊਅᔀ㇢㧘਄↰୶ᒄ㧘ਛ᎑㗬ବ㧘ᨋ ା㧘⮮↰᣽ብ㧘ᩊ↰ᢅਯ㧚ᣧᦼߦਅ㗶㛽ォ⒖ࠍ᧪ߒߚ
⢖≸ߩ 2 ଀㧘ᣣᧄญ⣧⸻ᢿቇળ㔀⹹ 2007 ᐕ㧧20 Ꮞ㧦354㧙359㧚
6㧕 ጊᧄ⌀↱⟤㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘૒ᯅᢥੳ㧘’↰ᶈ᮸㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰ ⚐㧚ጘ㒂ᄢቇ↢ߦᱤ⑼ஜᐽ⸻ᢿࠍታᣉߒߡ㧘Campus Health 2007 ᐕ㧧44 Ꮞ㧦109㧙114㧚
7㧕 ᧄᄙᕶሶ㧘૒ᯅᢥੳ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ㧘↰ਛ↢㓷㧘’↰ᶈ᮸㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰ ⚐㧘ጊᧄ⌀↱⟤㧚ᄢቇ↢ߦ߅ߌࠆญ⣧ߩஜᐽ⁁ᘒߣ↢ᵴ⠌ᘠߣߩ㑐ㅪߦߟ޿ߡ㧘ቇᩞ଻ஜ⎇ⓥ 2007
ᐕ㧧49 Ꮞ㧦112㧙116㧚
8㧕 ࿯੗↰ ⺈㧘ධ⼱␭Ꮧ㧘ᮮ᫪⾆ሶ㧘㘵↰Ꮢⷙ㧘દ⮮ ᖘ㧘㚍႐᡽ม㧘ା↰᥉ፏ㧘᪢᧛⋥Ꮖ㧘᧻ᧁብ◊㧘㊄శᘷሶ㧘ᄥ↰᣽⑲㧘ട⮮ᕺਃ㧘’↰ᶈ᮸㧘ጊਅ⍮Ꮘ㧘ᩊ↰ᢅਯ㧚ጘ㒂Ꮢㄭ㇠ߩ৻⥸૑᳃ߦ߅ߌࠆ࠼࡜ࠗࡑ
࠙ࠬߩታᘒߦ㑐ߔࠆ⎇ⓥ㧘ᣣᧄญ⣧⑼ቇળ㔀⹹ 2007 ᐕ㧧56 Ꮞ㧦301㧙308㧚
9㧕 㘵↰৻ⷙ㧘’↰ᶈ᮸㧘☨ᧄ๺ᒄ㧘ጊਅ⍮Ꮘ㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧚⒖ᬀ⣺㛽ߦౣ‫࡞ࡔ࠽ࠛߚߒ⊒ޘ‬਄⊹⣲ߩ 1 ଀㧘ᣣᧄญ⣧ᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧54 Ꮞ㧦435439㧚
10㧕 ༑ਭ↰೑ᒄ㧘ฎ↰ ൠ㧘ศỈାᄦ㧘ᄢ⷏ ⌀㧘ᚸౝ⑲᮸㧘ᩊ↰ᢅਯ㧘ፉේ᡽ม㧘ᩙ↰⾫৻㧘ᩊේቁᒾ㧘ἑᚭ⊧৻㧚ᣣᧄญ⣧ᄖ⑼ቇળᜰቯ⎇ୃᯏ㑐ߢߩ⑌ᾍኻ╷߅ࠃ߮ળຬߩ༛ᾍߦ㑐ߔࠆ⾰໧␿⺞ᩏ㧘ᣣᧄญ⣧ᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧54 Ꮞ㧦400408㧚
11㧕 ⇗ጊᄢੑ㇢㧘ᬮ ᐘඳ㧘’↰ᶈ᮸㧘ጊਅ⍮Ꮘ㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧚ⴚᓟߦறຜ㗡࡝ࡦࡄ▵ߦォ⒖ࠍ߈ߚߒߚญ⣧ᚳᐔ਄⊹≸ߩ 2 ଀㧘ᣣᧄญ⣧⸻ᢿቇળ㔀⹹ 2008 ᐕ㧧21 Ꮞ㧦4548㧚
12㧕 ጊਅ⍮Ꮘ㧘᧻ᧄ␭᮸㧘ᵻ㚅㓶৻㇢㧘’↰ᶈ᮸㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧚⚻ญࡆࠬࡈࠜࠬࡈࠜࡀ࡯࠻⵾೷ߦ
㑐ㅪߒߚਅ㗶㛽უᱫߩᴦ≹⚻㛎㧘ᣣᧄญ⣧ᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧54 Ꮞ㧦243247㧚
13㧕 ☨ᧄ๺ᒄ㧘㚍႐᡽ม㧘ጊਅ⍮Ꮘ㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧚Ⴧᱺ᭽ᑼ߇㘃ផߐࠇߚ㓸วᕈᱤ‎⣲ߩ 1 ଀㧘ᣣᧄญ⣧⸻ᢿቇળ㔀⹹ 2008 ᐕ㧧21 Ꮞ㧦103106㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Kato K, Hara A, Kuno T, Mori H, Yamashita T, Toida M, Shibata T. Aberrant promoter
hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding
normal mucosa. J Cancer Res Clin Oncol. 2006;132:735-743.
2㧕 Kato Y, Shibata T, Yamashita T, Kobayashi A, Yonemoto K, Makita H, Mizuta K, Hayashi S, Toida M.
Parapharyngeal and retropharyngeal space infection of odontogenic origin. Asian J Oral Maxillofac
Surg. 2006;18:224-227.
3㧕 Suwa T, Saio M, Umemura N, Yamashita T, Toida M, Shibata T, Takami T. Preoperative radiotherapy
contributes to induction of proliferative activity of CD8+ tumor-infiltrating T-cells in oral squamouscell carcinoma. Oncol Rep. 2006;15:757-763.
4㧕 Yamashita T, Toida M, Hatakeyama D, Yonemoto K, Kusunoki Y, Shibata T. Schwannoma of the oralcavity. Asian J Oral Maxillofac Surg. 2006;18:75-78.
5㧕 Shibata T, Nagayasu H, Kitajo H, Arisue M, Yamashita T, Hatakeyama D, Iwasaki T, Kobayashi H.
Inhibitory effects of fermented brown rice and rice bran on the development of acute hepatitis inLong-Evans Cinnamon rats. Oncol Rep. 2006;15:869-874.
6㧕 Matsuo M, Hayashi S, Maeda S, Tanaka O, Mizuta K, Shibata T, Itou Y, Hoshi H. 4 Gy single fraction
palliative radiotherapy for the treatment of painful recurrent soft palate carcinoma by high-dose-ratemold branchytherapy: a case report. Oral Oncol. 2006;42:305-307.
7㧕 Kobayashi A, Tomida M, Ishimaru JI, Negawa T, Murayama K, Era S, Shibata T. Correlation between
the oxidative state of the synovial fluid and the radiological morphorogy of the temporomandibular
joint disorder. Asian J Oral Maxillofac Surg. 2006;18:185-190.
8㧕 Imai H, Saio M, Nonaka K, Suwa T, Umemura N, Ouyang GF, Nakagawa J, Tomita H, Osada S,
Sugiyama Y, Adachi Y, Takami T. Depletion of CD4+CD25+regulatory T cells enhancesinterleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci.
2007;98:416-423.
9㧕 Kato H, Kanematsu M, Kusunoki Y, Shibata T, Murakami H, Mizuta K, Ito Y, Hirose Y. Nasoalveolar
cyst: imaging findings in three cases. Clinical Imaging. 2007;31:206-209.
10㧕 Long NK, Makita H, Yamashita T, Toida M, Kato K, Hatakeyama D, Shibata T. Chemopreventive㧙㧙

IF 2.366

IF 1.597

IF 1.597

IF 2.569

IF 3.165
IF 0.742effect of fermented brown rice and rice bran on 4-nitroquinoline 1-oxide-induced oral carcinogenesis inrats. Oncol Rep. 2007;17:879-885.
11㧕 Makita H, Mutoh M, Murayama T, Yonemoto K, Kobayashi A, Fujitsuka H, Toida M, Shibata T,
Miyamoto S, Yasui Y, Suzuki R, Wakabayashi K, Tanaka T. A prostaglandin E2 receptor subtype
EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue
carcinogenesis. Carcinogenesis. 2007;28:677-684.
12㧕 Nakagawa J, Saio M, Tamakawa N, Suwa T, Frey AB, Nonaka K, Umemura N, Imai H, Ouyang GF,
Ohe N, Yano H, Yoshimura S, Iwama T, Takami T. TNF expressed by tumor-associated macropfages,
but not microglia, can eliminate glioma. Int J Oncol. 2007;30:803-811.
13㧕 Tanaka K, Mikamo H, Nakao K, Watanabe K. In vitro antianaerobic activity of DX-619, a new
des-fluoro(6) quinolone. Antimicrob Agents Chemother. 2006;50:3908-3913.
14㧕 Yura S, Terahara S, Ohga N, Yamashita T. A case of carcinosarcoma arising in the submandibular
gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:820-824.
15㧕 Zhi H, Yamada Y, Hirose Y, Kato K, Sheng HO, Zheng Q, Oyama T, Asano N, Kuno T, Hara A, Mori H.
Effect of 2-(carboxyphenyl)retinamide and genistein on the formation of early lesions in
1,2-dimethylhydrazine-induced colon carcinogenesis in rats. Asian Pacific Journal of Cancer
Prevention. 2007;8:33-38.
16㧕 Haniffa A.M., Saitoh M, Abiko Y, Takeshima M, Nishimura M, Yamazaki M, Nagayasu H, Sugiura C,
Muthumala M, Kaku T, Chiba I, Shibata T. Expression pattern of p63 in oral epithelial lesions andsubmucous fibrosis associated with betel-quid chewing in Sri Lanka. Med Mol Morphol.
2007;40:203-207.
17㧕 Kato K, Long NK, Makita H, Toida M, Yamashita T, Hatakeyama D, Hara A, Mori H, Shibata T.
Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral
squamous cell carcinoma cells. Br J Cancer. 2008;99:647-654.
18㧕 Long NK, Kato K, Yamashita T, Makita H, Toida M, Hatakeyama D, Hara A, Mori H, Shibata T.
Hypermethylation of the RECK gene predicts poor prognosis in oral squamous cell carcinomas. Oral
Oncol. 2008;44:1052-1058.
19㧕 Miyazaki Y, Hara A, Kato K, Oyama T, Yamada Y, Mori H, Shibata T. The effect of hypoxic
microenvironment on matrix metalloproteinase expression in xenografts of human oral squamous cell
carcinoma. Int J Oncol. 2008;32:145-151.
20㧕 Takeda T, Tezuka Y, Horiuchi M, Hosono K, Iida K, Hatakeyama D, Miyaki S, Kunisada T, Shibata T,
Tezuka K. Characterization of dental pulp stem cells of human tooth germs. J Dent Res
2008;87:676-681.
21㧕 Takeshima M, Saitoh M, Kusano K, Nagayasu H, Kurashige Y, Malsantha M, Arakawa T, Takuma T,
Chiba I, Kaku T, Shibata T, Abiko Y. High frequency of hypermethylation of p14, p15 and p16 in oral
pre-cancerous lesions associated with betel-quid chewing in Sri Lanka. J Oral Pathol Med.
2008;37:475-479.
22㧕 Umemura N, Saio M, Suwa T, Kitoh Y, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata
T, Takami T. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamedmonocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol. 2008;83:1136-1144.

IF 1.597

IF 5.406

IF 2.295
IF 4.390
IF 1.597

IF 1.338

IF 4.635

IF 2.569

IF 2.295

IF 3.496

IF 1.711

IF 4.1284㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᩊ↰ᢅਯ㧘⎇ⓥಽᜂ⠪㧦ජ⪲ㅺᦶ㧘࿯੗↰⺈㧘⍹ፒ᣿㧘A. ࡜ࠪ࠽ࡂ㧘ㇳ⧷㓶㧘๟ᝄ⧷㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)(2)㧦ࠬ࡝࡜ࡦࠞ࡮บḧߦ߅ߌࠆญ⣧߇ࠎߩಽሶ∉ቇ⊛Ყセ⺞ᩏ㧧ᐔᚑ
16㧙19 ᐕᐲ㧧13,000 ජ౞(3,500㧦3,300㧦3,100㧦3,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦⇗ጊᄢੑ㇢㧘⎇ⓥಽᜂ⠪㧦ᩊ↰ᢅਯ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦㛽ᒻᚑߦ߅ߌࠆ
ⴊ▤ౝ⊹Ⴧᱺ࿃ሶ(VEGF)⺃ዉᯏ᭴ߩ⸃ᨆ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧3,400 ජ౞(1,800㧦800㧦800 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ട⮮ᕺਃ㧘⎇ⓥಽᜂ⠪㧦ጊਅ⍮Ꮘ㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ญ⣧ᚳᐔ਄⊹≸ߦ߅ߌࠆ RECK ㆮવሶߩ㑐ࠊࠅߣ⣕ࡔ࠴࡞ൻߦࠃࠆ⊒≸࡮ᶐẢߩ೙ᓮ㧧ᐔᚑ 17㧙
18 ᐕᐲ㧧2,400 ජ౞(1,900㧦500 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᩊ↰ᢅਯ㧘⎇ⓥಽᜂ⠪㧦⇗ጊᄢੑ㇢㧘’↰ᶈ᮸㧘ട⮮ᕺਃ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦ᥓᱤᱤ⢦߆ࠄߩ⚵❱ᐙ⚦⢩ߩ᮸┙ߣಽൻ࡮Ⴧᱺ⢻ߩ⹏ଔ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,200 ජ౞(1,600㧦
1,600 ජ౞)5㧕 ⎇ⓥઍ⴫⠪㧦ᩊ↰ᢅਯ㧘⎇ⓥಽᜂ⠪㧦ጊਅ⍮Ꮘ㧘࿯੗↰⺈㧘ട⮮ᕺਃ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦
ࡅ࠻ญ⣧☼⤑∛ᄌߦ߅ߌࠆㆮવሶࡔ࠴࡞ൻ⇣Ᏹߩ㑐ਈ㧧ᐔᚑ 18㧙21 ᐕᐲ㧧13,200 ජ౞(3,200㧦
3,300㧦3,300㧦3,400 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦’↰ᶈ᮸㧘⎇ⓥಽᜂ⠪㧦ᩊ↰ᢅਯ㧘࿯੗↰ ⺈㧘ട⮮ᕺਃ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ㧙㧙

(C)㧦4NQO ⺃⊒࡜࠶࠻⥠⊒≸ߦ߅ߌࠆㆮવሶࡔ࠴࡞ൻ⇣Ᏹߩ⸃ᨆ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,200 ජ౞(1,100㧦1,100 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦࿯੗↰ ⺈㧘⎇ⓥಽᜂ⠪㧦ട⮮ᕺਃ㧘’↰ᶈ᮸㧘ጊਅ⍮Ꮘ㧘ᩊ↰ᢅਯ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ญ⣧ᚳᐔ਄⊹≸ߩ㗪ㇱ࡝ࡦࡄ▵ォ⒖ߦ㑐ߔࠆᨴ⦡૕࡮ㆮવሶ⇣Ᏹߩ⸃ᨆ㧧ᐔᚑ 19
㧙21 ᐕᐲ㧧3,100 ජ౞(1,200㧦900㧦1,000 ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦ጊਅ⍮Ꮘ㧘⎇ⓥಽᜂ⠪㧦ട⮮ᕺਃ㧘’↰ᶈ᮸㧘⇗ጊᄢੑ㇢㧘࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ญ⣧≸ߦ߅ߌࠆⴊẏਛߩࡔ࠴࡞ൻ⇣Ᏹㆮવሶᢿ ߩᬌ⚝ߣ⥃ᐥ∛ᘒߣߩ⋧㑐㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,500 ජ౞(1,700㧦900㧦900 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰⍮ሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࡅ࠻ᱤ㜑⚵❱ᐙ⚦⢩ߩ᮸┙ല₸ะ਄ߣ iPS⚦⢩ൻߩᬌ⸛㧧ᐔᚑ 20㧙21 ᐕᐲ㧧2,540 ජ౞(1,360㧦1,180 ජ౞)
10㧕 ⎇ⓥઍ⴫⠪㧦ችፒᐽ㓶㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ૐ㉄⚛ⅣႺߦࠃࠆࡅ࠻ญ⣧߇ࠎߩ EMT ⺃ዉ㧧ᐔᚑ 20㧙21 ᐕᐲ㧧2,540 ජ౞(1,340㧦1,200 ජ౞)
11㧕 ⎇ⓥઍ⴫⠪㧦⇗ጊᄢੑ㇢㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࡅ࠻ᱤ⢦⚵❱ᐙ⚦⢩ߦ߅ߌࠆࠝࠬ࠹ࠝࠞ
࡞ࠪࡦ⊒⃻ߣⴊ▤ౝ⊹Ⴧᱺ࿃ሶ⺃ዉᯏ᭴ߩ⸃ᨆ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,100 ජ౞(1,100㧦1,000㧦1,000ජ౞)
12㧕 ⎇ⓥઍ⴫⠪㧦ᵻ㚅㓶৻㇢㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࡅ࠻ญ⣧≸ Bcl-2 ࡈࠔࡒ࡝࡯ㆮવሶߩ⊒⃻᭽ᑼߣᴦ≮ലᨐߩᬌ⸛㧧ᐔᚑ 20㧙22 ᐕᐲ㧧2,800 ජ౞(1,000㧦900㧦900 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ࿯੗↰⺈㧘ട⮮ᕺਃ㧘☨ᧄ๺ᒄ㧘’↰ᶈ᮸㧘⇗ጊᄢੑ㇢㧘ᬮᐘඳ㧘ችᧄ⻞㧘⮮Ⴆ⑲᮸㧘ጊਅ⍮Ꮘ㧘⍹ਣ⚐৻㧘ᩊ↰ᢅਯ㧦ࠪࠚ࡯ࠣ࡟ࡦ∝୥⟲ᖚ⠪ߩญ⣧ੇ῎∝ᴦ≮ߦ߅ߌࠆႮ㉄࠮ࡆࡔ࡝ࡦ᳓๺‛ߩ೽૞↪⊒⃻ߣߘߩ੍㒐ߦ㑐ߔࠆ⥃ᐥ⊛⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧120 ජ౞(120 ජ౞)㧦ᣣᧄൻ⮎(ᩣ)
2㧕 ᩊ↰ᢅਯ㧘࿯੗↰ ⺈㧘ጊਅ⍮Ꮘ㧘’↰ᶈ᮸㧘ട⮮ᕺਃ㧘⇗ጊᄢੑ㇢㧘ᬮ ᐘඳ㧘☨ᧄ๺ᒄ㧘ᵻ㚅㓶৻㇢㧦ࠗ࠻࡝࠱࡯࡞ౝ↪ᶧ 1%૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞(200 ජ౞)㧦ࡗࡦ࠮ࡦࡈࠔ࡯ࡑ(ᩣ)
3㧕 ᩊ↰ᢅਯ, ࿯੗↰ ⺈㧦ญ⣧ੇ῎∝࡮⥠∩∝ߩ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧200 ජ౞(200 ජ౞)㧦ᄢᱜንጊක⮎ຠ(ᩣ)
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ᚻႦᑪ৻࡮ᩊ↰ᢅਯ࡮࿡⽵㓉ᒄ࡮₹⟎਽೰࡮ጊਛિᒎ࡮㜞ᯅ๺೑㧦ࡅ࠻ᱤ⢦ᐙ⚦⢩߆ࠄߩੱᎿᄙ⢻ᕈᐙ⚦⢩(iPS ⚦⢩)ߩ㜞ല₸⺃ዉᴺ㧧ᐔᚑ 20 ᐕᐲ(․⸵಴㗿ਛ)
6㧚ቇળᵴേ
1㧕ቇળᓎຬᩊ↰ᢅਯ㧦
1㧕 ᣣᧄญ⣧ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄญ⣧ᄖ⑼ቇળࠞ࡝ࠠࡘ࡜ࡓᆔຬળᆔຬ(㨪⃻࿷)3㧕 ᣣᧄญ⣧ᄖ⑼ቇળ࠲ࡃࠦኻ╷ᆔຬળᆔຬ(㨪⃻࿷)4㧕 ᣣᧄญ⣧ᄖ⑼ቇળኾ㐷ක⹺ቯᆔຬળᆔຬ(㨪⃻࿷)5㧕 ᣣᧄญ⣧ᄖ⑼ቇળ㔀⹹✬㓸ᩏ⺒ᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 9 ᦬㨪⃻࿷)
6㧕 ᣣᧄญ⣧⑼ቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄญ⣧⣲≌ቇળ⹏⼏ຬ(ᐔᚑ 17 ᐕ 9 ᦬㨪⃻࿷)8㧕 ᣣᧄญ⣧㗶㗻㕙ᄖ்ቇળℂ੐(㨪⃻࿷)9㧕 ᣣᧄญ⣧ࠤࠕቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 9 ᦬㨪⃻࿷)࿯੗↰ ⺈㧦
1㧕 ᣣᧄ∛ℂቇળ⹏⼏ຬ(㨪⃻࿷)㧙㧙2㧕ቇળ㐿௅ᩊ↰ᢅਯ㧦
1㧕 ╙ 33 ࿁ᣣᧄญ⣧ᄖ⑼ቇળਛㇱ࿾ᣇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹ᩊ↰ᢅਯ㧦
1㧕 ᣣᧄญ⣧ᄖ⑼ቇળ㔀⹹㧦✬㓸ᩏ⺒ᆔຬ(ᐔᚑ 18 ᐕ 9 ᦬㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙṶ⠪㧘ᐳ㐳ᩊ↰ᢅਯ㧦
1㧕 ╙ 61 ࿁ᣣᧄญ⣧⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫(≸ޟ‬ၮ␆)6‫ޠ‬ᐳ㐳)2㧕 ᣣᧄ⡊㥦ຜ༄⑼කળ ╙ 32 ࿁⥃ᐥኅࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 8 ᦬㧘㜞ጊ㧘․೎⻠Ṷ‫ޟ‬ญ⣧ੇ῎∝ߣญ⣧☼⤑∔ᖚߩ⸻ᢿߣᴦ≮㧦㜞㦂ൻ␠ળࠍ߰߹߃ߚญ⣧ੇ῎∝࡮⥠∩∝߳ߩኻᔕ‫ޠ‬Ṷ⠪)3㧕 ጘ㒂⋵ਃᏧળวหቇⴚ⻠Ṷળг㛽☻㝃∝ᴦ≮ߣᱤ⑼⸻≮(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ࠬࡎࠬࡆޟ‬ࡎࡀ࡯࠻⵾೷ߦࠃࠆ㗶㛽უᱫߩෂ㒾ᕈߣක࡮ᱤ࡮⮎ㅪ៤ߩᔅⷐᕈ‫ޠ‬Ṷ⠪)
4㧕 ╙ 6 ࿁ᣣᧄ㛽☻㝃∝⎇ⓥળቇⴚᄢળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬㛽☻㝃∝ᴦ≮⮎(ࡆࠬࡎࠬࡎ
ࡀ࡯࠻⵾೷)ߣᱤ⑼ᴦ≮—㗶㛽უᱫߩෂ㒾ᕈߣකᱤ⮎ㅪ៤ߩᔅⷐᕈ‫ޠ‬Ṷ⠪)
5㧕 ╙ 1 ࿁ጘ㒂⋵ญ⣧ࠤࠕࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ญ⣧ࠤࠕ࡯ߘߩᣂߒ޿น⢻ᕈߦߟ޿ߡ‫ޠ‬ᐳ㐳)
6㧕 ╙ 1 ࿁ጘ㒂⋵ญ⣧ࠤࠕࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ญ⣧ࠤࠕߩ޿ࠈߪ࡯ᕆᕈᦼ㧘᦭∛⠪ߦኻߔࠆญ⣧ࠤࠕ‫ޠ‬ᐳ㐳)7㧕 ╙ 11 ࿁ጘ㒂✭๺ක≮⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ࡮㑐ㅪ⻠Ṷ‫✭ޟ‬๺ක≮ߦ߅ߌࠆญ⣧ࠤࠕ‫ޠ‬ᐳ㐳)8㧕 ╙ 33 ࿁ᣣᧄญ⣧ᄖ⑼ቇળਛㇱ࿾ᣇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥃ޟ‬ᐥ㤗㈮ߩㅴᱠߣᖚ⠪ߩ቟ోᕈ‫ޠ‬ᐳ㐳)9㧕 ╙ 33 ࿁ᣣᧄญ⣧ᄖ⑼ቇળਛㇱ࿾ᣇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬PK-PD ℂ⺰ߦၮߠߊᗵᨴ∝ᴦ≮⮎ߩㆡᱜ૶↪ᷝઃᢥᦠߤ߅ࠅߢߪᖚ⠪ࠍᢇ߃ߥ޿‫ޠ‬ᐳ㐳)10㧕 ╙ 33 ࿁ᣣᧄญ⣧ᄖ⑼ቇળਛㇱ࿾ᣇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘࡝ࡈ࡟࠶ࠪࡘ࠮ࡒ࠽࡯‫࡯ࡀࡑࠢࠬ࡝ޟ‬ࠫࡔࡦ࠻੍⍮ᕈߩะ਄‫ޠ‬ᐳ㐳)11㧕 ጘ㒂⋵଻㒾කදળ ᱤ⑼⎇ⓥળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫⸻∛ޟ‬ㅪ៤ߦࠃࠆࠗࡦࡊ࡜ࡦߣᴦ≮ߩዷ㐿቟ᔃ࡮቟ోߩࠗࡦࡊ࡜ࡦߣᴦ≮ࠍ⋡ᜰߒߡ‫ޠ‬Ṷ⠪)࿯੗↰ ⺈㧦
1㧕 ╙ 60 ࿁ᣣᧄญ⣧⑼ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ฬฎደ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᔃりකቇ‫ޠ‬Ṷ⠪)
2㧕 ╙ 61 ࿁ᣣᧄญ⣧⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫⥃(⤑☼ޟ‬ᐥ)‫ޠ‬Ṷ⠪)
3㧕 ╙ 18 ࿁ᣣᧄญ⣧∛ℂቇળ✚ળ(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂㧘ࠬ࡜ࠗ࠼࠮ࡒ࠽࡯‫ޟ‬ญ⣧∛ᄌߩ⡺⌒ᚲ⷗‫ޠ‬Ṷ
⠪)
4㧕 AGORA21—ᣂ਎ઍ H2 ࡉࡠ࠶ࠞ࡯ߩㅴൻ⺰(ᐔᚑ 20 ᐕ 4 ᦬㧘ᄢ㒋㧘⻠Ṷ‫(∝∩⥠ޟ‬ญ⣧☼⤑ἳᾲᗵ)ߦኻߔࠆ࡜ࡈ࠴ࠫࡦߩ✭๺ലᨐߦߟ޿ߡ‫ޠ‬Ṷ⠪)
5㧕 ╙ 33 ࿁ᣣᧄญ⣧ᄖ⑼ቇળਛㇱ࿾ᣇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫∝ࡦ࡟ࠣ࡯ࠚࠪޟ‬୥⟲ߦ઻߁ญ⣧ੇ῎∝ߦኻߔࠆฦ⒳ᴦ≮ᚑ❣ߣߘߩᗧ⟵‫ޠ‬ᐳ㐳)
6㧕 ╙ 34 ࿁ࠕ࡞ࠞࡠࠗ࠼⎇ⓥળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᄢ㒋㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬ᣣᏱ⸻≮ߦ߅ߌࠆᘟᕈ−∩ߩ
▤ℂ‫ޠ‬Ṷ⠪)7㧕 ╙ 19 ࿁ᣣᧄ⥃ᐥญ⣧∛ℂቇળࠬ࡜ࠗ࠼࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 8 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬ญ⣧∛ᄌߩ⡺⌒ᚲ⷗‫ޠ‬
Ṷ⠪)
ጊਅ⍮Ꮘ㧦
1㧕 ╙ 25 ࿁ᣣᧄญ⣧⣲≌ቇળ✚ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ฬฎደ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ญ⣧≸ᴦ≮ߩ⃻⁁ߣߎࠇ߆ࠄ‫ޠ‬Ṷ⠪)2㧕 ╙ 61 ࿁ᣣᧄญ⣧⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫⥃(≸ޟ‬ᐥ)3‫ޠ‬Ṷ⠪)ᵻ㚅㓶৻㇢㧦
1㧕 ╙ 61 ࿁ᣣᧄญ⣧⑼ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘␹ᚭ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᄖ்‫ޠ‬Ṷ⠪)㧙㧙⺪⸰㆐ᒾ㧦
1㧕 ╙ 60 ࿁ᣣᧄญ⣧⑼ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ฬฎደ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫ ∉఺ߩ≸ޟ‬1‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ട⮮ᕺਃ㧦ࠧ࡯࡞࠼࡝ࡏࡦ⾨(ᐔᚑ 19 ᐕ 10 ᦬ 5 ᣣ)
9㧚␠ળᵴേᩊ↰ᢅਯ㧦
1㧕 ⑼⎇⾌ክᩏᆔຬ(ᐔᚑ 18 ᐕ 9 ᦬㨪⃻࿷)2㧕 ࿖଻ክᩏળᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⋵ᱤ⑼ᛛᎿ჻⹜㛎ᆔຬ(㨪⃻࿷)࿯੗↰ ⺈㧦
1㧕 ጘ㒂⋵ᱤ⑼ᛛᎿ჻⹜㛎ᆔຬ(ᐔᚑ 16 ᐕ 12 ᦬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᩊ↰ᢅਯ㧦EGF ฃኈ૕࡮ࠪࠣ࠽࡞વ㆐ࠍಽሶᮡ⊛ߣߔࠆญ⣧߇ࠎᴦ≮ߩၮ␆⊛ᬌ⸛㧦ᐔᚑ 15 ᐕᐲ
㧙17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙102(2006 ᐕ 1 ᦬)
2㧕 ᩊ↰ᢅਯ㧦ࠬ࡝࡜ࡦࠞ࡮บḧߦ߅ߌࠆญ⣧߇ࠎߩಽሶ∉ቇ⊛Ყセ⺞ᩏ㧦ᐔᚑ 16 ᐕᐲ㧙19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙50(2008 ᐕ 4 ᦬)
11㧚ႎ㆏1㧕 ᩊ↰ᢅਯ㧦DICOM Viewer(࠳ࠗࠦࡓ࡮ࡆࡘ࡯ࡢ࡯)ߣߪ㧦ጘᱤᣂႎ(2006 ᐕ 4 ᦬ 22 ᣣ)
2㧕 ࿯੗↰ ⺈㧘ᩊ↰ᢅਯ㧦৻⥸Ꮢ᳃ߩ 3 ഀߦ࠼࡜ࠗࡑ࠙ࠬ㧦Medical Tribune(2006 ᐕ 6 ᦬ 8 ᣣ)
3㧕 ᩊ↰ᢅਯ㧦∛㒮ᱤ⑼⚫੺Ԛ㧦ጘ㒂⋵଻㒾කᣂ⡞(2006 ᐕ 8 ᦬ 10 ᣣ)
4㧕 ᩊ↰ᢅਯ㧦ࡆࠬࡈࠔࠬࡈࠜࡀ࡯࠻⵾೷ߣᱤ⑼ᴦ≮—㗶㛽უᱫߩෂ㒾ᕈߣකᱤ⮎ㅪ៤ߩᔅⷐᕈ㧦ጘᱤᣂႎ(2007 ᐕ 10 ᦬ 22 ᣣ)
5㧕 ᩊ↰ᢅਯ㧦ࡆࠬࡈࠔࠬࡈࠜࡀ࡯࠻⵾೷ߦࠃࠆ㗶㛽უᱫߩෂ㒾ᕈߣකᱤ⮎ㅪ៤ߩᔅⷐᕈ㧦ጘ㒂⋵කᏧળႎ(2007 ᐕ 11 ᦬ 1 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔญ⣧∛ᘒቇಽ㊁ߣߒߡߩ✚ว⊛⹏ଔߣߒߡ㧘᭎ߨ⋡ᮡࠍ㆐ᚑߒߡ޿ࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷․ߦᵴേࠍផㅴߔࠆߚ߼ߦᦨ߽ᔅⷐߢ޽ࠆ⾗㊄㕙ߪ㧘ᐔᚑ 15 ᐕᐲએ㒠⃻࿷߹ߢㅪ⛯ߒߡ⑼ቇ⎇ⓥ⾌
1000 ਁએ਄ߩ₪ᓧ⋡ᮡࠍ㆐ᚑߒߡ᧪ߡ޿ࠆ‫ߚ߹ޕ‬㧘⎇ⓥ᧚ᢱ㧔⥃ᐥ᧚ᢱ㧕ߩ㓸Ⓧ߽⚻ᤨ⊛ߦⓍߺ㊀ߥߞߡ᧪ߡ޿ࠆ‫ߩࠄࠇߎޕ‬㕙ߢߪ㧘ߎߩ߹߹ߩദജࠍ⛮⛯ߔࠆߎߣߦࠃࠅ⏕ታߦᚑᨐ߇ᓧࠄࠇࠆߣ⠨߃ࠄࠇࠆ‫ࠄ߇ߥߒ߆ߒޕ‬㧘⑼⎇⾌ߪߘߩ㗵࡮ᦼ㑆ߣ߽ߦ⎇ⓥࠍᄢ߈ߊዷ㐿ߔࠆߦߪዊ㗵߆ߟ⍴ᦼߢ޽ࠅ㧘ᦝߥࠆᄢဳߩᄖㇱ⎇ⓥ⾗㊄ࠍ₪ᓧߔࠆᔅⷐᕈࠍ∩ಾߦᗵߓߡ޿ࠆ‫ߚ߹ޕ‬㧘⃻᦭ੱຬߩ࡝ࠨ࡯࠴ࡑࠗࡦ࠼ࠍೝ
ỗߔࠆߎߣ߽㕖Ᏹߦ㊀ⷐߣ⠨߃㧘2004 ᐕࠃࠅ⛮⛯ߒߡ޿ࠆಽ㊁ౝ࡝ࠨ࡯࠴ࠞࡦࡈࠔ࡜ࡦࠬࠍᒝൻ࡮⊒ዷߐߖࠆߚ߼ߦၮ␆ߩฦಽ㊁ߣߩㅪ៤߽㊀ⷐߣ⠨߃ߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ⃻࿷㧘ࡅ࠻ᱤ⢦࡮ᱤ㜑߆ࠄߩ⚵❱ᐙ⚦⢩ߩ㓸Ⓧ࡮ࡃࡦࠢൻߣ iPS ⚦⢩ൻࠍዷ㐿ਛߢ޽ࠅ㧘᦭ᦸߥ⚿ᨐࠍ␜ߒߟߟ޽ࠆ‫ࠍࠇߎޕ‬ᚑ㐳ࠛࡦࠫࡦߩᩇߩ৻ߟߣߒߡട߃㧘㑐ㅪಽ㊁ߣߩ⊒ዷࠍᮨ⚝ߒߡ޿ࠆ㧔ᄢᄌ᦭ᦸߥ⎇ⓥ⾗Ḯߣߥࠆน⢻ᕈ߇㜞ߊ㧘ㅴ᝞ߦࠃࠅᄙᄢߥࠆᚑᨐࠍᓧࠆߣᦼᓙߒߡ޿ࠆ㧕‫ޕ‬㧙㧙